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                                                      Abstract 
 
The World Health Organization (WHO) defines obesity as a condition in which body fat 
is increased to the extent that health and well-being are impaired. Obesity and type-2 
diabetes are two of the leading healthcare challenges facing this generation. Bariatric 
surgery is the most effective therapeutic option for morbid obesity. A systematic review 
has concluded that surgery is superior to conventional treatment in reducing weight. 
However, the review failed to show the superiority of one surgical method over others. 
It is thought that the re-routing of food through an anatomically altered and/or shorter 
gastrointestinal tract leads to an increased delivery of incompletely digested nutrients to 
the ileum and colon. This leads to over-stimulation of the specialized entero-endocrine 
L cells. Others argue that the exclusion of an inhibitory factor from the foregut may 
mediate the rapid improvement in diabetes. Several studies have shown a blunted hind 
gut hormone (PYY and GLP-1) response in the morbidly obese patients that is 
reversed by Roux-en-Y gastric bypass (RYGBP) and sleeve gastrectomy (SG). Recent 
studies on patients undergoing bariatric surgery have revealed a key role for PYY, 
GLP-1 and acyl-ghrelin in regulating appetite, bodyweight and glucose homeostasis. A 
correlation between changes in gut hormone secretion and weight loss has not yet 
been shown in humans, but has been shown in rats after RYGBP. This discrepancy 
may be related to study design and sample processing, as not all studies have 
measured the active forms of the circulating hormone, and standardized for collection 
of blood samples. Some have compared post-surgical changes in gut hormones 
against control groups, not their pre-operative state, making it difficult to draw 
conclusions on individual physiological changes and corresponding correlations to 
anthropometry. Further, no study to date has found correlation between change in 
active gut hormones and change in perception of hunger and satiety. 
 
In my study, RYGBP and SG led to a differential change in hunger, prospective food 
consumption and satiety. RYGBP had a more pronounced influence on prospective 
food consumption and hunger, despite non-significant changes in acyl-ghrelin. As 
RYGBP led to a more pronounced PYY3-36, GLP-1 and amylin response, it would be 
expected to alter satiety more. SG by contrast led to a more pronounced and significant 
decline in acyl-ghrelin, but only mediated a lesser change in hunger in comparison to 
RYGBP. However, my study does provide a link between the change in gut hormones 
and measures of appetite and satiety. My study also confirms gut hormone changes 
that occur after RYGBP and SG correlate to a decline in appetite and an increase in 
satiety, and therefore mediate weight loss. I also compared the change in hunger, 
prospective food consumption and satiety from baseline, and confirm a significant 
13 
 
decrease in Δ hunger and Δ prospective food consumption, and a significant increase 
in Δ satiety after RYGBP and SG.  
 
There is equivalent excess weight loss (%EWL) after both RYGBP and SG at 6 weeks 
and 12 weeks after surgery. Despite starting with a lower BMI, the SG group lost similar 
BMI points to the RYGBP group at 6 weeks and at 12 weeks after surgery. This is in 
keeping with other recent short term and long term human studies. RYGBP and SG led 
to equivalent fat mass loss and decline in plasma leptin. RYGBP led to a pronounced 
hind gut hormone response, and SG led to a similar but less pronounced hind gut 
response. SG alone led to a significant decline in acyl-ghrelin. The amylin response 
after RYGBP and SG are divergent. In our study patients continued to lose weight from 
the first post-operative study point at 6 weeks to the second study point at 12 weeks, 
however there was no significant change in the fasting or meal stimulated insulin, 
PYY3-36, acyl-ghrelin, GLP-1 and amylin response from 6 to 12 weeks, apart from 
acyl-ghrelin in the RYGBP group, where acyl-ghrelin did increase between these time 
points. I also explored the role of insulin/ amylin ratio in appetite and weight loss. It is 
thought that an increased ratio of amylin/ insulin expression may act as a marker for 
beta cell dysfunction. Hyperglycaemia is thought to lead to the hypersecretion of amylin 
relative to insulin, and increase the amylin /insulin ratio in insulin-resistance. In the 
RYGBP group changes in PYY3-36 and insulin: amylin ratio correlates to weight loss. 
In the SG group change in PYY3-36, acyl-ghrelin, GLP-1 and amylin correlate to weight 
loss after surgery. RYGBP and SG seem to utilize different mechanisms to engender 
weight loss. The outcome after SG is dependent on the hormonal changes that ensue, 
whereas RYGBP may mediate its effects through neuro-anatomical changes 
associated with surgery. My findings, like those of others recently, lend support to the 
hind gut mediating the effects of weight loss after RYGBP and SG surgery.  
 
The resolution of type 2 diabetes occurs immediately after RYGBP and SG. RYGBP 
and SG markedly improved glucose homeostasis by improving insulin secretion 
through the augmented GLP-1 response, weight loss and the decrease in acyl-ghrelin 
secretion seen after SG, leading to improved insulin sensitivity. These changes in 
insulin secretion and insulin resistance are seen early after surgery before any 
substantial weight loss has occurred. My study confirms RYGBP and SG to be equally 
efficacious as metabolic surgical options. The disparity in GLP-1 response after 
RYGBP and SG is further complicated by the GLP-1 stimulated insulin release 
displaying a threshold phenomenon. Thus the GLP-1 response after RYGBP and SG 
did not lead to equivalent glucose-dependent insulin secretion. The GLP-1 stimulated 
amylin response also showed a threshold phenomenon. However, there did not seem 
14 
 
to be any difference between the two groups. In our study there was a decline in HOMA 
IR after RYGBP and SG. The decline after SG showed a trend towards statistical 
significance. This discrepancy can partly be explained by the significant decline in acyl-
ghrelin seen only after SG but not RYGBP. The duodenal exclusion hypothesis is 
unlikely to be a viable explanation given our results on sleeve gastrectomy, which occur 
in spite of a functional duodenum. The differential insulin/ amylin ratio after RYGBP and 
SG is noteworthy. In our study, there was a significant decrease in insulin: amylin ratio 
after RYGBP. Insulin secretion was not significantly altered after RYGBP. However 
there was an increase in amylin secretion after RYGBP leading to a decrease in insulin: 
amylin ratio at 6 and 12 weeks after surgery. There was a significant increase in meal 
stimulated insulin secretion after SG. This led to lower insulin: amylin ratio after SG. 
The lower amylin seen after SG may also contribute to the improved glucose 
homeostasis after SG, and further compensate for the relatively lower GLP-1. However, 
relative increase in amylin secretion did not adversely influence glucose homeostasis 
after RYGBP. The contrasting alteration in ratio did not correlate to satiety, prospective 
food consumption or weight loss. In our study GLP-1 secretion did show a positive 
correlation to amylin secretion in both groups, before and after surgical intervention. 
 
It is known that some patients fail to lose weight after RYGBP and SG, but the 
mechanisms behind this failure have yet to be explored. One patient in our SG group 
was noted to have lost no further weight between 3 and 12 months following surgery. 
This patient had a three month meal stimulated amylin, Δ PYY3-36 and Δ acyl-ghrelin 
curve below the baseline curve for the respective hormones. This was in sharp contrast 
to all the other patients in the SG group. In other words a poor hormone response after 
surgery predicts failure to respond after SG. This altered meal stimulated response 
could be utilized to fast-track patients predicted to fail to a second stage procedure.  
My second study suggests that an individual’s metabolic state influences their 
monetary decisions. The risk-sensitive monetary decisions were influenced by both 
long-term metabolic signals indexing energy stores and short-term metabolic signals 
that index energy gains. At the neurobiological level, my results suggest an overlap 
between food and monetary reward. This has significant implications for all decisions 
that incorporate risk and monetary reward. In other words an individual’s body mass 
index and his nutritional intake could alter risky behaviour. 
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1 Introduction  
1.1 Obesity 
The World Health Organization (WHO) defines obesity as a condition in which body fat 
is increased to the extent that health and well-being are impaired (WHO 1998). The 
operational definition of obesity is based on BMI. Obesity, defined as a body mass 
index (BMI = weight in kg/ height m
2
) of above 30 (WHO 2000). The currently used cut-
off points for overweight (i.e., 25 kg/m
2
) and obesity (i.e., 30 kg/m
2
) are based on 
morbidity and mortality data in relation to BMI from population studies in Caucasians 
(WHO 1998). It is a leading cause of death worldwide (Kopelman PG 2000). Obesity is 
set to overtake infectious disease as the most significant contributor to poor health 
worldwide (Kopelman PG 2000, Ogden CL et al 2004).  
1.2Classification of obesity 
A classification of obesity into four subclasses of obesity proposed: obesity 1 (30–34.9 
kg/m
2
); obesity 2 (35–39.9 kg/m
2
); extreme obesity (>40 kg/m
2
); and super obesity (>50 
kg/m
2
) (Leff and Heath 2009). This classification also fits in well with the guidelines for 
obesity surgery (Leff and Heath 2009). 
Body mass index (kg/m
2
)  Classification 
18.5-24.9 Normal weight 
25.0-29.9 Overweight 
30.0-34.9 Obesity type I 
35.0-39.9 Obesity type II 
≥40.0 Morbid obesity/obesity type III 
≥50.0 Super obesity 
Figure-1 Classification of obesity based on body mass index thresholds (Leff and Heath 
2009). 
Worryingly the trend in morbid obesity accelerated above that of non-morbid obesity 
between 2000 and 2005. There was a 24% increase in obesity rates, but a 50% 
increase in extreme obesity (BMI >40), and an even greater 75% increase in severe 
obesity (BMI>50) (Sturm 2007). This trend will lead to an increase in healthcare 
utilization costs, as healthcare costs for the morbidly obese are 81% above those for 
the non-obese population and 47% above costs for the non–morbidly obese population. 
(Flegal et al 2002, Arterburn et al 2005)   
 
18 
 
1.3 Obesity prevalence 
 
In England and Wales One in four adults are obese, 32% of women and 46% of men 
are overweight , with a BMI of >25 but <30 kg/m2 (the NHS information centre 2010) 
The direct cost of treating obesity and overweight individuals is estimated to be over 
three billion pounds per annum in the UK (Allender S et al 2007).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2; Obesity rates in England from 1993 to 2012- Health Survey for England 2012.  
 
Women had a significantly higher rate of obesity in the early nineties, but the rates did 
converge with no significant difference by 2006. There was a 68% increase in the 
overall trend from 1993 to 2006.  
1.4 Economic costs of obesity 
In 2005 over 871,000 prescription items were dispensed for the treatment of obesity. 
This compares with 127,000 in 1999 (NHS Information centre, England, 2006). The 
Foresight Report forecasts that by 2050, 60% of men and 40% of women could be 
clinically obese. Without action, obesity-related diseases will cost the UK economy £45 
billion a year, including £6.5 billion to the NHS in treatment costs (Foresight Report 
2007). 
1.5 Mortality associated with obesity 
 
Approximately 30,000 deaths annually in the UK are attributable to obesity (National 
Audit Office, 2001). There has been a substantial recent increase in mortality ascribed 
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to obesity in the U.K national data (Haslam and James, 2005). However this was not 
consistent in all regions of England (Marie Duncan et al 2010). It is not yet clear if this 
represents a geographical variation in the contribution of obesity to mortality, in 
certification practice, or both. It seems likely that this reflects the increase in the 
prevalence of obesity. However, other factors, such as increased clinical awareness of, 
and willingness to certify obesity may have played a role too. Approximately 300,000 
deaths in the USA are attributed to obesity (Allison et al 1999), where obesity is set to 
overtake smoking as the main preventable cause of premature death (Mokdad et al 
2004). A number of prospective studies in Caucasian and Asian populations have 
demonstrated an increase in mortality with a BMI >30, but not with a BMI within the 
range of 18.5 and 25 (Stevens et al 2003). Further, a recent systematic review of over 
890000 participants found that each 5 point increase in body mass index (kg/m
2
) over 
25 was associated with a 30% increase in overall mortality (Hitlock et al 2009). 
 
1.6  Co-morbidities associated with obesity 
Obesity is a medical disorder that leads to co-morbidities (Haslam and James, 2005). 
This association is profoundly important for the affected individuals, but the associated 
morbidity is also economically damaging for society (Haslam and James, 2005). At 
least 18 co-morbid conditions are known to be associated with obesity (asthma, 
coronary artery disease, diabetes mellitus, dyslipidemia, gallstones, gastroesophageal 
reflux, hypertension, nonalcoholic steatohepatitis or nonalcoholic fatty liver disease, 
sleep apnea, and urinary incontinence, breast cancer, congestive heart failure, 
lymphoedema, major depression, osteoarthritis, polycystic ovary syndrome, 
pseudotumor cerebri, and venous stasis or leg ulcers) (Cremieux  et al 2008). Further 
the risk of developing these co-morbidities is directly correlated to the degree of obesity 
(figure-4) (Leff and Heath 2009). 
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Relative risk 
Diseases associated with 
metabolic consequences 
(indirect association) 
Diseases associated with 
excess weight (direct 
association) 
Greatly increased risk (>3) Type 2 diabetes, 
gallbladder disease, 
hypertension, 
dyslipidaemia, insulin 
resistance, non-alcoholic 
fatty liver 
Sleep apnoea, 
breathlessness, asthma, 
social isolation, depression, 
daytime sleepiness/fatigue 
Moderately increased risk (2-
3) 
Coronary heart disease, 
stroke, gout 
Osteoarthritis, respiratory 
disease, hernia, 
psychological problems 
Slight increased risk (1-2) Cancer, impaired fertility, 
polycystic ovaries, skin 
complications, cataract 
Varicose veins, 
musculoskeletal problems, 
backache, stress 
incontinence, 
oedema/cellulitis 
 
Figure-3; Co-morbidities associated with obesity. Data adapted from guidance from the 
National Institute for Health and Clinical Excellence (Leff and Heath 2009) 
 
 
Figure-4; Proportion of people with a major co-morbidity, by degree of obesity (Leff and 
Heath 2009) 
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1.7 Type-2 diabetes mellitus 
A dramatic rise in the incidence of T2DM has paralleled the rise in obesity. Diabetes 
mellitus is a metabolic disease characterized by insufficient insulin and/or resistance to 
the actions of insulin in the target tissues, resulting in chronic hyperglycaemia. A 
diagnosis of type-2 diabetes mellitus (T2DM) is made from either fasting blood glucose 
of greater than or equal to 7mmol/L or a two hour plasma glucose above 11.1 mmol/ L 
during an oral glucose tolerance test. More recently a haemoglobin A1c above 6.5% 
has also been utilized to diagnose diabetes. The elevated glucose leads to excessive 
glycation of molecules, β-cell damage, cardiovascular dysfunction, blindness, nerve 
demyelination and nephropathy (Alberti and Zimmet, 1998). T1DM is thought to result, 
for the most part, from autoimmune destruction of insulin-producing pancreatic β- cells 
resulting in an absolute insulin deficiency and is generally not associated with obesity. 
The failure to respond normally to insulin is called “insulin resistance”. This coupled 
with the inability to produce enough insulin to overcome this resistant state leads to 
T2DM (Lazar 2005). However, a number of other causes including genetic defects in β-
cell development, β-cell function, and dysfunctional insulin action at target sites, 
infection, drug-induced and gestational diabetes have also been identified. The majority 
of T2DM is associated with obesity resulting in a concurrent global T2DM pandemic 
(WHO, 2008). It is estimated that the prevalence of T2DM will rise from 171 million in 
2000 to over 350 million by 2030 globally. It is also estimated that diabetes related 
deaths will rise by more than 50% worldwide in the next decade (WHO, 2008). 
1.8  Obesity and T2DM 
The prevalence of T2DM in obese population is 5-10 times that of the normal 
population (reviewed by Diamond J 2003). The current epidemics of these two 
conditions are seemingly related (Mokdad et al 2003). Conventional wisdom links 
T2DM to obesity by virtue of the insulin resistance that arises from an excess of body 
fat (reviewed by Diamond J 2003, Kahn S E et al 2006, and O’Rahilly S 2009). Adipose 
tissue is now recognized as an endocrine organ that communicates with the brain and 
peripheral tissues through hormones to regulate appetite and metabolism (Kershaw 
and Flier, 2004). Obesity is associated with biochemical resistance to both insulin and 
leptin (Porte Jr. 2001). The brain is known to utilize input from insulin, leptin, and 
nutrient-related signals to regulate body fat content and hepatic insulin sensitivity. It is 
thought that impaired neuronal signaling by these afferent signals causes hyperphagia, 
weight gain, and hepatic insulin resistance (reviewed by Schwartz and Porte Jr.  2005). 
This led to a model based on brain insulin resistance (reviewed by Schwartz and Porte 
Jr.  2005). The association of diet-induced obesity (DIO) with both higher serum
 
levels 
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of insulin and leptin and increased activation of inflammatory
 
signaling pathways raises 
the possibility that these two alterations
 
are causally linked. Disruption of inflammatory 
pathways in neurons protects against DIO
 
and insulin resistance (reviewed by Thaler 
and Schwartz, 2010). Inflammation, mitochondrial dysfunction and endoplasmic 
reticulum stress are three of the proposed theories to explain the aetiology of T2DM in 
the presence of obesity (O’Rahilly S 2009).  
 
1.9 Regulation of food intake and energy homeostasis 
 
Adequate food and water are a pre-requisite for an organism’s survival. Energy balance 
encompasses the exquisite matching of energy intake and energy expenditure to 
maintain homeostasis. Ingested nutrients must provide a supply of adequate fuel, 
essential to bodily functions including somatic maintenance, thermogenesis, metabolic 
processes, muscle action and reproduction. Constant supply of fuel to all body tissues 
is achieved through the maintenance of blood glucose concentrations. The homeostatic 
pathway is concerned with regulating an organism’s energy balance to maintain 
growth, repair, reproduction and somatic maintenance. Although energy intake is a 
highly regulated process excess energy can be stored as body fat for future use. The 
regulation of energy balance requires integration of information on acute nutrient status 
as well as body energy stores; a process that is achieved through signalling of 
circulating hormones and metabolites upon neural circuits. Furthermore, a host of 
environmental cues and genes influence all aspects of energy balance (Lenard and 
Berthoud, 2008). Galen hypothesized that stomach contractions regulated appetite. It 
was thought that the physical contents of the abdominal cavity determined appetite 
(Mayer and Thomas, 1967). This ‘peripheral control’ hypothesis was challenged by the 
theory of ‘central control’. The presence of centres within the brain that regulate feeding 
was proposed as an alternative (Anand BK and Brobeck JR 1951, Stellar, 1954). With 
further investigation and technological advances, the concept of brain regions involved 
in appetite regulation was replaced with the identification of discrete neuronal sub-
populations involved in feeding behaviour and bodyweight regulation (Schwartz et al 
2000). The procurement of food and food intake is regulated by a complex neuro-
endocrine network (Lenard NR and Berthoud HR 2008).  The neural network regulating 
food intake can be divided into homeostatic and non-homeostatic pathways (Gao Q 
and Horvath TL 2008). The non-homeostatic pathway is thought to mediate the 
rewarding aspects of food (Lenard NR and Berthoud HR 2008, Gao Q and Horvath TL 
2008). The two pathways are thought to interact to govern feeding behaviour (Morton 
GJ et al 2006).  More recently, a number of studies have begun to explore the 
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importance of non-hypothalamic and cortical regions in feeding behaviour (Berthoud, 
2007).  
 
Despite large daily fluctuations in food intake and energy expenditure, bodyweight 
remains relatively stable over time (Seeley RJ and Woods SC 2003). It is well 
documented that a reduction in bodyweight results in increased appetite and food 
intake, whilst an increase in bodyweight through experimental manipulation (with 
resultant fat deposition) can proportionally reduce appetite. Interestingly, bodyweight 
and adiposity resolve to baseline levels when ad libitum food intake is resumed (Bray, 
1991; Sims et al, 1973; Weigle, 1994). Maintenance of bodyweight requires adjustment 
of both energy intake and energy expenditure. Energy expenditure comprises 
thermogenesis, resting metabolic rate and physical activity, and compensatory changes 
in these modalities occur in situations of both energy deficit and energy excess (Leibel 
et al, 1995). From an evolutionary standpoint, this control mechanism is likely to exist 
not only to maintain energy stores to avoid starvation, but also prevent excessive fat 
accumulation to avoid predation (Mercer and Speakman, 2001). Several hypotheses 
have been presented to account for the maintenance of bodyweight. The most widely 
accepted of these is the ‘lipostatic’ theory. This proposes that humoral signals released 
by body fat stores are responsible for conveying information regarding the quantity of 
body fat to the CNS in order to modulate appetite, maintain and/or restore bodyweight 
(Kennedy, 1953). The lipostatic theory suggests that changes in bodyweight alter 
secretion of humoral factors signaling an alteration in energy balance. An afferent 
humoral factor would need to fulfill a set of criteria. They must firstly be in proportion to 
body fat. Secondly, signal transduction mechanisms mediating the effect should be 
located within CNS regions demonstrated to be involved in bodyweight regulation. 
Finally, administration of the signal, either into the circulation or directly into the brain 
should alter both food intake and bodyweight (McMinn et al 2000). Insulin and leptin 
have both been classified as lipostatic signals that accurately reflect and regulate 
bodyweight status. 
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Figure-5; The control of energy balance is a complex process requiring bidirectional 
integration of information regarding nutrient status and body fat stores with homeostatic 
circuits in the central nervous system. A homeostatic regulator is thought to modulate 
energy intake and expenditure. Environment and genetics further influence the control 
of homeostatic processes. (WAT = white adipose tissue) (Adapted from Lenard and 
Berthoud, 2008)  
 
1.10 The homeostatic pathway 
 
1.10.1 Hypothalamus 
 
Early case reports of obesity in patients with pituitary adenoma linked the 
hypothalamus to obesity (Frohlich A 1901).  Animal model studies initially utilized 
systematic anatomical lesions in the hypothalamus, to identify areas that influence food 
intake (Anand BK and Brobeck JR 1951). More recent in vivo studies have led to the 
identification of specific populations of neurons in the hypothalamus that govern food 
intake (Morton GJ et al 2006, Lenard NR and Berthoud HR 2008, Gao Q and Horvath 
TL 2008). The hypothalamus acts as a primary integrator of nutritional information, with 
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populations of neurons directly and differentially sensitive to leptin, insulin, ghrelin, 
PYY3-36 and circulating metabolites including glucose, fatty acids, and amino acids 
(Morton GJ et al 2006, Lenard NR and Berthoud HR 2008, Gao Q and Horvath TL 
2008). It contains structures involved in integrating both satiety and hunger pathways 
including the arcuate nucleus (ARC), ventromedial nucleus (VMN) and lateral 
hypothalamic area (LHA) (Schwartz et al 2000, Stellar 1954). It is the primary centre for 
regulation of food intake and energy metabolism. In addition, the hypothalamus 
receives afferent information from the brainstem. Information regarding nutrient status 
and energy stores is relayed via nervous afferents or hormones to regions involved in 
homeostatic control of feeding and also project to areas of the brain that integrate the 
rewarding features of food intake- reward and limbic pathways (Lenard NR and 
Berthoud HR 2008)  
 
The ARC is a circumventricular collection of neuronal cell bodies, superior to the base 
of the third ventricle in the brain, possessing a modified blood brain barrier, allowing 
access to circulating nutrients as well as peptides and hormones (Brightman and 
Broadwell 1976). First order neurons in the ARC are thought to respond to humoral 
signals which project to second order neurons in the paraventricular nucleus (PVN), 
VMN, LHA and dorsomedial nucleus (DMN) (Elmquist et al 1999). Electrical stimulation 
of the VMN suppresses food intake whilst ablation induces profound hyperphagia and 
the subsequent development of obesity. Conversely, stimulation or lesioning of the LHA 
induces the opposite responses (Stellar 1954).  
 
The neurons in the lateral hypothalamus responsible for food intake seem to be 
constrained by tonic inhibition that can be relieved by activation of the reward pathway, 
and thought to promote motor programs to stimulate feeding behaviour
 
(Kelley et al 
2005). Lateral hypothalamic area neurons may also attenuate the response to satiety 
signals, increasing the amount of food consumed during a meal. These considerations 
support the view that the lateral hypothalamic area may act as an integrative neural site 
for homeostatic, satiety and reward-related neural input, and collectively activates 
feeding behaviour (Morton G et al 2006). 
 
1.10.2 Brainstem 
 
Neural afferents from the GI tract and abdominal viscera are relayed to the CNS via the 
vagus nerve which terminates in the nucleus tractus solitarius (NTS) at the base of the 
brainstem (Grill 2006). The brainstem has been proposed to integrate and relay this 
information to the hypothalamus. Similar to the ARC nucleus, the NTS has an 
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incomplete blood brain barrier at the area postrema, allowing access for circulating 
factors. Interestingly, the NTS has well-established reciprocal connections with several 
other regions in the brain involved in energy balance, suggesting a role for the 
brainstem as a primary integration centre of meal-related sensory input (Berthoud, 
2002). 
 
1.11 Non-homeostatic regulation of food intake- the reward pathway 
 
The hypothalamus and brainstem are crucial to energy homeostasis. The strongest 
evolutionary pressure driving the development of this system was the deficiency of food 
for survival, resulting in the development of robust mechanisms to defend against the 
lower limits of adiposity (Zheng and Berthoud, 2008). Food intake is not just driven by 
homeostatic mechanisms but also by the rewarding value of food in the current calorie 
abundant environment (Berridge KC 1996). Several authors have recently questioned if 
the homeostatic pathway plays a primary role in our current calorie abundant 
environment (Volkow ND and Wise RA 2005, Palmiter RD 2007, Lenard NR and 
Berthoud HR 2008). Hence brain regions involved in the processing of the 
psychological features of appetite, such as liking (pleasure), wanting (motivational 
value-cognitive incentives/ explicit desire), hedonic value (objective affective reactions) 
and reward, as well as the memories of these features, have been under investigation 
recently (Berthoud, 2003, Berridge KC 2009). Neuronal tracing studies demonstrate the 
hypothalamus to be well connected to many other regions in the brain, resulting in a 
complex circuit that allows adaptation and coordination in an unpredictable 
environment (Berthoud, 2002). The lateral hypothalamus is thought to play an 
integrative role in feeding behaviour. The lateral hypothalamus is known to potently 
stimulate food intake, and is inter-connected to homeostatic and reward pathways, 
leading some to suggest that it may play a mediators role in promoting consumption of 
palatable food (Kelley et al 2005).  
 
The ventral tegmental area (VTA) and its projection to the nucleus accumbens (NAc), 
which forms part of the reward pathway have been known to mediate the rewarding 
effects of drug addiction (Volkow ND and Wise RA 2005). This pathway is associated 
with motivation and hedonic behaviour, and recently has also been shown to mediate 
the rewarding aspects of food (Volkow ND and Wise RA 2005, Lenard NR and 
Berthoud HR 2008, Lutter M and Nestler EJ 2009). A parallel between obesity and drug 
addiction has been drawn, in that both are ingestion habits pursued to catastrophic 
ends, leading some to claim that the reward pathway may play a part in the aetiology of 
obesity (Volkow ND and Wise RA 2005, Stoeckel LE et al 2008, Lutter M and  Nestler 
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EJ 2009). Preliminary evidence for this comes from functional magnetic resonance 
imaging studies where a differential activation pattern in normal weight and obese 
individuals is seen. Obese women presented with images of high-calorie food showed 
increased activation in brain regions that mediate reward and emotion (Stoeckel LE et 
al 2008). Also imaging studies have begun to demonstrate that circulating appetite 
signals can modulate brain activity in the reward pathway (Malik et al 2008, Batterham 
et al 2007). The “priming” effect of a small amount of palatable food on binge eating 
parallels the ‘priming’ effect of drugs in addiction behaviour,  where even a small dose 
tends to elicit a strong ‘craving’ and compulsion for further use, hence some argue that 
food can be thought of as a drug that can lead to dependence (Davis et al 2004). 
 
The concept that reward perception is subject to homeostatic regulation derives from 
evidence that food deprivation strongly augments the reward value of addictive drugs 
including heroin, amphetamine and cocaine (Carroll et al 1979 and Stuber et al 2002). 
One mechanism to explain this effect proposes that metabolic signals leptin and insulin 
tonically inhibit brain reward circuitry and that, by lowering circulating levels of these 
hormones, energy restriction increases the sensitivity of reward circuits
 
(Fulton et al 
2000 and Figlewicz et al 2004). Consistent with this hypothesis, centrally administered 
insulin or leptin diminish food reward (Figlewicz et al 2004). This has led to some 
authors proposing that energy restriction may decrease inhibitory neuronal input and in-
turn increase the animal’s response to rewarding stimuli as an adaptive mechanism 
motivating animals threatened by caloric insufficiency to seek and obtain palatable 
foods (Figlewicz et al 2003).  
 
1.12 Reward pathway and feeding behaviour 
 
It is clear that not everyone exposed to a calorie abundant environment over eats 
(Engelmann JB 2006). The role of the reward pathway in feeding behaviour is the 
subject of much investigation at present (Lowe and Levine 2005). Food consumption is 
known to stimulate the reward pathway and lead to motivated behaviour in animals and 
humans (Hoebel et al 1989, Berridge 1996, Schultz 1998, Bassareo and Di Chiara 
1999, Volkow et al 2002, Dawe S and Loxton N 2004). Further, high calorie foods are 
more rewarding (Cummings DE and Foster KE 2003). The current ease of access to 
palatable energy-dense food is considered an environmental factor predisposing to 
obesity (Volkow and Wise 2005). Palatable foods are able to override homeostatic 
signals, and stimulate brain reward systems independent of their caloric value 
(reviewed by Kenny PJ 2011). 
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The effects of palatable food consumption on brain reward systems have been directly 
assessed in laboratory animals. Animals given prolonged access to palatable food went 
on to gain significant amounts of weight (reviewed by Kenny PJ 2011). Further, studies 
on animals exposed to an environment with an abundance of food, point to feeding 
behaviour being driven by the rewarding value of food and not energy homeostasis 
(Berridge 1996 and Berridge 2004). A diet-induced reward deficit is noted in these rats, 
and may reflect an adaptive response to overstimulation by palatable food (reviewed by 
Kenny PJ 2011). Animal studies also suggest that the reward pathway in the brain can 
be dysregulated by starvation and intermittent access to palatable food (Carr 2007).  
 
On the one hand some propose a theory based on a lack of neuro-transmission in the 
reward pathway, known as the Reward Deficiency Syndrome (RDS) to explain a range 
of addictions to alcohol, cocaine, and pathological gambling (Bowirrat and Oscar-
Berman 2005). Obesity and drug addiction are thus thought to be reward deficiency 
syndromes (Wang et al 2001, 2002, and 2003). It is proposed that individual’s 
compensate for this reward deficiency by frequent food consumption (Blum et al 2000). 
It is thought that the reward pathway does not differentiate between rewarding 
experiences provoked by natural re-inforcers like food, illicit drugs like cocaine, or 
behaviours like gambling (Kelley et al 2005).  A high rate of co-morbidity is observed for 
drug addiction and obesity (Wolfe and Maisto 2000). However, eating is not known to 
produce the neuro-adaptive effects known to be produced by drugs of abuse, that lead 
to withdrawal effects, central to drug addiction (Rogers and Smit, 2000). Adiposity 
(leptin) does correlate to feeding behaviour in obese and underweight individuals 
(Adami et al 2002, Prittwitz et al 1997). The development of leptin resistance in the 
reward pathway may play a role in the dysregulation of feeding behaviour and 
compulsive overeating in obesity (reviewed by Kenny PJ 2011).  
 
The converse of RDS with enhanced neuro-transmission in the reward pathway 
promoting appetitive response to primary re-inforcers such as food has also been 
linked to obesity (Volkow e al. 1999, Cohen et al 2005, Davis et al 2007). An Individual 
with high reward sensitivity is thought to have a reactive reward pathway that 
encourages hyperphagia (Pickering and Gray 2001). It is thought that an individual’s 
personality and personality trait may predispose him/ her to overeating and obesity 
(Ryden et al 2003, Dawe S et al 2004, Davis C et al 2004 and Beaver JD et al 2006). 
An individual’s reward drive
 
does predict relative body weight in normal and overweight 
populations (Bulik et al 2003, Davis et al 2004, Dawe and Loxton 2004, Franken and 
Muris 2005). Further, behavioural studies have shown a link between reward 
sensitivity, feeding behavior, body weight and binge eating through greater sensitivity 
29 
 
towards food-related cues (Franken and Muris 2005, Dawe and Loxton 2001, S Dawe 
& N J Loxton 2004, D.J. Mela 2006). Individuals with higher reward sensitivity were 
shown to display enhanced activity in brain regions implicated in food reward in 
response to palatable foods (Beaver et al 2006). This study linked personality trait to 
over eating (Beaver JD et al 2006), and could give us an insight into neurobiological 
factors that contribute to over eating and obesity (Beaver JD et al 2006). Other recent 
functional imaging studies (Rothemund et al 2007 and Stoeckel et al 2008) did also 
show that food cues are related to hedonic responses in obese individuals. Other 
functional imaging studies have shown that monetary reward (Elliott et al 2000, Ernst et 
al 2004 and Matthews et al 2004) is also mediated through the reward pathway.  
 
 
 
 
Figure-6; Complex neural circuitry governs many aspects of energy balance. 
Information from the periphery is conveyed by circulating hormones and vagal afferents 
to the caudal brainstem, hypothalamus and cortico-limbic brain regions. Cortico-limbic 
regions integrate meal-related sensory input and nutrient information with internal 
emotional factors. Together, these circuits regulate ingestive behaviour and 
bodyweight. (Adapted from Gomez-Pinilla, 2008) 
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The addiction model may result in social stigmatization from the labeling of obese 
individuals as food addicts. This may lead to adverse outcomes as obese individuals 
already feel subjected to societal stigmas and bias (Boroni MAP et al 2012). This could 
lead to a sense of lack of control or choice over their behavior leading to a disease 
label and hampering change. The suggestion of addictive foods also shifts the focus 
away from promoting healthy behaviour and onto particular types of food (Boroni MAP 
et al 2012).  
 
In studying the aetiology and treatment of obesity, it is important to remember the 
contribution of energy expenditure (Cizza G and Rother KI 2012). In humans this is 
determined by basal metabolic rate, diet-induced thermogenesis, physical activity and 
non-exercise activity thermogenesis (Cizza G and Rother KI 2012). The latter is an 
important determinant of total energy expenditure and is thought to be under the control 
of neuro-peptides including leptin, and account for 100 to 700 kcal/day, this in part 
genetically determined (Cizza G and Rother KI 2012). The role of sleep in obesity has 
also been studied, with chronic sleep deprivation linked to obesity. Acute sleep 
deprivation increased Cortisol, decreased GH and leptin and increased ghrelin (Cizza 
G and Rother KI 2012) leading to appetite and insulin resistance (Cizza G and Rother 
KI 2012).  
 
The role of external organisms in human physiology has also taken on new 
perspectives with evidence confirming that microbes can influence host physiology, and 
the role of gut microbiota in the development of obesity has received much attention 
recently (Boroni MAP et al 2012). Obese and lean subjects have different microbiota 
composition profile, with those of obese subjects having capacity to harvest more 
energy from the diet through lipogenic pathways (Boroni MAP et al 2012). Further, 
microorganisms are also able to influence lipoprotein lipase activity, and triglyceride 
content of adipose tissue. In turn the dietary composition (fatty acids, carbohydrates, 
micronutrients, prebiotics, and probiotics) can modulate gut microbiota (Boroni MAP et 
al 2012). Obese twins had reduced bacterial diversity, and altered metabolic pathways. 
A study to test fecal transplantation as a viable treatment option for obesity is currently 
under way (Boroni MAP et al 2012).  
 
Further, recent reviews have challenged the gut hormone mediated reversal of T2DM 
(Knop FK and Taylor R 2013). An acute negative calorie balance has been proposed 
as the only pre-requisite for reversal of type T2DM (Knop FK and Taylor R 2013). 
Taylor and colleagues argue that plasma glucose is normalised within days of a low 
calorie diet (Knop FK and Taylor R 2013). In our study the pre-operative mixed meal 
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study and the gut hormone changes observed does not support this hypothesis, as 
patients were still glucose intolerant and hyper-insulinaemic despite being on a liver 
reducing diet. Critics of gut hormone mediated changes, whilst accepting the 
contribution of incretins, note that the proportional effect of these changes is yet to be 
quantified. It is also difficult to rule out the role of energy restriction in most studies. The 
role of GLP-1 mediated improvement in β-cell function following bariatric surgery is also 
hotly debated as this is thought to be responsible for the delayed improvement in 
glucose homeostasis (Knop FK and Taylor R 2013). The difficulty in teasing out the 
mechanisms leading to the improvement in liver glucose handling either through 
reduction in liver fat content, or gut hormones will need to be addressed. It also 
remains to be seen if incretins or pancreatic fat content mediates the improved long 
term changes in glucose homeostasis (Knop FK and Taylor R 2013).  
  
1.13 Pathogenesis of obesity 
 
Modern molecular genetics has been deployed to obtain mechanistic insights into the 
pathophysiology of obesity (O’Rahilly 2009).
 
Two cardinal
 
features of obesity are 
energy intake in excess of requirement
 
and the biological defence of an elevated level 
of body fat
 
mass (reviewed by Thaler and Schwartz 2010). The search for an 
aetiological factor for the current obesity pandemic has led some authors to point to an 
evolutionary advantage. They propose that prolonged periods of famine were common 
in early human hunter-gatherer communities. Therefore genes that favour economical 
use of energy will be selected for, as they offer a survival advantage. These genes 
involved in economical use and storage of energy are called “thrifty” genes (Zimmet 
and Thomas, 2003). Thrifty genes would promote an increase in adipose tissue as an 
efficient storage of energy resource. The current calorie abundant environment and 
sedentary lifestyle is thought to lead to mal-adaptation leading to the twin epidemics of 
obesity and diabetes (Zimmet and Thomas 2003) (reviewed by Lazar et al 2005). 
Proponents of the thrifty gene hypothesis point out that a low BMI is known to be 
associated with amenorrhoea. Leptin replacement reverses this amenorrhea in leptin-
deficient females with low bodyweight (Welt et al 2004). This provides the mechanistic 
explanation for the link between body fat and reproductive capacity seen in 
epidemiological studies (Frisch and McArthur 1974). This promotes survival of 
nutritionally fit individuals (reviewed by Lazar et al 2005). This contrasts with the “thrifty 
phenotype” hypothesis (Neel 1962). He noted that fetal malnutrition results in tissue 
adaptations favouring efficient use and storage of nutrients in-utero. This is thought to 
predispose to obesity and T2DM later in life in the setting of adequate nutrition (Hales 
and Barker 1992). They proposed that epigenetic memory from the prenatal 
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environment as a putative mechanism. This epigenetic regulation is thought to be 
mediated by energy dependent modification to enzymes (Jenuwein and Allis 2001, 
Blander and Guarente 2004). In the thrifty phenotype model, selective pressures for 
genes that protect from early malnutrition then promote obesity and diabetes under 
modern conditions by preserving glucose for use by the brain during these periods. 
This is also thought to lead to insulin resistance in peripheral tissues (reviewed by 
Lazar et al 2005).  
 
It is proposed that genetic polymorphisms affect the central sensing and control of 
energy balance through an alteration in appetite and satiety to mediate the adverse 
outcome (reviewed by O’Rahilly 2009). The inheritance of several polymorphisms with 
small differences in expression can make populations more or less susceptible to 
obesity and diabetes (Diamond 2003). Leptin is thought to be one such candidate 
gene. Rodents and humans with one functional copy of the leptin gene have increased 
body fat (Farooqi et al 2001). Genome-wide association studies are beginning to 
identify the common genetic variation that underpins difference in adiposity across the 
normal population. FTO were the first to emerge as unequivocally associated with 
human obesity (O’Rahilly 2009). FTO is highly expressed in hypothalamus, where its 
expression is regulated by feeding and fasting O’Rahilly 2009). Recently four reported 
genome-wide linkage studies have identified several  loci that show positive evidence 
for linkage to the pro-opiomelanocortin (POMC) gene in which a complete loss-of-
function causes monogenic obesity in mice and humans  (reviewed by Barsh GS et al 
2000). The pro-opiomelanorcotin neurons in the hypothalamus are known play a 
significant role in appetite regulation. It is proposed that the genetic determinants of 
inter-individual variation predisposing to obesity are likely to be multiple with most 
single variants producing only a moderate effect (reviewed by Barsh GS et al 2000). 
Further, rare forms of monogenic obesity stem from genetic
 
defects in leptin or 
melanocortin signalling pathways (Farooqi and O'Rahilly 2006). Mutations in the 
melanocortin-4 receptor account for up to 4% of cases of severe obesity. Common 
monogenic forms of human obesity seem to increase the 'set point' at which body 
adipose stores stabilize in an individual (reviewed by O’Rahilly 2009). Some argue that 
susceptibility to obesity is determined largely by genetic factors, but the environment 
determines phenotypic expression (Barsh GS et al 2000). Animal studies indicate 
difference in adiposity among inbred strains can be magnified by a high-fat diet 
(reviewed by Barsh GS et al 2000). This has led to calls for public health efforts to 
prevent obesity be focused on recognition and counseling of susceptible individuals 
(Barsh GS et al 2000). The determinants of BMI do vary between ethnic groups 
(reviewed by Barsh GS et al 2000). 
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High fat diet is one such environmental factor. Animal studies identify hypothalamic 
inflammation as a reversible mediator of high fat diet (HFD) induced weight gain 
(Thaler JP and Schwartz MW 2010). Inflammatory changes are
 
detectable in the brain 
of HFD-fed animals (Zhang X et al 2005), and manifested to an even greater degree in 
animals lacking leptin signaling (Zhang X et al 2008). This has led some authors to 
propose a causal role for hypothalamic inflammation
 
in HFD-induced obesity. Neuron-
specific disruption of inflammatory pathways protects against DIO,
 
hypothalamic leptin 
resistance, and systemic insulin resistance (Zhang X et al 2008). Further, over 
expression of a dominant-negative inflammatory marker
 
in hypothalamic neurons 
reduce food intake and
 
weight gain during HF feeding, and neuronal expression of a 
constitutively active
 
inflammatory marker increases food intake (reviewed by Thaler and 
Schwartz 2010), suggesting that hypothalamic
 
inflammation is both necessary and 
sufficient for weight gain during HF feeding (reviewed by Thaler and Schwartz 2010). 
Interventions
 
that limit hypothalamic inflammatory signaling can prevent obesity
 
from 
developing, implicating the latter as cause rather than
 
just a consequence of obesity 
(reviewed by Thaler and Schwartz 2010). In the hypothalamus inflammatory signaling 
leads to insulin
 
and leptin resistance.  
 
HF feeding also induces inflammatory signaling in peripheral tissues, resulting in 
peripheral insulin resistance (Thaler JP and Schwartz MW 2010). A low-grade chronic 
inflammation is known to accompany excess visceral adiposity. This is accompanied by 
increased circulating levels of inflammatory cytokines (Thaler JP and Schwartz MW 
2010). Leptin and insulin signal through common downstream pathways including the 
insulin receptor substrate protein (IRS), phosphatidylinositol-3 (PI3) kinase and 
(mitogen activated protein kinase) MAPK pathways. It is thought that inflammatory 
pathways interfere with these signal transduction mechanisms and lead to central and 
peripheral resistance to leptin and insulin (Thaler JP and Schwartz MW 2010). Other 
mechanisms such as up-regulation of suppressor cytokine signaling, and the unfolded 
protein response may also contribute to high fat diet induced hypothalamic 
inflammation and leptin/ insulin resistance  (Thaler JP and Schwartz MW 2010). It is not 
yet clear if hypothalamic inflammation results from consumption of HFD irrespective of 
dietary composition (Thaler JP and Schwartz MW 2010).  
1.14 Metabolic signals modulate neural pathways 
The central pathways rely on metabolic signals from the periphery to assay an 
organism’s energy stores. These metabolic signals can be divided into, those that relay 
information on long term energy stores in adipocytes (leptin and insulin) and those that 
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relay information on short term energy gains from food intake (ghrelin, insulin, PYY, 
GLP-1, amylin) (Morton GJ et al 2006, Murphy KG and Bloom SR 2006). A number of 
hormones released from the GI tract with receptors in areas of the brain characterised 
for their involvement in appetite and bodyweight regulation have been investigated for 
their roles in energy balance (Chaudhri et al 2006). These GI peripheral signals 
relaying information regarding nutrient status also appear to be essential for appetite 
regulation (Murphy KG and Bloom SR 2006). Gut hormones are sensitive to ingested 
nutrients. Hunger and satiety and therefore energy intake is partly mediated by 
changes in circulating gut hormone levels (Murphy KG and Bloom SR 2006). Ghrelin, 
PYY, amylin, GLP-1 act on homeostatic pathways to maintain energy homeostasis 
(Murphy KG and Bloom SR 2006). Leptin, insulin and ghrelin are known to act on both 
the hypothalamic homeostatic centres and the dopamine reward pathway. They 
stimulate (ghrelin) or inhibit (leptin and insulin) dopaminergic signalling, and alter the 
subjective reward value attached to food (Palmiter RD 2007). Several areas of the 
gastrointestinal tract have also been implicated in relaying these signals to the brain. 
Nervous afferents arising from stomach mechanoreceptors and chemoreceptors are 
transmitted via vagal afferent nerves to the hindbrain where visceral input is integrated. 
In addition, satiety is thought to be dependent upon nutrient passage into the small 
intestine (Sepple and Read, 1989).  
1.14.1.1 Leptin 
The cloning of leptin and the characterization of its molecular pathways in the 
hypothalamus has led to the elucidation of the mechanisms that govern energy 
homeostasis (Schwartz et al 2000, Morton et al 2006). A set of experiments in 
spontaneously occurring strains of obese (ob/ob) and diabetic (db/db) mice 
demonstrated the existence of a humoral factor regulating food intake. The coupling of 
circulation between normal and obese ob/ob mice, led to a reduction in food intake and 
bodyweight in the ob/ob mice. The authors suggested a deficiency in a humoral 
lipostatic factor in ob/ob mice (Coleman, 1973). A 167 amino acid polypeptide 
produced primarily by adipocytes in proportion to body fat mass is incorrectly 
synthesized in ob/ob mice (Zhang et al 1994). The obesity displayed in ob/ob mice can 
be reversed with exogenous leptin treatment (Halaas et al 1995). However studies in 
db/db mice shown them to be leptin unresponsive. The db/db gene was characterized 
as the leptin receptor (Chen et al 1996). Leptin serves as a circulating
 
signal of energy 
stores by providing feedback inhibition
 
to hypothalamic orexigenic pathways (reviewed 
by Thaler and Schwartz 2010). Circulating leptin levels correlate strongly with adiposity 
in both rodents and humans (Maffei et al 1995). Adipose tissue is now recognized to be 
an endocrine organ that communicates with the brain and peripheral tissues by 
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secreting hormones regulating appetite and metabolism (Kershaw and Flier 2004). 
These functions appear to be modulated by the location of the adipose tissue (visceral 
versus subcutaneous) (Das et al 2004), by the size of the average adipocyte in the 
tissue (Weyer et al 2001), and by adipocyte metabolism of glucose (Abel et al 2001). 
Mutations in the leptin gene can also cause severe obesity in humans, and can be 
improved with recombinant leptin therapy in children and adults (Farooqi et al1999, 
Licinio et al 2004). Administration of leptin leads to a reduction in fasting induced 
hyperphagia in rodents (Ahima et al 1996). Chronic administration leads to reduced 
food intake and decreased adiposity (Halaas et al 1995). 
 
Obesity is
 
strongly associated with hyperleptinemia in both humans and
 
rodents placed 
on a high-fat diet (HFD) (reviewed by Thaler and Schwartz 2010). Once obesity is 
established leptin
 
is relatively ineffective in reducing food intake or body weight. It is 
postulated that DIO arises at least in part from a
 
failure of key hypothalamic 
neurocircuits to respond to leptin, and has been compared to the central and
 
peripheral 
insulin resistance that occurs in this setting (Myers et al 2008, Schenk et al 2008, 
Shoelson et al 2006). Mechanisms underlying obesity-induced insulin
 
resistance at the 
cellular level can also impair leptin signalling
 
(Myers et al 2008, Schenk et al 2008, 
Shoelson et al 2006, Hotamisligil GS 2006, and Wisse et al 2007). However, whether 
leptin resistance causes common
 
forms of obesity or is a consequence of excess 
weight
 
gain is still not known (reviewed by Thaler and Schwartz 2010). 
 
Furthermore, leptin levels reflect changes in energy balance independently of modest 
changes in body fat. A reduction in leptin is observed during short-term fasting and food 
restriction whilst an increase is seen following re-feeding and overfeeding (Kolaczynski 
et al 1996, Weigle et al 1997). Human studies have demonstrated dynamic changes in 
circulating leptin with changes in weight. Weight loss is associated with a significant 
decrease in leptin and the converse with weight gain (Rosenbaum et al 1996). These 
changes in leptin were not directly associated with modulation of energy expenditure 
(Rosenbaum et al 1996). Circulating leptin acts on the hypothalamic homeostatic 
centres that govern food intake, to regulate energy stores and maintain energy 
homeostasis (Morton GJ et al 2006). Leptin has a pivotal role in regulating negative 
feedback to the homeostatic centres, to maintain body energy stores (Morton GJ et al 
2006). Peripheral and centrally administered leptin led to intra-cellular second 
messengers in the reward pathway, altering neuronal firing rate and decreasing food in-
take, and long-term genetic knockdown of the leptin receptor in the reward pathway led 
to an increase in food intake, but does not alter body weight (Hommel et al 2006). 
Others have also shown leptin regulation of dopamine levels in the reward pathway 
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(Krugel et al 2003). Leptin can modulate behavioral responses to rewarding, novel food 
by its action on the reward pathway (Schultz and Dickinson, 2000 and Bassareo and Di 
Chiara, 1999). The metabolic sensing by the reward pathway may provide a 
mechanism for the well-described increase in drug sensitivity seen during states of food 
restriction and leptin’s ability to reverse this sensitivity (Carr et al 2002 and Shalev et al 
2001). It is thought that leptin signals directly to independent, inter-connected brain 
circuits encompassing the homeostatic and non-homeostatic centre’s, to generate an 
overall behavioral response (Hommel et al 2006). Leptin is thought to diminish the 
perception of food reward and palatability of food through direct and indirect actions 
(Morton GJ et al 2006).  Functional leptin receptors have been isolated in VTA 
dopamine neurons (Palmiter RD 2007, Figlewicz DP and Benoit SC 2009). Leptin is 
known to reduce firing rate in these neurons (Palmiter RD 2007). In addition to its acute 
inhibitory effect on midbrain dopamine systems, there is accumulating evidence that 
tonic leptin signaling may also be necessary to maintain appropriate levels of 
mesostriatal dopamine signalling (reviewed by Kenny PJ 2011). On the one hand, 
acute activation of leptin receptors in the VTA exerts an inhibitory effect on 
mesoaccumbens dopamine transmission and can inhibit feeding behavior. On the 
other, leptin signaling in the midbrain is necessary to maintain appropriate dopamine 
production and signal transmission (reviewed by Kenny PJ 2011). Furthermore, a 
recent functional magnetic resonance imaging (fMRI) study assessed the sensitivity of 
brain regions to exogenous leptin administration before and after weight loss in 
overweight individuals. It was demonstrated that following weight loss leptin 
administration reversed neural activity patterns in response to visual food cues in 
feeding-related brain regions including the brainstem, hypothalamus, as well as the 
parahipppocampal, inferior and middle frontal gyri (Rosenbaum et al 2008). Thus, it 
appears leptin influences both behavioural and passive responses to changes in 
energy stores; a decrease in body fat leads to a decrease in leptin resulting in an 
increase in food intake; conversely increased adiposity causes a rise in leptin which 
reduces food intake allowing maintenance of bodyweight. fMRI to assess neural activity 
in the reward pathway to visual food stimuli was noted to be higher in genetically leptin-
deficient adolescents, returning to normal levels with leptin administration. Further, in 
these leptin-deficient individuals whilst activity in the reward pathway correlate to 
ratings of liking in the fasted and fed state, the correlation was only noted in the fasted 
state after leptin treatment, and in normal individuals (Abizaid et al 2006). 
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1.14.1.2 Leptin Resistance 
 
The switch to a highly
 
palatable, energy-dense diet favours weight gain. DIO in both 
humans and rodent models is characterized by an increase in the defended
 
level of 
body fat stores (Levin and Keesey 1998, Rosenbaum et al 2002, Leibel 2008, reviewed 
by Thaler and Schwartz 2010). Obesity is
 
strongly associated with hyperleptinemia in 
both humans and
 
rodents placed on a high-fat diet (HFD) (reviewed by Thaler and 
Schwartz 2010). Acquired leptin resistance is implicated in the predisposition to DIO in 
rodent models (reviewed by Thaler JP and Schwartz MW 2010). However, the 
mechanisms responsible for the defence of an elevated adiposity are unclear. Leptin 
resistance seems to occur as a result of obesity, and reduced sensitivity may in turn 
contribute to the aetiology of obesity (Heymsfield et al 1999). However, whether leptin 
resistance causes common
 
forms of obesity or is a consequence of excess weight
 
gain 
is still not known (reviewed by Thaler and Schwartz 2010).  
 
A small proportion of obese humans have relative leptin deficiency. The vast majority of 
obese individuals are hyperleptinaemic (Considine et al 1996). Exogenous leptin 
administration does not affect food intake in rodents with diet induced obesity (DIO) 
(Van Heek et al 1997). Leptin infusion in obese humans has only moderate effects on 
bodyweight (Heymsfield et al 1999). However the anorexigenic effects of leptin are 
retained with central administration in obese rodents (Van Heek et al 1997), suggesting 
isolated peripheral leptin resistance in obesity. The mechanism underlying leptin 
resistance is not fully understood. It is thought that leptin transporter complexes that 
cross the blood brain barrier are saturated in obesity (Banks et al 1999). Once obesity 
is established leptin
 
is relatively ineffective in reducing food intake or body weight. It is 
postulated that DIO arises at least in part from a
 
failure of key hypothalamic 
neurocircuits to respond to leptin, and has been compared to the central and
 
peripheral 
insulin resistance that occurs in this setting (Myers et al 2008, Schenk et al 2008, 
Shoelson et al 2006). Mechanisms underlying obesity-induced insulin
 
resistance at the 
cellular level can also impair leptin signalling
 
(Myers et al 2008, Schenk et al 2008, 
Shoelson et al 2006, Hotamisligil GS 2006, and Wisse et al 2007). Methods to improve 
leptin sensitivity have been investigated. The co-administration of the pancreatic 
hormone amylin with leptin reduces food intake and bodyweight and induces leptin 
signalling pathways greater than either treatment alone (Roth et al 2008). The 
‘chemical chaperones’ 4-phenyl butyric acid and tauroursodeoxycholic acid, implicated 
in endoplasmic reticulum stress, can potentially act as leptin-sensitizing agents (Ozcan 
et al, 2009). Leptin did also show the propensity to extend the anorectic effects of the 
gut hormone PYY3-36 (Unniappan and Kieffer 2008). 
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1.14.2 Insulin 
Insulin is primarily produced within the β-cell of the islet of Langerhans as preproinsulin 
and subsequently cleaved by proteolytic enzymes to produce insulin. It has also been 
localised in the CNS (Schwartz et al 1992). The β-cell is able to sense elevated plasma 
glucose. Glucose enters the β-cell via glucose transporter-2 (GLUT2) leading to an 
increase in adenosine triphosphate, and an alteration in ATP/ADP ratio. This activates 
the ATP-dependant potassium channels (KATP channels) resulting in depolarization of 
the cell membrane and calcium entry into the cell. This leads to insulin vesicle 
exocytosis. Furthermore, amino acids, parasympathetic nerve stimulation and gut 
hormones can also stimulate insulin secretion from beta cells. Insulin is rapidly 
transported to the liver where it exerts its effects by binding to the insulin receptor to 
activate a cascade of signalling events which culminate in the phosphorylation and 
activation of glycogen synthase. This results in an increase in glycogen production and 
a lowering in plasma glucose. Plasma glucose is also influenced by insulin 
concomitantly inhibiting lipolysis, gluconeogenesis and activating protein synthesis. In 
the periphery, insulin also leads to an increase in the number of plasma membrane 
GLUT4 molecules (Pessin and Saltiel 2000). It has long been known that gut-derived 
factors can stimulate endocrine secretions from the islets of Langerhans following 
nutrient ingestion (Bayliss and Starling 1902). This endocrine effect is highlighted when 
oral glucose stimulated insulin secretion is compared to intravenous glucose infusion 
(Elrick et al 1964). This is termed the ‘incretin effect’. The incretin effect accounts for 
between 50 and 70 % of total insulin secretion following an oral glucose administration. 
Two major incretins have been characterized glucose-dependant insulinotropic 
polypeptide (GIP) and glucagon-like peptide-1 (GLP- 1) (Drucker 2006). 
 
Insulin was first implicated in the control of body weight in the 1970’s (reviewed by 
Figlewicz DP 2008). Plasma insulin is proportional to body fat content. The saturable 
relationship between CNS and plasma insulin is consistent with a receptor-mediated 
transport process (reviewed by Schwartz MW
 
et al 2000). Central insulin levels in the 
cerebrospinal fluid are decreased in obesity, therefore chronic peripheral hyper-
insulinaemia in obesity will lead to less adiposity signaling in the CNS (reviewed by 
Figlewicz DP 2008). It is also known that functional insulin receptors are expressed in 
the homeostatic and reward pathways including the hypothalamus, hippocampus and 
amygdala (reviewed by Figlewicz DP 2008). The central administration of leptin and 
insulin leads to a reduction in food intake and body weight (reviewed by Figlewicz DP 
2008). As with leptin, insulin serves as a humoral signal in a negative-feedback loop 
linking feeding behaviour to adiposity (reviewed by Figlewicz DP 2008). Insulin 
39 
 
mediates its central effects through the activation of key hypothalamic nuclei to regulate 
energy balance. Central insulin administration is able to modify behaviors that reflect 
acute and learned reward evaluation. High-fat diet can lead to impairment in centrally 
administered insulin’s ability to maintain body weight (reviewed by Figlewicz DP 2008). 
Further direct administration of insulin to the reward pathway is able to reverse feeding 
of palatable foods (reviewed by Figlewicz DP 2008). 
 
Some point to the difficulties in separating out the central effects of insulin and leptin 
(Michael W. Schwartz
 
et al 2000).  They point out that as insulin promotes both fat 
storage and leptin synthesis it is difficult to tease out their independent influences. 
Further, weight gain cannot occur when insulin deficiency is present, even if food is 
consumed in large amounts as this leads to loss of calories through renal excretion 
(Schwartz M W et al 2000). However, the fact that leptin deficiency causes severe 
obesity, with hyperphagia that persists despite high insulin levels has led some to 
argue that insulin does not play as important part as leptin (Schwartz
 
M W et al 2000). 
Also obesity is not induced by insulin deficiency. A recent study sought to clarify this 
issue by conducting a study in diabetic hyperphagia. This study selectively replenished 
leptin (but not insulin) to non-diabetic levels in an animal model of uncontrolled, insulin-
deficient diabetes. The finding that this intervention prevented diabetic hyperphagia has 
added further weight to the conclusion that leptin deficiency, but not insulin, is required 
for hyperphagia (Schwartz
 
M W et al 2000). Therefore current evidence points to leptin 
having a critical role in obesity. However both leptin and insulin participate in the CNS 
control of energy homeostasis (Schwartz MW et al 2000).  
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Figure 7; the central role of leptin and insulin in energy balance is displayed in this 
schematic diagram. Leptin and insulin are secreted in proportion to body fat stores. 
They act on the homeostatic (hypothalamus and brainstem) and reward pathways to 
modulate energy balance.   A reduction in adiposity leads to compensatory changes in 
anabolic and catabolic pathways. This in turn maintains adiposity. This diagram was 
reproduced from a recent publication by Schwartz and colleagues (Schwartz MW et al 
2000).  
1.14.3 Ghrelin 
Ghrelin is a 28 amino acid peptide formed by cleavage of precursor, pre-proghrelin. It is 
released from X/A-like cells of the gastric oxyntic glands. Lower levels of ghrelin are 
also expressed in the small intestine and hypothalamus (Kojima et al 1999). The 
biologically active acyl-ghrelin has post-translational modification on the third serine 
amino acid with a medium chain fatty acid molecule, typically octanoate (Kojima et al 
1999).  Gastric O-acyl transferase (GOAT) enzyme is responsible for this acylation 
(Yang et al 2008). Ghrelin is degraded by butyrylcholinesterase and lysophospholipase 
(De Vriese et al 2004). Acyl-ghrelin is extremely labile in the circulation and is readily 
degraded by endogenous non-specific enzymes including esterases (e.g. 
butyrylcholinesterase) and phospholipases (e.g. lysophospholipase 1) resulting in the 
production of des-acyl ghrelin, the likely inactive yet more abundant form (Hosoda et al 
2000). Ghrelin stimulates food intake, and is thought to be a putative meal initiator 
(Cummings et al 2001, Callahan HS et al 2004). It has been shown to stimulate short 
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term food intake in animal and human studies, and even in obese individuals 
(Cummings D E 2006). Ghrelin is released in a pulsatile manner. Fasting leads to an 
increase in plasma ghrelin levels, in anticipation of meals and then decline with feeding. 
Further, the timing of plasma ghrelin peaks can be altered by modifying eating habits 
(Drazen et al 2006).The diurnal variation in ghrelin secretion is related to meal times 
and sleep (Figure 8) (Shiiya T et al 2002). Plasma ghrelin levels decline in proportion to 
calorie ingestion` (Callahan HS et al 2004), and correlates to the inter-meal interval 
(Blom WA et al 2009), but is not altered by ingestion of water illustrating that gastric 
distension does not regulate the post-prandial decrease in circulating ghrelin (Tschop 
et al 2000). Plasma ghrelin levels peak immediately before meals and fall to a nadir 
about an hour after feeding (Callahan HS et al 2004) (Figure 8). Circulating plasma 
ghrelin reflects recent food intake, thus circulating ghrelin acts as a short term signal of 
energy stores or energy gains, to hypothalamic neurons that govern food intake 
(Callahan HS et al 2004, Palmiter RD 2007, Lenard NR and Berthoud HR 2008). The 
elevation in pre-prandial ghrelin concentrations strongly correlate with subjective 
hunger scores (Cummings et al 2004). 
 
The raised ghrelin levels seen during the first hours of sleep are thought to promote 
growth hormone secretion and contribute to the promotion of slow wave sleep (Dzaja et 
al 2004). Interestingly, lack of sleep has been associated with increased ghrelin, 
decreased leptin and a higher BMI (Taheri et al 2004). Only acyl-ghrelin binds to GHS-
R1a (growth hormone secretagogue receptor) and cross the blood–brain barrier (Banks 
et al 2002). GHS-R1a is present in many tissues (Hosoda et al 2006); further, the 
appetite-stimulating effects of ghrelin are thought to be mediated, in part by neurons 
within the arcuate nucleus of the hypothalamus (Nakazato et al 2001 and Tamura et al 
2002). Tamura and colleagues also demonstrated total abolition of ghrelin's effect on 
food intake by ablating the arcuate nucleus; however the brainstem and vagus nerve 
are also important in mediating ghrelin-induced food intake (Williams et al 2003 and le 
Roux et al 2005a). 
 
Ghrelin is the only gut hormone known to increase food intake, and weight-gain over a 
week (Tschop et al 2000).  Intravenous infusion of ghrelin increased calorie intake at a 
buffet meal by 28% in healthy volunteers (Wren et al 2001), Ghrelin secretion is 
dysregulated in obese individuals (Tschöp M et al 2001, Cummings DE et al 2002). 
Diet-induced weight loss leads to a compensatory rise in ghrelin (Tschöp M et al 2001, 
Cummings DE et al 2002). This rise in ghrelin is thought to contribute to the rebound 
weight gain by stimulating appetite (Shiiya T et al 2002, Cummings DE et al 2002). 
Conversely anorexic individuals have abnormally high ghrelin concentrations which 
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decline following weight gain (Otto et al 2001). High ghrelin level precedes the 
development of obesity in Prader-Willi syndrome (Cummings et al 2002a). 
Furthermore, genetic abnormalities in the ghrelin gene and its receptor have also been 
identified and are associated with both risk and protection from obesity respectively 
(Hinney et al 2002, Korbonits et al 2002, Ukkola et al 2002, and Wang et al 2004). 
Circulating plasma ghrelin concentration is negatively correlated with bodyweight in 
both rodents (Moesgaard et al 2004, Qi et al 2008) and humans (Cummings et al 
2002b, Haqq et al 2003, Shiiya et al 2002, Tschop et al 2001). Plasma ghrelin has 
been inversely correlated with BMI; obese individuals have low circulating ghrelin 
levels; they do not show the typical ghrelin spikes throughout the day coincident with 
meal times and ghrelin levels do not fall rapidly in response to a meal (Shiiya et al 
2002, le Roux et al 2005b), suggesting a role for ghrelin in the long-term regulation of 
body weight (Tschop et al 2001). The lower ghrelin in obesity was thought to suggest 
greater sensitivity, therefore despite low endogenous levels, blocking its activity could 
still lead to an anorectic effect. The reduction in 24-hour ghrelin levels concomitant with 
a profound reduction in hunger after bariatric by-pass surgery is supportive of this 
(Cummings et al 2002 and le Roux et al 2007), and the converse seen after diet-
induced weight-loss is thought to be responsible for the increased appetite that 
promotes weight regain (Cummings et al 2002). Blocking ghrelin-induced food intake in 
individuals on a diet may help to sustain weight-loss. 
 l surges, Cummings et al, 2001) Pre-meal surges, Cummings 
et al, 2001 
 
 
Figure-8, Temporal profile of ghrelin through the day (Cummings D E et al 2001). 
Circulating levels of ghrelin peak prior to a meal and reach a nadir within an hour.  
 
Ghrelin’s influence on appetite is thought to be mediated through the bloodstream and 
not through the vagal afferents, after a careful analysis of results from rats with 
selective vagal de-afferentation (Arnold et al 2006, Lenard and Berthoud 2008). The 
breakfast Lunch Dinner 
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majority of studies suggest that ghrelin regulates appetite via central mechanisms 
(Nakazato et al 2001). Only the acylated form is able to cross the blood brain barrier 
and bind to the specific ghrelin receptor, GHSR1a (Banks et al 2002). Peripheral 
injection of ghrelin alters c-fos expression in the NTS (Lawrence et al 2002), and in the 
ARC. The chemical ablation of ARC neurons abolishes the orexigenic effects of 
peripheral ghrelin administration (Tamura et al 2002). A recent functional imaging study 
has also implicated ghrelin in brain activity in reward centres such as the OFC, ventral 
tegmental area (VTA), insular and amygdala (Malik et al 2008). In addition, ghrelin 
administration has been shown to reduce metabolic rate and increase fat deposition 
(Kawakawa et al 2001, Tschop et al 2000). Ghrelin activates dopamine neurons in the 
reward pathway and stimulates food intake when locally administered (Jerlhag et al 
2007 and Balleine 2007, Palmiter RD 2007), and ghrelin receptor blockade in the 
reward pathway blunted feeding following fasting (Jerlhag et al 2007), suggesting that 
the orexigenic actions of ghrelin are at least in part mediated by the dopaminergic 
reward pathway. Intravenous ghrelin administration increased neural response to 
images of food in the above areas (Malik et al 2008). Further, activity in these areas 
correlated with hunger. Thus ghrelin may promote food consumption by enhancing 
hedonic responses to food cues (Malik et al 2008). The exact interaction between these 
regions of the brain to bring about ghrelin-induced feeding is still unclear. An integrated 
complex neuro-humoral pathway is thought to mediate feeding behavior (Lenard and 
Berthoud 2008). The high ghrelin and low leptin seen in the fasting state will sensitize 
the dopaminergic reward pathway to “go for” the food represented and retrieved from 
memory. Once food is consumed, the drop in ghrelin and the rise in leptin, PYY3-36, 
GLP-1, and amylin mediate meal termination, and satiety maintained for a certain time 
beyond the end of nutrient absorption by PYY3-36 and GLP-1. The cycle repeats itself 
when glucose availability diminishes, until eventually, fat oxidation returns. Ghrelin also 
appears to play a role in glucose homeostasis. Several studies have demonstrated an 
inverse relationship between fasting ghrelin and fasting insulin levels (Purnell et al 
2003). Additionally, insulin resistance and T2DM are associated with reduced fasting 
total ghrelin levels, (Poykko et al 2003) a correlation that has even been shown to exist 
independently of bodyweight (McLaughlin et al 2004). It appears that intravenous 
administration of ghrelin improves glucose disposal in vivo through peripheral insulin 
sensitization (Heijboer et al 2006), but curiously has been shown to inhibit insulin 
secretion both in vivo and in vitro (Dezaki et al 2008, Reimer et al 2003). Ghrelin 
increases gastric motility and gastric emptying and intestinal transit (Masuda et al 
2000). The role of ghrelin in glucose homeostasis is unclear but may provide 
therapeutic potential for T2DM in the future.  
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Several strategies targeting the ghrelin axis have been explored for the treatment of 
obesity. Firstly, ghrelin receptor (GHSR1a) antagonism reduced food intake and 
bodyweight in obese rodents (Asakawa et al, 2003a, Beck et al 2004).  However, as yet 
these findings have not been replicated in man (Halem et al 2004). Secondly, ghrelin 
specific RNA-spiegelmers (stable oligonucleotides which bind acyl-ghrelin) are being 
developed and have been shown to reduce food intake and bodyweight in rodents 
(Helmling et al 2004, Kobelt et al 2006 and Shearman et al 2006). However the efficacy 
of these compounds in humans is yet to be realised. Thirdly, an anti-ghrelin vaccine 
has been trialed with promising results in animals but no effect on obese humans 
despite strong antibody responses (Cytos Biotechnology 2006, Vizcarra et al 2007, 
Zorrilla et al 2006). Finally, the recent discovery of GOAT presents a new treatment 
target through inhibition of acylation and hence activation of ghrelin. A recent study 
suggests inhibition of GOAT is possible by administration of octanoylated 
pentapeptides in vitro (Yang et al 2008b). 
 
1.14.4 Peptide tyrosine tyrosine 
 
PYY has a tyrosine residue (amino acid abbreviation, Y) at each terminus of the 36 
amino acid polypeptide, and was first isolated from porcine intestine in 1980. It is 
primarily synthesized and secreted from the entero-endocrine L-cells in the distal GI 
tract (Tatemoto and Mutt 1980). It has also been identified in the pancreas and 
brainstem (Adrian et al 1985a). Nutrient content and neural reflexes are thought to 
govern secretion (Anini et al 2002, Herrmann et al 1995a, and Herrmann et al 1995b). 
PYY, neuropeptide Y (NPY) and pancreatic polypeptide (PP) are members of the 
pancreatic polypeptide-fold family of peptides, and share a common structure 
consisting of a hairpin-fold motif which mediates receptor binding (Fuhlendorff et al 
1990b). The NPY family of peptides bind to the NPY Y-subtype of G-protein coupled 
receptors with varied affinity. PYY1-36 is synthesized by the L-cells throughout distal 
gut. It undergoes cleavage of tyrosine and proline from the N-terminus of PYY1-36 to 
produce PYY3-36 (Grandt D et al 1992); the major circulating form of PYY in the fed 
and fasted state (Batterham et al 2006 and Korner J et al 2006). Several studies have 
demonstrated that DPP-IV is responsible for this cleavage (Grandt et al 1993, Mentlein 
et al 1993, Unniappan et al 2006), The process of elimination of PYY3-36 is unknown 
at present. Circulating levels of PYY begin to rise within 15 minutes of a meal, continue 
to increase over the next 2 hours, and reach peak levels at 1-2 hours after the meal, 
and remains elevated for several hours (Adrian et al 1985). This temporal profile with a 
sustained elevation of PYY post-meal ingestion suggest PYY is a satiety factor, in other 
words it is involved in delaying the next meal rather than acting as a meal terminator. 
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Circulating concentrations of PYY reflect calorie intake as well as macronutrient 
composition (Adrian et al 1985, Batterham et al 2006, Essah et al 2007, Helou et al 
2008).  
 
Exogenous administration of PYY3-36 leads to a dose-dependent reduction in food 
intake (Batterham et al 2002). PYY null animals exhibit hyperphagia resulting in 
significantly increased bodyweight and a marked elevation in body fat percentage 
(Batterham et al 2006). The initial controversy surrounding the anorexigenic functions 
of PYY3-36 (Tschop et al 2004), has been resolved following the replication of the 
original findings in rodents (Challis et al 2003, Cox and Randich 2004, Halatchev et al 
2004, Martin et al 2004, Pittner et al 2004), primates (Koegler et al 2005) and humans 
(Degen et al 2005, le Roux C W et al 2006, Sloth et al 2007). Furthermore, chronic 
administration of PYY3-36 to PYY null animals led to a reversal of the obese phenotype 
(Batterham et al 2006). PYY over expression protects against diet-induced obesity, and 
genetic obesity (Boey et al 2008). In humans, peripheral administration of PYY3-36 
reduces appetite and food intake in both lean and obese subjects (Batterham et al 
2003a). PYY1-36 also reduces food intake but in an order of magnitude less potent 
than PYY3-36 (Chelikani et al 2004, DeCarr et al 2007). It is thought that the inhibitory 
effects of PYY1-36 on food intake occur following truncation of the peptide in vivo 
(Chelikani et al 2004, DeCarr et al 2007). These findings demonstrate that PYY plays a 
critical role in the regulation of food intake. The role of the vagus nerve in mediating the 
central effects of PYY is ambiguous. It is known that vagotomy abolishes the 
anorexigenic effects of PYY3-36 (Abbott et al 2005a, Koda et al 2005). However, 
others have reported the opposite (Halatchev and Cone 2005). At the cellular level 
anorectic effects of PYY3-36 are thought to be mediated by the Y2-receptor, found 
throughout the CNS and vagal afferents (Batterham et al 2002, Abbott et al 2005). 
Peripheral administration of  PYY3-36 up-regulates c-fos  expression (a marker of 
neuronal activation) in hypothalamic feeding centres including the arcuate nucleus 
(Batterham et al 2002, Challis et al 2003). The administration of PYY3-36 directly into 
the ARC causes a dose-dependent decrease in food intake. This is ablated in PYY Y2 
receptor (Y2R) knock-outs, and in pharmacological antagonism of the Y2R, suggesting 
that Y2R mediates these effects (Abbott et al 2005b, Batterham et al 2002).  Radio-
labelled PYY accumulates in the median eminence and area postrema suggesting PYY 
does also influence brainstem circuits (Dumont et al 2007). Recent evidence points to 
PYY3-36 activating non-homeostatic areas. In this functional magnetic resonance 
imaging study (fMRI), PYY3-36 was infused to mimic fed-state concentrations. This led 
to significant modulation of brain activity in areas involved in reward processing, such 
as: the orbital frontal cortex (OFC), ventral tegmental area (VTA), insula and globus 
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pallidus (Batterham et al 2007). Furthermore, post-prandial PYY3-36, and concomitant 
changes in neural activity in the OFC predicted subsequent feeding behaviour. This 
has led some to propose that the regulation of appetite has switched from homeostatic 
to hedonic control. The subjective hunger scores strongly correlate with changes in 
plasma PYY concentrations both in a post-prandial setting (Guo et al 2006, Stoeckel et 
al 2007) and during infusion of PYY (Batterham et al 2007).  
 
Animals exposed to a high-fat diet have reduced PYY levels (le Roux et al 2006, 
Rahardjo et al 2007, and Yang et al 2005). In humans, bodyweight is negatively 
correlated with plasma PYY levels in adults (Alvarez Bartolome et al 2002, Batterham 
et al 2003a, Guo et al 2006, le Roux et al 2006 and Sodowski et al 2007). However not 
all studies concur (Kim et al 2005, Korner et al 2006, Pfluger et al 2007). Obese 
individuals have an attenuated post-prandial PYY secretion (Batterham et al 2003a, le 
Roux et al 2006). The converse is also true in patients with anorexia, where an 
elevated fasting and post-prandial PYY is seen (Misra et al 2006, Nakahara et al 2007). 
Stress can increase plasma PYY3-36 levels, and must be controlled for when 
measuring PYY in animals and humans (Chandarana et al 2009). 
  
In contrast to leptin, obese individuals retain sensitivity to PYY3-36, raising the 
possibility of therapeutic potential (Batterham et al 2003a). Therefore pharmacological 
therapies aimed at the modulation of the PYY-Y2R axis are under development. Trials 
on modified PYY molecules that are potent Y2R agonists have demonstrated reduced 
feeding and a reduction in bodyweight (Balasubramaniam et al 2007, Ortiz et al 2007). 
PYY and glucagon-like peptide-1 (GLP-1) are co-secreted by entero-endocrine cells in 
the lower small intestine and colon. PYY3-36 combined with GLP-1 or GLP-1R agonist 
synergistically reduces food intake in humans and rodents (Neary et al 2005, Talsania 
et al 2005). Trials on the PYY3-36 nasal spray were terminated despite encouraging 
reduction in food intake and weight loss due to a lack of efficacy above current 
available treatments (MDRNA, 2008).  
1.14.5 Glucagon like peptide-1 
GLP-1 is made by the post-translational modification of pre-proglucagon precursor 
polypeptide. The tissue-specific activities of pro-hormone convertases 1 and 2 direct 
the differential cleavage of pre-proglucagon. These convertase enzymes are expressed 
in the α-cells of the pancreas, L-cells of the intestine and also within the CNS. The 
pattern of enzyme expression determines hormone synthesis. GLP-1 is secreted 
primarily from entero-endocrine L-cells in two forms: GLP-1(1-37) and GLP-1(1-36) 
amide and cleaved at the N-terminus to form the biologically active fragments GLP-1(7-
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37) and GLP-1(7-36) amide (Mojsov et al 1986). GLP-1(7-36amide) is thought to be 
present in greater concentration but both isoforms are equipotent (Orskov et al 1994). 
GLP-1 is rapidly degraded by the ubiquitously expressed aminopeptidase dipeptidyl-
peptidase IV (DPP-IV). DPP-IV is expressed in endothelial and epithelial tissues. The 
enzyme selectively cleaves N-terminal dipeptides (Lambeir et al 2003), and in the case 
of GLP-1 leading to inactive metabolites GLP-1(9-37) or GLP-1(9-36amide) (Deacon et 
al 1995). A significant amount of GLP-1 is degraded to the inactive metabolite before 
leaving the gut (Hansen et al 1999), with further degradation in the liver (Deacon 2005). 
Therefore it is thought that only a small proportion of intact active GLP-1 reaches the 
systemic circulation. Therefore DPP-IV inhibitors should be added to blood samples to 
prevent degradation of active GLP-1 after collection. Luminal nutrients are thought to 
be the main stimulus for GLP-1 release. Plasma GLP-1 is noted to rise 10 min after a 
meal and peak at 30 min after a meal. Plasma GLP-1 levels remain elevated for 
several hours (Orskov et al 1996, Vilsboll et al 2003). Quickly absorbed proteins lead to 
a greater GLP-1 response (Herrmann et al 1995). A quicker luminal passage has been 
linked to GLP-1 secretion. Entero-endocrine L-cells are located throughout the GI tract 
and the presence of nutrients in the proximal GI tract also stimulates GLP-1 release 
(Roberge and Brubaker 1991, Eissele et al 1992). The processes underlying GLP-1 
synthesis and secretion from the L-cell are not unknown. Vagotomy abolishes nutrient-
stimulated GLP-1 from the proximal GI tract suggesting a neural control mechanism 
directing GLP-1 secretion (Rocca and Brubaker 1999). GLP-1 has a short half-life 
(~ 2 min) and therefore peripheral and vagal GLP-1 receptors may play a substantial 
role in mediating the anorectic effects of GLP-1. It is possible that GLP-1 activates 
receptors before entering the local capillary network. GLP-1 evokes action potentials in 
vagal afferent neurons (Nakagawa et al 2004 and Kakei et al 2002). Lesions on the 
neuronal projections linking the brainstem to the hypothalamus lead to a decline in the 
anorectic effects of GLP-1, implicating these in the relaying of anorectic signals to the 
hypothalamus (Abbott et al 2005).  
GLP-1 activates the GLP-1 receptor (GLP-1R), a G-protein coupled receptor widely 
expressed in pancreatic islets, brain, heart, kidney and throughout the GI tract (Bullock 
et al 1996). GLP-1 may act directly on gastric GLP-1 receptors to delay gastric 
emptying (Young et al 1996 and Naslund et al 1999, Nauck et al 1997). Centrally, the 
afferent nodose ganglion is known to be activated and in turn sending impulses to the 
NTS and hypothalamus (Holst and Deacon 2005). Peripherally and centrally 
administered GLP-1 lead to a reduction in food intake (Tang-Christensen et al 1996 
and Turton et al 1996). Global deletion of the GLP-1R led to impaired glucose tolerance 
(Scrocchi et al 1996). The activation of GLP-1R in the hepatic portal vein augments the 
insulin response through a neural reflex (Balkan and Li 2000). It is thought that active 
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GLP-1 at lower concentrations activates neural pathways, and at higher concentrations 
activates islet and CNS receptors. Intra-cerebroventricular administration of GLP-1 
leads to c-fos expression in the hypothalamus and inhibited feeding (Turton et al 1996). 
Peripheral injection of GLP-1 led to c-fos expression in the brainstem, also an important 
site of action (Baggio et al 2004). Further, central GLP-1 receptor blockade, doubled 
food intake in satiated rats (Turton et al 1996).  
Exogenous GLP-1 directly stimulates insulin secretion from isolated islets in vitro 
(Fridolf and Ahren 1991). Furthermore, studies on isolated islets have displayed that 
GLP-1 potentially inhibits apoptosis and promotes cell proliferation (Drucker 2003). 
GLP-1 acts as an incretin, enhancing glucose-stimulated insulin release. The meal 
associated increase in GLP-1 is responsible for the glucose-dependant insulinotropic 
effect (Holst et al 1987, Kreymann et al 1987). Conversely, blockade of the GLP-1R by 
GLP-1R antagonist exendin 9-39, significantly impairs glucose tolerance (Kreymann et 
al 1987, Tseng et al 1999, Wang et al 1995). GLP-1 stimulates insulin gene 
transcription and biosynthesis (Drucker et al 1987), and improves α-cell glucose 
sensing leading to inhibition of glucagon secretion from α-cells (Byrne et al 1998, 
Orskov et al 1988).  
 
The exact mechanisms underlying GLP-1 central effects remain unclear (Tang-
Christensen et al 1996). Intra-cerebro ventricular (ICV) and PVN administration of 
active GLP-1 in rodents leads to a decrease in food intake, and chronic administration 
leads to a reduction in bodyweight (Meeran et al 1999, Turton et al 1996, Verdich et al 
2001a). Interestingly deletion of GLP-1R does not lead to obesity reflecting the 
redundancy in this signalling pathway (Scrocchi et al 1996). Studies in humans have 
demonstrated that obesity is associated with reduced fasting and post prandial total 
GLP-1 secretion (Holst et al 1983, Ranganath et al 1996, Verdich et al 2001b). 
However, not all studies are in agreement (Laferrere et al 2007) and one study has 
even reported hyper-secretion in obese individuals (Fukase et al 1993). Furthermore, 
when weight-matched patients with T2DM, are compared to their obese counterparts, 
the incretin effect is severely reduced in T2DM patients, and thought to contribute to 
the pathogenesis of the disease (Nauck et al 1986). Patients with T2DM display a dose 
dependent response to exogenous GLP-1 (Kjems et al 2003). Glucose-induced insulin 
secretion can be normalized with infusion of GLP-1 in subjects with T2DM (M A Nauck 
et al 1993). A six week infusion of GLP-1 in patients with T2DM led to a significant 
improvement in HbA1c and an associated weight loss (Zander et al 2002). A naturally 
occurring GLP-1R agonist was isolated from the saliva of the Gila monster (Heloderma 
suspectum) and led to the drug exenatide being developed (Byetta; Eli Lilly, IN, USA). 
Exenatide has a half-life 30 times longer than GLP-1 (60 - 90 minutes) (Buse et al 
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2004). It is used in the treatment of T2DM. However, exenatide can lead to nausea; this 
together with the sub-cutaneous route of administration can lead to poor compliance. 
An acylated, albumin-bound long-acting GLP-1 analogue named Liraglutide (Novo 
Nordisk, Denmark) has now been developed. Liraglutide shows 97% similarity to native 
human GLP-1. It has a half-life of up to 14 hours (Agerso et al 2002). An alternative 
approach to extend the half life of GLP-1 is inhibition of DPP-IV. Vildagliptin and 
Sitagliptin are examples of DPP-IV inhibitors that are currently in use for the treatment 
of T2DM. The therapeutic effects of DPP-IV inhibitors are similar to incretin mimetics, 
although weight loss is not a common feature with this class of drugs (Aaboe et al 
2008). 
1.14.6 Amylin 
Amylin is a 37 amino acid peptide produced by the β-cells in the islets of Langerhans. It 
is cleaved from a precursor and amidated at the C-terminal. It is co-released with 
insulin in a molar ratio (100:1, insulin: amylin). This molar ratio can be perturbed in 
T2DM or obesity (Butler et al 1990, Moore and Cooper 1991). The meal-stimulated 
amylin profile mirrors that of insulin (Butler et al 1990), Amylin is degraded by the 
insulin-degrading enzyme (Shen et al 2006). Amylin binds to the calcitonin receptor. 
Tissue specificity is conferred by receptor activity modifying proteins (RAMPs) binding 
to the receptor (chen et al 1997). The central anorectic effects of amylin appear to be 
mediated through the nucleus tractus solitarius (NTS) and area postrema in the 
brainstem (Riediger et al 2001), and the hypothalamus (Clline et al 2008). Vagotomy 
does not abolish the anorectic effects of amylin (Morley and Flood 1991). Amylin 
inhibits gastric emptying (Young et al 1996) and glucagon secretion (Silvestre et al 
2001). The latter makes amylin a T2DM drug candidate. Peripheral amylin 
administration led to a reduction in food intake in normal fed and food-deprived mice. 
This reduction was independent of diabetes status (Morley and Flood 1991). Centrally 
administered amylin reduced 24-hour food intake by up to 30% in a week (Rushing et 
al 2000). The temporal profile of amylin, and its ability to reduce food intake, support a 
role for amylin in satiety. Obese subjects exhibit fasting hyper-amylinaemia, conversely 
obese individuals with impaired glucose tolerance or diabetes exhibit lower fasting 
levels. However, both diabetic and non-diabetic obese subjects demonstrate a post-
prandial increase in circulating amylin levels. This temporal profile is thought to be 
mediated by hyperglycaemia and cortisol (Hartter et al 1991 and Thomaseth et al 
1997). It is thought that an increased ratio of amylin/ insulin expression may act as a 
marker for beta cell dysfunction (Weng HB et al 2008). Hyperglycaemia is thought to 
lead to the hyper secretion of amylin relative to insulin, and increase the amylin /insulin 
ratio in insulin-resistant rats (Leahy JL et al 1998). GLP-1 (7–36) stimulates the 
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expression and secretion of amylin, whilst also increasing insulin protein expression in 
GK rats treated with GLP-1. Amylin has multiple physiologic effects on glucose 
homeostasis (Karlsson E 1999, Nyholm B et al 1999), including making GLP-I a less 
effective stimulus for insulin secretion (reviewed by Cluck MW et al 2005). It has been 
proposed that the amylin/ insulin ratio may be a better measure than the absolute 
amylin mRNA level (Weng HB et al 2008). Whilst the promoter elements and 
transcription factors that regulate rat and human insulin gene expression have been 
described, amylin gene expression is not well characterized (reviewed by Cluck MW et 
al 2005). The amylin promoter does contain elements similar to those present in insulin 
genes. Therefore a mechanism for parallel gene expression may exist (reviewed by 
Cluck MW et al 2005). It is thought that separate transcription factors regulate 
independent transcription of amylin and insulin (reviewed by Cluck MW et al 2005). 
Several transcription factors such as HNF-1 are now implicated in the selective 
expression of the amylin gene (reviewed by Cluck MW et al 2005). Under normal 
physiological conditions amylin and insulin are regulated in concert, but in pathological 
states such as diabetes and obesity their regulation may diverge (reviewed by Cluck 
MW et al 2005). Second messengers utilised by GIP/ GLP-1, calcium and fatty acyl 
molecules can differentially regulate amylin, insulin secretion, and gene expression 
(reviewed by Cluck MW et al 2005). Amylin and insulin mRNA content does increase in 
parallel following glucose challenge (Mulder H et al 1996). Supra-physiologic levels of 
exogenous amylin inhibit glucose-induced insulin secretion in humans, (Bretherton-
Watt D et al 1992). Insulin secretion is inhibited by amylin both in vitro and in vivo, 
(Gebre-Medhin S et al 1998, Wang ZL et al 1993 and reviewed by Cluck MW et al 
2005). Also recent studies have highlighted a role for amylin therapy in obesity 
(Ravussin E et al 2009, Smith SR et al 2008).  
1.15 Treatments for obesity 
1.15.1 Lifestyle Intervention 
Pharmacotherapy and lifestyle intervention programs to modify diet, feeding behavior 
and encourage exercise, are widely used in various combinations to treat obesity 
(Guntram and Morton 2008). These approaches to managing obesity achieve long term 
weight loss in only a small minority of highly motivated individuals (Mark 2008). 
Clinically significant weight loss is generally very modest and transient, particularly in 
patients with severe obesity (Guntram and Morton 2008). Poor compliance and high 
rates of relapse are thought to be driven by the homeostatic mechanisms that exist to 
maintain bodyweight (Heymsfield et al 2003, Leibel et al 1995, Tsai and Wadden 
2005). However, when patients with a BMI >40 kg/m
2
 were willing to complete an 
intensive behavioral program they did achieve a remarkable weight loss of 35% of 
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initial weight after 40 weeks (Anderson et al 2006), but The long-term maintenance of 
this weight loss was difficult for most (Anderson et al 2006).  
 
1.15.2 Pharmacological treatments 
Orlistat, the only pharmacological weight loss therapy available in Europe for the 
treatment of obesity has limited efficacy and is associated with undesirable side effects. 
It is a bacterial enzyme that blocks pancreatic lipase. This leads to a reduction in 
triglyceride digestion (reviewed by Bray GA and Tartaglia LA 2000). Orlistat blocked 
digestion of 30% of triglyceride when taken as 120 mg three times daily. Orlistat 
therapy leads to about 9–10% weight loss in a year (reviewed by Bray GA and 
Tartaglia LA 2000). However, diabetics lost less, reaching 6% after one year. It is 
thought that orlistat may increase postprandial GLP-1 levels by an increase in intestinal 
fat content, thereby enhancing the insulin secretory response to the meal and improve 
weight loss (Tanner et al 2004). Clinically orlistat leads to a modest weight loss in 
patients who tolerate it, and can only be prescribed for short periods of time 
(Rosenbaum et al 1997). The side effects of Orlistat therapy include oily spotting, 
faecal urgency and increased defecation. These side effects decline over time 
(reviewed by Bray GA and Tartaglia LA 2000). A study of 80 adults with mild to 
moderate obesity (BMI 30–35 kg/m
2
) compared lifestyle intervention with 
pharmacotherapy (very-low-calorie diet, orlistat, and lifestyle change) to surgical 
intervention (gastric banding). Surgical treatment was significantly more effective than 
nonsurgical therapy in reducing weight, resolving the metabolic syndrome, and 
improving quality of life during a 24-month treatment program (O'Brien et al 2006). At 2 
years, the surgical group had greater weight loss- 21.6% of initial weight, whereas the 
nonsurgical group had only a 5.5% of initial weight loss. The XENDOS study 
demonstrated that orlistat accompanied with lifestyle changes was able to significantly 
reduce the incidence T2DM over 4 years through weight loss when compared to 
lifestyle changes alone (Torgerson JS et al 2004). This was through halting progression 
from impaired glucose tolerance. (Torgerson JS et al 2004) The comparator group also 
lost a meaningful amount of weight over the 4 years. A relative risk reduction of 37.3% 
was noted with Orlistat. The mean weight loss after 4 years was significantly greater 
with Orlistat (Torgerson JS et al 2004). Orlistat 120mg is FDA-approved for use in 
adults and adolescents age 12–16y. The increase in undigested stool triglycerides may 
cause considerable gastrointestinal adverse effects (reviewed by Yanovski SZ and 
Yanovski JA 2014).  
 
Recent reviews on new drugs to treat obesity point to clinically meaningful weight loss 
with Orlistat, lorcaserin, and phentermine/topiramate-ER when combined with lifestyle 
intervention over a year (reviewed by Yanovski SZ and Yanovski JA 2014). The 
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comparison to placebo has ranged from ~3% for orlistat and lorcaserin to 9% for 
phentermine/topiramate-ER at one year. However, it is noted that the risks may out 
weigh the benefits for those that do not lose weight, and in some cases pose a 
cardiovascular risk in susceptible individuals (reviewed by Yanovski SZ and Yanovski 
JA 2014). The teratogenic risk and regular pregnancy tests whilst on 
phentermine/topiramate-ER must be weighed against the weight loss benefits 
(reviewed by Yanovski SZ and Yanovski JA 2014). The use of antidepressants is 
common in the obese population and the interaction with Locaserin may lead to 
serotonin syndrome (reviewed by Yanovski SZ and Yanovski JA 2014). Phentermine is 
low cost and has many years of clinical experience, but long-term effects on 
cardiovascular outcomes are unknown (reviewed by Yanovski SZ and Yanovski JA 
2014). 
 
A naltrexone-SR and bupropion combination drug is currently undergoing late-phase 
safety trials to assess cardiovascular risk (reviewed by Yanovski SZ and Yanovski JA 
2014). Trials point to 5-10% weight loss at 1 year, varying with intensity of lifestyle 
intervention (reviewed by Yanovski SZ and Yanovski JA 2014).  
phentermine/ topiramate-ER at the top dose led to a mean loss of 10.9% at a year 
against 1.6% with placebo (reviewed by Yanovski SZ and Yanovski JA 2014). However, 
31% of participants withdrew. This is an area of considerable concern (reviewed by 
Yanovski SZ and Yanovski JA 2014). Women with childbearing potential should have a 
negative pregnancy test prior to starting phentermine/topiramate-ER and monthly 
thereafter (reviewed by Yanovski SZ and Yanovski JA 2014). 
 
Lorcaserin is a selective serotonin 2C receptor agonist. It was approved in 2012 
following two large randomized, placebo-controlled trials in nondiabetic patients 
(reviewed by Yanovski SZ and Yanovski JA 2014). There was 3.2% weight loss in 
comparison to placebo. The average weight loss of 5.6 kg was noted over 2 years 
(reviewed by Yanovski SZ and Yanovski JA 2014). Diabetics treated with lorcaserin had 
lower body weight and improved glycated hemoglobin concentrations. The FDA has 
requested a post-approval trial to assess long-term valvulopathy and hypertension 
(reviewed by Yanovski SZ and Yanovski JA 2014).  
 
Further novel treatments options are keenly anticipated (Neary and Batterham, 2009). 
Others are less optimistic (Ledford H 2010). A recent review of drugs considered for 
approval by the food and drug administration (FDA) authority paints a bleak picture 
(Ledford H 2010). It is argued that appetite regulatory pathways overlap with mood and 
other important cerebral functions leading to long periods of monitoring on therapy, in 
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turn leading to an increase in development costs. They site this as a cause for the 
difficulty in developing new therapies. The most recent drug to be recommended by the 
FDA is a combination of an anti-depressant and neurotransmitter. It is thought to 
reduce hunger by its effects on the hypothalamic neurons (Ledford H 2010). They also 
propose that GLP-1 agonists are the next set of drugs to be considered for obesity 
therapy (Ledford H 2010). GLP-1 an injectable incretin used to treat type 2 diabetes is 
also known to produce weight loss. A meta-analysis points to 3% weight loss at 6 to 12 
months, further studies in non-diabetic obese highlights 3.5 to 5.8 kg weight loss at 6 to 
12 months (reviewed by Yanovski SZ and Yanovski JA 2014). liraglutide and exenatide 
are currently undergoing trials for treatment of obesity. Initial results point to 6.2% 
weight loss at 1 year when compared to placebo, with both groups undergoing effective 
lifestyle advice (reviewed by Yanovski SZ and Yanovski JA 2014).  Those on GLP-1 
were more likely to maintain weight loss and to lose ≥5%-10% (reviewed by Yanovski 
SZ and Yanovski JA 2014).  
1.15.3 Bariatric surgery 
Bariatric medicine deals with the causes, prevention and treatment of overweight and 
obesity. Bariatric surgery is the only effective treatment that randomized controlled 
trials have shown to produce effective long term weight loss (Buchwald H et al 2004, 
Colquitt et al 2009, and Sjöström L et al 2007). A systematic review has concluded that 
surgery is superior to conventional treatment in reducing weight. However, the review 
failed to show the superiority of one surgical method over another (Colquitt et al 2005). 
In recent decades the use of bariatric surgery to treat obesity has evolved significantly. 
Current National Institute for Clinical Excellence (NICE) guidelines advise consideration 
for bariatric surgery where non-surgical therapies have failed in individuals with a BMI > 
40 kg/m2 or with BMI 35-40 kg/m2 with other significant disease that could be improved 
by weight loss (NICE, 2006). All non-surgical methods should have failed to achieve or 
maintain clinically beneficial weight loss for at least six months. Surgery is appropriate 
only if the patient will receive specialist management, is fit for general anaesthesia, and 
is committed to long term follow-up-(NICE 2006).  Surgery can be considered as a first 
line option in patients with a body mass index >50. Recent evidence from the United 
States and Australia also shows the benefit of bariatric surgery in patients with lower 
body mass indices (30 to 35) (Yermilov I et al 2009).  
1.16 Classification of bariatric surgery 
Surgical procedures are categorized by presumed mechanisms of action. Procedures 
are called malabsorptive, restrictive or a combination of the two. The first mal-
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absorptive surgical bypass to report weight loss was done in dogs (Kremen et al 1954). 
The distal small intestine was connected proximally with the jejunum, resulting in 
profound weight loss due to malabsorption of lipids- jejunoileal bypass (JIB) (Kremen et 
al 1954). Jejuno-ileal bypass (JIB), duodenal–jejunal bypass (DJB) and biliopancreatic 
diversion (BPD) are all classed as mal-absorptive procedures. These procedures are 
associated with significant mal-absorption and nutritional deficits. This limits their use in 
clinical practice (Organ et al 1984). Restrictive procedures work by limiting stomach 
volume, and restrict food entry into the stomach. They include laparoscopic adjustable 
gastric band (LAGB). In LAGB an inflatable synthetic band device is placed below the 
gastro-oesophageal junction, and the degree of restriction is adjusted by injecting 
saline through a subcutaneous port to inflate a balloon. Vertical gastric banding (VBG) 
leads to restriction by combining vertical stapling of the stomach with banding. In 
sleeve gastrectomy (SG), a ‘‘sleeve’’ of stomach is created by stapling and removing a 
large part of the stomach. SG was originally described as a first-stage procedure in a 
staged process for patients deemed high risk for invasive surgical intervention. SG was 
followed by either bilio-pancreatic diversion-duodenal switch (BPDDS) or Roux-en-Y 
gastric bypass (RYGB) in high risk patients with a BMI >60 kg/m
2
. More recently, SG 
has been undertaken as a stand-alone bariatric procedure as an alternative to RYGB 
(Bohdjalian A et al 2010). SG is no longer considered a restrictive procedure. Early 
results suggest that SG results in comparable weight loss and resolution of co-
morbidities, but longer term outcome studies are awaited. Hybrid operations include 
RYGB and BPD-DS. RYGB is the most commonly performed bariatric operation and is 
considered the ‘‘gold standard’’ treatment for severe obesity (Buchwald et al 2004, 
Sjostrom et al 2007). In RYGB a small stomach is created, and connected to the Roux 
limb of small bowel. Bowel continuity is restored by an entero–entero anastomosis, 
between the biliary limb and alimentary limbs (Cummings DE et al 2004). Ingested 
nutrients bypass most of the stomach, duodenum and the proximal jejunum (Buchwald 
et al 2004). Biliary and pancreatic secretions mix with the nutrients at the site of the 
entero–entero anastomosis.  RYGB combines mal-absorptive and restrictive elements 
and is more effective and successful (Sjostrom et al, 2007).  
 
Approximately 80% of bariatric surgery patients are women In the U.S. (Santry et al 
2005) and in various European countries (Favretti et al 2007), as well as in New 
Zealand (White et al 2005). Women and patients from more socially deprived areas 
were more likely than men, and patients from more affluent areas to have bariatric 
surgery in NHS hospitals (Burns et al 2010). Between April 2000 and March 2008, 
6953 adults had a primary elective bariatric procedure in the NHS. Of these, 3191 
patients had gastric bypass, 3649 had a gastric banding procedure, and 113 patients 
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had a sleeve gastrectomy. There was a marked increase in the number of bariatric 
procedures carried out during the study period from 238 in 2000-1 to 2543 to 2007-8, 
and a substantial increase in the use of laparoscopy over time was also noted. In 2000, 
28% (66/238) of bariatric procedures were done laparoscopically by 2007 74.5% 
(1894/2543) of procedures were laparoscopic (Burns et al 2010). 
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Figure-9; The GI tract anatomy (a), Restrictive procedures are shown in (b): (i) gastric 
banding (GB), an inflatable device is placed below the gastro-oesophageal junction, 
and the degree of restriction is adjusted by injecting saline through a subcutaneous 
port. (ii) Vertical gastric banding (VBG) a small pouch of stomach is created with a 
band and staples. This pouch opens into the GI tract at the lower end (iii) Sleeve 
gastrectomy (SG), a ‘‘sleeve’’ of stomach is created by stapling and removing a large 
part of the stomach. (c) Malabsorptive procedures (iv) Jejunoileal bypass (JIB), the 
jejunum and ileum are excluded from contact with food. (v) Duodenal–jejunal bypass 
(DJB), duodenum and jejunum are bypassed. It is an experimental procedure in 
humans. (vi)  Biliopancreatic diversion (BPD), a section of the stomach is resected, and 
the smaller stomach connected to the distal gut, and the nutrients flow directly into the 
ileum. (d) Hybrid procedures aim to combine restriction with malabsorption. (vii) Roux-
en-Y gastric bypass (RYGB) is the most widely performed procedure; the divided 
stomach is connected to the divided parts and the small bowel. The small bowel is 
divided into two and rearranged into a Y-configuration. Nutrients pass from the small 
stomach pouch to the jejunum via a ‘‘Roux limb’’. The biliary limb and the alimentary 
limb are connected by an entero–entero anastomosis. The bile and pancreatic 
secretions enter the common channel and mix with nutrients at the entero–entero 
anastomosis. (viii) Biliopancreatic diversion with duodenal switch (BPD-DS), A large 
part of the stomach is resected to create a ‘‘sleeve’’ of stomach, and a lengthy part of 
the small bowel is rerouted and re-arranged into a Y configuration. Food flows from the 
stomach into the shorter bowel loop, called the digestive loop and then to the common 
channel. Bile and pancreatic enzymes empty through the longer bowel loop, the 
biliopancreatic loop, and in to the common channel (Reproduced from Karra E et al 
2009). 
Surgical outcome is evaluated by change in weight or body mass index, or percentage 
loss of excess body weight and by resolution or improvement in co-morbidities. Excess 
body weight is calculated by subtracting the ideal weight of a patient, assuming a body 
mass index of 25, from his or her actual weight (Biagini and Karam 2008). A systematic 
review of bariatric surgery published in 2006 examined 43 studies, the mean 
percentage excess weight loss for Roux-en-Y gastric bypass was 67% at one and two 
years. The excess weight loss for Roux-en-Y gastric bypass at 10 years was 52% 
(O’Brien et al 2006). The Swedish Obese Subjects (SOS) study, in which 2,010 
overweight patients wishing surgery were matched with 2,037 obese patients not 
desiring surgery, is an important long-term prospective outcome study. There was a 
greater percentage of initial weight loss after bariatric surgery (gastric bypass 32%, 
vertical banded gastroplasty 25%, and gastric banding 20%) than with conventional 
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treatment (2%) (Sjostrom et al 2007).  There was also a significant reduction in the 
adjusted hazard ratio for death (29%) after an average follow-up of 10.9 years.  
Surgery is more effective at ensuring weight loss and controlling co-morbidities than 
medical treatment (Sjostrom et al 2007). It reverses, ameliorates, or eliminates major 
cardiovascular risk factors, including diabetes, hypertension, and lipid abnormalities 
(Sjöström et al 2007). Another long term (11 years follow up) study of 228 gastric 
bypass patients with a significant proportion (36.8%) of extremely obese patients (BMI 
>50 kg/m
2
), showed that the extremely obese patients lost weight more rapidly, but also 
went on to gain weight more rapidly. In the morbidly obese, the BMI before surgery was 
44.3 kg/m
2
; the nadir was 26.4 kg/m
2
, and occurred 1.9 years after surgery but 
increased again to 31.0 after 11.4 years after surgery. In the extreme obese, the initial 
BMI of 56.2 kg/m
2
 decreased to 31.4 kg/m
2
 at 2.2 years after surgery, but increased to 
38.3 kg/m
2
 at 11.6 years after surgery (Christou et al 2006). Patients who regain large 
amounts of weight say they are eating almost as much as before the operation 
(Christou et al 2006). The study by Pories and colleagues showed a remarkable 
stability of postoperative weight for up to 14 years after gastric bypass. This study on 
608 patients showed a 58% excess weight loss after 5 years, and 55% at 10 years 
(Pories et al 1995). Even though there are varying degrees of evidence for different 
surgeries, there is a clear preponderance of evidence for all weight loss surgeries to be 
vastly superior to traditional weight loss therapies in promoting weight reduction. 
 
Figure 10; Mean change in bodyweight following bariatric surgery procedures: This 
graph outlines the results from the SOS study demonstrating mean percentage change 
in bodyweight over 10 years following bariatric surgery procedures; gastric banding (n = 
156), vertical-banded gastroplasty (n = 451) and gastric bypass (n = 34). The control 
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group (n = 627) consisted of matched obese individuals receiving non-surgical 
treatment for obesity, adapted from (Sjostrom et al 2004). 
1.17 Mechanisms mediating weight loss after surgery 
Clinical observation that patients who underwent partial gastrectomy for peptic ulcer 
disease remained underweight, led Mason and Ito to undertake the first gastric bypass 
(Mason and Ito 1967). It was initially thought that reducing the stomach volume would 
lead to early satiety and smaller meals (Halmi et al 1981). However, the compensatory 
homeostatic mechanisms that maintain bodyweight would be expected to limit weight 
loss and increase meal frequency. In fact to the contrary patients report a reduction in 
appetite, reduction in energy-dense foods and fewer meals (Halmi et al 1985). The 
mechanisms mediating the beneficial effects of bariatric surgery are still not elucidated. 
Studies in patients having bypass surgery indicated that malabsorption was not the 
major cause of weight loss after intestinal bypass (Sclafani et al 1978). The changes 
associated with malabsorptive states, such as reduced circulating levels of albumin and 
proalbumin and increased faecal fat excretion are not observed following RYGB 
(MacLean et al 2001). Furthermore, despite a significantly higher malabsorptive 
component in JIB, there is comparable weight loss after RYGB and JIB (Griffen et al 
1977). It was noted that after JIB, food intake and preference for sweets was reduced 
and feeding patterns normalized (Sclafani et al 1981). This was reproduced in obese 
rats undergoing JIB. A reduction in caloric intake and decreased palatable food 
consumption was noted (Sclafani et al 1978). Several lines of evidence now suggest 
malabsorption does not play a significant role in the weight loss post-RYGBP (Kenler et 
al 1990). The changes in bodyweight are consequential to a reduction in appetite 
(Hafner et al 1991, Halmi et al 1981, Borg et al 2006, Korner et al 2005). A number of 
recent studies have demonstrated that changes in the concentrations of gut hormones 
may underlie the observed effects of bariatric surgery (Korner J et al 2005, Le Roux et 
al 2006, de Fatima Haueisen Sander Diniz et al 2006, Karamanakos SN et al 2008, 
Peterli R et al 2009, Neary and Batterham, 2009, Karra et al 2010, De Paula et al 2010, 
Basso N et al 2011, Chambers AP et al 2011, Yousseif A and Emmanuel J et al 2013). 
Though changes in gut hormones favour weight loss, correlation between changes in 
gut hormone secretion and weight loss has not yet been shown in humans. The pace of 
resolution of T2DM does differ between days (RYGB) to months to years (GB) 
(Pories1995, Cummings and Flum 2008, Dixon et al 2008). The rapid resolution of 
T2DM cannot be explained by weight loss alone. This effect is also able to overcome 
the up regulation of counter-regulatory stress hormones- cortisol and catecholamine 
(McAlister et al 2003) seen after surgery. There is increasing evidence that alterations 
in circulating gut hormone concentrations engendered by surgery play a key role in 
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mediating both the altered eating behaviour and improved glucose homeostasis 
(reviewed by Karra E et al 2010).  
 
1.17.1 The hindgut hypothesis 
 
It is thought that the re-routing of food through an anatomically altered and/or shorter 
gastrointestinal tract leads to an increased delivery of incompletely digested nutrients to 
the ileum and colon. This leads to over stimulation of the specialised enteroendocrine L 
cells. The greater nutrient exposure of the L-cells leads to an exaggerated GLP-1 and 
PYY release (reviewed by Karra and Batterham 2010). GLP-1 also exerts gluco-
regulatory properties. Surgical procedures that increase nutrient delivery to the distal 
gut such as BPD, JIB and RYGB result in rapid resolution of T2DM (Buchwald et al 
2004). Further, compelling evidence from ileal transposition (IT) studies in rodents, 
where interposition of an ileal segment, with intact neural and vascular supply, to the 
proximal intestine mount an exaggerated nutrient-stimulated PYY, GLP-1 and 
enteroglucagon responses and exhibit reduced food intake and body weight 
(Koopmans et al 1984, Strader et al 2005, Patriti et al 2005). In IT the total gut length 
remains unchanged but the exposure of the transposed ileum to undigested nutrients is 
enhanced, leading to improved insulin sensitivity and overall glucose homeostasis 
(Koopmans et al 1984, Strader et al 2005, Patriti et al 2005, Wang et al 2008). These 
changes are seen in the absence of any restrictive or mal-absorptive surgery, and 
some argue leave no doubt that the hindgut plays a major role in mediating the weight 
loss and anti-diabetic effects of bariatric surgery (Karra E et al 2010). 
 
1.17.2 The foregut exclusion hypothesis 
 
An alternative explanation for the improvements in weight and glucose homeostasis 
was proposed by Hickey and colleagues (Hickey et al 1998). They proposed that the 
exclusion of an inhibitory factor from the foregut may mediate the rapid improvement in 
diabetes (Hickey et al 1998). Studies of exclusion of the foregut by doudeno-jejunal 
bypass (DJB) (a stomach-sparing variation of RYGB with a comparable extent of 
foregut exclusion, where food is diverted from the pyloric area to the jejunum, 
bypassing the duodenum and the proximal jejunum) led to no alteration in food intake 
or body weight in Goto–Kakizaki (GK) rats. However, there was an improvement in 
glucose homeostasis and resolution of T2DM (Rubino and Marescaux 2004). They also 
undertook gastro-jejunostomy (GJ), in GK rats. GJ creates a shortcut for ingested 
nutrients between the stomach and jejunum. Nutrients can either empty directly into the 
jejunum or follow the physiological pyloric–duodenal route. This procedure failed to 
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improve glycaemic control in these rats. They proposed that the foregut produces an 
unidentified factor with anti-incretin properties in the diabetic state, and foregut 
exclusion prevents the release of this molecule resulting in improved glucose 
homeostasis (Rubino and Marescaux J 2004, Rubino et al 2006). Foregut exclusion 
improved T2DM independently of weight loss (Rubino and Marescaux J 2004). GK rats 
are a spontaneous non-obese model of T2DM. Results from another duodenal 
exclusion procedure, duodenal–jejunal sleeve (insertion of a plastic endoluminal sleeve 
into the duodenum that extends into the jejunum) that results in early impressive 
improvements in glucose homeostasis (Aguirre et al 2008, Rodriguez-Grunert et al 
2008), is also proposed as an example for the foregut anti-incretin molecule. However, 
these procedures increase the exposure of the hindgut L-cells to nutrients also 
resulting in an exaggerated hind gut response. Further, DJB disrupts the pylorus and 
thus loss of control over gastric emptying rate and nutrient delivery to the duodenum. 
The entry of food into the duodenum usually stimulates duodenal osmoreceptors and 
results in pyloric contraction and a slowing down in gastric emptying (Mason 2005). 
Procedures that eliminate the pyloric muscle control on gastric emptying result in 
accelerated gastric emptying, stimulation of intestinal peristalsis and rapid nutrient 
delivery to the hindgut and an exaggerated hind gut response (Mason 2005).  Some 
have argued that Rubino and colleagues findings resulted from pyloric disruption 
(Mason 2005). The endoluminal duodenal–jejunal sleeve insertion is thought to prevent 
nutrient digestion and absorption in the proximal gut, and abolishes the duodenal 
control of pyloric contraction and therefore again resulting in enhanced hindgut nutrient 
exposure (Mason 2005). A recent study to compare IT and duodenal-jejunal exclusion 
(DJE) in GK rats reported comparable weight loss, glucose tolerance and rise in GLP-1 
in both groups post-operatively. Interestingly exendin 9-39, a GLP-1 receptor 
antagonist did reverse the improvement in glucose homeostasis seen after DJE. These 
findings are thought to indicate that the postoperative improvement in glucose 
homeostasis is mediated by enhanced GLP-1 signaling rather than from absence of a 
presumed foregut anti-incretin molecule (Kindel et al 2009, reviewed by Karra et al 
2010).  
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1.18 Mortality rate and complications after bariatric surgery 
Author Patients 
(n) 
Peri-
operativ
e 
mortality 
Complic
ations 
(%) 
Early(<30day
s) 
complications 
late (>30 
days) 
complications 
Re-
operatio
n rate 
Biertho 
et al  
456 2 NR 19 37 8 
Boza et 
al  
91 0 NR 12 33 16 
Christou 
and 
Efthimiou 
886 3 15.2 74 27 49 
Jan et al 492 1 32 73 115 82 
Kim et al  232 0 5.6 5.2% 0.43% NR 
Lakdawal
a et al  
50-SG 
50- 
RYGBP 
0 
0 
2 
3 
NR 
NR 
NR 
NR 
1 
1 
Lee et al  25 0 32 NR NR 4 
Weber et 
al  
103 1 NR 21 14 11 
Wong et 
al  
30 –SG 
7- 
RYGBP 
0 
0 
3 
4 
NR 
NR 
NR 
NR 
0 
2 
 
Figure 11-A table to summarize mortality and morbidity after bariatric surgery (Franco 
JVA et al 2011). In the study by Biertho et al early was defined as <1 week and late as 
>1 week. Patients requiring therapeutic endoscopic interventions were included in the 
re-operation rate. 
 
Bariatric surgery patients are at risk of developing nutrient deficiencies following 
surgery, as risk of vomiting compounds, decreased food intake and food intolerance 
(reviewed by Sawaya RA et al 2012). This is further complicated by the reduction in 
gastric secretions and reduction in small bowel surface area for absorption. Therefore it 
is necessary to routinely screen for metabolic bone disease and deficiencies of iron, 
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thiamine, B12, calcium, folate, and Vitamin A and D (reviewed by Sawaya RA et al 
2012). As most patient undergoing bariatric surgery are women of childbearing age 
folic acid and iron levels are particularly important (reviewed by Sawaya RA et al 2012). 
Monitoring every three months in the first year after surgery, every six months in the 
second year, and every 6–12 months in the third year is recommended (reviewed by 
Sawaya RA et al 2012). It is widely recommended that all patients undergo selective 
micronutrient measurements before and after bariatric surgery, and be guided by the 
type of surgical procedure even in the absence of vomiting or diarrhea (reviewed by 
Sawaya RA et al 2012). The supplementation regimen varies according to the 
procedure, following RGYBP multivitamin–mineral preparation with iron, vitamin B12, 
and calcium with vitamin D is common (reviewed by Sawaya RA et al 2012). 
 
Iron deficiency is thought to be prevalent following bariatric surgery, and is thought to 
be multi-factorial; reduced iron intake with reduced meat intake, reduced gastric 
capacity, and reduced hydrochloric acid production leading to reduced conversion to 
Fe
2+
 ion, also limiting the release of iron from structural proteins, and reduction in its 
affinity to specific co-transporters (reviewed by Sawaya RA et al 2012). Following 
RYGBP there is reduced exposure to the duodenum and proximal jejunum, primary 
sites of iron absorption. The presence of peri-operative iron deficiency anemia further 
compounds this problem (reviewed by Sawaya RA et al 2012). The serum iron along 
with the total iron binding capacity is the preferred testing method (reviewed by Sawaya 
RA et al 2012). In some cases, despite appropriate supplementation and addition of 
Vitamin C, intravenous doses of iron gluconate are required (reviewed by Sawaya RA 
et al 2012).   
 
Recent studies point to vitamin D deficiency in up to 60% of obese patients (reviewed 
by Sawaya RA et al 2012). This lipid soluble vitamin is essential to optimize bone 
mineralization and maintain calcium homeostasis (reviewed by Sawaya RA et al 2012). 
Prolonged deficiency can lead to osteopenia, osteoporosis, and hypocalcemia 
(reviewed by Sawaya RA et al 2012). It is thought that adipose tissue is able to take-up 
and clear 1, 25-dihydroxycholecalferol (reviewed by Sawaya RA et al 2012). Multiple 
prospective case series report 50% deficiency and 25% hypocalcaemia after RYGB, 
with the risk of developing metabolic bone disease, and thus lifelong prophylaxis with 
oral calcium and vitamin D supplementation is strongly recommended, calcium citrate 
is significantly better absorbed than its carbonated form, and supra-physiological doses 
are recommended (reviewed by Sawaya RA et al 2012).  
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Vitamin B12 and folate deficiency can lead to macrocytic anemia (reviewed by Sawaya 
RA et al 2012). Further, long-standing B12 deficiency can lead to irreversible neurologic 
sequelae (reviewed by Sawaya RA et al 2012). The reduction in intrinsic factor after 
bariatric surgery leads to vitamin B12 deficiency, leading to about one third developing 
vitamin B12 deficiency after RYGBP (reviewed by Sawaya RA et al 2012). Folate 
deficiency occurs commonly after RYGBP, due to by-passing the proximal small bowel 
where most absorption occurs (reviewed by Sawaya RA et al 2012).  Red cell folate 
and homocysteine levels are measured (reviewed by Sawaya RA et al 2012). The 
reduction in Fat malabsorption can lead to vitamin A deficiency and night blindness or 
ocular xerosis, Vitamin K deficiency may lead to clotting abnormalities and 
chondrogenesis during fetal development, and Vitamin E deficiency with reduced 
antioxidant levels (reviewed by Sawaya RA et al 2012). 
 
The numerous post-prandial symptoms including “dumping syndrome” do pose a 
difficulty in characterizing these set of symptoms (reviewed by Foster-Schubert KE 
2011). Dumping syndrome occurs due to food reaching the small intestine rapidly after 
surgery with the altered anatomy, with ensuing abdominal symptoms of pain, bloating, 
and diarrhea, associated with vasomotor symptoms of flushing, hypotension, and 
tachycardia (reviewed by Foster-Schubert KE 2011). Hypoglycemia occurs late at 1-3 
hours after meals, and typically responsive to dietary modification encompassing 
frequent small, low carbohydrate meals (reviewed by Foster-Schubert KE 2011). 
Medical therapy encompassing: alpha-glycosidase inhibitors (acarbose); somatostatin 
analogs to reduce gastric emptying and inhibit gastrointestinal hormone release, and 
diazoxide to inhibit calcium-induced insulin release have all been tried (reviewed by 
Foster-Schubert KE 2011). Difficult cases rarely require reversal of surgical intervention 
or enteral feeding (reviewed by Foster-Schubert KE 2011). The post-gastric bypass 
hypoglycemia has required more invasive intervention with majority requiring partial 
pancreatic resection at 2 years (reviewed by Foster-Schubert KE 2011). Thus 
establishing symptoms of hypoglycemia confirming low plasma glucose with symptoms 
and relief of symptoms with the correction and concomitant measurement of C-peptide 
together with a negative sulfonylurea screen (Whipple's triad) is useful in order to avoid 
un-necessary invasive intervention (reviewed by Foster-Schubert KE 2011). The timing 
of these measurements has led some to utilize the oral glucose tolerance test (OGTT), 
to induce symptoms and signs. Historically OGTT was used to identify reactive 
hypoglycemia. This test was found to be positive in at least 10% of normal people, 
Continuous glucose monitoring may help document low glucose episodes in free-living 
conditions (reviewed by Foster-Schubert KE 2011).  
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It is not yet clear as to the aetiology of severe, hyperinsulinaemic hypoglycemia 
following RYGBP (reviewed by Foster-Schubert KE 2011). Some propose an extreme 
altered physiology following surgery, bringing metabolic benefit. Others propose an 
underlying genetic predisposition unmasked by surgery. A better understanding of this 
will enable us to prevent this complication, through careful selection (reviewed by 
Foster-Schubert KE 2011). A range of severity in post-gastric bypass patients is 
reported, with mild “dumping syndrome” cases at one end and hyperinsulinemic 
hypoglycemia associated with neuro-glycopenic symptomatology on the other 
(reviewed by Foster-Schubert KE 2011). The former managed with dietary manipulation 
and the latter requiring invasive intervention as outlined above. There was no notion of 
pre-operative hypo-glycaemia in these patients, nor did diabetes state play a part 
(reviewed by Foster-Schubert KE 2011). These symptoms were also absent in patients 
undergoing a restrictive procedure, and pointing to the exclusion of the foregut and 
faster nutrient delivery playing a part (reviewed by Foster-Schubert KE 2011). The 
absolute risk remains low 0.2% post RYGBP, compared to 0.04% of the general 
population (reviewed by Foster-Schubert KE 2011). Beta cell mediated and non-beta 
cell mediated factors have been proposed; hypertrophic islets with obesity, however 
onset is late after surgery, and typically years later. A median time of 2.7 years from 
surgery has been reported; also the lack of incidence with restrictive procedures goes 
against this. The difficulty obtaining pancreatic specimens in appropriately matched 
patients precludes the use of islet morphology in post-gastric bypass hypoglycemia 
(reviewed by Foster-Schubert KE 2011). Interestingly the severity of nesidioblastosis 
does not seem to correlate with duration following RYGBP (reviewed by Foster-
Schubert KE 2011). GLP-1 is a possible candidate as an exaggerated response is seen 
after RYGBP, and with RYGBP patients with neuro-glycopenic symptoms had higher 
GLP-1 matched for duration post-surgery without hypoglycemia, and non-surgical 
weight-matched controls (reviewed by Foster-Schubert KE 2011). GLP-1 does correlate 
to insulin secretion. The post-gastric bypass hypoglycemic patients also had higher 
insulin and C-peptide levels (reviewed by Foster-Schubert KE 2011). It is not yet clear if 
GLP-1 plays a causative role or is simply a marker. The lower ghrelin with its insulin 
counter-regulatory mechanisms has also been proposed to play a part (reviewed by 
Foster-Schubert KE 2011). The opponents site no difference in these peptide hormones 
whilst others site case reports leading to amelioration by feeding through the bypassed 
gut, and suggesting the altered nutrient flow with gastric bypass being the only 
difference causing the exaggerated incretin response and hence hypoglycemia. Other 
as yet unknown factors could play a role; anatomic changes could still contribute, but 
seem unlikely given that reversal of anatomy does not ameliorate the symptoms 
(Foster-Schubert KE 2011).  
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1.19 Gut and islet hormone alterations after RYGBP and SG 
An accurate assessment of appetite scores and gut hormone levels are dependent on 
study design and experimental protocol in human studies on obesity surgery. The 
heterogeneity in study protocols and procedures has led to difficulties in making 
substantial comparison between studies. Though changes in gut hormones favour 
weight loss, correlation between changes in gut hormone secretion and weight loss has 
not yet been shown in humans, but has been shown in rats after RYGBP (Shin AC et 
al, 2010). This discrepancy may be related to study design and sample processing. 
Several studies have looked at gut hormone changes after surgery (Cummings D E et 
al 2002, Langer et al 2005, Korner J et al 2006, Whitson BA et al 2007, Karamanakos 
SN et al 2008, De Paula et al 2009, Y Wang et al 2009, Li F et al 2009, Peterli R et al, 
2009, Bose M et al 2010, Abbatini F et al 2010, Bohdjalian A et al 2010, Basso N et al 
2011, Chambers AP et al 2011). However, not all have measured the active forms of 
the circulating hormone (Cummings D E et al 2002, Langer et al 2005, Korner J et al 
2006, Whiston BA et al 2007, Karamanakos SN et al 2008, De Paula et al 2009, Y 
Wang et al 2009, Li F et al 2009, Bose M et al 2010, Abbatini F et al 2010, Bohdjalian A 
et al 2010, Basso N et al 2011, Chambers AP et al 2011). Further, samples were not 
collected in to tubes containing protease inhibitors to ensure no degradation of these 
peptides occur prior to analysis (Cummings De et al 2002, Korner J et al 2005, Langer 
FB et al 2005, Korner J et al 2006, Whitson BA 2007, Wang Y et al 2009, Li F et al 
2009, Lopez PP et al 2009, Bohdjalian A et al 2010, N Basso et al 2011). This has led 
some authors to admit poor collection practice and being unable to detect consistent 
changes in hormone profiles (Buchwald et al 2007). Some studies that have looked at 
PYY 3-36 and active GLP-1 but have failed to add DPP4 inhibitor to the samples 
(DePaula AL et al 2009, Korner J et al, 2005, Korner J et al 2006, Whitson BA et al 
2007, Karamanakos et al 2008, Li F et al 2009, Valderas JP et al 2010). Other studies 
have shown a low initial hind gut response that increased with the passage of time after 
SG (Peterli R et al 2009), perhaps suggesting a lack of standardisation in study 
protocol. In the case of acyl-ghrelin no study to date has collected blood samples with 
HCL and protease inhibitors to measure this active octanoylated form prior to 
degradation, as per manufacturer’s instructions on assay protocols. The meal 
stimulated acyl-ghrelin is not significantly altered after RYGBP in rats
 
(Shin AC et al 
2010). There have been no studies to investigate meal stimulated PYY3-36 secretion 
after SG. Several studies looked at post operative changes several months to years 
after surgery (Korner J et al, 2005, Korner J et al 2006, Y Wang et al 2009, 
Karamanakos et al 2008, Bohdjalian A et al 2010), perhaps missing early physiological 
changes. Others have compared post-surgical changes in gut hormones against 
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control groups (Cummings De et al 2002, Korner J et al, 2005Lopez PP 2009, Whitson 
BA 2007, Oliván B et al 2009, Bose M et al 2010, Valderas JP et al 2010), and not to 
their pre-operative state, making it difficult to draw conclusions on an individual’s 
physiological changes and corresponding correlations to anthropometry. Comparison of 
matched cohorts can lead to natural inter-individual variation masking true change in an 
individual. Further, it is not possible to make comparisons across temporal profiles of 
individual’s and correlate this to outcome measures.  
No study to date has found a correlation between changes in active gut hormones after 
RYGBP/ SG and changes in perception of hunger, satiety or prospective food 
consumption. This may be because those studies that have looked at visual analogue 
scores (VAS) utilised only two time points per visit to assay change (Korner J et al, 
2005, Korner J et al 2006, Karamanakos et al 2008) and when they did employ several 
time points to measure VAS, suitable inhibitors to prevent degradation of the hormones 
were not added  (Buchwald et al 2007, Karamanakos SN et al 2008, DePaula AL et al 
2009, Valderas JP et al 2010). Also, whilst several studies have examined the change 
in insulin, glucose, insulin resistance (HOMA IR) post RYGBP (Korner J et al 2005, 
Whiston BA et al 2007, De Paula AL et al 2009, Oliván et al 2009, Bose M et al 2010, 
Abbatini F et al 2010, Chambers AP et al 2011, Basso N et al 2011), none have so far 
examined insulin: amylin ratio nor explored the relationship between acyl-ghrelin and 
insulin resistance measured by the HOMA IR model, in morbidly obese individuals 
undergoing RYGBP and SG. A significant increase in meal stimulated amylin secretion 
is seen on rats undergoing RYGBP
 
(Shin AC et al 2010). However, no correlation 
between increased amylin secretion and weight loss is seen (Shin AC et al 2010). 
There have been no studies on meal-stimulated active amylin secretion after SG. 
Sleeve gastrectomy (SG) has gained prominence as a sole operation for morbid 
obesity (Bohdjalian A et al 2010). The gut hormone changes that follow this procedure 
have also been extensively investigated recently
 
(Karamanakos SN et al 2008, Peterli 
R et al 2009, De Paula et al 2009, 2010, Basso N et al 2011, Chambers AP et al 2011, 
Valderas JP et al 2010, Papailiou J et al 2010). Gut hormone changes that occur after 
SG are thought to be similar to that seen after RYGBP, favouring weight loss and early 
satiety (Karamanakos SN et al 2008, Peterli R et al 2009, De Paula et al 2009, 2010, 
Basso N et al 2011, Chambers AP et al 2011, Valderas JP et al 2010, Papailiou J et al 
2010). No study has yet documented paradoxical changes in gut hormones in patients 
who fail to respond to SG, perhaps if failure could be predicted at an early stage and 
second stage procedure instituted on time; this would enable long term weight loss, in 
those patients. 
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Prospective (Sjostrom et al 2004) and retrospective studies (Rosenthal et al 2008) 
have shown resolution of T2DM after bariatric surgery. The mechanism underlying this 
has been attributed to weight loss (Rosenthal et al 2008, Karamanakos SN, et al 2008), 
improved incretin response (Peterli R et al 2009, Li F et al 2009, Dezaki K et al 2008, 
Chambers A P et al 2011) and improvement in insulin resistance independent of weight 
loss (Peterli R et al 2009, De Paula et al 2009). A significant reduction in serum 
glucose, insulin and HOMA IR was seen at two weeks after SG but not in the control 
cholecystectomy group. This remained unchanged at 1 and 2 months after surgery 
despite further significant weight loss (Rizzello M et al 2010), and confirms no role for 
pre-operative interventions. 
1.19.1 Insulin 
A study to compare the effects of SG, RYGBP on glucose homeostasis in morbidly 
obese T2DM patients, that evaluated patients at 3 years after surgery to examine the 
role of weight loss in the resolution of T2DM, found similar resolution rates of 81.2% 
and 80.9% after RYGBP and SG (Abbatini et al 2010). Insulin resistance was restored 
to normal values in all the patients, including those patients with persisting T2DM 
(Abbatini et al 2010). RYGBP and SG led to a significant improvement in fasting 
plasma glucose at 3 months after the surgery. The resolution rate did not alter at 3 
years, however longer follow up has led to halving in resolution of T2DM (Sjostrom et al 
2007). The authors conclude that RYGBP and SG resulted in comparable resolution 
and improvement in glucose homeostasis after surgery (Abbatini et al 2010). In both 
groups resolution occurred at 3 months, and was unchanged at 12 months, despite 
further significant weight loss, between these time points in the two groups, suggesting 
a more direct effect after RYGBP and SG, probably mediated by endocrine 
mechanisms leading to an improvement in glycaemia independent of weight loss 
(Abbatini et al 2010). Interestingly, there was no statistically significant difference in 
weight loss between cured and T2DM patients, in any of the groups. However there 
was a statistically significant difference in the change in BMI between the cured and 
type-2 patients after RYGBP. This was not the case after SG (Abbatini et al 2010). In a 
randomised prospective parallel group study conducted by Peterli and colleagues, the 
fasting insulin concentrations and HOMA indices were significantly reduced a week 
after surgery before any significant weight loss had occurred (Peterli R et al 2009, 
Peterli R et al 2012, Jacobsen SH et al 2012).  
 
Several studies have also explored the role of incretins post RYGBP and SG (Korner J 
et al 2005, Korner J et al 2006, Karamanakos SN et al 2008, De Paula et al 2009, Y 
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Wang et al 2009, Li F et al 2009, Peterli R et al, 2009, Bose M et al 2010, Abbatini F et 
al 2010, Basso N et al 2011, Chambers AP et al 2011). However some of these studies 
have been marred by the lack of standardization, and lack of suitable inhibitors being 
added to prevent degradation of the active hormone moiety (Korner J et al 2005, 
Buchwald et al 2007, Karamanakos SN, et al 2008, DePaula et al 2009). This again 
has led some authors to admit poor collection practice and being unable to detect 
consistent changes in hormone profiles (Buchwald et al 2007). The pronounced GLP-1 
response seen after RYGBP is thought to promote insulin secretion in this group 
(Peterli R et al 2009, Li F et al 2009 and Dezaki K et al 2008). It is thought that the lack 
of such a pronounced GLP-1 response after SG may be compensated for by the 
decrease in ghrelin seen after SG and this is thought to lead to improved insulin 
sensitivity after SG (Peterli R et al 2009, Li F et al 2009 Papailiou J et al 2010, and 
Peterli R et al 2012).  
 
Sleeve gastrectomy (SG) has gained prominence as a sole operation for morbid 
obesity (Bohdjalian A et al) and T2DM (DePaula AL et al 2009, Karamanakos SN et al 
2008, Peterli R et al 2008, BassoN et al 2011, Chambers A P et al 2011). Studies on 
patients undergoing SG to explore the role of incretins in patients with a lower BMI and 
more advanced diabetes (De Paula et al 2009), found SG in combination with proximal 
ileal inter-position led to an exaggerated incretin response, restoration of the first phase 
insulin secretion and resolution of T2DM in two thirds of patients. However, the incretin 
response was probably under-estimated due to the lack suitable inhibitors to prevent 
degradation (De Paula et al 2009). The gut hormone changes that follow this procedure 
have also been extensively investigated recently
 
(DePaula A L et al 2009, 
Karamanakos SN et al 2008, Peterli R et al 2008, Valderas JP et al 2010, Papailiou J 
et al 2010, BassoN et al 2011, Chambers A P et al 2011), and are thought to be similar 
to that seen post RYGBP. Faster gastric emptying
 
(Braghetto I et al 2009) and small 
bowel transit time
 
(Shah S et al 2010) post-surgery is thought to lead to quick delivery 
of nutrients to the hindgut and in-turn evoke a hind gut incretin hormone response not 
dissimilar to that seen following RYGBP (Peterli R et al 2009), leading to an 
improvement in insulin secretion (DePaula AL et al 2009).  
 
1.19.2 Ghrelin 
There has been much debate on the importance of ghrelin after LSG (Langer FB et al 
2005, Frezza E E et al 2008). Several studies have assessed the impact of bariatric 
surgery on circulating ghrelin measuring both total (acyl- and desacyl-ghrelin) or acyl-
ghrelin in the fasted and/ or meal-stimulated state (le Roux et al 2006, Korner et al 
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2005, Karamanakos et al 2008, C. Holdstock et al 2003, M. Sundbom et al 2007, 
Leonetti et al 2003, Wang and Liu, 2009). Some groups have reported significantly 
increased circulating ghrelin levels post-RYGB (Holdstock et al 2003, Sundbom et al 
2007), whilst others showed no difference in circulating ghrelin levels after RYGB (le 
Roux et al 2006, J. Korner et al 2005, S.N. Karamanakos et al 2008, F. Leonetti et al 
2003). Total ghrelin is known to be elevated after diet induced weight loss
 
(Oliván B et 
al 2009) and it was initially thought that a decrease in total ghrelin after SG may explain 
the superior weight loss and maintenance of weight loss after LSG (Langer FB et al 
2005). However, a recent meta-analysis of several studies was unable to reach a 
conclusion
 
(Frezza E E et al 2008). A recent review points out that patients actively 
undergoing weight loss exhibit increased circulating ghrelin concentrations while this is 
not the case in weight stable patients (reviewed by Karra E et al 2010). These findings 
indicate that overall energy balance might be a more important determinant for 
postsurgical circulating ghrelin levels and explain the discrepancy between studies (M. 
Faraj et al 2003). To date no study has measured acyl-ghrelin, the active octanoylated 
form collected under standardised conditions to prevent degradation as recommended 
by the assay. The meal stimulated acyl-ghrelin is not significantly altered after RYGBP 
in rats
 
(Shin AC et al 2010). The significant decline in acyl-ghrelin after SG is thought to 
be due to the complete removal of the gastric fundus, the segment of the stomach, 
thought to produce the vast majority of acyl-ghrelin
 
(Langer F B et al 2005). The vagus 
nerve is also thought to play a part in this response (Papailiou J et al 2010). The 
suppression of ghrelin secretion seen after RYGBP is thought to be secondary to a 
permanent deprivation of nutrient stimulation to oxyntic gland cells responsible for the 
production and release of acyl-ghrelin (Papailiou J et al 2010). In support of this, recent 
evidence also points to prolonged fasting leading to a decline in acyl-ghrelin in the 
plasma (Papillou J et al 2010). Others have suggested that the absence of food from 
the stomach and duodenum after bypass surgery could lead to suppression of ghrelin 
by override inhibition, and this favours weight loss after RYGBP surgery (Cummings et 
al 2002). It is not yet clear if the reduced production of acyl-ghrelin seen after SG is 
temporary that may be reversed over time, through post-surgical gastric hyperplasia or 
other gastro-intestinal sites such as the duodenum taking over acyl-ghrelin production. 
Alternatively the central orexigenic effect of ghrelin may be restored by adaptations at 
the central sites of ghrelin action (Papailiou J et al 2010). Conversely ghrelin is 
increased in weight-matched subjects who achieved similar weight loss with dieting and 
therefore lead to compensatory food intake (Cummings et al 2002, Korner J et al 2005). 
Studies in patients undergoing SG report a significant and sustained decrease in 
fasting and meal-stimulated ghrelin concentrations immediately after surgery 
(Karamanakos et al 2008, Wang and Liu 2009, Peterli R et al 2012). Therefore it is 
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plausible that reduced ghrelin post surgery plays a role in mediating weight loss and 
improved glucose homeostasis after bariatric surgery. 
The many effects of acyl-ghrelin linked to insulin resistance (eg suppression of the 
insulin-sensitizing hormone adiponectin, blocking of hepatic insulin signalling and 
inhibition of insulin secretion, increase in growth hormone cortisol, and epinephrine 
secretion) may be the reason why decreased acyl-ghrelin secretion after SG may help 
restore insulin sensitivity (Peterli R et al 2009). This has led some to speculate that the 
weight independent resolution of T2DM and improvement in glucose homeostasis seen 
after bariatric surgery may in part be mediated by acyl- ghrelin (Papailiou J et al 2010). 
The decline in acyl-ghrelin is thought to facilitate maximal capacity in the islets enabling 
the islets to respond adequately to the hyperglycaemia and meet the increased 
demand associated with obesity (Papailiou J et al 2010). Ghrelin is also known to 
decrease insulin secretion in vitro and in vivo ((Dezaki et al, 2008; Reimer et al, 2003). 
In the SG group where acyl-ghrelin is significantly reduced after surgery, the 
improvement in glucose homeostasis will lead to improvements in Type-2 DM (Peterli R 
et al 2012). 
1.19.3 Peptide tyrosine tyrosine 
A study to compare surgical intervention against medical treatment for obesity was able 
to achieve similar weight loss after RYGBP, SG, and medical treatment. However 
favourable PYY change was only seen after RYGBP and SG. The meal stimulated total 
PYY AUC did increase significantly after RYGB and SG, the magnitude of increase was 
significantly higher in the RYGBP group compared to the SG group and lean controls 
(Valderas JP et al 2010). Two studies reported comparable increases in fasting and 
meal-stimulated circulating PYY levels following RYGB and SG (Peterli et al 2009, S.N. 
Karamanakos et al 2008). A recent publication highlighted a similar pronounced hind-
gut response after SG to that seen after RYGBP (Peterli R et al 2009). The one study 
to investigate PYY3-36 in patients undergoing RYGBP studied PYY3-36 response to a 
3 hour glucose tolerance test (GTT) (Oliván B et al 2009). It is known that the meal 
stimulated total PYY response following SG is similar to that seen after RYGBP (Korner 
J et al 2005, Karamanakos SN et al 2008, Peterli R et al 2012). Fasted and meal 
stimulated PYY levels were noted to be elevated for up to twenty years after bypass 
surgery in humans (Naslund et al 1997). The numbers of enteroendocrine cells 
containing PYY are significantly increased at 30 years after by-pass surgery (Ockander 
et al 2003). This increase was in comparison to obese and normal weight controls, 
suggesting JIB increases PYY-containing cells (Ockander et al 2003). PYY levels are 
increased after JIB associated with a decrease in food intake, and PYY-antisera 
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increased food intake, indicating a role for PYY in mediating reduced food intake after 
bariatric surgery (le Roux et al 2006). Subsequent studies have since consistently 
reported increases in fasting and/or meal-stimulated PYY levels after RYGB (Korner J 
et al 2005, Morinigo et al 2006 and Korner J et al 2006, Peterli R et al 2009, Peterli R et 
al 2012, Jacobsen SH et al 2012, Yousseif A and Emmanuel J et al 2013). Three 
studies reported comparable increases in fasting and meal-stimulated circulating PYY 
levels following RYGB and SG (Peterli et al 2009, S.N. Karamanakos et al 2008, and 
Peterli R et al 2012). In summary, there appears to be a clear trend towards increased 
PYY levels after bariatric surgery. Overstimulation of the hindgut by increased nutrient 
exposure is the likely explanation for this exaggerated response. Recent evidence 
points to a more direct effect of PYY3-36 on insulin sensitivity (van den Hoek et al 
2007), PYY3-36 is known to be co-secreted with GLP-1 by intestinal L cells in response 
to food intake, the role of PYY3-36 on insulin sensitivity independent of food intake is 
not confirmed (Papailiou J et al 2010). 
1.19.4 GLP-1 
The vast majority of studies have shown increases in basal and/or nutrient-stimulated 
GLP-1 levels after RYGBP (le Roux C W et al 2006, Korner J et al 2005, Morinigo R et 
al 2006 and Korner J et al 2007, Peterli R et al 2009, Peterli R et al 2012, Jacobsen SH 
et al 2012). Some recent studies have examined the role of active GLP-1 in patients 
undergoing RYGBP and SG (Peterli R et al 2009 and DePaula AL et al 2009, Basso N 
et al 2011, Chambers A P et al 2011, Peterli R et al 2012, Yousseif A and Emmanuel J 
et al 2013)
 
 though one study did not add DPP4 inhibitor to the samples (DePaula AL et 
al 2009), and a second had much lower plasma levels (Peterli R et al 2009), suggesting 
differences in collection protocols. Another recent study in rodents undergoing RYGBP 
found a significant post-prandial increase in GLP-1 that led to significantly higher post 
prandial plasma insulin, higher than lean controls, and significantly improved insulin 
resistance. The 20 minute peaks of GLP-1 and insulin did correlate after RYGBP. 
Further, there were significantly lower post-prandial plasma glucose levels reaching 
that of lean controls (Shin AC et al 2010). The study by Peterli and colleagues points to 
similar changes in GLP-1 after both RYGBP and SG (Peterli R et al 2009, Peterli R et 
al 2012). Although SG entails no mal-absorptive component, accelerated gastric 
emptying is thought to mediate this. However, a progressive decrease in gastro-
esophageal reflux following SG is noted and may be indicative of increasing gastric 
compliance with time. These adaptive changes post-SG could potentially alter gastric 
emptying and consequently GLP-1 levels (J. Himpens et al 2006). A significant and 
similar decline in fasting glucose, insulin and HOMA-IR was seen in two groups after 
the loss of 10 kg when diet therapy and RYGBP were compared. However, a significant 
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increase in GTT stimulated GLP-1 occurred only after RYGBP but not after diet 
induced weight loss (Oliván et al 2009). This suggests that RYGB per se rather than 
weight reduction mediated the increased in GLP-1 (Laferrere B et al 2008, Ahren B et 
al 2003). A very recent publication compared GLP-1 (7-36) after RYGB and SG using a 
model of high fat diet-induced obese hyper-insulinaemic rats (Chambers et al 2011-b). 
The two bariatric surgery procedures led to a comparable improvement in glucose 
tolerance and GLP-1(7–36) secretion (Chambers AP et al 2011-b). The authors 
demonstrate that these improvements in glucose homeostasis are weight independent 
and GLP-1 (7-36) dependent (Chambers AP et al 2011- a). However, these studies 
were undertaken several months after the procedures. Basso and colleagues also 
recently demonstrated an improvement in glycaemia after SG mediated by restoration 
of the first phase of insulin secretion in diabetic obese patients mediated by GLP-1 
(Basso N et al 2011). 
1.19.5 Amylin 
It is thought that amylin synthesis and secretion may be under the influence of GLP-1 
(Ahrén B et al 1997), and amylin in turn may mediate some of the biological actions of 
GLP-1 (Asmar M
 
et al 2010).  A significant increase in meal-stimulated amylin secretion 
is seen in rats undergoing RYGBP
 
(Shin AC et al 2010), though contrary to others who 
reported a decrease in amylin after RYGBP (Mousumi Bose et al 2010). Bose and 
colleagues found a non-significant decline in amylin after RYGBP. However, a decline 
in amylin in the diet induced weight loss control group suggests that sample collection 
and processing may have played a part in this un-expected result (Mousumi Bose et al 
2010). Others have found a significant increase in amylin when SG is combined with an 
ileal interposition on to the proximal duodenum and proximal jejunum (DePaula AL et al 
2009). However, no correlation between increased amylin secretion and weight loss is 
seen (Shin AC et al 2010). There have been no studies on meal stimulated active 
amylin secretion after SG. 
1.20 Improvement in mortality after bariatric surgery 
 A recent longitudinal study found that the overall mortality of obese patients was 
0.68% in the surgically treated group (vertical banded gastroplasty and Roux-en-Y 
gastric bypass) and 6.17% in obese patients who had not had bariatric surgery 
(Christou et al 2004). The Swedish Obese Subjects Study also found fewer deaths 
related to myocardial infarction and cancer in the surgically treated group (Sjostrom et 
al 2007), and Adams et al found a 40% reduction in mortality in surgically treated obese 
patients (Adams et al 2007).  Even when the risks of death associated with surgery are 
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taken into account, the patients who have surgery are more likely to be alive a year 
after surgery than the patients who choose conservative treatment (Christou et al 
2004). 
1.21 Resolution of co-morbidities after bariatric surgery 
In addition to the significant weight loss associated with bariatric surgery, vast 
improvement in hyperlipidaemia, hypertension, obstructive sleep apnoea and T2DM 
has been reported (Buchwald et al 2009, Sjostrom et al 2004) and surgery has been 
directly linked with a reduction in mortality from diabetes related illness, cardiovascular 
diseases and cancer (Adams et al 2007). The SOS study also showed that surgical 
intervention leads to considerable improvements in obesity related co-morbidities and 
heath related quality of life when compared to patients treated with diet alone (Sjostrom 
et al 2004). At two years, the incidence of hypertension is 3% in surgical patients, and 
10% in those receiving conventional treatment (10%) (Sjostrom et al 2004). Bariatric 
surgery is associated with weight loss and improvements in glucose homeostasis 
(Buchwald et al 2009). A long-term controlled bariatric surgical intervention study on 
obesity showed that surgery resolved or markedly improved diabetes, reduced 
myocardial infarction by 43%, and provided a 31% reduction in overall mortality. 
Interestingly, the benefit in the reduction of myocardial infarction and overall mortality 
was almost exclusively seen in diabetic patients. The patients were matched by age, 
sex, BMI, and co-morbidities and both groups were followed for 15 years (Sjostrom et 
al 2006). Another meta-analysis of 22,094 patients where the mean age was 47 years, 
and mean BMI 46, showed diabetes resolution in 76.8% of patients and improvement in 
86.0%. Further, other co-morbidities were also significantly improved after surgery. This 
included hyperlipidemia, which improved in ≥70% of patients, and hypertension which 
resolved in 61.7% and improved in 78.5%. Obstructive sleep apnea was resolved in 
85.7% of patients (Buchwald et al 2004). A smaller long-term follow-up study of 342 
severely obese patients who underwent gastric bypass in New Zealand also confirms 
excellent long-term outcomes. The excess weight loss after 1, 5, and 10 years were 
89%, 70%, and 75% respectively. In addition, hypertension was resolved in 62% of 
individuals, and a further 25% had improved blood pressure. T2DM was resolved in 
85%, and a further 10% showed improvement (White et al 2005). The weight loss and 
improvement in co-morbidities seen after surgery are maintained in the longer term 
(White et al 2005).  
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1.22 Bariatric surgery leads to an improvement in glucose homeostasis 
Morbid obesity is known to be associated with insulin resistance and insulin hyper-
secretion by the pancreatic β cells. However, β-cell function, β-cell glucose sensitivity, 
and potentiation are preserved (Camastra et al 2007). Diabetes is characterized by a 
progressive loss of β-cell function, independent of insulin resistance (Ferrannini et al 
2005). Bariatric surgery leads to a 2-3 fold improvement in insulin sensitivity. This is 
seen early after surgery before any substantial weight loss has occurred. The absolute 
insulin secretion decreases significantly after bariatric surgery (Kopp et al 2003, 
Wickremesekera et al 2005 Camastra et al 2005). The mechanisms underlying these 
dramatic effects on insulin sensitivity and β-cell function are yet to be elucidated. 
However, several mechanisms have been proposed (Cummings et al 2007). Among 
them, caloric restriction and changes in gut hormone release have received the most 
attention. Studies suggest that gastric bypass surgery results in an effective cure of 
T2DM in up to 79 % of cases (Buchwald et al, 2009). Hence surgery is now cautiously 
being considered as a treatment for T2DM in individuals with BMI’s lower than the 
ranges prescribed by the current healthcare guidelines (Cummings and Flum 2008). A 
systematic review and meta-analysis of the resolution of T2DM after bariatric surgery 
also found a 78% total remission rate, and an improvement in 87% (Buchwald et al 
2009). The relative effectiveness in resolving T2DM for Roux-en-Y gastric bypass was 
80.3% (Buchwald et al 2009).  
 
Others have reported much lower rates of remission at 5 years; complete and partial 
remission rates were 24% and 26%, and 16% remained unchanged (Brethauer SA et al 
2013). Shorter duration of T2DM and higher long-term weight loss predicted long-term 
remission (Brethauer SA et al 2013). Recurrence was associated with longer duration 
of T2DM and weight regain (Brethauer SA et al 2013). Thirty-four percent of all patients 
had improvement in long-term diabetes control (Brethauer SA et al 2013). Overall, 
patients were taking fewer numbers of diabetic medications and requiring insulin 
therapy (Brethauer SA et al 2013). Patients with T2DM of 5 years or less had a high 
76% long-term remission rate, compared with a 21% in those with longer duration 
(Brethauer SA et al 2013). There is generally agreement that RYGBP achieve higher 
rates of remission than procedures involving restriction of the gastric fundus and longer 
duration of T2DM have lower remission rates (Brethauer SA et al 2013).  
A recent study to assess long term remission of diabetes after RYGBP noted 62% 
remission of diabetes maintained at 6years (Adams TD et al 2012). The mean total 
weight loss in the surgical group changed from 35% to 28% along with diabetes 
remission from 75% to 62% (Adams TD et al 2012).The pooled T2DM remission in four 
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studies with only T2DM patients highlighted a 22 times higher remission with bariatric 
surgery when compared to conservative approaches. However, Different definitions for 
diabetes remission were used. A conservative estimate puts remission at five times 
after bariatric surgery (Gloy et al 2013). 
 
1.23 The economic costs of obesity can be counteracted by obesity surgery  
A recent study attempted to quantify the effect of bariatric surgery on direct medical 
costs (Cremieux  et al 2008). This study assessed the time required for third-party 
payers to recover the initial investment associated with bariatric surgery (the return on 
investment). Each bariatric surgery patient was matched to controls on multiple 
baseline characteristics, including age, sex, total pre-surgery medical costs, and co-
morbid conditions, the control group of morbidly obese patients never underwent 
bariatric surgery (Cremieux  et al 2008). Total surgery costs are fully recovered after 53 
months. Costs of open surgery performed between 1999 and 2002 are fully recovered 
after 77 months and, as expected, costs of open surgery performed between 2003 and 
2005 are recovered after 49 months. The costs associated with laparoscopic surgery 
are fully recovered after 25 months. These returns on investment result from reductions 
in prescription drug costs, physician visit costs, and hospital costs (including 
emergency department visits and inpatient and outpatient visits). The reduced costs 
are associated with multiple diagnosis categories, including diabetes mellitus, coronary 
artery disease, hypertension, and sleep apnoea (Cremieux  et al 2008). This study 
demonstrates significant cost savings start accruing after 25 months for patients 
undergoing laparoscopic bariatric surgery. The study also shows that, whilst bariatric 
surgical costs took more than 6 years to be fully recovered in 2002, this was reduced to 
just over 2 years in 2005 for laparoscopic bariatric surgery. Examination of the cost per 
quality adjusted life year (QALY) for bariatric surgery has shown that bariatric surgery 
in European countries is also more cost effective than conventional treatment (Ackroyd 
et al 2006). Further a study of patients in employment found that significantly more 
worked after surgery than before (76% v 58%). Further, significantly more patients 
worked longer hours than they did before (35.8 h v 30.1 h), and fewer patients claimed 
welfare benefits (Hawkins et al 2007). Suggesting that the economic benefits to the 
individual and economy are further enhanced. 
1.24 Our hypothesis and rationale for the study 
Recent studies have compared weight loss and resolution of T2DM after RYGBP and 
SG (Karamanakos SN et al 2008, Peterli R et al 2009, and Valderas JP et al 2010, 
Chambers AP et al 2011, Kehagias I et al 2011, Woelnerhanssen B et al 2011, Peterli 
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R et al 2012, Ramon JM et al 2012). The mechanisms mediating weight loss and 
amelioration of T2DM after these procedures are yet to be fully elucidated. We 
conducted a prospective parallel group study to examine changes in fasting and meal 
stimulated gut hormones and subjective measures of hunger, fullness and prospective 
food consumption simultaneously after RYGBP and SG in a tertiary care hospital 
setting. Exclusion criteria were: male, smokers, positive hepatitis B or C status. 
Patients were studied at three time points; week before surgery, 6 and 12 weeks post 
surgery, to coincide with routine surgical follow up.  Each Individual was compared 
against themselves. The hormones studied in this thesis are insulin, leptin, acyl-ghrelin, 
glucagon-like peptide-1 (GLP-1), peptide tyrosine-tyrosine (PYY) and amylin. We 
hypothesized a similar hind gut hormone response after RYGBP and SG. However, we 
proposed that acyl-ghrelin and amylin would be differentially altered following these 
procedures. We also hypothesized that the change in active plasma gut hormones may 
mediate the loss of weight through changes in appetite and satiety, and that the 
improvement in glucose and insulin resistance may also be mediated through active 
plasma gut hormones.    
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2.1 Suppliers  
Laboratory plastics, pipette tips, solvents and reagents were purchased from Sigma 
Aldrich (Sigma Aldrich, Dorset, UK), Invitrogen (Invitrogen, Paisley, UK) or VWR (VWR, 
Lutterworth, UK), if otherwise, it is indicated in the text. All clinical supplies were 
obtained through the NHS Supply Chain (NHS Supply Chain, Alfreton, UK). Purified 
and deionised water from an Elga water purification system was used in the 
experiments conducted (Elga; Veolia, Wycombe, UK). 
2.2 Bariatric study  
We conducted a prospective parallel group study on patients undergoing RYGBP and 
SG to measure changes in fasted and meal-stimulated active gut peptide hormones 
PYY3-36, acyl-ghrelin, GLP-1, active amylin and subjective measures of appetite 
simultaneously in a tertiary care setting, in order to study the mechanisms mediating 
weight loss after RYGBP and SG. Exclusion criteria were: male, smokers, positive 
hepatitis B or C status. Patients were studied at three time points; week before surgery, 
6 and 12 weeks post surgery, to coincide with routine surgical follow up.  Each 
individual was compared against themselves.  
2.2.1 Ethics 
 
Ethical approval was obtained from the University College London Hospital research 
ethics committee. The study was carried out in accordance with the principles of the 
Declaration of Helsinki. Patients attended a preliminary screening session where they 
received both oral and written information about the study. An informed consent form 
was completed on the first day of the study. Data was collected stored in accordance 
with the Data Protection Act 1998. 
2.2.2 Subject recruitment 
 
Patients undergoing Roux-en-Y gastric by-pass and sleeve gastrectomy surgery  
who met the inclusion criteria (females aged 18-65 with a BMI of 40-55 Kg/m2) and 
exclusion criteria (male, smokers, positive hepatitis B or C status) were invited to 
participate in the study. 
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A consort flow diagram to illustrate patient assignment to surgical procedure through an 
multi-disciplinary team (MDT) approach. CNS- clinical nurse specialist.  
 
The patient is seen by the psychologist, dietician, bariatric surgeon and bariatric 
physician. The best choice of procedure was discussed based on clinical criteria, by the 
multidisciplinary team. The patient was reviewed by the clinical nurse specialist and 
details of the study discussed with the aid of a leaflet. If the patient agreed to 
participate, then the patient was reviewed by the clinical research fellow (Julian 
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to discuss 
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Emmanuel). The clinical assessment formed the basis of choice, and as such could 
have introduced a selection bias in the patients recruited. Every patient meeting 
inclusion and not conforming to the exclusion criteria was given the opportunity to take 
part in the research study.  
2.2.3 Subject standardisation and acclimatization  
 
Patients followed a standardization and acclimatization protocol (Chandarana K et al 
2009). Patients were asked to refrain from alcohol on the day before the clinical study. 
They consumed a standard meal between 7PM and 8PM on the night before the study. 
They were then asked to fast with water only till 9AM on the study morning. Patients 
attended the clinical research centre at 9AM. Patients were cannulated and then rested 
for an hour to accommodate the stress of cannulation. 
2.2.4 Blood collection 
 
On arrival at the clinical facilities, a 20-gauge cannula (BD, Oxford, UK) was placed in 
the patients forearm vein by aseptic technique. A three-way tap (BD, Oxford, UK) was 
attached to the cannula and secured. The three-way tap was used for all subsequent 
blood collection. It was flushed with normal saline (BD, Oxford, UK) after each 
collection. Blood was collected into chilled syringes and immediately transferred to 
vaccutainers (BD, Oxford, UK) coated with ethylenediaminetetraacetic acid (EDTA). All 
blood samples were collected and processed according to the manufacturers’ 
instructions of the commercially available assays that were subsequently used for 
quantification of hormones. 
2.2.5 Standard meal 
 
Patients were asked to consume a 250 ml liquid meal (Resource 2.0+fibre, Nestle, UK) 
over fifteen minutes at the end of the rest period. Baseline blood samples were taken 
prior to the meal. The nutritional composition of the meal is outlined in Figure- 13. 
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Constituent Per 100 ml Per meal 
Energy (Kcal) 200 500 
Protein (g) 9 22.5 
Carbohydrate (g) 21.4 53.5 
of which sugars (g) 6 15 
Fat (g) 8.7 21.75 
of which saturated fatty acid 
(g) 0.54 1.35 
Mono-unsaturated fatty acid 
(g) 5.43 13.575 
Poly-unsaturated fatty acid 
(g) 2.72 6.8 
Fibre (g) 2.5 6.25 
 
Figure-12; The nutrient composition of the liquid meal given to patients after an 
overnight fast. 
2.2.6 Reagents added to blood to prevent degradation of active hormone. 
 
Reagent    Location Amount Manufacturer 
DPP-IV inhibitor  Syringe 10 μl/ml blood  
Millipore, Watford, 
UK 
Aprotinin (Trasylol) Vaccutainer 5000 KIU/ml blood 
Bayer, Newbury, 
UK 
HCl (1 N) Plasma Tube  50 μl/ml plasma 
Sigma, Dorset, 
UK 
4-(2-Aminoethyl)-
benzenesulfonyl 
fluoridehydrochloride 
(AEBSF) Plasma Tube 100 mg/ml Fluka, Dorset, UK 
 
Figure-13; The protease inhibitors and HCL added to blood samples or plasma to 
prevent degradation of the active hormone assayed.  
2.2.7 Visual analogue score 
 
Subjective appetite, satiety, prospective food consumption nausea and irritability were 
assessed through visual analogue scores (VAS). Each VAS was 100 mm in length with 
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text expressing the most positive and the negative ratings anchored at either end 
(Batterham et al 2007). VAS has been validated for the assessment of subjective 
hunger and satiety with a high degree of reproducibility (Flint A, 2000; Raben et al, 
1995). Subjects were instructed to place a cross on a linear scale and complete each 
scale. Subjects were discouraged from looking at their previous scores.  An example of 
the VAS sheet is displayed below (figure-15). VAS was measured with the aid of a 
300mm ruler; and the measurement from the negative end was recorded.  The actual 
value and the change from baseline (which was defined as score at t=0) calculated and 
recorded for each time point at each visit. The area under curve (AUC) for each 
individual visit was calculated utilizing the trapezoidal method. The change in AUC was 
used to analyze correlation to change in plasma hormones. 
 
 
 
 
 
 
 
 
 
 
 
 
84 
 
PLEASE PLACE A CROSS AT THE POINT WHICH REPRESENTS YOUR ANSWER.  
HOW HUNGRY DO YOU FEEL RIGHT NOW? 
 
 
 
         
NOT AT ALL       EXTREMELY 
 
 
HOW MUCH DO YOU THINK YOU COULD EAT RIGHT NOW? 
 
 
 
         
NOTHING       THE MOST I’VE  
EVER EATEN 
 
 
HOW FULL DO YOU FEEL RIGHT NOW? 
 
 
 
         
NOT AT ALL       EXTREMELY 
 
 
HOW SICK DO YOU FEEL RIGHT NOW? 
 
 
 
         
NOT AT ALL       EXTREMELY 
 
 
HOW IRRITABLE ARE YOU RIGHT NOW? 
 
 
 
         
NOT AT ALL       EXTREMELY 
 
 
 
 
Figure-14; A sample VAS score sheet. 
2.2.8 Hormone assays 
All assays were performed according to the manufacturer’s instructions. 
Hormone Assay  Sensitivity Intra-assay 
variation 
Inter assay 
variation 
Catalogue 
number 
Insulin RIA 2 µU/ml 2.9 9.1 HI-14 HK 
PYY3-36 RIA 20 pg/ml 4.4 8.9 PYY-67 HK 
Acyl-ghrelin RIA 7.8 pg/ml 4.0 9.4 GHRA-88 HK 
Leptin ELISA 0.5 ng/ml 3.3 N/A EZHL-80 SK 
Active GLP-1  ELISA 2 pM 5.8 2.3 EGLP-35 K 
Amylin ELISA 1 pM 4.4 3.6 EZHA-52 K 
 
Figure-15; A list of all the assays used to measure plasma hormone levels in the study 
is listed. All assays were purchased from Millipore (Millipore, Watford, UK). 
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2.2.9 Radioimmunoassay (RIA) 
 
RIAs were used to quantify hormones in plasma samples. The principle of a RIA is 
based on competitive binding between a fixed quantity of radioactively (Iodine-125, 
125
I) 
labeled tracer antigen molecule of interest and a known concentration of standards of 
that antigen. This reaction utilises a constant volume of antibody with a fixed amount of 
binding sites, to the antigen molecule of interest. The amount of tracer bound to the 
antibody is proportionate to the concentration of the un-labelled antigen in solution. The 
binding of unlabeled antigen to antibody competitively inhibits tracer binding. The 
antibody-bound tracer antigen is precipitated from free tracer in solution. The 
radioactivity in the precipitate is measured with a gamma counter. The bound tracer 
antigen radio-activity is plotted against known standards, and this standard curve is 
utilized to measure samples with unknown concentration of antigen molecule of 
interest. 
 
All RIA kits have similar protocols with hormone (antigen) specific reagents, antibodies 
and tracers. All reactions were carried out in duplicate. Each labelled polystyrene test 
tube (12 x 75 mm), apart from the total count tubes (TC) had the same reaction volume 
of 300 µl. The total count tubes had only the tracer added on the second day (100 µl). 
The non-specific binding tubes (NSB) consisting of assay buffer alone were utilized to 
assess background binding. The total binding tubes (Bo) with assay buffer (200 µl) and 
antibody (100µl) was utilized to assay the total binding capacity of the antibody. This 
ranges from 35-50% in each assay. Six serial dilutions of a known standard supplied by 
the manufacturer was undertaken to construct the standard curve. In all the other 
tubes, 100 µl assay buffer, 100 µl known standards (standard curve) or 100 µl of 
unknown samples and 100 µl antibody was added. This mixture was vortexed, and 
underwent incubation for 20-24 hours at 4 °C. The tracer was added on the second 
day, and again the reaction mixture vortexed, and incubated overnight for 20-24 hours 
at 4 °C. On the final day of the assay, 1 ml of precipitating reagent was added to all 
tubes except TC tubes. Tubes were vortexed and incubated for 20 minutes at 4 °C, and 
all tubes except the TC tubes were centrifuged at 10,000 rpm for 20 minutes at 4 °C. 
The supernatant was aspirated with the aid of a glass pipette and the radioactivity in 
the precipitate was quantified with a gamma emission counter (Packard Cobra, MN, 
USA). A flow chart of this procedure is presented in figure-17.  
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Figure-16; sample flow diagram for RIA 
 
The average count from the duplicates was calculated. The average NSB value was 
subtracted from all the average counts. These values were used for subsequent 
calculations. The percentage binding for each sample was calculated by dividing the 
average counts by the total binding (Bo) count. The measured counts per minute of 
radiation are proportional to the amount of bound labeled tracer antigen antibody 
complex. A standard curve graph of known concentration versus percentage binding 
constructed, and the concentrations of unknown samples extrapolated from this curve. 
The assay was accepted if the quality controls measured with the assay were within the 
range provided by the manufacturer. Quality controls supplied by the manufacturer 
were run in duplicate. The quality control sample values from each assay were utilized 
to calculate inter-assay variability. Intra-assay variability was calculated from the mean 
variability in the standard curves. 
2.2.10 Enzyme linked immunosorbant assay ELISA 
 
ELISA’s were used to quantify the concentrations of peptide hormones in plasma. The 
principle of an ELISA is based on capture of the antigen molecule of interest with an 
immobilised biotinylated antibody; this is followed by the attachment of an enzyme to 
this antigen-antibody complex and proportional conversion of a substrate to an end 
product that can be quantified with a spectrophotometer. The hormone (antigen) 
specific ELISA plate, reagents, and protocol varied between assays. All samples were 
done in duplicate. The following is an overview of the assay procedure. The 96-well 
plate coated with a pre-titred amount of specific monoclonal antibody to the hormone 
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molecule of interest was washed with 300 µl wash buffer to initiate the assay. This was 
decanted and residual buffer removed by tapping smartly on to absorbent paper. A 
specified amount of assay buffer was added to all wells apart from the standard curve 
wells. Matrix solution (consisting of charcoal-stripped plasma) was added to the 
standard curve and NSB wells. Then known standards, quality controls and unknown 
samples were added to the plate. This is followed by a constant volume of detection 
antibody to each well to allow formation of antibody-protein complexes with biotinylated 
polyclonal antibodies, the plate sealed and incubated for 2 hours at room temperature 
on an orbital microtitre plate shaker set at 600 rpm. The plastic film was removed, the 
contents of the wells decanted and residual solution removed as above, the plate was 
washed 3 times to remove unbound material, each wash followed by tapping the plate 
on to absorbent paper. Then a specified amount of enzyme solution was added to each 
well; the plate sealed again and incubated on the plate shaker for a further 30 minutes. 
At the end of the incubation period the contents of the wells were decanted and 
residual solution removed as above. The plate was washed 5 times to remove all 
unbound materials, each wash followed by tapping smartly onto paper towels. Finally, a 
specified amount of substrate solution was added to each well and the plate covered 
with foil to prevent degradation of the light sensitive substrate. This reaction was 
terminated after 15 minutes by the addition of an acidic buffer. The substrate 
concentration in each well was measured by a spectrophotometer, within 5 minutes. A 
sample flow diagram of assay procedure is attached below (figure-18). 
 
The enzyme and substrate used for the leptin ELISA was horseradish peroxidase and 
3,3’5,5’ tetramethylbenzidine (TMB). The end product of TMB degradation is a coloured 
product. The active GLP-1 and active amylin ELISA both utilize alkaline phosphatase 
as the enzyme and methyl umbelliferyl phosphate (MUP) as substrate. The MUP 
degradation product is fluorescent. The concentration of the end products in each well 
was measured spectrophotometrically through absorbance (leptin) or fluorescence 
(GLP-1 and amylin) on a plate reader. The results were analysed with Magellan 
software (Tecan, Reading, UK). As with RIA, an average of the duplicates was 
calculated. A standard curve constructed from known standards. The concentrations of 
the unknown samples were extrapolated from this curve. The assay was accepted if 
the manufacturer’s quality control fell within the manufacturer’s specified range.  
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Figure-17 sample flow diagram for ELISA 
2.2.11 Glucose assay 
 
The glucose oxidase method was employed to assay plasma glucose concentrations in 
plasma samples. The glucose oxidase reaction with an auxiliary hydrogen peroxide 
indicator reaction which couples 4-aminoantipyrine to a coloured phenolic compound 
was used to determine glucose concentration. The amount of phenolic compound 
formed is proportional to the glucose concentration in solution. Six serial dilutions of a 
known glucose standard was incubated with glucose oxidase to construct a standard 
curve, As per manufacturer’s instructions 3µl of plasma and 450 µl glucose oxidase 
was incubated at room temperature for 5 minutes in a translucent 96 well plate. The 
plate was then read on a spectrophotometer. The results were analysed with Magellan 
software (Tecan, Reading, UK). Assay sensitivity was 0.035 mmol/L, intra/ inter-assay 
variability: 2.59 and 2.63% respectively. All reagents for this assay were supplied by 
Thermo scientific, Auchtermuchty Fife, UK. 
2.2.12 HOMA IR 
 
An individual’s insulin resistance at each visit was calculated using the fasting glucose 
and fasting insulin values from each visit and the HOMA calculator available on line at 
www.dtu.ox.ac.uk. 
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2.2.13 body composition analysis 
 
Each patient’s weight and anthropometry at each visit was measured with a body 
composition analyser (Inbody 720, Derwent Healthcare, UK). The body composition 
analyzer combines the use of multi frequency current with a direct segmental 
measurement to give a detailed printout. Height was measured with a stadiometer. BMI 
was calculated from the above values. 
 
It is known that the electrical resistance of tissues is directly related to their fluid 
content. The fat-free mass is a good electrical conductor, whereas adipose tissue is an 
electrical insulator. Bio-impedence correlates to total body water. The conducting 
volume can be measured utilizing Ohm’s law; volume of constant is proportional to the 
length squared divided by its resistance. Limitations include geometry of conductor. 
There is a linear relationship between height and fat free mass, provided the conductor 
measured is cylinder or has a constant section. This is not accurate as most machines 
utilise wrist to ankle, and consists of two long thin conductors (limbs) separated by a 
shorter and thicker one (trunk). The measured impedance of the trunk is dependent on 
body position and respiratory cycle.  An assumption of homogeneous conductor is also 
made. It is also worth noting that the anatomic disposition of the injecting and sensing 
electrodes also play a part in determining accuracy. The relative error rates when 
compared DEXA is dependent on the segment measured (Martinsen OG and Grimnes 
S 2011) 
 
2.2.14 Statistical analysis 
 
All data was collected in Microsoft Excel and further analysis and preparation for 
graphical presentation was carried out in SPSS 11.0 (SPSS, IL, USA) and GraphPad 
Prism 4 (GraphPad Software, CA, USA). All data is presented as mean ± standard 
error of mean (SEM), otherwise indicated. The sample size for the two human studies 
are noted in each section by ‘n =’. Area under curve was calculated using the trapezoid 
rule. Statistical analysis was performed using paired or unpaired two-tailed Students’ t-
test, repeated measures one way and two way analysis of variance (ANOVA) with 
Bonferroni post-hoc tests as described. The change in plasma hormone values from 
baseline is shown as Δ and displayed where appropriate. P values of * p < 0.05, ** p < 
0.01 and ***p < 0.001 were reported as statistically significant.  
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This was a pilot study. However, previous studies from Batterham and colleagues 
(Batterham R et al 2003) did point us towards expected means, standard deviations (6 
pmol/ L) and assay variability. In the application we suggested a sample size of 12 
subjects per group which will have a 90% power to detect a difference in PYY levels of 
5.85 pmol/L at the 5% confidence level. We supplemented this knowledge with initial 
data on our first 7 patients: Insulin; pre-op peak 94.4± 18.8 pM at 6 weeks 262.8± 96.4 
and at 12 weeks 159.9± 54.4, PYY3-36; pre-op peak 38.3 ±3.6 and 82.2 ±8.5 at 6 
weeks and 94.4± 18.8 at 12 weeks. We utilized this data to supplement our initial 
assertions. The inter-assay variation for PYY3-36 was 6.4% (Chandarana K et al 
2009). The inter-assay variation for acyl-ghrelin was 4.5% (Chandarana et al 2009), 
and for active GLP-1 the inter-assay variability was 6.4% (Chandarana et al). We were 
able to recruit 17 patients in 2 years.  
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Chapter 3 
Appetite and weight loss after 
RYGBP and SG correlate to gut 
hormones    
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3 The effect of RYGBP and SG on appetite, anthropometric indices and gut 
hormones 
3.1 Introduction 
The homeostatic mechanisms to maintain bodyweight limit the effectiveness of lifestyle 
interventions (Heymsfield et al, 2003; Leibel et al, 1995; Tsai and Wadden, 2005). 
Current National Institute for Clinical Excellence (NICE) guidelines advice bariatric 
surgery for individuals with a BMI > 40 kg/m
2
 or BMI 35-40 kg/m
2
 with other significant 
disease such as T2DM and OSA that could be improved with weight loss, and where 
non-surgical therapies have failed (NICE, 2006). Bariatric surgery is the most effective 
therapy for morbid obesity (Buchwald H et al 2004, SOS- Sjostrom et al 2007). A 
greater percentage excess weight loss and (29%) reduction in mortality is seen after an 
average follow-up of 10.9 years (Sjostrom et al 2007).  RYGBP is the commonest 
bariatric surgical procedure performed (Buchwald et al 2009). SG has gained 
prominence as a sole operation for morbid obesity (Bohdjalian A et al 2010). SG 
represented 5.3% of all bariatric procedures performed worldwide in 2008 (Buchwald et 
al 2009). The change in gut hormones after RYGBP has been shown to correlate to 
weight loss in animal models (Shin AC et al 2010). Further, changes in bodyweight are 
thought to be a consequence of a reduction in appetite (Hafner et al 1991, Halmi et al 
1981, Borg et al 2006, Korner et al 2005).  
 
The equivalent outcome after RYGBP and SG has led to studies and reviews  
comparing RYGBP and SG with respect to weight loss and glucose homeostasis 
(karamanakos SN et al 2008, Peterli R et al 2009, Li F et al 2009, Juan P. Valderas et 
al 2010, F Abbatini et al 2010, Valderas JP et al 2010, Franco JVA et al 2011, Basso N 
et al, Chambers AP et al 2011, Peterli R et al 2012 and Ramon J M et al 2012, 
Yousseif A and Emmanuel J et al 2013). They highlight gut hormone changes that are 
not dissimilar despite quite different anatomical arrangements of the gastrointestinal 
tract after these two procedures. However, the mechanisms mediating weight loss after 
these procedures are still debated (Sharkey KA 2011, Kenny PJ et al 2011, De Silva A 
et al 2011, Gass M et al 2011, Karra et al 2010, Scott W and Batterham R 2011, Peterli 
R et al 2012, Ramon J M et al 2012, Yousseif A and Emmanuel J et al 2013).  
 
The one study to compare PYY3-36 after RYGBP and SG found a similar response 
after both procedures; this response was attenuated at 3 months after surgery (Peterli 
R et al 2009). Valderas and colleagues confirmed improvement in appetite scores after 
surgery, further total PYY AUC did correlate to appetite (Valderas JP et al 2010). A 
cross sectional study found correlation between increase in total PYY and appetite after 
RYGBP (Pournaras DJ et al 2010). Most studies have measured total ghrelin following 
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RYGBP and SG (Langer et al 2005, Karamanakos et al 2008, Li F et al 2009, Wang Y 
et al 2009, Peterli R et al 2009, Bohdjalian A et al 2010, Lee WJ et al 2011, and Peterli 
R et al 2012). One has noted a decline in fasting total ghrelin after SG (Ramon J M 
2012), the decline in total ghrelin is maintained for up to 5 years after SG (Bohdjalian A 
et al 2010). Other studies have shown no change or rise in ghrelin (reviewed by 
Papilou J et al 2010). No study to date has measured acyl-ghrelin after RYGBP and 
SG. Others have recently shown a paradoxical rise in acyl-ghrelin after RYGBP at 12 
months after surgery (Barazzoni R et al 2013). 
 
Recent studies have also examined the active GLP-1 response after RYGBP in 
humans (Bose M et al 2009, Peterli R et al 2009, Mela L et al 2011, and Peterli R al 
2012) and animals (Shin AC et al 2010). Studies comparing RYGBP and SG have 
noted; significantly less pronounced response after SG (Peterli R et al 2009, and Peterli 
R et al 2012). The cross sectional study by Pournaras and colleagues found correlation 
between GLP-1 and appetite (Pournaras DJ et al 2010). The active GLP-1 response 
has also been noted to correspond to weight loss after surgery, when an arbitrary cut 
off was utilised (le Roux CW et al 2007). Somatostatin, an inhibitor of gut hormone 
release reversed appetite. Further, a recent study on patients having undergone 
RYGBP showed that infusions of PYY3-36 and long acting GLP-1 analogoues at 
pharmacological doses were able to cause further weight loss. 
 
A significant increase in meal stimulated active amylin secretion is seen in rats 
undergoing RYGBP,
 
but no correlation between active amylin secretion and weight loss 
is seen (Shin AC et al 2010). Two other studies (Bose M et al 2010, Jacobsen S H et al 
2012) have examined the role of total amylin after RYGBP. There have been no studies 
on meal stimulated active amylin secretion after RYGBP and SG in humans.  
 
The heterogeneity in study protocols and procedures has led to difficulties in making 
substantial comparison between studies. An accurate assessment of appetite scores 
and gut hormone levels are dependent on study design and experimental protocol in 
human studies on obesity surgery. Though changes in gut hormones favour weight 
loss, correlation between changes in individual gut hormones and weight loss has not 
yet been shown in humans. This may be related to study design and sample 
processing. Several studies have looked at gut hormone changes after surgery 
(Cummings De et al 2002, Langer et al 2005, Korner J et al 2006, le Roux et al 2006, le 
Roux et al 2007, Whitson BA et al 2007, Karamanakos SN et al 2008, De Paula et al 
2009, Y Wang et al 2009, Li F et al 2009, Peterli R et al, 2009, Bose M et al 2010, 
Abbatini F et al 2010, Bohdjalian A et al 2010, Basso N et al 2011, Chambers AP et al 
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2011, Jacobsen S H et al 2012, Peterli R et al 2012). However, not all have measured 
the active forms of the circulating hormone under investigation (Cummings De et al 
2002, Langer et al 2005, Korner J et al 2006, Whiston BA et al 2007, Karamanakos SN 
et al 2008, De Paula et al 2009, Wang Y et al 2009, Li F et al 2009, Bose M et al 2010, 
Abbatini F et al 2010, Bohdjalian A et al 2010, Basso N et al 2011, Chambers AP et al 
2011, Peterli R et al 2012, Jacobsen S H et al 2012). Further samples were not 
collected into tubes containing protease inhibitors to ensure no degradation of these 
peptides occur prior to analysis (Cummings De et al 2002, Korner J et al 2005, Langer 
FB et al 2005, Korner J et al 2006, Whitson BA 2007, Wang Y et al 2009, Li F et al 
2009, Lopez PP et al 2009, Bohdjalian A et al 2010, N Basso et al 2011). Some studies 
looked at post operative changes several months to years after surgery (Korner J et al, 
2005, Korner J et al 2006, Y Wang et al 2009, Karamanakos et al 2008, Bohdjalian A et 
al 2010, Chambers A P et al 2012) missing early physiological changes. Others have 
utilized cohorts to compare post-surgical changes in gut hormones in patients against 
control groups (Cummings De et al 2002, Korner J et al, 2005Lopez PP 2009, Whitson 
BA 2007, Oliván B et al 2009, Bose M et al 2010, Valderas JP et al 2010), and not to 
their pre-operative state, making it difficult to draw conclusions on individual 
physiological changes and correlation to outcomes after surgery. Comparison of 
matched cohorts can also lead to natural inter-individual variation masking procedure 
related small changes in gut hormones in individuals. Further, it is not possible to make 
comparisons of temporal profiles across cohorts of individual’s and correlate this to 
outcome measures. In the case of acyl-ghrelin no human study to date has collected 
blood samples with HCL and protease inhibitors to measure this active octanoylated 
form prior to degradation, as per manufacturer’s instructions on assay protocols. The 
suppression of acylated ghrelin did correlate to weight loss after RYGBP in rats
 
(Shin 
AC et al 2010). However, this study like others (Oliván B et al 2009, Langer FB 2005, 
Bohdjalian A et al 2010) only added protease inhibitors but not HCL to the collection 
tubes. Other studies measured total ghrelin without the addition of protease inhibitors 
or HCL (Lopez PP et al 2009, Korner J et al 2005, Whitson BA et al 2007, 
Karamanakos et al 2008, Bose M et al 2010, Wang Y 2009, Li F et al 2009, Peterli R et 
al 2012- only Aprotinin, Ramon J M et al 2012) or did use HCL without protease 
inhibitors (Korner J et al 2006). Further, some studies that have looked at PYY 3-36 
and active GLP-1, failed to add DPP4 inhibitor to the samples (DePaula AL et al 2009, 
Korner J et al, 2005, Korner J et al 2006, le Roux CW et al 2006, Whitson BA et al 
2007, le Roux CW et al 2007, Karamanakos et al 2008, Li F et al 2009, Valderas JP et 
al 2010, Umeda L M et al 2011). There have been no studies to investigate meal 
stimulated PYY3-36 secretion after SG in humans.  
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With respect to how gut hormones mediate weight loss; no study to date has found 
correlation between changes in active gut hormones after RYGBP and changes in 
appetite. This may be because only a few studies have looked at appetite scores 
alongside gut hormones (Korner J et al, 2005, Korner J et al 2006, Buchwald et al 
2007, Karamanakos SN et al 2008, DePaula AL et al 2009, Valderas JP et al 2010). 
Studies that have looked at visual analogue scores (VAS) utilised only two time points 
per visit (Korner J et al, 2005, Korner J et al 2006, Karamanakos et al 2008). Therefore 
correlation analysis between changes in gut hormones measured at several time points 
after a mixed meal and change in appetite and satiety measured at a single time point 
after a meal has not been feasible.  Some studies did employ several time points to 
measure VAS (Buchwald et al 2007, Karamanakos SN et al 2008, DePaula AL et al 
2009, and Valderas JP et al 2010).  
We conducted a prospective parallel group study on patients undergoing RYGBP and 
SG to measure changes in fasted and meal-stimulated active gut peptide hormones 
PYY3-36, acyl-ghrelin, active GLP-1, active amylin and subjective measures of appetite 
simultaneously in a tertiary hospital setting. Patients were studied at three time points; 
week before surgery whilst mid-way through the liver reducing diet, and at 6 and 12 
weeks post-surgery. This enabled us to standardise patients prior to the study day 
across three visits. Patients consumed a high calorie standardised mixed liquid meal 
following acclimatisation to the stress of canulation. This enabled us to study 
comparative post prandial response on all three visits, after SG and RYGBP, where 
volumes consumed over a 15 minute period were severely restricted. The calorie 
content of the mixed meal drinks offered to patients was in keeping with previous 
published studies by Batterham and colleagues (le Roux et al 2006). An estimated 
percentage of energy requirement mixed meal drink would have required higher 
volumes to be consumed soon after surgery, and thus longer to consume. This would 
have led to difficulties with standardisation across three visits and would have also 
skewed the timing of hormone sampling after the meal. The restrictive nature of these 
procedures limit volume consumed immediately after the procedure, and thus a large 
volume liquid meal post-operatively may adversely influence hormone measurements 
and analysis for comparison across three visits. 
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3.2 Results 
3.2.1 Comparison of baseline anthropometry/ biochemistry/ gut hormone profile 
and VAS between RYGBP and SG groups   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
N=18 in all calculations 
apart from when noted 
RYGBP mean± (95%CI) SG mean ± (95%CI) 
Age (years) 49.3 ± (45.6-53.0)  41.5 ± (34.0-49.0) 
weight (kg) 125.7 ± (116.4-135.0) 127.5 ± (109.0-133.1) 
fat mass (kg) 68.1 ± (62.0-74.2) 66.0 ± (54.9-69.2) 
BMI kg/m
2
 47.6 ± (44.6-50.6) 46.7 ± (40.2-47.9) 
Fasting glucose (mmol/L) 5.61 ± (4.1-6.5) 4.93 ± (4.3-5.3) 
Hunger AUC (mm) 4018 ± (1271-6764) 4377 ± (2188-6566) 
Fasting hunger (mm) 34.7 ± (12.4-57.2) 48.5 ± (37.5-59.5) 
Satiety AUC (mm) 7614 ± (4302-10925) 6829 ± (3977-9680) 
Fasting satiety (mm) 23.4 ± (10.4-36.5) 
22.3 ± (9.6-34.9) 
Prospective food 
consumption AUC (mm) 
4498 ± (2015-6980) 5372 ± (3569-7175) 
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Figure-18: A comparison of baseline anthropometric characteristics; baseline AUC and 
fasting values of measured VAS; calculated HOMA IR (calculator available on line at 
www.dtu.ox.ac.uk); fasting and calculated baseline AUC of all the plasma hormone 
temporal profiles and fasting plasma leptin in the two groups of patients. The SG group 
was significantly younger. 
 
The SG group was significantly younger, and tended to have a lower BMI than the 
RYGBP group (Figure-19). Other published comparative studies have also had similar 
differences. The patients in the SG group were younger in the study by Karamanakos 
and colleagues (Karamanakos et al 2008). This difference in baseline BMI was within 
the inclusion criteria at recruitment, and within the criteria for referral for bariatric 
surgery. Two patients in the SG group had a BMI below 40. This was due to peri-
operative weight loss. In the study by Valderas and colleagues some patients did also 
start with a BMI below expected due to the peri-operative diet (Valderas JP et al 2010).  
N=18 in all calculations 
apart from when noted 
RYGBP mean ± (95%CI) SG mean ± (95%CI) 
Fasting prospective food 
consumption (mm) 
30.6 ± (11.9-49.4) 45.8 ± (34.0-57.5) 
HOMA IR 1.5 ± (0.85-2.1) 3.1 ± (0.75-2.27) 
PYY 3-36 AUC pM 6364 ± (5443-7284) 6083 ± (2485-9680) 
Fasting PYY3-36 pM 19.4 ± (11.7-27.1) 21.9 ± (2.4-41.4) 
Acyl- ghrelin AUC pM 7606 ± (5520-9692) 7023 ± (5791-8254) 
Fasting acyl-ghrelin pM 53.0 ± (32.8-73.2) 44.7 ± (34.6-54.9) 
Insulin AUC pM 83743 ± (43478-118041) 111133 ± (27190-195077) 
Fasting insulin pM 76.7 ± (47.0-106.5) 180.2 ± (15.4-345.1) 
Amylin AUC pM (n=17) 2123 ± (582-3665) 2317 ± (1394-3241) 
Fasting amylin pM (n=17) 6.5 ± (0.8-12.3) 6.9 ± (3.6-10.2) 
GLP-1 AUC pM (n=17) 1339 ± (819-1859) 931 ± (836-1026) 
Fasting GLP-1 pM (n=17) 4.4 ± (2.9-5.9) 4.2 ± (4.0-4.4) 
Leptin pM 4596 ± (3754-5438) 4278 ± (3491-5065) 
99 
 
 
All patients followed a low calorie diet for two weeks prior to surgery. There was no 
difference in any other baseline characteristics (weight, fat mass, glucose, HOMA IR, 
meal-stimulated PYY3-36/ acyl-ghrelin/ insulin/ active amylin/ active GLP-1/ leptin, 
subjective hunger/ fullness/prospective food consumption) between the two groups.    
3.2.2 Equivalent excess weight and BMI loss in both RYGBP and SG groups 
 
At 6 weeks post-surgery we found that both groups had similar percentage excess 
weight loss (%EWL) after RYGBP (23 ± 2%) and SG (26 ± 4%) p=0.46 (see table). At 
12 weeks post-surgery we also found similar percentage excess weight loss (%EWL) 
after RYGBP (34 ± 3%) and SG (37 ± 5%) p= 0.66. There is also equivalent BMI loss at 
6 weeks and 12 weeks after both procedures. Despite starting with a lower BMI, the SG 
group lost similar BMI points (4.5 ± 0.45) to the RYGBP group (4.9 ± 0.28, p=0.43) at 6 
weeks, and at 12 weeks SG after surgery (6.6 ± 0.62) RYGBP (7.4 ± 0.40, p=0.28). 
This is in keeping with the published literature (Karamanakos et al 2008, Peterli R et al 
2009, Valderas JP et al 2010 and De Gordejuela AG et al 2011) 
 
 
 RYGBP SG t-test  p value 
% EWL at 6week  23 ± 2% 26 ± 4% 0.46 
Change in BMI at 6wk (kg/m
2
) 4.9 ± 0.28 4.5 ± 0.45 0.43 
% EWL at 12 weeks 34 ± 3% 37 ± 5% 0.66 
Change in BMI at 12 wk (kg/m
2
) 7.4 ± 0.40 6.6 ± 0.62 0.28 
Figure-19; a comparison of excess weight and BMI loss after RYGBP and SG, 
an equivalent excess weight loss and BMI loss at 6 and 12 weeks after both surgical 
procedures. 
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3.2.3 Visual analogue scores for hunger, satiety and prospective food 
consumption. 
3.2.3.1 Hunger VAS in the RYGBP group  
 
Subject 
Number 
Pre-op 
fasting 
(mm) 
Pre-op 
AUC 
(mm) 
6 wk 
fasting 
(mm) 
6 Wk 
AUC 
(mm) 
12 wk 
fasting 
(mm) 
12  wk 
AUC 
(mm) 
2 44 10853 5 975 6 1358 
5 56 3833 5 697.5 5 922.5 
6 56 7268 4 1005 5 1020 
7 16 4215 25 2985 16 1358 
8 84 6218 15 877.5 92 1448 
9 0 30 2 713 3 900 
11 5 802.5 6 862.5 3 855 
12 46 2070 25 1208 14 1463 
14 6 870 4 1020 5 900 
Figure-20; Fasting and total AUC hunger before and after RYGBP 
3.2.3.2 Hunger VAS in the SG group  
Subject 
Number 
Pre-op 
fasting  
(mm) 
Pre-op 
AUC 
(mm) 
6-wk 
fasting 
(mm) 
6 wk 
AUC 
(mm) 
12 wk 
fasting 
(mm) 
12 wk 
AUC 
(mm) 
1 24 7763 94 1500 54 3278 
4 55 3750 14 2235 96 2715 
10 44 1380 75 7193 65 1380 
13 47 4770 6 967.5 6 2130 
15 44 1650 43 1410 97 3398 
17 45 3105 6 1313 26 967.5 
18 65 4005 26 1725 14 3315 
19 64 8595 14 3533 75 4283 
Figure-21; Fasting and total AUC hunger before and after SG 
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Figure-22; Temporal changes in hunger VAS over the three visits in the RYGBP (A) 
and SG (B) groups are shown. In the RYGBP group surgery leads to a significant 
(p<0.0001) decline in hunger- two way matched ANOVA, comparison of pre-operative 
against post-operative time points. This decline does not reach statistical significance in 
the SG group (p>0.05) - two way matched ANOVA, comparison of pre-operative 
against post-operative time points. Post-hoc analysis with Bonferroni tests shows 
significant decline at fasting (t=0) and at t=150, t=180 at 6 weeks, and at t=120, t=180 
at 12 weeks in the RYGBP group (*p<0.05, ** p<0.01, ***p<0.001 at 6 weeks, # p<0.05, 
## p<0.01, ### p<0.001 at 12 week). 
3.2.3.3 Prospective food consumption in the RYGBP group  
 
subjects 
Pre- op 
fasting 
(mm) 
Pre-op 
AUC 
(mm) 
6-wk 
fasting 
(mm) 
6 wk 
AUC 
(mm) 
12 wk 
fasting 
(mm) 
12 wk 
AUC 
(mm) 
2 44 10635 35 2168 15 3300 
5 6 4785 14 780 16 1103 
6 46 6488 5 960 5 937.5 
7 25 5303 14 1178 6 1268 
8 74 6263 15 840 43 1170 
9 0 795 3 705 5 975 
11 4 907.5 43 1155 5 1665 
12 33 4163 26 1035 24 1410 
14 44 1140 15 1005 25 1305 
 
Figure-23; Fasting and total AUC prospective food consumption VAS before 
 and after RYGBP 
 
 
 
102 
 
3.2.3.4 Prospective food consumption in the SG group 
 
subjects 
Pre-op 
fasting 
(mm) 
AUC 
(mm) 
6-wk 
fasting 
(mm) 
AUC 
(mm) 
12 wk 
fasting 
(mm) 
AUC 
(mm) 
1 25 7238 87 1575 75 5550 
4 64 6210 36 3165 95 2453 
10 35 2655 55 1545 43 2738 
13 64 7178 24 2325 25 3750 
15 44 2153 34 1395 95 3075 
17 44 5078 16 1838 36 1170 
18 36 4530 14 1620 25 3488 
19 54 7935 24 4208 54 4215 
 
Figure-24; Fasting and total AUC prospective food consumption VAS before  
and after SG 
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Figure-25; The temporal changes in prospective food consumption VAS over the three 
visits for the RYGBP (A) and SG (B) groups are shown. In the RYGBP group surgery 
leads to a significant (p<0.0001) decline in prospective food consumption- two way 
matched ANOVA, comparison of pre-operative against post-operative time points. This 
decline is also significant in the SG group (p=0.0011)- two way matched ANOVA, 
comparison of pre-operative against post-operative time points. Post-hoc analysis with 
Bonferroni tests shows significant decline at t=60, t=90, t=120, t=150 and t=180 at 6 
weeks, and at t=120, t=150 at 12 weeks after RYGBP. In the SG group significant 
decline is only noted at t=60 at 6 weeks after surgery, (*p<0.05, ** p<0.01, ***p<0.001 
at 6 weeks, # p<0.05, ## p<0.01, ### p<0.001 at 12 week). 
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3.2.3.5 Satiety VAS in the RYGBP group 
 
subjects 
Pre-op 
fasting 
(mm) 
Pre-op 
AUC 
(mm) 
6-wk 
fasting 
(mm) 
6 wk 
AUC 
(mm) 
12 wk 
fasting 
(mm) 
12 wk 
AUC 
(mm) 
2 15 4148 75 15473 44 4688 
5 45 7673 84 17040 24 16305 
6 8 5363 65 16560 75 16148 
7 25 2918 44 15593 15 15098 
8 5 7380 66 11655 4 12180 
9 50 4553 62 11535 5 2783 
11 35 7695 5 6030 4 5738 
12 23 12405 26 15743 63 15818 
14 5 16388 5 14753 6 15930 
 
Figure-26; Fasting and total AUC satiety VAS before and after RYGBP 
 
3.2.3.6 Satiety VAS in the SG group 
 
Subjects 
Pre-op 
fasting 
(mm) 
AUC 
(mm) 
6-wk 
fasting 
(mm) 
AUC 
(mm) 
12 wk 
fasting 
(mm) 
AUC 
(mm)   
1 36 6915 5 14715 5 11423 
4 34 9600 6 12458 6 14753 
10 15 8093 7 14858 15 14790 
13 44 7283 48 14415 47 13485 
15 26 2475 5 14828 5 12998 
17 5 12690 77 16058 56 16688 
18 16 3525 84 15248 65 13853 
19 2 4050 45 11348 16 11220 
 
Figure-27; Fasting and total AUC satiety VAS before and after SG 
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Figure-28; A comparison of changes in satiety VAS over the three visits for the RYGBP 
(A) and SG (B) groups are shown. In the RYGBP group surgery leads to a significant 
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(p<0.0001) increase in satiety- two way matched ANOVA, comparison of pre-operative 
against post-operative time points. This increase is also highly significant (p<0.0001) in 
the SG group- two way matched ANOVA, comparison of pre-operative against post-
operative time points. Post-hoc analysis with Bonferroni tests shows significant 
increase at t=30, 60, 90 and 150 at 6 weeks after RYGBP and at t=30 at 12weeks after 
surgery. This increase is significant at t=30, 6, 90, 120 and 150 at 6 weeks after SG, 
and at t=30, 60, 120 and 150 at 12 weeks after surgery (*p<0.05, ** p<0.01, ***p<0.001 
at 6 weeks, # p<0.05, ## p<0.01, ### p<0.001 at 12 week). 
3.2.4 A differential change in subjective appetite and satiety after RYGBP and SG 
 
There was a significant decline in the hunger score AUC from 4018 ± 1191mm at 
baseline pre-operative state to 1149 ± 236 mm (p=0.044) at 6 weeks after surgery and 
to 1136 ± 88 mm (p=0.036) at 12 weeks after surgery in the RYGBP group. There is no 
significant difference between 6 and 12 week AUC (p=0.95, paired t-test). In contrast 
no significant change in hunger AUC was observed following SG, which declines from 
4377 ± 926 mm at baseline pre-operative state to 2485 ± 728 mm at 6 weeks (p=0.189) 
and then to 2683 ± 396 mm at 12 weeks (p=0.059). However, this change from 
baseline to 12 weeks does show a trend towards significance. As with the RYGBP 
group there is no significant (p=0.83, paired t-test) difference between 6 and 12 weeks. 
Comparison of RYGBP and SG groups hunger AUC at 6 weeks does show a trend 
towards significance (p=0.15). This difference is highly significant (P=0.0036) at 12 
weeks. The hunger AUC decreased in both surgical
 
groups but was statistically 
significant only in the RYGB group. The satiety AUC was found to be significantly
 
augmented in the RYGB and SG groups. 
 
In the RYGBP group baseline pre-operative prospective food consumption AUC 
significantly (p=0.009) declined from 4498 ± 1077 mm to 1092 ± 145 mm at 6 weeks, 
and then to1459 ± 242 mm (p=0.013) at 12 weeks. This increase between the 6 and 12 
week time point is highly significant (p=0.0096). In the SG group there was also a 
significant (p=0.001) decline from 5372 ± 763 mm at baseline pre-operative state to 
2209 ± 351 mm at 6 weeks and to 3305 ± 458 mm (p=0.018) at 12 weeks. This rise 
between 6 and 12 weeks does show a trend towards significance (p=0.086).  Further, 
there is a significant difference between the RYGBP and SG groups at 6 weeks 
(p=0.033) and 12 weeks (p=0.0003), this latter difference is highly significant.  
 
Following the mixed meal a more pronounced improvement in satiety was seen after 
surgery in the SG group. In the RYGBP group the pre-operative baseline satiety AUC 
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significantly (p=0.0093)  increased from 7614 ± 1436 mm to 13820 ± 1172 mm at 6 
weeks and to 11632 ± 1870 mm (p=0.057) at 12 weeks. The latter rise from baseline 
did show a trend towards significance. The increase between 6 and 12 weeks did also 
show a trend towards significance (p=0.171). The increase from baseline was more 
pronounced after SG. The baseline pre-operative AUC significantly (p=0.0005)  
increased from 6829 ± 1206 mm to 14241 ± 548 mm at 6 weeks and to 13651 ± 642 
mm (p=0.0001) at 12 weeks. There was no significant (p=0.355) change between 6 
and 12 weeks after SG. A comparison of RYGBP and SG groups does not show a 
significant difference at 6 weeks (p=0.759) and 12 weeks (p=0.291). Statistical analysis 
with two way matched ANOVA comparing pre-operative temporal profile to post–
operative temporal profile at 6 weeks and 12 weeks after surgery does point to a 
differential response in hunger, satiety and prospective food consumption VAS 
between the RYGBP and SG groups. There is a more pronounced decline in hunger 
VAS after RYGBP (two way matched ANOVA, p<0.0001). In this group Bonferroni post 
tests analysis indicates significant decline at t=0 (p<0.01), t=150 (p<0.05) and t=180 
(p<0.05) at 6 weeks, and at t=120 (p<0.05) and t=180 (p<0.05) at 12 weeks after 
surgery (figure-23). The same analysis comparing pre-operative temporal profile with 6 
and 12 week post-operative temporal profiles points to no significant decline in hunger 
after SG (two way matched ANOVA, p>0.05). Bonferroni post tests also confirm no 
significant change at any time points. Interestingly, similar analysis with a two way 
matched ANOVA of the change in hunger VAS (delta hunger) from baseline (t=0) did 
not show a significant disparity between the procedures: after RYGBP (p=0.0159), and 
SG (p=0.0074). This analysis seems to point towards a more prominent decline after 
SG. Further, Bonferroni post-test analysis did not show any significant difference at any 
time point after both surgical procedures (figure-30) 
3.2.5.1 Change in delta hunger 
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Figure-29; The temporal change in delta hunger VAS over three visits for the RYGBP 
(A) and SG (B) groups are shown. In the RYGBP group, surgery leads to a significant 
(p=0.0159) decline in delta hunger- two way matched ANOVA, comparison of pre-
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operative against post-operative time points. Post-hoc analysis with Bonferroni tests 
shows no significant decline at any time point. This decline does also reach statistical 
significance (p=0.0074) in the SG group- two way matched ANOVA, comparison of pre-
operative against post-operative time points. Post-hoc analysis with Bonferroni tests 
shows no significant decline at any time point (*p<0.05, ** p<0.01, ***p<0.001 at 6 
weeks, # p<0.05, ## p<0.01, ### p<0.001 at 12 week). 
 
The pronounced decline in hunger after RYGBP is also reflected in the analysis of 
prospective food consumption. In the RYGBP group surgery leads to a highly 
significant (p<0.0001) decline in pre-operative temporal profile (two way matched 
ANOVA). Bonferroni post-test analysis reveals significant decline at t=60 (p<0.05), t=90 
(p<0.05), t=120 (p<0.01), t=150 (p<0.001), and t=180 (p<0.01) at 6 weeks, and at 
t=120 (p<0.01), t=150 (p<0.01) at 12 weeks after surgery. The prospective food 
consumption temporal profile does also decline significantly (p=0.0011) after SG, but is 
not as pronounced. Further, Bonferroni post-test analysis only shows significant decline 
at t=60 (p<0.05) at six weeks after surgery (figure-26). There is no significant decline at 
any time point at 12 weeks after surgery in the SG group. There was a significant 
decline in delta (change from baseline/ t=0) prospective food consumption after 
RYGBP (p=0.0505) and SG (p<0.0001). As with delta hunger there was a more 
pronounced decline in delta prospective food consumption after SG when compared to 
RYGBP. Again Bonferroni post-test analysis did not show any significant change at any 
time point after surgery in both groups (figure-31). 
 
3.2.5.2 Change in delta prospective food consumption 
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Figure-30; the change in delta prospective food consumption VAS over the three visits 
in the RYGBP (A) and SG (B) groups are shown. In the RYGBP group surgery leads to 
a significant (p=0.0505) decline in prospective food consumption (two way matched 
ANOVA, comparison of pre-operative against post-operative time points). This decline 
is also highly significant in the SG group (p<0.0001) - two way matched ANOVA, 
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comparison of pre-operative against post-operative time points. Post-hoc analysis with 
Bonferroni tests shows no significant decline at any time point at 6 week and  12 weeks 
after RYGBP and SG (*p<0.05, ** p<0.01, ***p<0.001 at 6 weeks, # p<0.05, ## p<0.01, 
### p<0.001 at 12 week). 
 
There is a similar increase in satiety temporal profile after RYGBP and SG. Statistical 
analysis comparing pre-operative temporal profile with post-operative 6 week and 12 
week temporal profiles shows a highly significant increase in both groups (two way 
matched ANOVA, p<0.0001 in both groups). However, Bonferroni post-test analysis 
does point to a more pronounced response after SG. After RYGBP at 6 weeks there is 
significant increase at t=30 (p<0.0001), t=60 (p<0.01), t=90 (p<0.05), t=150 (p<0.01), 
and after 12 weeks there is significant increase at t=30 (p<0.05) only. However, after 
SG there is a significant increase at 6 weeks at t=30 (p<0.001), t=60 (p<0.001), t=90 
(p<0.01), t=120 (p<0.001), t=150 (p<0.05), and at t=30 (p<0.001), t=60 (p<0.001), 
t=120 (p<0.01) and t=150 (p<0.05) after 12 weeks (figure-29).  The increase in delta 
satiety VAS (change from baseline/ t=0) was similar but more pronounced after SG. In 
the RYGBP group comparison of pre-operative time point with post operative time 
points point to a significant (p=0.0005) increase in delta satiety temporal profile (two 
way matched ANOVA). After SG there was a more pronounced significant (p<0.0001) 
increase in delta satiety after the mixed meal. Further, Bonferroni post test analysis did 
confirm a significant improvement in delta satiety at t=30 (p<0.01) at 6 weeks, and at 
t=30 (p<0.01), t=60 (p<0.01) at 12 weeks after SG but at no time points after RYGBP 
(figure-32). 
 
3.2.5.3 Change in Delta satiety 
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Figure-31; the temporal changes in delta satiety (change from t=0) VAS over the three 
visits in the RYGBP (A) and SG (B) groups are shown. In the RYGBP group surgery 
leads to a significant (p=0.0005) increase in delta satiety (two way matched ANOVA, 
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comparison of pre-operative against post-operative time points). This increase is also 
highly significant (p<0.0001) in the SG group (two way matched ANOVA, comparison of 
pre-operative against post-operative time points). Post-hoc analysis with Bonferroni 
tests shows no significant increase at any time point after RYGBP, and at t=60 (p<0.01) 
at 6 weeks and at t= 30 (p<0.01) and t=60 (p<0.01) at 12 weeks after SG (*p<0.05, ** 
p<0.01, ***p<0.001 at 6 weeks, # p<0.05, ## p<0.01, ### p<0.001 at 12 week). 
3.2.6 Comparison between RYGBP and SG plasma leptin  
 
There is a similar reduction in plasma leptin after RYGBP and SG at 6 and 12 weeks 
after surgery (figure-33/ 34). The circulating fasting plasma leptin does decline in 
keeping with adiposity (figure-33). The leptin declined from 4596 ± 365 pM at baseline 
to 3266 ± 343 pM at 6 weeks (p=0.0032) and 3077 ± 346 pM at 12 weeks (p=0.0009) 
after RYGBP. There is no significant (p=0.43) difference between the 6 week and 12 
week fasting leptin in the RYGBP group. Similarly, following SG a comparable 
reduction in fasting leptin was seen at 6 and 12 weeks post-surgery. After SG this 
declined from 4278 ± 333 pM at baseline to 2904 ± 356 pM at 6 weeks (p=0.0005) and 
2575 ± 337 at 12 weeks (p=0.0003). There was no significant (p=0.12) decline between 
6 and 12 weeks.  There was no significant difference between RYGBP and SG groups 
at baseline (p=0.53), 6 weeks (p=0.48) and 12 weeks (p=0.32).  
 
  
fat 
mass  leptin 
fat 
mass  leptin 
fat 
mass  leptin 
Subject visit A Visit A Visit B Visit B Visit C Visit C 
1 63.5 4341.8 55.2 3492.2 49.8 2725.1 
2 71.5 4059.7 64 3094.5 58.4 3282.7 
4 74.2 4974.4 70.2 4186.9 66.6 4372.7 
5 66.2 5283.4 59.8 4680.3 54.6 3679.4 
6 74.4 5877.3 67.4 4914.7 63.6 4751.8 
7 69.1 4821.3 59.8 2255.2 54.6 2962.5 
8 59.3 5398.6 50 2327.2 40.6 1974.6 
9 64.6 4728.4 57.6 3722.8 52.6 3610.3 
10 66 5635.8 53.8 3470.8 47.7 2508.2 
11 75.9 3881.6 64.9 2572.6 64.4 3379.2 
12 77.9 5109.7 66.6 3581.4 60 2922 
13 71.7 3375.8 63.2 1797.3 51.9 2055.7 
14 54.1 2204 45.5 2245.3 38.8 1131.4 
15 54.8 5384.2 46.8 3790 46.9 3475.9 
17 49 3640.2 39.4 1321.8 33.8 1473.5 
18 60.6 3515.9 52.6 2383.1 47.5 2239.5 
19 56.7 3355.2 50.7 2791.4 47.6 1746 
Figure-32; Patients fat mass (kg) and circulating fasting plasma 
 leptin levels (pmol/L)  
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Figure-33; Bar chart to display change in plasma leptin concentration after RYGBP and 
SG, when pre-operative levels compared to 6 and 12 weeks after surgery in the 
RYGBP and SG groups- one way ANOVA (** p<0.01, ***p<0.001).  
 
3.2.7 Weight, BMI, Fat mass and VFA correlate to leptin 
 
In the RYGBP group weight (p<0.0001/ r=0.47), BMI (p<0.0001/ r=0.63), fat mass 
(p<0.000/ 1r=0.53) and visceral fat area (p<0.0001/ r=0.53) does correlate to circulating 
fasting leptin (figure-35). In SG group weight (p=0.004, r=0.32), BMI (p=0.0006/ 
r=0.42), fat mass (p=0.0007/ r=0.42) and visceral fat area (p=0.0024/ r=0.35) does also 
correlate circulating leptin (figure-36). 
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Figure-34; Plasma leptin does correlate to weight (A), BMI (B), fat mass (C) and VFA 
(D) in the RYGBP group. 
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Figure-35; Plsma leptin does correlate to weight (A), BMI (B), fat mass (C) and VFA (D) 
in the SG group. 
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3.2.8 Comparison between RYGBP and SG plasma hormone profiles 
 
Figure-36; Summary of leptin, PYY3-36, acyl-ghrelin, active GLP-1 and amylin in the 
RYGBP and SG groups, mean ± SEM is shown, *p<0.05, ** p<0.01, ***p<0.001 when 
pre-operative values are compared with 6, 12 week post-operative values, and # 
p<0.05, ## p<0.01, ### p<0.001 for difference between RYGBP and SG groups. 
 
3.2.9 Change in PYY3-36 after RYGBP and SG  
 
There is a rise in fasting circulating PYY3-36 levels from 19.4±3.4 pM at baseline to 
22.5±3.4 pM at 6 weeks, and to 27.9±7.8 pM at 12 weeks after RYGBP. At 6 weeks 
post-RYGBP the increase in fasting PYY3-36 was not significant. However, by 12 
weeks post-RYGBP this became significant (p=0.015). Fasting circulating PYY3-36 
levels change from 21.9±8.2 pM at baseline to 23.6±7.5 pM at 6 weeks and to 27.9±7.8 
pM at 12 weeks after SG. Following SG there was no significant effect on fasting 
PYY3-36 at either 6 or 12 weeks. Between groups comparisons of fasting PYY3-36 
  Pre-operation 6 weeks post-op 12 weeks post-op 
  Bypass Sleeve Bypass Sleeve Bypass Sleeve 
Leptin pM 4596±365 4278±333 3266±343 2904±356 3077±346 2575±337 
      **     ***     ***      *** 
Fasting 
PYY3-36 
pM 
19.4±3.4 21.9±8.2 22.5±3.4 23.6±7.5 24.5±3.9 27.9±7.8 
               *   
PYY3-36  
AUC 
6364±399 6083±1522 13780±1458 10875±1868 13186±976 10372±1940 
           ***      ***     ***       ** 
Fasting 
acyl-
ghrelin 
pM 
53.0±8.8 44.7±4.3 39.3±2.5 35.9±1.8 53.5±6.6 33.6±2.1 
        *P=0.096    *P=0.059, # 
Acyl-
ghrelin 
AUC 
7606±905 7023±521 6878±342 6204±388     
*P=0.056 
7491±530 5738±252 
*P=0.052, # 
Fasting 
active 
GLP-1pM 
4.4±0.6 4.2±0.1 5.6±1.2 4.2±0.1 5.1±1.0 4.2±0.1 
              
Active 
GLP-1 
AUC 
1339±220 931±38 6095±1092 2804±414 6106±786 2254±307 
  #(P=0.089)       **, #     **  *** , ###     ** 
  (1diabetic)            
Fasting 
amylin pM 
6.5±2.4 6.9±1.4 11.0±6.4 6.5±1.3 11.5±7.3 6.0±1.0 
              
Amylin 
AUC 
2123±652 2317±390 3151±1490 2328±388 3032±1189 2524±610 
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revealed no difference between groups at either 6 or 12 weeks post surgery.  Analysis 
of temporal profiles by a two way matched ANOVA to compare pre-operative time point 
to post operative time points reveals the temporal profile of PYY3-36 is significantly 
(p<0.001- two way matched ANOVA) increased after RYGBP. Bonferroni post-hoc 
tests show significant increase at t=30, 60, 90, 120, 150 and 180 at 6 weeks, and at 
t=30, 60, 90, 120, 150 and 180 at 12 weeks after RYGBP (figure-38). The temporal 
profile of PYY3-36 is also significantly (p<0.001- two way matched ANOVA) increased 
after SG. Bonferroni post-hoc tests show significant increase at t=15, 30, 60, 90, 120, 
150 and 180 at 6 weeks, and at t=15, 30, 60, 90, 120 and 150 at 12 weeks after SG 
(figure-38). The postprandial peak in PYY3-36 is significantly (p=0.0006) increased 
from 38.8±1.9 pM (t=180) at baseline to 93.9±10.0 pM (t=60) at 6 weeks, and 
significantly (p=0.0006) increased to 93.5±10.3 pM (t=60) at 12 weeks after RYGBP.  
After SG the postprandial peak is significantly (p=0.0018) increased from 39.3±9.2 pM 
(t=90) at baseline to 67.4±12.2 pM (t=60) at 6 weeks, and significantly (p=0.0036) 
increased to 70.0±11.6 pM (t=60) at 12 weeks after SG. The meal stimulated PYY3-36 
AUC is significantly increased from 6364±399 at baseline, to 13780±1458 (p=0.0007) 
at 6 weeks and 13186±976 (p=0.0001) at 12 weeks after RYGBP. The meal stimulated 
PYY3-36 AUC is also significantly increased from 6083±1521 at baseline to 
10875±1868 (p=0.001) at 6 weeks and 10372±1940 (p=0.007) at 12 weeks after SG. 
There is no significant difference between the RYGBP and SG PYY3-36 AUC at 
baseline, six week and 12 week time points (figure-38). 
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Figure-37; The temporal changes in meal stimulated circulating plasma PYY3-36 over 
the three visits in the RYGBP (A) and SG (B) groups are shown. In the RYGBP group 
surgery leads to a significant (p<0.0001) increase in PYY3-36 (two way matched 
ANOVA, comparison of pre-operative against post-operative time points). This increase 
is also highly significant (p<0.0001) in the SG group (two way matched ANOVA, 
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comparison of pre-operative against post-operative time points). Post-hoc analysis with 
Bonferroni tests does show significant increase at t=30 (p<0.001), t= 60 (p<0.001), t=90 
(p<0.001), t=120 (p<0.001), t=150 (p<0.001) and t=180 (p<0.01) at  6 weeks, and at 
t=30 (p<0.01), t=60 (p<0.001), t=90 (p<0.001), t=120 (p<0.001), t=150 (p<0.001) and  
t=180 (p<0.05) at 12 weeks after RYGBP. In the SG group Post-hoc analysis with 
Bonferroni tests point to significant increase at t=15 (p<0.01), t=30 (p<0.001), t= 60 
(p<0.001), t=90 (p<0.001), t=120 (p<0.001), t=150 (p<0.01) and t=180 (p<0.001) at  6 
weeks, and at t=15 (p<0.05), t=30 (p<0.05), t=60 (p<0.001), t=90 (p<0.001), t=120 
(p<0.01) and t=150 (p<0.05) at 12 weeks after SG. (*p<0.05, ** p<0.01, ***p<0.001 at 6 
weeks, # p<0.05, ## p<0.01, ### p<0.001 at 12 weeks).  
3.2.10 Change in acyl-ghrelin after RYGBP and SG 
 
Fasting acyl-ghrelin decreased from 53.0±8.8 pM at baseline to 39.3±2.5 pM at 6 
weeks and rose again to 53.5±6.6 pM at 12 weeks after RYGBP. Fasting acyl-ghrelin 
was not significantly affected by RYGBP. There is a decrease in fasting acyl-ghrelin 
from 44.7± 4.3 pM at baseline to 35.9±1.8 pM at 6 weeks, and to 33.6±2.1 pM at 12 
weeks after SG. These changes show a trend toward statistical significance at 6 weeks 
(P=0.096) and at 12 weeks (p=0.059) after SG. Further, the fasting plasma acyl-ghrelin 
in the SG group at 12 weeks after surgery is significantly lower than that seen in the 
RYGBP (p=0.0155) group. Analysis of the temporal profile of acyl-ghrelin with a 
matched two-way ANOVA, comparing pre-operative time point to post-operative time 
points shows a significant decrease after both RYGBP (p=0.015) and SG (p<0.001).  
The decline is more pronounced in the SG group. Further, Bonferroni post-hoc tests 
does not show significant decline at any time point in the RYGBP group. This contrasts 
with significant decline at t=15 (p<0.05) and t=30 (p<0.01) at 6 weeks, and t=0 
(p<0.05), t=15 (p<0.01) and t=30 (p<0.01) at 12 weeks after SG (figure-39). The trough 
acyl-ghrelin level is altered from 39.5±4.5 pM (t=120) at pre-operative state to 35.9±1.3 
pM (t=120) at 6 weeks (p=0.46), and 37.0±1.0 pM (t=60) at 12 weeks (p=0.56) after 
RYGBP. The trough acyl-ghrelin level is suppressed from 32.8±1.7 pM (t=120) at pre-
operative state to 31.5±2.5 pM (t=30) at 6 weeks (p=0.46), and 28.1±2.7 pM (t=150) at 
12 weeks (p=0.26) after SG. The acyl-ghrelin AUC declines from 7606±905 at baseline 
to 6878±342 at 6 weeks, and 7491±530 at 12 weeks after RYGBP. These changes do 
not reach statistical significance. The suppression in acyl-ghrelin AUC from 7023± 521 
at baseline to 6204±389 at 6 weeks and 5738±252 at 12 weeks after SG does show a 
trend towards significance (p=0.056) at 6 weeks, and (p=0.052) 12 weeks. The 
difference in AUC between RYGBP and SG groups does also show a trend towards 
significance (p=0.012) at 12 weeks after surgery. 
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Figure-38: The Comparison of meal stimulated plasma acyl-ghrelin response after 
RYGBP (A) and SG (B).  Analysis of the plasma temporal profile of acyl-ghrelin after a 
mixed meal test utilising a matched two-way ANOVA, comparing pre-operative time 
point to post-operative time points does show a significant decrease after both RYGBP 
(p=0.015) and SG (p<0.001). The decline is more pronounced in the SG group. 
Further, Bonferroni post-hoc analysis does not show significant decline at any time 
point in the RYGBP group. This contrasts with significant decline at t=15 (p<0.05) and 
t=30 (p<0.01) at 6 weeks, and t=0 (p<0.05), t=15 (p<0.01) and t=30 (p<0.01) at 12 
weeks after SG (figure-39) (*p<0.05, ** p<0.01, ***p<0.001 at 6 weeks, and # p<0.05, 
## p<0.01, ### p<0.001 at 12 weeks after surgery). 
3.2.11 Change in active GLP-1 after RYGBP and SG 
 
There was a no increase in fasting active GLP-1 at 6 weeks and at 12 weeks after 
RYGBP and SG. In contrast, the temporal profile of meal stimulated active GLP-1 
secretion was significantly altered after both RYGBP (p<0.0001) and SG (p<0.0001) 
(two way matched ANOVA, comparing pre-operative time point to post operative time 
points). Bonferroni post-hoc tests show significant increase at four time points at 6 
weeks and at 12 weeks after RYGBP. In the SG group there was significant increase at 
three time points at 6 weeks, and two time points at 12 weeks (figure-40). There was a 
significant (p=0.0016) almost 8 fold increase in the peak active GLP-1 from 9.9±2.4 
(t=30) pM at baseline to 76.1±13.5 pM (t=30) at 6 weeks, and (p=0.001) to 79.9±12.1 
pM (t=30) at 12 weeks after RYGBP. After SG there was a fivefold significant (p=0.001) 
increase in peak active GLP-1 from 6.0±0.7 pM (t=60) at baseline to 29.7±4.2 pM 
(t=30) at 6 weeks, and (p=0.0091) to 27.2±5.4 pM (t=30) at 12 weeks. There was no 
significant difference between baseline active GLP-1 AUC in the RYGBP 1339±220 
and SG 931±38 group, There was a significant (p<0.01) increase in meal stimulated 
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active GLP-1 AUC from 1339±220 at baseline to 6095±1092 at 6 weeks and 6106±786 
(p<0.001) at 12 weeks after RYGBP. After SG there was also a significant (p<0.01) 
increase in active GLP-1 AUC from 931±38 to 2804±414 at 6 weeks and (p<0.01) 
2254±306 at 12 weeks. Further, there was a significant difference in the GLP-1 AUC 
between the two groups at 6 (p= 0.014) and 12 (p=0.0005) weeks after surgery (figure-
37).  
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Figure-39; Comparison of meal-stimulated GLP-1 response between RYGBP (A) and 
SG (B) groups. Analysis of the plasma temporal profile of GLP-1 after a mixed meal 
test utilizing a matched two-way ANOVA, comparing pre-operative time point to post-
operative time points does show a significant increase after both RYGBP (p<0.0001) 
and SG (p<0.0001).  Bonferroni post-hoc analysis does show significant increase at 
t=15 (p<0.001), 30 (p<0.001), 60 (p<0.001), and t=90 (p<0.01) at 6 weeks, and at t=15 
(p<0.001), 30 (p<0.001), 60 (p<0.001) and at t=90 (p<0.05) at 12 weeks after RYGBP. 
This analysis in the SG group does also show significant increase at t=15 (p<0.001), 30 
(p<0.001), 60 (p<0.001) at 6 weeks, and at t=15 (p<0.001), t=30 (p<0.001) at 12 weeks 
(figure-40). The symbols denote: *p<0.05, ** p<0.01, ***p<0.001 at 6 weeks, # p<0.05, 
## p<0.01, ### p<0.001 at 12 weeks 
3.2.12 Change in amylin after RYGBP and SG 
 
There were no significant alterations in baseline fasting active amylin at 6 weeks and at 
12 weeks after RYGBP and SG (figure-37). Analysis of the temporal profile of plasma 
active amylin following a mixed meal test, comparing pre-operative profile to post-
operative time points (two way matched ANOVA) does show a significant (p=0.005) 
increase in active amylin secretion after RYGBP, but not after SG (p=0.588). Bonferroni 
post-hoc analysis did not show any significant increase at any time point in the RYGBP 
group at 6 and 12 weeks. There was no increase in the peak amylin after RYGBP and 
SG. SG does not lead to any significant change in the peak amylin level at 6weeks 
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(p=0.45), and 12 weeks (p=0.29). There was no significant effect of either surgical 
procedure on active amylin AUC (figure-41). 
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Figure-40; The comparison of meal stimulated amylin response between RYGBP (A) 
and SG (B) groups. Analysis of the plasma temporal profile of amylin after a mixed 
meal test utilizing a matched two-way ANOVA, comparing pre-operative time point to 
post-operative time points does show a significant increase after RYGBP (p=0.0048), 
but not after SG (p=0.588). Bonferroni post-hoc analysis does not show significant 
increase at any time points after RYGBP. This analysis in the SG group does also not 
show any significant change. The symbols denote: *p<0.05, ** p<0.01, ***p<0.001 at 6 
weeks, # p<0.05, ## p<0.01, ### p<0.001 at 12 weeks 
3.2.13 Gut hormone changes are independent of weight loss 
 
There was continued weight loss in the RYGBP and SG groups between 6 and 12 
weeks after surgery (figure-42).  However, there was no significant difference between 
6 and 12 week PYY3-36, acyl-ghrelin, GLP-1, amylin and insulin in both groups.  
  
Ä 12-6 wk 
RYGBP  
t-test, p 
value 
Ä 12-6 wk 
SG  
t-test, p 
value 
%EWL 11 ± 1 *<0.0001 10 ± 2 *0.0003 
BMI loss (Kg/m
2
) 2.53 ± 0.3 *<0.0001 2.15 ± 0.33 *0.0003 
AUC PYY3-36 pM 594 ± 1365 0.657 503 ± 999 0.63 
AUC Acyl-ghrelin pM 613 ± 629 0.358 467 ± 386 0.266 
AUC GLP-1 pM 189 ± 700 0.794 550 ± 397 0.209 
AUC Amylin pM 105 ± 327 0.744 196 ± 387 0.629 
AUC Insulin pM 
18173 ± 
16129 0.293 
15132 ± 
14246 0.323 
 
Figure-41; A comparison of change in anthropometry and gut hormones after the two 
procedures between 6 and 12 weeks after surgery. There is a significant change in 
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percentage excess weight loss and BMI loss from 6 to 12 weeks in both groups. 
However, there is no significant change in AUC in any of the hormone indices through 
this same period.  
 
3.2.14 Correlation analysis  
 
We examined the relationship between change in individual hormones and change in 
appetite. This was undertaken in individual patients. The change in AUC from baseline 
to 6 weeks and 12 weeks was correlated to changes in appetite in the corresponding 
time periods. Correlation analysis between change in hormone indices, and change in 
hunger, prospective food consumption and satiety after RYGBP and SG was 
examined. 
 
Statistical analysis is based on the assumption of independence of variables being 
studied, with no correlation in time or space. A study with repeated measures in 
individual subjects does therefore contain potential sources of non-independence. It is 
postulated that in repeated measures, unmeasured factors can produce correlations or 
temporal auto-correlation. Thus systematic bias can be introduced when we fail to 
account for this temporal non-independence and incorrectly inflate test statistics and 
increase the likelihood of false positives. This is termed type 1 errors in statistics. In our 
study the correlation between PYY3-36, acyl-ghrelin, active GLP-1, insulin/ amylin ratio 
and appetite and satiety and with excess weight loss may not be causally linked. It is 
possible that weight loss alone co-ordinated the change in both parameters. Others 
have argued a change in the gut anatomy and still others a change in calorie 
consumption may explain some of the changes seen following bariatric surgery.  
However, the comparison of the same individual across three visits and utilising the 
change in an individual to assay correlation attempts to mitigate this. Animal model 
studies with reproducible phenotype when active hormone supplementation overcomes 
the absence of the active hormone or the receptor would imply causation. Causation is 
difficult to establish in human studies. 
 
3.2.14.1 VAS and hormone correlation analysis in the RYGBP group 
 
In the RYGBP group; change in hunger and satiety did not correlate to PYY3-36, acyl-
ghrelin, active GLP-1 and amylin. However, change in prospective food consumption 
was significantly and positively (p= 0.014. r=0.23) correlated to acyl-ghrelin and 
negatively to change in acyl-ghrelin from baseline (p=0.039, r=0.17) (figure-43). 
Further, PYY3-36 (p=0.011, r=0.23) and change in PYY3-36 from baseline (p=0.008, 
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r=0.25) and GLP-1 (p=0.036, r=0.19) did also negatively correlate to prospective food 
consumption in the RYGBP group (figure-43). Amylin did not correlate to satiety or 
prospective food consumption. At the 12 week time point the change in GLP-1 did 
correlate to the change in satiety. The very low r values may reflect the small sample 
size or a weak association. However the p values indicate significant correlation.  
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Figure-42; In the RYGBP group, prospective food consumption does correlate to GLP-1 
(A), PYY3-36 (B), change in PYY3-36 from baseline (C), acyl-ghrelin (D) and change in 
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acyl-ghrelin from baseline (E). Further, the change in GLP-1 correlates to change in 
satiety. All VAS AUC is in mm. All plasma hormone measurements are in pM. 
 
3.2.14.2 VAS and hormone correlation analysis in the SG group 
 
By comparison in the SG group change in hunger did not correlate to change in any of 
the hormones studied. However, satiety after the liquid meal, did positively correlate to 
change in PYY3-36 from baseline (p=0.005, r=0.31) and GLP-1 (p=0.001, r=0.4) 
(figure-44). Further, prospective food consumption did negatively correlate to GLP-1 
(p=0.004, r=0.33), change in PYY3-36 from baseline (p=0.043, r=0.17) and change in 
acyl-ghrelin from baseline (p=0.037, r=0.19). There was no correlation to amylin. Again 
low r values reflect small sample size, or a weak association. The p values indicate 
significant correlation (figure-44). 
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Figure-43; After SG; GLP-1 does correlate to Satiety (A) and prospective food 
consumption (B). The change in PYY3-36 from baseline does also correlate to satiety 
(C) and prospective food consumption (D). Further, change in acyl-ghrelin from 
baseline correlates to prospective food consumption (E). The change in PYY3-36 does 
also correlate to change in satiety (F). All VAS AUC is in mm. All plasma hormone 
measurements are in pM. 
 
3.2.14.3 Change in hormone correlates to weight loss after RYGBP 
 
In order to examine any causative link between change in gut hormones and weight 
loss correlational analysis was undertaken. The correlation between change in 
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hormone AUC and %EWL from baseline to corresponding time points were 
undertaken. The correlational analysis examined the change in PYY3-36, acyl-ghrelin, 
GLP-1 and amylin AUC from baseline to 6 weeks and 12 weeks and %EWL at those 
respective time points. I also examined the ability of hormone changes at 6 weeks to 
predict %EWL at 12 weeks. In the RYGBP group PYY3-36 did show a trend towards 
correlation to %EWL at 6 weeks (p=0.079, r=0.38) and 12 weeks (p=0.092, r=0.35) 
(figure-45). There was no significant correlation between change in acyl-ghrelin, GLP-1, 
amylin AUC from baseline to 6 weeks and 12 weeks and corresponding %EWL, nor 
change in AUC at 6 weeks to weight loss at 12 weeks. Further, the change in the 
composite islet hormone ratio correlated to weight loss. The insulin/ amylin ratio after 
RYGBP at six weeks (p=0.032, r=0.56) and twelve weeks (p=0.039, r=0.54) negatively 
correlated to %EWL at those time points (figure-45). The physiological significance of 
insulin/ amylin ratio after bariatric surgery is discussed in detail in section 4.3.14. 
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Figure-44; Scatter plots to display correlation between percentage excess weight loss 
(%EWL), and PYY AUC at 6 (A) and 12 (B) weeks, and insulin/ amylin ratio AUC at 6 
(C) and 12 (D) weeks after RYGB. 
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3.2.14.4 Change in hormones correlates to weight loss after SG 
 
Interestingly in the SG group the changes in PYY3-36, acyl-ghrelin, GLP-1 and amylin 
AUC correlated to weight loss after surgery. The change in hormone AUC from 
baseline to 6 weeks and 12 weeks correlated to change in %EWL at the corresponding 
time points. The change in PYY3-36 AUC from baseline to six weeks did show a trend 
towards positive correlation with %EWL at 6 weeks (p=0.056, r=0.48). This trend 
reached statistical significance (p=0.029, r=0.58) when change in PYY3-36 at six 
weeks was correlated to %EWL at 12 weeks (figure-46). The change in acyl-ghrelin at 
6 weeks did correlate positively to %EWL at 6 weeks (p=0.042, r=0.6) and showed a 
trend towards correlation at twelve weeks (p=0.059, r=0.54) (figure-46). Also in this 
group, the change in amylin at 6 weeks does show a trend towards positive correlation 
with %EWL six weeks (p=0.068, r=0.45) and 12 weeks (p=0.075, r=0.44) (figure-46), 
change in amylin at 12 weeks did show a trend towards positive correlation with %EWL 
at 12 weeks (P=0.097, R2=0.40) (figure-46). The change in GLP-1 at 12 weeks after 
SG does correlate positively to %EWL at 12 weeks (p=0.044, r=0.52) (figure-46), 
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Figure-45; scatter plots to show correlation between change in PYY3-36 from baseline 
to six weeks and %EWL at 6 (A) and 12 (B) weeks. The change in acyl-ghrelin AUC at 
6 weeks does correlate to %EWL and 6 (C) and 12 (D) weeks. Further, %EWL at 6 (E) 
and 12 (F) weeks correlates to change in amylin AUC at 6 weeks, also the EWL at 12 
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weeks correlate to change in amylin (G) and GLP-1 (H) AUC at 12 weeks in the SG 
group.  
3.2.15 RYGBP and SG leads to correlation of PYY3-36 and GLP-1 secretion  
 
Meal stimulated GLP-1 secretion across all visits correlated withPYY3-36 secretion in 
the RYGBP (p<0.0001, r=0.60) and SG (p=0.02, r=0.22) groups. However the strength 
of correlation is more pronounced in the RYGBP group.  
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Figure-46; Scatter plots to show correlation between GLP-1 and PYY3-36 in the 
RYGBP (A) and SG (B) groups 
3.2.16 Gut hormone changes precede failure to respond to surgery  
One patient in the SG group did not lose any further weight between 3 and 12 months 
after surgery. This patient’s meal stimulated PYY3-36, acyl-ghrelin and amylin 
response at 3 months after surgery did differ from those of others in the SG group 
(figure-48). The three month meal stimulated Δ PYY3-36 (change from baseline) 
response was below the pre-operative response. A comparison of the three month 
response with a two-tailed students t-test does show a significant (p=0.0002) difference 
between means, however the variance is not significantly different between the two 
temporal profiles (p=0.108). A comparison between this patient’s Δ acyl-ghrelin 
response at three months and the mean of other patients did also show a trend towards 
significance (p=0.098). The variance was significantly (p<0.001) different between the 
two temporal profiles. This patient’s amylin response was consistently below the pre-
operative levels at 6  and 12 weeks after surgery and again analysis with  Student’s t-
test comparing the 3 month responses did show a significant (p=0.002) difference in 
the means. The variance was also significantly different from the group (p=0.032) 
(figure-48).  
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Figure-47; One patient in the SG group had a poor amylin (A), PYY3-36 (C) and acyl-
ghrelin (E) response at 3 months after SG. This does contrast with changes seen in the 
respective hormones, in the rest of the group as shown opposite (B, D and F). This 
altered response was associated with a poor outcome after surgery. 
3.3 Discussion  
The two surgical interventions for morbid obesity had equivalent excess weight loss 
and BMI loss. This is in keeping with other recent studies (Karamanakos SN et al 2008 
Peterli R et al 2009, Valderas JP et al 2010, Franco JVA et al 2011 and De Gordejuela 
AG et al 2011, Peterli R et al 2012). There was an equivalent change in leptin after 
both procedures, in keeping with loss of fat mass after surgery. Despite several studies 
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evaluating gut-hormone response in obese patients undergoing bariatric surgery
 
(Cummings De et al 2002, Langer et al 2005, Korner J et al 2006, le Roux et al 2006, le 
Roux et al 2007, Whitson BA et al 2007, Karamanakos SN et al 2008, De Paula et al 
2009, Y Wang et al 2009, Li F et al 2009, Peterli R et al, 2009, Bose M et al 2010, 
Abbatini F et al 2010, Bohdjalian A et al 2010, Basso N et al 2011, Chambers AP et al 
2011, Peterli R et al 2012, Ramon J M et al 2012), none
 
has been able to correlate gut 
hormone changes after surgery to outcome after surgery. This may be due to a lack of 
standardization prior to blood sampling for gut hormones and differences in blood 
sample processing (Chandarana K et al 2009). Others have compared post-surgical 
changes in gut hormones in patients against control groups (Cummings De et al 2002, 
Korner J et al, 2005Lopez PP 2009, Whitson BA 2007, Oliván B et al 2009, Bose M et 
al 2010, Valderas JP et al 2010), and not to their pre-operative state, making it difficult 
to draw conclusions on individual physiological changes and correlation to outcomes 
after surgery. Some studies have correlated poor response in a group to poor outcome 
after surgery (le Roux CW et al 2007). The change in gut hormones after RYGBP has 
been shown to correlate to weight loss in animal models (Shin AC et al 2010). We have 
shown that standardization of subjects, acclimatization and addition of protease 
inhibitors, DPP-4 and HCL to blood collected for gut hormone assays does influence 
plasma PYY3-36, GLP-1 and acyl-ghrelin
 
(Chandarana K et al 2009), our study is the 
first to follow this standardization protocol to assay gut hormone changes after RYGBP 
and SG. 
3.3.1 The role of PYY3-36 
In our study, there was a similar and exaggerated meal stimulated PYY3-36 secretion 
after both procedures, but fasting PYY3-36 was only significantly reduced at 12 weeks 
after RYGBP, further; changes in PYY3-36 did correlate to perception of satiety and 
show a trend towards correlation to weight loss after RYGBP. This relationship 
between PYY3-36 and satiety and weight loss was also seen after SG, and the 
correlation to weight loss did reach statistical significance in this group. Recent 
publications have highlighted a pronounced PYY response after SG similar to that seen 
after RYGBP (Peterli R et al 2009), in keeping with our findings. Peterli and colleagues 
propose a quicker delivery of nutrients to the L-cells that secret PYY is thought to lead 
to a similar PYY response after RYGBP and SG, leading to earlier satiety and weight 
loss. A study to compare surgical intervention against medical treatment for obesity, 
was able to achieve similar weight loss after RYGBP, SG, and medical treatment, 
however favourable total PYY change was only seen after RYGBP and SG (Valderas 
JP et al 2010). In this study the meal stimulated total PYY AUC did increase 
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significantly after RYGB and SG, as with our study the magnitude of increase was 
significantly higher in the RYGBP group compared to the SG group and lean controls 
(Valderas JP et al 2010).  Some studies have evaluated PYY3-36 after RYGBP in 
humans (Olivan B et al 2009, Bose M et al 2010). The study by Olivan and colleagues, 
and Bose and colleagues to investigate PYY3-36 in patients undergoing RYGBP did 
not employ VAS, and studied PYY3-36 response to a glucose tolerance test (GTT) 
(Oliván B et al 2009, Bose M et al 2010).  A mixed liquid meal is more representative of 
a true meal than a GTT. Other studies to compare RYGBP and SG measured total 
PYY (Karamanakos SN et al 2008, Valderas JP et al 2010, Peterli R et al 2009, and 
Peterli R et al 2012). In the study by Karamanakos and colleagues fasting PYY levels 
increased significantly and progressively after surgery in both study groups. 
Furthermore, total PYY 2 hours after meal also increased significantly and equivalently 
in both study groups (Karamanakos et al 2008). A significant positive correlation 
between
 
the change in AUC of total PYY level and satiety was seen in a study to 
compare RYGBP and SG (Valderas JP et al 2010) 
3.3.2 The role of acyl-ghrelin 
In our study fasting and meal stimulated acyl-ghrelin is decreased after SG, showing a 
trend towards significance, but not after RYGBP. This finding is in keeping with that of 
others studying RYGBP in rats
 
(Shin AC et al 2010), further at 12 weeks there is a 
significant difference in fasting and meal stimulated acyl-ghrelin secretion between 
groups. A paradoxical rise in acyl-ghrelin at 6-12 months after surgery has recently 
been identified after RYGBP (Barazzoni R et al 2013). This is in keeping with the 
changes in acyl-ghrelin between 6 and 12 weeks, seen in our study. The significant 
decline in acyl-ghrelin after SG is thought to be due to the complete removal of the 
gastric fundus, the segment of the stomach, thought to produce the vast majority of 
acyl-ghrelin
 
(Langer FB et al 2005). The change in acyl-ghrelin after RYGBP does 
significantly correlate to change in prospective food consumption after surgery, but not 
weight loss. This relationship between acyl-ghrelin and prospective food consumption 
is more pronounced in the SG group. Furthermore there is a positive correlation 
between change in acyl-ghrelin and weight loss after SG. Another study on weight 
regain after surgery, plasma ghrelin levels were higher in weight regain patients, but 
due to the small number of patients no significant differences were observed 
(Bohdjalian A et al 2010). 
The suppression of ghrelin secretion seen after RYGBP is thought to be secondary to a 
permanent deprivation of nutrient stimulation to oxyntic gland cells responsible for the 
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production and release of acyl-ghrelin (Papailiou J et al 2010). The vagus nerve is also 
thought to play a part in this response (Papailiou J et al 2010). It is not yet clear if the 
reduced production of acyl-ghrelin seen after SG is temporary, and may be reversed 
over time, through post-surgical gastric hyperplasia or if other gastro-intestinal sites 
such as the duodenum take over acyl-ghrelin production, alternatively the central 
orexigenic effect of ghrelin may be restored by adaptations at the central sites of ghreln 
action (Papailiou J et al 2010). Whitson and colleagues also noted no significant 
contribution by acyl-ghrelin to weight loss after RYGBP (Whitson BA et al 2007). 
Further, they admit to poor collection practice. There has been much debate on the 
importance of ghrelin after SG (Langer FB et al 2005, Frezza EE et al 2008, Barazzoni 
R et al 2013). Total ghrelin is known to be elevated after diet induced weight loss
 
(Cummings De et al 2002, Oliván B et al 2009) and it was initially thought that a 
decrease in total ghrelin after SG may explain the superior weight loss and 
maintenance of weight loss after SG (Langer FB et al 2005). However, a recent meta-
analysis of several studies was unable to reach a conclusion
 
(Frezza EE et al 2008). To 
date no study has measured acyl-ghrelin, the active octanoylated form collected under 
standardized conditions to prevent degradation (as recommended by the assay). A 
recent study points to the merits of measuring the active moiety, as the ration of the 
active moiety does rise with the passage of time, perhaps leading to weight regain 
(Barrazzoni et al 2013). 
3.3.3 The role of GLP-1 
 
Some studies have also examined the active GLP-1 response after RYGBP in humans 
(Peterli R et al 2009, Umeda L M et al 2011, and Peterli R et al 2012) and animals 
(Shin AC et al 2010). The human studies by Peterli and colleagues points to similar but 
smaller changes in GLP-1 after SG (Peterli R et al 2009 and Peterli R et al 2012), 
though no standardization protocol was followed in this study. It is worth noting that the 
baseline GLP-1 AUC are a third of the AUC in our study (Peterli R et al 2009 and 
Peterli R et al 2012), authors of the earlier study report an equivalent meal stimulated 
GLP-1 AUC after RYGBP and SG at three months after surgery (Peterli R et al 2009). 
In our study by contrast there is a significant increase in meal stimulated GLP-1 
secretion after both procedures at 6 and 12 weeks, however, there is a more 
pronounced (3 fold) increase in meal stimulated GLP-1 secretion after RYGBP when 
compared to SG, that is maintained at 12 weeks, and is similar to the latter study profile 
(Peterli R et al 2012). This significant difference between RYGBP and SG meal 
stimulated GLP-1 secretion at both 6 and 12 weeks, the baseline difference in GLP-1 
AUC, the four fold higher AUC of meal stimulated GLP-1 after RYGBP and the two fold 
increase seen after SG, when compared to the above study, even allowing for the 
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higher calorie content (400Kcal vs. 500Kcal) in our meal, does suggest differences in 
measurement protocol, and the importance of standardization. This may also explain 
why SG GLP-1 AUC levels approach that of RYGBP at 3 months in the first study. 
Furthermore the above study did not examine the role of GLP-1 in weight loss or 
satiety, nor the association of GLP-1 to other satiety hormones. Other studies that have 
assayed for active GLP-1 have done so without the addition of DPP-4 to samples 
(DePaula AL. et al 2009, Bose M et al 2010), making it difficult to interpret these 
results. In our study, there is a significant correlation between GLP-1 and prospective 
food consumption in the RYGBP group, though no correlation between change in GLP-
1 and weight loss is observed in this group. However in the SG group there is 
correlation between GLP-1 and satiety, prospective food consumption and weight loss 
after surgery at 12 weeks, our study is the first study to show correlation between 
active GLP-1 change and outcome measures after SG. It is thought that a faster 
nutrient delivery to the hind gut after these procedures leads to a pronounced GLP-1 
response after surgery (Peterli R et al 2009, Peterli R et al 2012). 
3.3.4 The role of amylin 
 
In our study there was a significant increase in meal stimulated active amylin secretion 
after RYGBP this is in keeping with recent reports on rats undergoing RYGBP
 
(Shin AC 
et al 2010). No significant change in meal stimulated amylin secretion was seen after 
SG in our study. Others have found a significant increase in amylin when SG is 
combined with an ileal interposition on to the proximal duodenum and proximal jejunum 
(DePaula AL et al 2009). In our study the amylin changes on their own did not correlate 
to satiety, prospective food consumption or %EWL in the RYGBP group, a recent study 
on rats also found no correlation between increased amylin secretion and weight loss 
(Shin AC et al 2010). 
3.3.5 Gut hormone changes precede weight loss 
 
Recent studies on RYGBP and SG have shown that gut hormone changes occur 
independently of and precede weight loss
 
(Korner J et al 2006 , Oliván B et al 2009, 
Peterli R et al 2009, Valderas JP et al 2010, Mousumi Bose et al 2010, Basso N et al 
2011, Chambers AP et al 2011). In our study, patients continued to lose weight from 
the first post-operative study point at 6 weeks to the second study point at 12 weeks. 
However there was no significant change in the fasting or meal stimulated insulin, 
PYY3-36, acyl-ghrelin, GLP-1 and amylin from 6 to 12 weeks.  
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3.3.6 Gut hormone change correlates to weight loss after surgery 
  
In the SG group changes in PYY3-36, acyl-ghrelin, GLP-1 and amylin independently 
correlate to weight loss. Taken together, these findings suggest that gut hormone 
changes alone could account for the weight loss seen after SG, this contrasts with 
RYGBP, where despite equivalent or even more pronounced gut hormone change, 
correlation of gut hormone change to weight loss is poor. This fundamental difference 
between the two surgical procedures may be due to alteration in neural “circuitry” that 
follows the more invasive RYGBP surgery. It is possible that RYGBP leads to other 
changes in neural signaling that favour weight loss, working alongside the endocrine 
changes that favour weight loss. Our findings, like that of  others recently 
(Karamanakos et al 2008, Peterli R et al 2009, Oliván B et al 2009, Valderas JP et al 
2010, Basso N et al 2011, Chambers AP et al 2011) also lend support to a hind gut 
factor mediating the effects of weight loss after RYGBP and SG surgery. It is also 
possible that local gut changes that occur after the two procedures promote a 
divergence in the metabolic outcome as outlined recently (Saeidi et al 2013). In the 
RYGBP group insulin/ amylin ratio alone correlated to weight loss after surgery, we 
also note that RYGBP patients continued to lose weight despite an increase in acyl-
ghrelin secretion between 6 and 12 weeks. This is in keeping with recent findings at 
longer follow up after RYGBP leading to an increase in the active moiety of ghrelin 
(Barazzoni R et al 2013). It is also in keeping with other studies recently that have 
shown a significantly higher fasting and GTT stimulated total ghrelin AUC; an increase 
of 46% from a month after surgery to a year after RYGBP, despite a greater amount of 
weight loss after RYGBP (Bose M et al 2010). 
3.3.7 Appetite and satiety correlate to hormone change 
 
It is thought that gut hormones alter appetite and satiety after surgery and thus 
engender weight loss after RYGBP and SG surgery (Korner J et al 2005, Peterli R et al 
2009, and Karamanakos SN et al 2008, Valderas JP et al 2010). No study to date had 
employed all three (hunger, satiety and prospective food consumption) questions on 
the VAS sheet, at several time points after a meal in conjunction with measurement of 
the active gut hormone. This does facilitate the assessment and correlation of the post 
meal active gut hormone response to VAS, and allow correlation of this hormone 
response to changes in VAS and weight loss; our study is unique in this respect. To 
date no correlation between changes in VAS and gut-hormones have been reported in 
the literature. The study by Valderas and colleagues (Valderas JP et al 2010) did also 
assay appetite at several time points following a meal and found appetite scores were 
significantly altered only after surgical intervention and not after medical treatment; 
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hunger AUC
 
was significantly decreased only after RYGBP and satiety AUC 
significantly increased after RYGB and SG (Valderas JP et al 2010). This differential 
alteration in hunger and satiety after RYGBP and SG is similar to our study findings. 
However unlike our study they were unable to find any correlation between % EWL and 
change in plasma total PYY AUC in the whole sample or within each surgical group. 
However, as with our study, the PYY AUC did show positive correlation with satiety 
AUC in the three obese groups. This study did not add DPP4 inhibitor to blood samples 
and assays for total PYY and not PYY3-36 were done. 
 
 
In our study, there is a significant decrease in prospective food consumption after 
RYGBP and SG at 6 and 12 weeks after surgery, further this decline is significantly 
lower after RYGBP at both time points after surgery. The change in acyl-ghrelin from 
baseline (Δ acyl-ghrelin) does show negative correlation to prospective food 
consumption in both groups, further, GLP-1, PYY3-36 and change in PYY3-36 from 
baseline (Δ PYY3-36) does also show negative correlation to prospective food 
consumption after RYGBP. In common with RYGBP, GLP-1 and Δ PYY3-36 do show a 
negative correlation to prospective food consumption after SG; conversely acyl-ghrelin 
does positively correlate prospective food consumption after RYGBP. RYGBP leads to 
a significant decrease in hunger after the meal at 6 and 12 weeks after surgery despite 
the non-significant change in acyl-ghrelin seen after RYGBP; the decrease in hunger 
after SG does show a trend towards significance at 12 weeks. A significant decrease in 
hunger after RYGBP relative to SG is seen after meals at both 6 and 12 weeks, despite 
the opposite in acyl-ghrelin changes. The meal related satiety response is very similar 
in the two groups at 6 weeks, but do differ at 12 weeks, where the increase remains 
significant only in the SG group. In the SG group, GLP-1 and Δ PYY does show 
positive correlation to satiety. These correlations between active gut hormones, hunger, 
prospective food consumption and satiety have not been reported before. Our study 
provides a link between the change in gut hormones and measures of appetite and 
satiety, and confirms gut hormone changes that occur after RYGBP and SG may lead 
to a decline in appetite and an increase in satiety, and therefore favour weight loss. We 
calculated the Δ hunger, Δ prospective food consumption and Δ satiety for all visits, 
and confirm that the meal leads to a significant decrease in Δ hunger and Δ prospective 
food consumption, and a significant increase in Δ satiety after RYGBP and SG. 
 
In our study, RYGBP and SG seem to alter hunger, prospective food consumption and 
satiety differentially. RYGBP has a more pronounced influence on prospective food 
consumption and hunger, despite non-significant changes in acyl-ghrelin; whilst the 
converse is true of satiety. This variability does not fit with the overall gut hormone 
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changes seen after these procedures, RYGBP leads to a more pronounced PYY3-36, 
GLP-1 and amylin response and would be expected to alter satiety more, and SG by 
contrast does lead to a more pronounced and significant decline in acyl-ghrelin and 
thus expected to suppress hunger more.  
 
3.3.8 Failure to respond to bariatric surgery 
It is known that some patients fail to lose weight after RYGBP and SG, but the 
mechanisms behind this failure have yet to be explored. One patient in our SG group 
was noted to have lost no further weight between 3 and 12 months following surgery. 
This patient did have a three month meal stimulated amylin, Δ PYY3-36 and Δ acyl-
ghrelin curve that was below the baseline curve for these hormones, this is in sharp 
contrast to all the other patients in the SG group, in other words a poor hormone 
response after surgery predicts failure to respond after SG. This altered meal 
stimulated response could be utilized to fast-track those patients predicted to fail to a 
second stage procedure. The correlation between weight loss; PYY3-36, acyl-ghrelin, 
active GLP-1 and active amylin, and the correlation between GLP-1, PYY3-36, acyl-
ghrelin and VAS after SG together with the relationship between a poor 3 month 
amylin, Δ PYY3-36 and Δ acyl-ghrelin and poor outcome, does suggest that these gut 
hormones may account for the positive changes seen after SG. Whether poor gut 
hormone changes after RYGBP lead to a similar outcome is not clear. 
3.3.9 Fasting plasma Leptin after bariatric surgery 
 
Some authors have proposed a reduction in leptin in keeping with weight loss 
(Geloneze B et al 2001). However, others have proposed that the early decline in leptin 
is unlikely to be mediated by weight loss alone (Woelnerhanssen B et al 2011, Ramon 
J M et al 2012). In our study plasma leptin levels did not fall below the normal range in 
women. Further, there was no accelerated decline noted in the six week plasma leptin 
after surgery. The circulating plasma leptin was broadly in line with adiposity in our 
subjects. The significant correlation between plasma leptin and weight/ BMI/ fat mass/ 
VFA in both groups before and after surgery does confirm this. Our findings are in 
keeping with other recent published literature (Borg C M et al 2006, Jacobsen S H et al 
2012).  
3.3.10 Metformin in T2DM, and interference with gut hormone levels 
 
One subject in the RYGBP group was on metformin therapy. This was stopped on the 
day of blood sampling before surgery, and patient was off metformin therapy at follow 
up visits at 6 and 12 weeks after surgery. Other comparative studies have also had this 
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discrepancy of diabetic patients in one group. In the study by Peterli and colleagues 
there were 3 T2DM patients in SG (2 patients were on insulin treatment and 1 on oral 
antidiabetic drugs) (Peterli R et al 2009). None of the patients of the RYGB group had 
T2DM. Also other published literature have included T2DM patients on metformin 
undergoing bariatric surgery, and examined PYY3-36, total ghrelin, total GLP-1, leptin, 
and amylin (Bose M et al 2010). In this study all but 3 were diabetic (Bose M et al 
2010). In the comparative study by Karamanakos and colleagues 2 patients in the 
RYGBP group had diabetes. Both patients were on oral antidiabetic drugs, their 
diabetes resolved after surgery. One patient in the SG group had glucose intolerance in 
this study. Metformin is known to increase total PYY levels. However to date no study 
has examined PYY3-36 and metformin therapy in obese humans. Metformin 
administration is associated with an increase in fasting total PYY levels in normal 
women and women with PCOS (Tasoula T et al 2008). Acylated and total ghrelin levels 
were suppressed to a similar degree after a mixed meal in patients with type 2 diabetes 
treated with diet and metformin monotherapy (Kiyici S et al 2009). English and 
colleagues also found no effect of Metformin treatment on plasma PYY concentrations 
in type 2 diabetes (English PJ et al 2007). However, English and colleagues found 
subjects with T2DM treated with metformin to have a prolonged postprandial 
suppression of ghrelin, when compared to those treated with diet alone (English PJ et 
al 2007). In metformin-treated patients the plasma ghrelin was significantly below 
baseline concentrations and stayed low for an additional hour (English PJ et al 2007). 
Others have argued against this and have in fact shown the opposite with metformin 
therapy. Doogue and colleagues point to an increase in plasma total ghrelin 
concentrations in T2DM patients treated with metformin (Doogue MP et al 2009). 
However, they also point out that despite significant changes in ghrelin no change in 
either hunger or satiety in response meals was seen (Doogue MP et al 2009). Others 
point to significant reduction in ghrelin after an oral glucose tolerance test with 
metformin therapy (Kusaka I et al 2008). However, fasting ghrelin levels were unaltered 
with metformin therapy. The area under the curve for the 2-h ghrelin profile also 
decreased significantly (Kusaka I et al 2008). Metformin did not alter fasting amylin 
levels (Zapecka-Dubno B et al 1999). This remained similar to healthy individuals 
(Zapecka-Dubno B et al 1999). Metformin did interfere with the glucagon stimulated 
amylin secretion (Zapecka-Dubno B et al 1999). Mannucci and colleagues first reported 
the increase in plasma active GLP-1 in obese subjects and diabetic subjects (Mannucci 
E et al 2001, Mannucci E et al 2004). A recent publication suggests this to be an L-cell 
mediated effect of metformin (Mulherin AJ et al 2011). Metformin is thought to exert 
direct effects on the intestinal L cell as a GLP-1 secretagogue (Mulherin AJ et al 2011). 
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Our study confirms RYGBP and SG to be equally efficacious as metabolic surgical 
options. RYGBP and SG lead to a differential alteration in appetite. RYGBP alters 
hunger, and SG satiety. Further, prospective food consumptions were altered to a 
similar extent after both procedures. PYY3-36, GLP-1 and acyl-ghrelin does correlate 
to appetite in both surgical groups. RYGBP and SG led to equivalent fat mass loss and 
decline in plasma leptin. RYGBP leads to a more pronounced hind gut hormone 
response. However, SG also leads to a similar but less pronounced hind gut response. 
SG alone leads to a significant decline in acyl-ghrelin. RYGBP and SG lead to a 
divergent amylin response. There is no significant change in hormone profile between 6 
and 12 weeks apart from acyl-ghrelin in the RYGBP group, where acyl-ghrelin does 
increase between these time points. This is in keeping with weight independent, and 
surgery mediated changes in the examined gut hormones. In the RYGBP group 
changes in PYY3-36 correlates to weight loss. In the SG group change in PYY3-36, 
acyl-ghrelin, GLP-1 and amylin correlate to weight loss after surgery. In the SG group a 
poor response in PYY3-36, acyl-ghrelin and amylin are associated with a poor outcome 
after surgery. RYGBP and SG seem to utilize different mechanisms to engender weight 
loss. The outcome after SG is dependent on the hormonal changes that ensue, 
whereas RYGBP may be dependent on other neuro-anatomical changes associated 
with surgery. 
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 Chapter 4 
Gut hormone changes after 
RYGBP and SG lead to 
improvements in glucose 
homeostasis 
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4.1 Introduction  
4.1.1 T2DM and obesity are linked 
The current epidemics of T2DM and obesity are thought to be related (Mokdad et al 
2003). T2DM is thought to be linked to obesity by virtue of the insulin resistance that 
arises from an excess of body fat (Lazar 2005). Others propose the brain to play a 
central part as an insulin sensitive organ (reviewed by Schwartz and Porte Jr. 2005). 
Recent reviews put forward a model in which reduced neuronal insulin and leptin 
signalling contributes to the link between excess body fat and glucose homeostasis 
(reviewed by Schwartz and Porte Jr.  2005). The association of diet-induced obesity 
(DIO) with both higher serum
 
levels of insulin and leptin and increased activation of 
inflammatory
 
signalling pathways raises the possibility that the two are causally linked 
(De Souza et al 2005, Zhang X et al 2008, reviewed by Thaler and Schwartz, 2010). 
Another such factor is the increased levels of adipocyte-derived free fatty acids that 
have been shown to contribute to insulin resistance in liver and muscle in obesity 
(Bergman and Ader 2000, Boden and Shulman 2002).  
 
4.1.2 Bariatric surgery to treat T2DM 
 
A recent statement on bariatric surgery as a treatment option for T2DM proposes that it 
be accepted as an option in patients with T2DM and BMI of at least 35 kg/m² (Zimmet 
P et al 2011). This statement by the International Diabetes Federation (IDF) proposes 
consideration of bariatric surgery where patients have failed to lose weight through 
weight-management programmes, and pharmacotherapy with an HbA1c of more than 
7.5% (Zimmet P et al 2011). Further, it also proposes that bariatric surgery be 
considered as an option in patients with a BMI of 30–35 kg/m² when diabetes is 
inadequately controlled by pharmacotherapy, especially if other major co-morbidities 
are present (Zimmet P et al 2011). The HBA1c reduction was maintained for up to 4 
years after RYGBP surgery (Kim S and Richards WO 2010). Hence surgery is now 
cautiously being considered as a treatment for T2DM in individuals with BMI’s lower 
than the ranges prescribed by the current healthcare guidelines (Cummings and Flum, 
2008). The international recommendations by the IDF are reflected in the recent 
National Bariatric Surgery Registry report in the UK (Welbourn R et al 2010). The 
improvement in T2DM has been confirmed in both morbidly obese and overweight 
group (Vidal et al 2008). However, by contrast the resolution rate in the over-weight 
group was halved a year after surgery (Lee et al 2010). A higher incidence of beta cell 
failure is present in the latter study group. The mean pre-operative fasting insulin levels 
were less than halved in the overweight group (Lee WJ et al 2010, Vidal J et al 2008). 
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RYGBP and SG do influence both beta cell failure and insulin resistance in the first 
week after surgery and maintained through the year of follow up (Lee et al 2010, Peterli 
R et al 2012, and Ramon J M et al 2012).  
 
BMI (kg/m²) Eligible for surgery         Prioritised for surgery 
 
<30–35               Yes,  conditional*            No 
35–40              Yes             Yes, conditional* 
>40                   Yes           Yes 
 
Figure-48; Eligibility and prioritisation for bariatric surgery in T2DM according to BMI 
(adapted from Zimmet P et al 2011). The statement proposes that the eligibility BMI 
lowered by 2·5 kg/m2 for Asians.  
 
*HbA1c >7·5% on optimised pharmacotherapy or other weight responsive co-
morbidities (blood pressure, dyslipidaemia, and obstructive sleep apnoea) not 
achieving targets on conventional therapies (adapted from Zimmet P et al 2011). 
4.1.3 Bariatric surgery outcome in T2DM 
Prospective (Sjostrom et al 2004, Buchwald et al, 2009) and retrospective studies 
(Rosenthal et al 2008) have shown resolution of T2DM after RYGBP. A meta-analysis 
of 135,246 patients in 621 studies by Buchwald and colleagues confirms 78.1% 
resolution, further 8.5% of patients showed improved glycaemic control after bariatric 
surgery (RYGBP, BPD and Gastric band) (Buchwald et al 2009). The mechanism 
underlying resolution of T2DM has been attributed to weight loss (Rosenthal et al 2008, 
Karamanakos SN, et al 2008), an improved incretin response (Peterli R et al 2009, Li F 
et al 2009, Dezaki K et al 2008, Peterli R et al 2012, Jacobsen S H et al 2012) and 
improvement in insulin resistance independent of weight loss (Pories et al 1995, Peterli 
R et al 2009, De Paula et al 2009, Umeda L M et al 2012, Jorgensen N B et al 2012). It 
has become clear that the improvement in T2DM and insulin resistance precedes 
weight changes and may be mediated by change in the hormone profile after RYGBP 
and SG but not after gastric band, despite equivalent weight loss (Oliván B et al 2009, 
Mousumi Bose et al 2010, Peterli R et al 2012, and Ramon J M et al 2012). RYGBP 
and SG led to the recovery in early-phase insulin secretion and an improvement in 
incretin levels (reviewed by Laferrère B. 2011, Ramon J M et al 2012, and Peterli R et 
al 2012).  
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A retrospective review of 262 T2DM patients after RYGB or SG over 8 years reveals 
similar numbers of patients remained off their diabetes medication (Bayham BE et al 
2011). RYGBP and SG had similar effects on glucose homeostasis in morbidly obese 
T2DM patients at 3 years after surgery (Abbatini et al 2010). The rate of resolution of 
T2DM did not alter with the passage of time for up to 3 years in the RYGBP and SG 
group despite further significant weight loss (Abbatini et al 2010). RYGBP and SG at 3 
years after surgery found similar resolution rates of 81.2% and 80.9% after (Abbatini et 
al 2010). However, others have shown a halving in resolution of T2DM over time 
(Sjostrom et al 2007). Also, several recent studies point to good T2DM resolution after 
SG (Silecchia G et al 2006, Cottam D et al 2006, and Shah S et al 2009, Vidal et al 
2008, reviewed by Gill RS et al 2011). Further, some argue that SG may have a higher 
degree of T2DM resolution (Silecchia G et al 2006, Shah S et al 2009, and Abbatini F 
et al 2010). Baso and colleagues note an immediate restoration of first phase of insulin 
secretion and improved insulin sensitivity in diabetic obese patients with shorter 
duration of T2DM (Basso N et al 2011). A recent study by Rizzelo and colleagues 
confirm that pre-operative interventions and intra-abdominal surgery alone does not 
lead to changes in glucose homeostasis seen soon after SG (Rizzello M et al 2010).  
4.1.4 Putative mechanisms for resolution of T2DM 
Some studies have put the resolution of T2DM and the improvement in glucose 
homeostasis down to the improvement in weight (Karamanakos SN, et al 2008 and 
Rosenthal et al 2008). The mechanisms underlying the dramatic effects on insulin 
sensitivity and β-cell function have yet to be elucidated. However, several mechanisms 
including changes in gut hormones have been proposed (Cummings et al 2007, Peterli 
R et al 2012, Umeda L M et al 2012, Jorgensen N B et al 2012 and Jacobsen S H et al 
2012). It has long been known that oral glucose stimulated insulin secretion is superior 
to intravenous glucose infusion (Elrick et al, 1964). This incretin effect accounts for 
between 50 and 70 % of total insulin secretion. Two major incretins have been 
characterized: glucose-dependant insulinotropic polypeptide (GIP) and glucagon-like 
peptide-1 (GLP- 1) (Drucker, 2006). Faster gastric emptying
 
(Braghetto I et al 2009) 
and small bowel transit time
 
(Shah S et al 2010) post SG surgery is thought to evoke a 
hind gut incretin hormone response not dissimilar to that seen following RYGBP (Peterli 
R et al 2009), leading to an improvement in insulin secretion (DePaula AL et al 2009, 
Peterli R et al 2012, Ramon J M et al 2012). This is in addition to the improvement in 
insulin resistance after surgery
 
(Rizzello M et al 2010). The hind gut and foregut have 
been thought to play a part in the resolution of T2DM after bariatric surgery (Hickey et 
al 1998, Rubino Marescaux, 2004, Peterli R et al 2012, Ramon J M et al 2012). It is 
thought that procedures that eliminate the pyloric muscle control on gastric emptying 
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result in accelerated gastric emptying, stimulation of intestinal peristalsis and rapid 
nutrient delivery to the hindgut and an exaggerated hind gut response (Mason 2005, 
Aguirre et al 2008, and Rodriguez-Grunert et al 2008).  A recent study to compare IT 
and duodenal-jejunal exclusion (DJE) in GK rats reported comparable weight loss, 
glucose tolerance and rise in GLP-1 in both groups post-operatively. Interestingly 
exendin 9-39, a GLP-1 receptor antagonist did reverse the improvement in glucose 
homeostasis seen after DJE indicating that the postoperative improvement in glucose 
homeostasis is mediated by enhanced GLP-1 signalling rather than from absence of a 
presumed foregut anti-incretin molecule (Kindel et al 2009, reviewed by Karra et al 
2010).  
 
Bariatric surgery (RYGBP and SG) leads to a 2-3 fold improvement in insulin sensitivity 
(Peterli R et al 2009, Papailiou J et al 2010, Basso N et al 2011 and Chambers AP et al 
2011, Jorgenson N B et al 2012, Jacobsen S H et al 2012). This is seen early after 
surgery before any substantial weight loss has occurred (Peterli R et al 2009, Rizzello 
M et al 2010, Jorgensen N B et al 2012, Peterli R et al 2012). RYGBP and SG surgery 
lead to an absolute decline in insulin secretion (Kopp et al 2003, Wickremesekera et al 
2005, Camastra et al 2005, Peterli R et al 2009 and Chambers AP et al 2011, Umeda L 
M et al 2012). RYGB and SG had comparable benefits in glucose metabolism in 
rodents. The insulin area-under the- curve (AUC) was greater when compared to 
controls (Chambers AP et al 2011). RYGBP and SG led to comparable loss of body 
weight and body fat and plasma insulin, and comparable improvements in glucose 
tolerance despite different anatomical rearrangement of the gastrointestinal system 
(Chambers AP et al 2011). 
 
 
Our prospective parallel group study design enabled us to gather pilot data on plasma 
active gut hormone related changes in appetite, satiety, and weight loss. The short 
duration of the study also enabled us to study early influence on glucose homeostasis 
in relation to active gut hormone changes, after bariatric surgery. The lack of random 
treatment assignment may have led to systematic bias. The lack of standardization for 
calorie intake after surgery is one such bias. Recent publications on very low calorie 
diet mediated improvements in glucose homeostasis have challenged the initial 
proposed incretin mediated mechanisms (Knop FK and Taylor R 2013). Further recent 
reviews highlight the possibility of a ‘medical bypass' utilizing a multi-modal medical 
approach, though lacking all the clinical and physiological effects of surgery (Miras AD
 
and le Roux CW 2014). The novel therapeutic targets identified in this multi-modal 
approach include food preferences, energy expenditure, gut microbiota, bile acid 
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signalling, inflammation, β-cell and hepatic glucose output (Miras AD
 
and le Roux CW 
2014). Initial studies in patients undergoing bariatric surgery pointed to weight 
independent changes in incretins after bariatric surgery (Laferre B 2011). This 
improvement is seen rapidly after the surgery, associated with recovery of the early 
phase insulin secretion and improved postprandial glucose levels not seen after an 
equivalent weight loss by diet, and blocked by the administration of a GLP-1 
antagonist, demonstrating that the favorable metabolic changes after RYGBP are at 
least in part, GLP-1 dependent (Laferrère B 2011). Other studies comparing per oral 
route with gastric catheter related feeding after surgery note that the oral meal led to 
the typical postoperative exaggerated postprandial insulin and GLP-1 responses, while 
gastric catheter feeding resulted in (insulin/ GLP-1) responses similar to those seen 
preoperatively, along with postprandial glucose intolerance (Reviewed by Knop F K and 
Taylor R). It seems likely the greater exposure of L cells in the distal small intestine to 
ingested nutrients to have a direct beneficial effect on postprandial glucose metabolism 
after RYGBP (Reviewed by Knop F K and Taylor R). Supporting this, caloric restriction 
to 600 kcal/day for a week resulting in 2.1 kg weight loss and gastric banding had no 
effect on hepatic or peripheral insulin sensitivity (Laferrère B 2011). The recent 
Counterpoint study on very low calorie diets identified improvement in fasting 
glycaemia to normal in keeping with a fall in liver fat immediately, and a slower return of 
β-cell function mediated by the fall in pancreatic fat (Reviewed by Knop F K and Taylor 
R).  
4.1.5 Insulin  
The improvement in T2DM has been confirmed in both morbidly obese and overweight 
group (Vidal et al 2008). A study on patients undergoing SG to explore the role of 
incretins in patients with a lower BMI and advanced diabetes found SG in combination 
with proximal ileal inter-position led to an exaggerated incretin response, restoration of 
the first phase insulin secretion and resolution of T2DM in two thirds of patients (De 
Paula et al 2009). The pre-operative delayed insulin secretion pattern seen during GTT 
gradually changed through the year to an early secretion pattern (De Paula et al 2009). 
Further, a normal 30 minute early peak in insulin secretion was seen at 52 weeks after 
SG (Lee et al 2010, Peterli R et al 2012, and Ramon J M et al 2012). Insulin resistance 
and hyper-insulinaemia are common features in the morbidly obese Type-2 DM 
patients, but not in those with a lower BMI, leading to a higher incidence of B-cell failure 
in the latter. RYGBP and SG influence both beta cell failure and insulin resistance (Lee 
W J et al 2011, Peterli R et al 2012, and Ramon J M et al 2012)  
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4.1.6 Ghrelin 
Several studies have demonstrated an inverse relationship between fasting ghrelin and 
fasting insulin levels (Purnell et al, 2003). Additionally, insulin resistance and T2DM are 
associated with reduced ghrelin levels, (Poykko et al, 2003) a correlation that has been 
shown to exist independently of bodyweight (McLaughlin et al, 2004). Ghrelin has been 
shown to inhibit insulin secretion both in vivo and in vitro (Dezaki et al, 2008; Reimer et 
al, 2003). Acyl-ghrelin is linked to insulin resistance through suppression of the insulin-
sensitizing hormone adiponectin, blocking hepatic insulin signalling, inhibiting insulin 
secretion, increasing growth hormone secretion, increasing cortisol secretion and 
increasing epinephrine secretion. Therefore the decline in acyl-ghrelin secretion after 
SG may help restore insulin sensitivity (Peterli R et al 2009, reviewed by Yada et al 
2008, Peterli r et al 2012, Ramon J M et al 2012). This has led some to speculate that 
the weight independent resolution of T2DM and improvement in glucose homeostasis 
seen after SG may in part be mediated by acyl- ghrelin (De Paula et al 2009, Abbatini 
et al 2010, Papailiou J et al 2010, Ramon J M et al 2012, Peterli R et al 2012). It is 
thought that the lack of a pronounced GLP-1 response after SG may be compensated 
for by the decrease in ghrelin seen after SG. This is thought to lead to improved insulin 
sensitivity after SG (Peterli R et al 2009, Li F et al 2009 and Papailiou J et al 2010, 
Peterli R et al 2012, Ramon J M et al 2012).  
4.1.7 GLP-1 
The incretin effect is severely reduced in T2DM patients compared to weight-matched 
controls, and is thought to contribute to the pathogenesis of T2DM (Nauck et al 1986). 
Patients with T2DM display a dose dependent response to exogenous GLP-1 (Kjems et 
al, 2003). RYGBP and SG lead to active GLP-1 plasma levels, 4 to 6 times higher than 
matched controls, after meals in humans (Peterli R et al 2009, Peterli R et al 2012, and 
Ramon J M et al 2012) and rodents (Chambers AP et al 2011). There were no 
differences in GLP-1 levels at any time point between the two groups in rodents 
(Chambers AP et al 2011). However, these studies were conducted five months after 
surgery. Studies in rodents and humans confirm a link between augmented GLP-1 
secretion and insulin secretion (Shin AC et al 2010, Umeda L M et al 2011). They found 
significant correlation between the peaks in GLP-1 and insulin.  
A recent study to examine GLP-1 antagonists on glucose homeostasis after bariatric 
surgery does point to reversal of the positive glucose homeostasis after DJB by GLP-1 
receptor antagonism (Kindel TL et al 2009). This provides direct evidence that at least 
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some of the improvement after RYGBP is mediated by hind gut hormones (reviewed by 
Laferrère B. 2011). Recent evidence point to a persistently elevated postprandial GLP-
1 at 4 and 20 years after RYGBP and DJB respectively (reviewed by Laferrère B. 2011 
and Naslund et al 1998 respectively).  
4.2 Aims of the study 
We assessed fasting and meal stimulated glucose and insulin response along with 
HOMA IR and the incretin response one week before and at six and twelve weeks after 
RYGBP and SG. The post-operative changes in acyl-ghrelin in relation to the changes 
in insulin resistance seen after RYGBP and SG was also examined. Furthermore, we 
also analysed insulin/ amylin ratio and GLP-1/ insulin ratio after the two surgical 
procedures.  
4.3 Results 
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4.3.1 Comparison of insulin resistance, glucose, insulin and GLP-1 between 
RYGBP and SG. 
 
Figure-49; Comparison of glucose, insulin, HOMA IR and GLP-1 in the RYGBP and SG 
groups, mean ± SEM is shown, *p<0.05, ** p<0.01, ***p<0.001 when pre-operative 
values are compared with 6, 12 week post-operative values, and # p<0.05, ## p<0.01, 
### p<0.001 for difference between RYGBP and SG groups. 
4.3.2 Glucose homeostasis after RYGBP and SG  
 
The fasting baseline glucose was not significantly altered at 6 and 12 weeks after 
RYGBP and SG (figure-50/ 51). There was a significant decline in the temporal profile 
of glucose (two way ANOVA, p=0.0409) after RYGBP (figure-51). Bonferroni post test 
analysis confirmed significant declines at five time points at 6 weeks and at three time 
points at 12 weeks after surgery (figure-51). A late peak in post-prandial glucose was 
noted at t=120 mmol/L prior to RYGBP. This peak in glucose occured early at t=30 at 6 
and 12 weeks (figure-51). There was also a significant (two way ANOVA, p=0.0014) 
decline in the temporal profile of glucose after SG. Bonferroni post test analysis 
 Pre-operation 6 weeks post-op 12 weeks post-op 
 Bypass Sleeve Bypass Sleeve Bypass Sleeve 
Fasting 
Glucose  
(mmol/L) 
Glucose 
AUC 
5.6 ± 0.5 
 
 
1257± 143 
 
4.9 ± 0.2 
 
 
1128 ± 47 
 
5.4 ± 0.5 
 
 
1164±129 
     **    
4.6 ± 0.2 
 *(P=0.087) 
 
1027 ± 40 
 *(P=0.076) 
5.4 ± 0.4  
  #(P=0.098) 
 
1139 ± 140 
    ** 
4.6 ± 0.2 
 
 
1013 ± 49 
 *(P=0.075) 
Fasting 
insulin 
(pM) 
Insulin 
AUC 
 76.7±  
12.9 
 
 80759± 
 16167 
180.2± 
69.7 
 
111133± 
 35499  
 64.7± 
 10.0 
 
 82696± 
 21232 
 84.3± 
 18.3 
 
166804± 
 60071 
 58.3 ± 
 8.0 
 
 64523± 
 11133 
 74.6± 
 15.5 
 
 151671± 
 54775 
HOMA 
IR 
1.48±0.27 3.10±1.10 1.22±0.20 1.51±0.32  
 *(P=0.095) 
 
1.10 ± 0.15 1.34 ± 0.27        
  *(P=0.093) 
 
Fasting 
active  
GLP-1 
(pM) 
GLP-1 
AUC 
 4.4 ± 0.6 
 
 
1339 ± 220 
#(P=0.089) 
 (1diabetic) 
 4.2 ± 0.1 
 
 
931± 38 
 5.6 ± 1.2 
 
 
6095±1092   
   ** # 
 4.2 ± 0.1 
 
 
2804± 414 
     ** 
 5.1 ± 1.0 
 
 
6106± 786   
  ***  ### 
 4.20 ± 0.1 
 
 
2254± 307  
    ** 
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confirmed a significant decline in glucose at four time points both at 6 and 12 weeks 
after surgery (figure-50/ 51). Again the peak plasma glucose prior to surgery at t=90, 
was altered to t=30 at 6 and 12 weeks after SG. In the RYGBP group baseline glucose 
AUC was significantly decreased from 1257±143 to 1164±129 (p=0.008) at 6 weeks, 
and 1139 ±141 (p=0.001) at 12 weeks after surgery (figure-50). In the SG group this 
change in baseline glucose AUC from 1128±47 at baseline to 1028±40 at 6 (p=0.076) 
and 12 weeks 1013 ±49 (p=0.075) does not reach statistical significance (figure-50).  
0 30 60 90 120 150 180 210
4
5
6
7
8
9
10
11
A
***
***
*
***
**
##
###
###
p=0.0409
time (mins)
G
lu
c
o
s
e
 (
m
m
o
l/
L
)
0 30 60 90 120 150 180
4
5
6
7
8
9
10
11
pre-op
post-op 6weeks
post-op 12 weeksB
p=0.0014
*
*
***
**
#
##
### #
time (mins)
G
lu
c
o
s
e
 (
m
m
o
l/
L
)
 
Figure-50; Comparison of plasma glucose following the standard liquid meal in the 
RYGBP (A) and SG (B) groups are shown. There was a significant (two way matched 
ANOVA, p=0.0409) decline in the temporal profile of glucose, comparing pre-operative 
time point to post-operative time points after RYGBP. Bonferroni post test analysis did 
confirm significant decline at t=15 (p<0.001), t=30 (p<0.001), t=90 (p<0.05), t=120 
(p<0.001), t=150 (p<0.01) at 6 weeks after surgery, and at t=30 (p<0.01), t=120 
(p<0.001), t=150 (p<0.001) at 12 weeks after surgery. There was also a significant (two 
way matched ANOVA, p=0.0014) decline in the temporal profile of glucose after SG, 
comparing pre-operative time point to post-operative time points. Bonferroni post test 
analysis confirm a significant decline in glucose at t=15 (p<0.05), t=90 (p<0.05), t=150 
(p<0.001), t=180 (p<0.01) at 6 weeks after surgery, and at t=30 (p<0.05), t=120 
(p<0.01), t=150 (p<0.001), t=180 (p<0.05) at 12 weeks after surgery. Over the three 
visits:  *p<0.05, ** p<0.01, ***p<0.001 at 6 weeks, # p<0.05, ## p<0.01, ### p<0.001 at 
12 weeks 
4.3.3 Fasting and post-prandial insulin response after RYGBP and SG 
 
RYGBP and SG led to no significant alterations in fasting plasma insulin at 6 and 12 
weeks, compared to pre-surgery values. Analysis of the temporal profile of insulin after 
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RYGBP with a two way matched ANOVA did not reveal any significant increase in 
insulin secretion (p=0.178), However, Bonferroni post tests did confirm a significant 
increase at t=30 (p<0.01), t=60 (p<0.001), and a significant decline at t=120 (p<0.01) at 
6 weeks, but not at 12 weeks. The baseline peak insulin after RYGBP was observed 
earlier at t=60 from t=120 at 6 and 12 weeks after surgery. Analysis of temporal profiles 
with a two way matched ANOVA in the SG group did confirm a significant (p=0.0009) 
increase in meal stimulated insulin secretion after surgery. Bonferroni post-test analysis 
confirms an increase at three time points at 6 weeks and at one time point at 12 weeks 
after surgery (figure-52). There was also a shift in the peak plasma insulin to an earlier 
time point, from t=90 at baseline before surgery to t=30 at 6 and 12 weeks after 
surgery. There was no significant effect on insulin AUC after either procedure (figure-
50). 
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Figure-51; Comparison of plasma insulin concentrations after the liquid meal following 
RYGBP (A) and SG (B) groups are shown. There is no change in the (two way 
matched ANOVA, p=0.1784) temporal profile of glucose, comparing pre-operative time 
point to post-operative time points after RYGBP. Bonferroni post test analysis did 
confirm a significant increase at t=30 (p<0.01), t=60 (p<0.001), and a significant decline 
at t=120 (p<0.01) at 6 weeks after surgery. The analysis at 12 weeks after surgery did 
not identify any significant increase or decline at any time points. There is a significant 
(two way matched ANOVA, p=0.0009) increase in the temporal profile of glucose after 
SG, comparing pre-operative time point to post-operative time points. Bonferroni post-
test analysis confirms an increase at t=15 (p<0.01), t=30 (p<0.001), t=60 (p<0.05) at 6 
weeks after surgery and at t=30 (p<0.01) at 12 weeks after surgery. Over the three 
visits: *p<0.05, ** p<0.01, ***p<0.001 at 6 weeks, # p<0.05, ## p<0.01, ### p<0.001 at 
12 weeks 
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4.3.4 Fasting and post-prandial GLP-1 response after RYGBP and SG 
 
There was no significant change in fasting active GLP-1 after RYGBP and SG. The 
temporal profile of meal stimulated active GLP-1 secretion was significantly altered 
after both RYGBP (p<0.0001) and SG (p<0.0001) (two way matched ANOVA). 
However the magnitude of change in the circulating active GLP-1 was three-fold higher 
after RYGBP. Bonferroni post-hoc analysis confirms significant increase at four time 
points at 6 and 12 weeks after RYGBP. Post hoc analysis following SG also point to 
significant increase at three time points at 6 weeks, maintained at two time points at 12 
weeks (figure-53). There was an almost 8-fold increase in the peak active GLP-1 from 
t=30 9.9±2.4 pM at baseline to t=30 76.1±13.5 pM at 6 weeks and t=30 79.9±12.1 pM 
at 12 weeks after RYGBP. After SG there was a five-fold increase in peak active GLP-1 
from baseline t=60 6.0±0.7 pM to t=30 29.7±4.2 pM at 6 weeks and t=30 27.2±5.4 pM 
at 12 weeks. There was no significant difference in baseline meal stimulated active 
GLP-1 AUC between RYGBP and SG groups despite the presence of a T2DM patient 
in the RYGBP group. There was a significant (p<0.01) increase in meal stimulated 
active GLP-1 AUC from 1339±220 at baseline to 6095±1092 at 6 weeks and to 
6106±786 (p<0.001) at 12 weeks after RYGBP. After SG there was also a significant 
(p<0.01) increase in active GLP-1 AUC from 931±38 to 2804±414 at 6 weeks and to 
(p<0.01) 2254±306 at 12 weeks. Further there was a significant difference in the active 
GLP-1 AUC between the two groups at 6 (p= 0.014) and 12 (p=0.0005) weeks. 
 
0 30 60 90 120 150 180
0
25
50
75
100
pre-op
6wk
12 wk
***
***
***
**
###
###
###
#
p<0.0001
time (mins)
G
L
P
-1
 p
M
0 30 60 90 120 150 180
0
25
50
75
100
***
***
***###
###
p<0.0001
time (mins)
G
L
P
-1
 p
M
A B
 
Figure-52; Comparison of meal stimulated GLP-1 response between RYGBP (A) and 
SG (B) groups. Analysis of the plasma temporal profile of GLP-1 after a mixed meal 
test utilising a matched two-way ANOVA, comparing pre-operative time point to post-
operative time points did show a significant increase after both RYGBP (p<0.0001) and 
SG (p<0.0001).  Bonferroni post-hoc analysis did show significant increase at t=15 
(p<0.001), 30 (p<0.001), 60 (p<0.001), and t=90 (p<0.01) at 6 weeks, and at t=15 
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(p<0.001), 30 (p<0.001), 60 (p<0.001) and at t=90 (p<0.05) at 12 weeks after RYGBP. 
This analysis in the SG group did also show significant increase at t=15 (p<0.001), 30 
(p<0.001), 60 (p<0.001) at 6 weeks, and at t=15 (p<0.001), t=30 (p<0.001) at 12 weeks 
(figure-40). Over the three visits: *p<0.05, ** p<0.01, ***p<0.001 at 6 weeks, # p<0.05, 
## p<0.01, ### p<0.001 at 12 weeks 
4.3.5 Change in insulin resistance after RYGBP and SG  
 
There was no significant (p=0.152) difference between the RYGBP and SG HOMA IR 
at baseline. There was a decrease in HOMA IR after RYGBP surgery from 1.5 ± 0.3, to 
1.2 ± 0.2 at 6 weeks and 1.1 ± 0.2 at 12 weeks after surgery (Turner RC et al 1979 and 
Levy JC et al 1998). This change did not reach statistical significance (p=0.2861) after 
RYGBP (one way matched ANOVA). There was a significant (p=0.05) (one way 
matched ANOVA) decline in insulin resistance measured by the homeostatic model of 
assessment after SG (Turner RC et al 1979 and Levy JC et al 1998). Post hoc analysis 
did not identify significant change at individual time points.  
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Figure-53; A comparison of change in insulin resistance measured by the HOMA IR 
model in the RYGBP and SG groups (one way matched ANOVA). There is a significant 
(p=0.0503) decline after SG but not RYGBP. There is also a trend towards significance 
at each time point in the SG group at 6 wk (p=0.095) and 12 weeks (p=0.093) 
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4.3.6 Acyl-ghrelin correlates to HOMA IR in the RYGBP and SG groups 
 
There was a significant (p=0.025, r=0.19) negative correlation between HOMA IR and 
meal stimulated acyl-ghrelin AUC all visits, in the RYGBP group. There was no 
significant correlation between HOMA IR and meal stimulated acyl-ghrelin AUC all 
visits in the SG group (p=0.12, r=0.099).  
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Figure-54; The negative correlation between HOMA IR and acyl-ghrelin in the RYGBP 
(A), and in the SG group (B) 
4.3.7 Active GLP-1 secretion after RYGBP and SG does correlate to insulin  
 
In the RYGBP group, change in active GLP-1 after surgery does positively correlate to 
change in insulin at 6 weeks (p=0.03, r=0.51) and 12 weeks (p=0.027, r=0.58) (figure-
56). This correlation is not seen after SG. However, there was a significant and positive 
(p=0.005, r=0.31) correlation between meal stimulated active GLP-1 and meal 
stimulated insulin in all patient visits in the SG group (figure-57).  
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Figure-55; Scatter plots to show positive correlation between change in meal stimulated 
active GLP-1 and change in meal stimulated insulin at 6 (A) and 12 (B) weeks in the 
RYGBP group. 
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Figure-56; Scatter plots to show positive correlation between meal stimulated GLP-1 
and meal stimulated insulin in all visits in the SG group  
4.3.8 Insulin: GLP-1 ratio before and after RYGBP and SG 
 
Recent studies have shown a reduction in insulin/ GLP-1 ratio after RYGBP (Hansen 
EN et al 2011). The meal stimulated insulin to active GLP-1 AUC ratio declined by 
around 60% after RYGBP (Hansen EN et al 2011). Further, there was no effect of 
gastrostomy tube feeding into the blind loop after RYGB. The active GLP-1 response 
after oral and gastrostomy tube delivered meal restored the aberrant preoperative 
active GLP-1 response (Hansen EN et al 2011). The authors propose that these 
findings are suggestive of more responsive distal L cells. Also both routes resulted in 
similar improvements in glucose tolerance, and argue against foregut exclusion as a 
primary mechanism (Hansen EN et al 2011). Despite the greater response in active 
GLP-1 after surgery insulin AUC/ active GLP-1 AUC declined after RYGB. There is a 
significant reduction in the amount of insulin secreted in response to an equivalent 
active GLP-1 stimulus after both procedures. However, the decline is more pronounced 
after RYGBP. The increased active GLP-1 release was not associated with an 
equipotent increase in insulin release. This may be related to a threshold effect, where 
beyond a certain concentration GLP-1 related augmentation of insulin secretion is seen 
to plateau.  
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Figure-57; comparison of meal stimulated temporal profile of Insulin/ GLP-1 ratio in the 
RYGBP (A) and SG (B) groups are shown. Analysis of the plasma temporal profile of 
insulin: GLP-1 ratio after a mixed meal test utilising a matched two-way ANOVA, 
comparing pre-operative time point to post-operative time points did show a significant 
decline after both RYGBP (p<0.0001) and SG (p<0.0001).  Bonferroni post-hoc 
analysis did show significant decline at t=60 (p<0.05), 90 (p<0.05), 120 (p<0.001), and 
t=150 (p<0.001) at 6 weeks, and at t=30 (p<0.05), 60 (p<0.01), 90 (p<0.01), t=120 
(p<0.001) and at t=150 (p<0.001) at 12 weeks after RYGBP. This analysis in the SG 
group did also show significant decline at t=90 (p<0.01), 120 (p<0.05), and at t= 150 
(p<0.05) at 6 weeks, and at t=90 (p<0.05) at 12 weeks. Over the three visits: *p<0.05, 
** p<0.01, ***p<0.001 at 6 weeks, # p<0.05, ## p<0.01, ### p<0.001 at 12 weeks 
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Figure-58; A bar graph to compare pre-operative with 6 and 12 weeks post-operative 
insulin/ GLP-1 ratio (one way matched ANOVA). There was a significant decline after 
RYGBP (p=0.0008) and SG (p=0.02). A comparison between RYGBP and SG groups 
are also made at each time point. There was a significant (p<0.01) decline at 6 weeks 
and (p<0.01) 12 weeks after RYGBP, and after SG a significant (p<0.05) decline is 
noted at 6 weeks but not at 12 weeks. There was a trend toward significant (p=0.067) 
decline in the RYGBP group at 6 weeks and also (p=0.059) at 12 weeks, when 
compared to the SG group. Over the three visits: *p<0.05, ** p<0.01, ***p<0.001 when 
pre-operative values are compared with 6, 12 week post-operative values, and # 
p<0.05, ## p<0.01, ### p<0.001 for comparison between RYGBP and SG groups. 
4.3.9 Amylin: GLP-1 ratio before and after RYGBP and SG 
 
Daily exenatide (GLP-1) treatment led to improved glucose and increased amylin/ 
insulin ratio in response to a mixed meal after islet graft dysfunction post islet 
transplantation (Faradji RN et al 2009). At three months after GLP-1 treatment a 
significant increase in amylin AUC and an increased baseline amylin/ insulin ratio were 
observed (Faradji RN et al 2009). At six months of treatment further increase in basal 
amylin/ insulin ratio was seen. It is thought that constant stimulation by exenatide may 
lead to supra-physiological amylin secretion made worse by hyperglycaemia (Rickels et 
al 2008). It is also possible that GLP-1 leads to amylin secretion from sites other than 
the islets (Zaki M et al 2002). The authors conclude that the effect of exenatide 
treatment in patients with islet allograft dysfunction is more metabolic than regenerative 
as the positive effects did not last long (Faradji RN et al 2009). In our study there is a 
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significant (p<0.0001) reduction in the amount of amylin secreted in response to an 
equivalent active GLP-1 stimulus after RYGBP and SG (analysis of the plasma 
temporal profile of amylin: GLP-1 ratio after a mixed meal test utilising a matched two-
way ANOVA, comparing pre-operative time point to post-operative time points). Again 
this may represent a threshold effect. Bonferroni post-hoc analysis did show significant 
decline at five time points at 6 and 12 weeks after RYGBP. This analysis in the SG 
group did also show significant decline at five time points at 6 weeks and at six time 
points at 12 weeks. The comparison of AUC of amylin: GLP-1 does also confirm a 
significant (p=0.0002) reduction after both RYGBP and SG surgery (matched one way 
ANOVA, comparison of pre-operative time point to post operative time points) (figure-
61). 
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Figure-59; Analysis of the plasma temporal profile of amylin: GLP-1 ratio after a mixed 
meal test utilising a matched two-way ANOVA, comparing pre-operative time point to 
post-operative time points did show a significant decline after both RYGBP (p<0.0001) 
and SG (p<0.0001). Bonferroni post-hoc analysis did show significant decline at t=15 
(P<0.001), t=30 (p<0.01), t=90 (p<0.001), t=120 (p<0.001), and t=150 (p<0.05) at 6 
weeks, and at t=15 (p<0.01),  t=30 (p<0.01), 60 (p<0.05), 90 (p<0.001), t=120 
(p<0.001) and at t=150 (p<0.05) at 12 weeks after RYGBP. This analysis in the SG 
group did also show significant decline at t=30 (p<0.01), t=60 (p<0.001), t=90 
(p<0.001), t=120 (p<0.001), and at t= 150 (p<0.01) at 6 weeks, and at t=15 (p<0.05), 
t=30 (p<0.01), t=60 (p<0.05), t=90 (p<0.001), t=120 (p<0.01), and t=150 (p<0.05) at 12 
weeks. Over the three visits: *p<0.05, ** p<0.01, ***p<0.001 at 6 weeks, # p<0.05, ## 
p<0.01, ### p<0.001 at 12 weeks 
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Figure-60; Bar chart to compare amylin: GLP-1 pre-operative AUC to post operative 
time points in the RYGBP and SG groups. A comparison between RYGBP and SG 
groups are also made at each time point.  *p<0.05, ** p<0.01, ***p<0.001 when pre-
operative values are compared with 6, 12 week post-operative values, and # p<0.05, 
## p<0.01, ### p<0.001 for difference between RYGBP and SG groups compared at 
each time point. 
4.3.10 Active GLP-1 secretion in the RYGBP and SG groups correlate to amylin 
secretion 
The meal stimulated plasma active GLP-1 AUC from all visits does correlate to the 
corresponding plasma amylin AUC in the RYGBP (p<0.0001, r=0.82) and SG (p=0.043, 
r=0.18) groups.   
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Figure-61; Scatter plots to highlight positive correlation between active GLP-1 (pM) and 
amylin (pM) for all visits in the RYGBP (A) and SG (B) groups. 
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4.3.11 Change in active GLP-1 secretion after SG does correlate to change in    
amylin secretion  
 
The change in active GLP-1 secretion at 12 weeks after SG correlated to the change in 
amylin secretion at the corresponding time point (p=0.007, r=0.72) (figure-63). This 
correlation was not seen after RYGBP (p=0.213, r=0.244) 
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Figure-62; Scatter plot confirms positive correlation between change in plasma active 
GLP-1 and change in plasma amylin at 12 weeks after SG.  
4.3.12 Change in insulin secretion and change in amylin secretion correlate after 
SG 
There was a positive correlation between the change in plasma insulin and change in 
plasma amylin secretion at 12 weeks after SG (p=0.071, r=0.45) (figure-64). No 
correlation between the change in plasma insulin and the change in plasma amylin 
secretion was seen after RYGBP (p=0.68, r=0.03). 
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Figure-63; Scatter plot points to a positive correlation between change in plasma insulin 
and change in plasma amylin secretion at 12 weeks after SG 
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4.3.13 High active GLP-1 and correspondingly high amylin levels in a patient 
 
One patient in the RYGBP group had meal stimulated active GLP-1 AUC levels 
markedly above the mean of the rest of the group (21615 vs 1339±622 at baseline, 
26039 vs 6095±1168 at 6 weeks and 24254 vs 6106±840 at 12 weeks after surgery, 
p=0.0007). This patient’s active GLP-1 response was also an outlier. Further, this 
patient’s meal stimulated amylin AUC response was also markedly above the mean for 
the rest of the group (67762 vs 2123±697 at baseline, 68416 vs 3151±1592 at 6 weeks, 
and 65895 vs 3032±1271 at 12 weeks after surgery). This patient’s active amylin 
temporal response to the mixed meal was also an outlier. The correlation analysis of 
the meal stimulated plasma active GLP-1 AUC and amylin AUC from all visits did 
include this patient and strengthened the correlation in the RYGBP group (p<0.0001, 
r=0.82).  
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Figure-64; The mixed meal related temporal profile of GLP-1 and amylin in a patient, 
noted to be an outlier for GLP-1 and amylin profile and total AUC.  
4.3.14 Insulin amylin ratio after bariatric surgery 
 
It is thought that an increased ratio of amylin/ insulin expression may act as a marker 
for beta cell dysfunction (Weng HB et al 2008). Hyperglycaemia is thought to lead to 
the hypersecretion of amylin relative to insulin, and increase the amylin /insulin ratio in 
insulin-resistant rats (Leahy JL et al 1998). The amylin to insulin mRNA ratio is 
increased in these untreated rats (Weng HB et al 2008). A recent study implemented a 
12 week regimen of recombined human GLP-1into spontaneously-diabetic rat related 
to an impairment of the glucose-induced release of insulin, to assess the effect on 
fasting and post-prandial amylin concentrations and islet amylin and insulin mRNA 
(Weng HB et al 2008). GLP-1 (7–36) stimulates the expression and secretion of amylin, 
whilst also increasing insulin protein expression in GK rats treated with GLP-1. GLP-1 
(7–36) significantly increased the amylin and insulin mRNA levels, but markedly 
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decreased the ratio of amylin/insulin mRNA in spontaneous diabetic rats. GLP-1 may 
promote amylin gene expression separate from insulin gene expression (Weng HB et al 
2008). In keeping with this GLP-1 elevated the levels of plasma amylin in response to 
an intraperitoneal glucose load (Weng HB et al 2008). However, it is not clear whether 
this is due to the direct effect of GLP-1(7–36) on stimulating amylin or due to the GLP-1 
(7–36) stimulating insulin. It has been proposed that the amylin/insulin ratio may be a 
better measure than the absolute amylin mRNA level (Weng HB et al 2008). The 
content of insulin and amylin mRNA is known to correlate to the content of plasma 
insulin and amylin (reviewed by Cluck MW et al 2005). Amylin and insulin gene 
expression have usually been examined together. The independent regulation of these 
genes has not been examined in detail (reviewed by Cluck MW et al 2005). Under 
normal physiological conditions amylin and insulin are regulated in concert, but in 
pathological states such as diabetes and obesity their regulation may diverge (reviewed 
by Cluck MW et al 2005). The normal ratio of the amount of amylin mRNA and peptide 
to the amount of insulin mRNA and peptide can be altered in diabetes and obesity, 
where a marked increase in pancreatic amylin mRNA/ peptide are noted (Permert J et 
al 1994, Kautzky-Willer A et al 1994, Enoki S et al 1992). Second messengers utilised 
by GIP/ GLP-1, calcium and fatty acyl molecules can differentially regulate amylin, 
insulin secretion, and gene expression (reviewed by Cluck MW et al 2005). Several 
transcription factors such as HNF-1 are now implicated in the selective expression of 
the amylin gene (reviewed by Cluck MW et al 2005). Amylin and insulin mRNA content 
does increase in parallel following glucose challenge (Mulder H et al 1996). 
Supraphysiologic levels of exogenous amylin inhibit glucose-induced insulin secretion 
in humans, (Bretherton-Watt D, et al 1992). Further, physiologic concentrations of 
endogenous amylin may also effect insulin secretion (reviewed by Cluck MW et al 
2005). Whilst the promoter elements and transcription factors that regulate rat and 
human insulin gene expression have been described, amylin gene expression is not 
well characterized (reviewed by Cluck MW et al 2005). The amylin promoter does 
contain elements similar to those present in insulin genes. Therefore a mechanism for 
parallel gene expression may exist (reviewed by Cluck MW et al 2005). It is thought 
that separate transcription factors regulate independent transcription of amylin and 
insulin (reviewed by Cluck MW et al 2005). Insulin secretion is inhibited by amylin both 
in vitro and in vivo, (Gebre-Medhin S et al 1998, Wang ZL et al 1993 and reviewed by 
Cluck MW et al 2005). Amylin has multiple physiologic effects on glucose homeostasis 
(Karlsson E 1999, Nyholm B et al 1999), including making GLP-I a less effective 
stimulus for insulin secretion (reviewed by Cluck MW et al 2005). Also recent studies 
have highlighted a role for amylin therapy in obesity (Ravussin E et al 2009, Smith SR 
et al 2008).  
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Our study is the first to examine changes insulin: amylin ratio after bariatric surgery, 
and its relationship to weight loss post RYGBP and SG surgery. In our study, there is a 
significant decrease in insulin: amylin ratio after RYGBP. Insulin secretion is not 
significantly altered after RYGBP. However there is a significant increase in amylin 
secretion after surgery. This does lead to a decrease in insulin: amylin ratio after 
surgery at 6 and 12 weeks. This change in ratio did correlate to %EWL at those time 
points after RYGBP. We did not find a correlation between insulin: amylin ratio and 
plasma glucose after RYGBP and SG. There have been no studies on meal stimulated 
amylin secretion after SG. We found no significant difference in amylin secretion after 
SG. The change in amylin secretion after SG did correlate to weight loss at 6 and 12 
weeks after surgery. In keeping with this there was a significant increase in meal 
stimulated insulin secretion after SG. This led to lower insulin: amylin ratio after SG 
surgery. This contrasting alteration in ratio did not correlate to satiety, prospective food 
consumption or weight loss. 
In our study GLP-1 secretion does show a positive correlation to amylin secretion in 
both groups, before and after surgical intervention. It is interesting that the change in 
meal-stimulated amylin does show a negative correlation to the change in meal 
stimulated insulin at six weeks and a positive correlation at 12 weeks after SG.  This is 
due to the amylin AUC largely remaining unchanged but the insulin secretion AUC is 
increased from baseline at six weeks but declines between six and twelve weeks. The 
insulin secretion is significantly improved after SG and does not change significantly 
between 6 and 12 weeks. However, the meal stimulated insulin AUC is lower at 12 
weeks when compared to 6 weeks. Also, the meal stimulated GLP-1 does decline from 
6 to 12 weeks, again not reaching statistical significance. The amylin secretion is 
unchanged between 6 and 12 weeks. Therefore it is likely that other factors such as 
GIP, fatty acyl molecules that can differentially regulate amylin, insulin synthesis and 
secretion lead to an alteration in the relationship between insulin and amylin after SG, 
between these time points. In the RYGBP and SG groups there was a significant 
correlation between the AUC for GLP-1 and amylin for all visits (p<0.0001, r=0.83) in 
the RYGBP and (p=0.043, r=0.18) SG groups. The markedly high GLP-1 and amylin 
response seen in one patient adds further weight to this correlation.  The post operative 
GLP-1 response in the SG group at 12 weeks correlated with the amylin response at 
that time point (p=0.0075, r=0.72). Therefore some of the change in correlation may be 
due to the non-significant reduction in GLP-1 secretion between these time points. In 
support of this, others have proposed that amylin synthesis and secretion may be 
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under the influence of GLP-1 (Ahrén B et al 1997), and amylin in turn may mediate 
some of the biological actions of GLP-1 (Asmar M et al 2010).  
4.3.15 Differential change in insulin/ amylin ratio after RYGBP and SG  
Amylin secretion is regulated by cAMP and (protein kinase A) PKA. GLP-1 signals 
through PKA. It is thought that GLP-1 promotes amylin and insulin gene expression via 
different intracellular pathways and result in a dissociation of their secretion (Asmar M 
et al 2010). Others propose that changes in the activity of the respective convertase 
enzymes may lead to the dissociation of these two peptides. Also, the biosynthesis and 
secretion of insulin is inhibited by amylin, both in vitro and in vivo (Furnsinn C et al 
1994). Improved glycaemic control in T2DM did not change insulin response to 
glucose, but did significantly improve GLP-1 potentiation of glucose-induced insulin 
secretion- (Hojberg PV et al 2008). Plasma amylin is decreased in T2DM (van 
Jaarsveld BC et al 1993). The ability of GLP-1 on glucose-induced amylin secretion 
was significantly increased after improved glycaemia in T2DM. The amylin/C-peptide 
ratio was also significantly higher with GLP-1 (Asmar M et al 2010). This may explain 
the change in insulin amylin ratio between the two groups in our study. The relative 
amylin content would be improved by better glycaemic control after RYGBP and SG 
surgery. Further as RYGBP leads to a more pronounced GLP-1 response, a more 
pronounced amylin response will be seen after RYGBP. The change in amylin is 
disproportionate to change in C-peptide (Asmar M et al 2010). Insulin/ amylin ratio is 
altered differentially after RYGBP and SG. There is a significant (p<0.0001) decrease in 
the ratio after RYGBP surgery, post hoc test show significant decrease at t=120 and 
t=150 at 6 weeks and at t=90, 120, 180 at 12 weeks after RYGBP (figure-66). In the SG 
group there is a significant (p=0.0002) increase in insulin amylin ratio after surgery, 
post-hoc test show significant increase at 15 minutes after the meal at 6 weeks after 
surgery (figure-66).  
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Figure-65; Analysis of the plasma temporal profile of insulin :amylin ratio after a mixed 
meal test utilising a matched two-way ANOVA, comparing pre-operative time point to 
post-operative time points does point to a differential response after RYGBP (A); where 
it was significantly (p<0.0001) decreased, and significantly (p=0.0002) increased after 
SG (B). Bonferroni post-hoc analysis did show significant decline at t=120 (p<0.01), 
and t=150 (p<0.05) at 6 weeks, and at t=90 (p<0.01), t=120 (p<0.05) and at t=180 
(p<0.05) at 12 weeks after RYGBP. This analysis in the SG group did not show any 
significant change at a time point. Over the three visits: *p<0.05, ** p<0.01, ***p<0.001 
at 6 weeks, # p<0.05, ## p<0.01, ### p<0.001 at 12 weeks.      
4.3.16 Change in active GLP-1 correlates to change in insulin/ amylin ratio after 
RYGBP  
 
The change in active GLP-1 AUC at 6 and 12 weeks after RYGBP did also correlate to 
the change in insulin/  amylin ratio after RYGBP at 6 weeks (p=0.029, r=0.58) and 12 
weeks (p0.057, r=0.48).  
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Figure-66; Scatter plots to display correlation between change in GLP-1 and change in 
insulin/ amylin ratio at 6 (A) and 12 (B) weeks after RYGBP. 
4.3.17 Analysis of RYGBP insulin profile excluding Type-2 DM patient  
 
The RYGBP group had one T2DM patient. We undertook comparative analysis of 
insulin and glucose excluding this patient. RYGBP led to a non-significant decline in 
fasting plasma insulin from 76.7±12.9 pmol/L to 64.7±10.3 pmol/L at 6 weeks, and 
58.3±8.0 pmol/L at 12 weeks. This did not alter significantly when the T2DM patient 
was excluded (p=0.59, paired t-test). After excluding the T2DM patient the baseline 
fasting plasma insulin declined from 67.3±10.1 pmol/L to 66.3±11.2 pmol/L at 6 weeks 
and to 59.4±9.0 pmol/L at 12 weeks. Analysis of the temporal profile of insulin after 
RYGBP with the diabetic patient did not reveal any significant increase in insulin 
secretion (p=0.178), However, Bonferroni post tests did confirm a significant increase 
at t=30 (p<0.01), t=60 (p<0.001), and a significant decline at t=120 (p<0.01) at 6 weeks 
after surgery. The analysis at 12 weeks after surgery did not identify any significant 
increase or decline at any time points. This was altered after excluding the T2DM 
patient. The temporal profile after surgery did now show a trend towards significance 
(p=0.06).  Further, Bonferroni post test analysis did confirm a significant increase at 
t=15 (p<0.05), t=30 (p<0.01), t=60 (p<0.001), and a significant decline at t=120 
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(p<0.01) at 6 weeks after surgery. The analysis at 12 weeks after surgery also 
confirmed a significant decline at t=120 (p<0.05). The baseline peak insulin in the 
RYGBP group was observed at t=120, 593.5±142.1 pmol/L. This did alter and occur 
earlier at t=60 1100.8±367.7 pmol/L at 6 weeks after surgery, and at t=60 753.3±191.1 
pmol/L at 12 weeks after surgery. The peak did alter significantly (p=0.045, paired t-
test) when the T2DM patient was excluded. However the time at which the peak insulin 
concentrations occur did not alter between the two groups. The baseline peak insulin in 
the RYGBP group excluding the T2DM patient was observed at t=120, 634.7±154.3 
pmol/L. Again this did alter and occur earlier at t=60 1154.1±412.6 pmol/L at 6 weeks 
after surgery, and at t=60 776.8±215.1 pmol/L at 12 weeks after surgery. There was a 
non-significant increase in plasma insulin AUC from 80759±16167 at baseline to 
82696±21232 at 6 weeks after RYGBP surgery. This increase was reversed by 12 
weeks after RYGBP surgery to 64523±11133. This did not alter significantly when the 
T2DM patient was excluded (p=0.82). The AUC in the group excluding the T2DM 
patient was 83742.8±18017 at baseline increasing to 85882±23803 at 6 weeks after 
RYGBP surgery. As with the RYGBP group this increase was reversed by 12 weeks 
after RYGBP surgery to 60253±11659. In summary the inclusion of a T2DM patient did 
not alter fasting insulin, time of peak insulin nor insulin AUC. However it did alter the 
peak plasma insulin concentration.     
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Figure-67; Comparison of plasma insulin concentrations after a mixed meal test 
utilising a matched two-way ANOVA, comparing pre-operative time point to post-
operative time points in the RYGBP (A) and RYGBP excluding T2DM patient (B) 
groups.  Analysis of the temporal profile of insulin after RYGBP with the diabetic patient 
did not reveal any significant increase in insulin secretion (p=0.178), However, analysis 
with Bonferroni post Hoc tests did confirm a significant increase at t=30 (p<0.01), t=60 
(p<0.001), and a significant decline at t=120 (p<0.01) at 6 weeks after surgery. The 
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analysis at 12 weeks after surgery did not identify any significant increase or decline at 
any time points. This was altered after excluding the T2DM patient.  The temporal 
profile after surgery did now show a trend towards significance (p=0.06).  Further, 
Bonferroni post test analysis did confirm a significant increase at t=15 (p<0.05), t=30 
(p<0.01), t=60 (p<0.001), and a significant decline at t=120 (p<0.01) at 6 weeks after 
surgery. The analysis at 12 weeks after surgery also confirmed a significant decline at 
t=120 (p<0.05). Over the three visits: *p<0.05, ** p<0.01, ***p<0.001 at 6 weeks, # 
p<0.05, ## p<0.01, ### p<0.001 at 12 weeks.       
4.3.18 Analysis of RYGBP group glucose profile excluding Type-2 DM patient  
 
The fasting baseline glucose of 5.6±0.5 mmol/L was not significantly altered to 5.4±0.5 
mmol/L at 6 weeks and to 5.4±0.4 mmol/L at 12 weeks after RYGBP. Again this 
baseline glucose of 5.14±0.2 mmol/L was not significantly altered to 4.98±0.3 mmol/L at 
6 weeks and 5.03±0.17 mmol/L at 12 weeks after RYGBP when the T2DM patient is 
excluded. However, the mean fasting glucose was significantly (p=0.0096) altered 
when the two groups are compared. There was a significant decline in the temporal 
profile of glucose (two way ANOVA, p=0.0409) after RYGBP (figure-69). Bonferroni 
post test analysis confirms a significant decline at t=15 (p<0.001), t=30 (p<0.001), t=90 
(p<0.05), t=120 (p<0.001), t=150 (p<0.01) at 6 weeks after surgery, and at t=30 
(p<0.01), t=120 (p<0.001), t=150 (p<0.001) at 12 weeks after surgery (figure-69). Again 
when the T2DM patient is excluded, there was a significant decline in the temporal 
profile of glucose (two way ANOVA, p=0.0168) after RYGBP (figure-69). Bonferroni 
post test analysis confirms significant decline at t=15 (p<0.001), t=30 (p<0.001), t=90 
(p<0.001), t=120 (p<0.001), t=150 (p<0.01) at 6 weeks after surgery, and at t=15 
(p<0.01), t=30 (p<0.001), t=90 (p<0.001), t=120 (p<0.001), t=150 (p<0.01) at 12 weeks 
after surgery (figure-69). A late peak in post-prandial glucose was noted at t=120 
7.6±0.9 mmol/L prior to RYGBP. This peak in glucose occurs early at 6 weeks t=30, 
9.2±1.1 mmol/L, and at 12 weeks t=30, 8.7±0.8 mmol/L (figure-69). There was a 
significant decline (p=0.0061) in the peak plasma glucose when the T2DM patient is 
excluded. However, the timing of the peak remains the same. The baseline peak 
glucose occurs late at t=120 6.74±0.16, this was brought forward to t=30 8.26±0.54 at 6 
weeks and t=30 7.97±0.41 at 12 weeks in the RYGBP group when the T2DM patient 
was excluded. In the RYGBP group baseline glucose AUC was significantly decreased 
from 1257±143 to 1164±129 (p=0.008) at 6 weeks, and 1139 ±141 (p=0.001) at 12 
weeks after surgery (table-x). The exclusion of the T2DM patient led to the baseline 
AUC to decline from 1117.7±37.6 to 1037.8±31.2 at 6 weeks and 1000.3±26.1 at 12 
weeks. Further, there was a significant (p=0.0009, paired t-test) decline in the mean 
plasma glucose AUC when the T2DM patient is excluded. In summary excluding the 
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T2DM patient did lead to a significant decline in mean fasting, mean peak plasma 
glucose, and mean glucose AUC. The temporal profile of glucose is also significantly 
altered.  
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Figure-68; Comparison of plasma glucose concentrations after a mixed meal test 
utilising a matched two-way ANOVA, comparing pre-operative time point to post-
operative time points in the RYGBP (A) and RYGBP excluding T2DM patient (B) 
groups. There was a significant decline in the temporal profile of glucose after RYGBP. 
Bonferroni post test analysis did confirm significant (p=0.041) decline at t=15 (p<0.001), 
t=30 (p<0.001), t=90 (p<0.05), t=120 (p<0.001), t=150 (p<0.01) at 6 weeks after 
surgery, and at t=30 (p<0.01), t=120 (p<0.001), t=150 (p<0.001) at 12 weeks after 
surgery (figure-69). Again when the T2DM patient is excluded, there was a significant 
decline in the temporal profile of glucose (p=0.0168) after RYGBP. Bonferroni post test 
analysis did confirm significant decline at t=15 (p<0.001), t=30 (p<0.001), t=90 
(p<0.001), t=120 (p<0.001), t=150 (p<0.01) at 6 weeks after surgery, and at t=15 
(p<0.01), t=30 (p<0.001), t=90 (p<0.001), t=120 (p<0.001), t=150 (p<0.01) at 12 weeks 
after surgery. Over the three visits: *p<0.05, ** p<0.01, ***p<0.001 at 6 weeks, # 
p<0.05, ## p<0.01, ### p<0.001 at 12 weeks. 
4.4 Discussion 
4.4.1 Remission of T2DM diabetes after bariatric surgery 
In our study there is a decline in HOMA IR after SG. The decline after RYGBP did not 
reach statistical significance. This discrepancy can partly be explained by the 
significant decline in acyl-ghrelin seen only after SG but not after RYGBP, both in our 
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study and in the study by Karamanakos and colleagues. Karamanakos and colleagues 
showed significant decrease in fasting and post-prandial ghrelin after SG but not after 
RYGBP (Karamanakos SN et al 2008). Samat and colleagues have also shown a 
correlation between suppression of total ghrelin and insulin sensitivity at 12 months 
after RYGBP (Samat A et al 2013). However, others have shown change in insulin 
resistance measured by HOMA IR to be significantly lower after RYGBP and SG 
surgery (Korner J et al 2005, Buchwald H et al 2009, Peterli R et al 2012, Ramon J M 
et al 2012). But these were cross sectional studies. In our study there is an 
improvement in post-prandial glucose after RYGBP and SG. This improvement is more 
pronounced after SG than RYGBP.  Others have also shown similar fasting and post 
prandial glucose AUC in the two groups at 12 months after surgery (Karamanakos SN 
et al 2008, Peterli R et al 2012, and Samat A et al 2013).  
Gill and colleagues point out that the duodenal exclusion hypothesis is unlikely to be a 
viable explanation given the remission of diabetes after sleeve gastrectomy in a large 
percentage of patients despite of a functional duodenum (Gill RS et al 2010, and 
reviewed by Laferrère B. 2011). In our study RYGBP and SG leads to comparable loss 
of body weight, body fat and a reduction in plasma insulin. This is in keeping with 
recent comparative studies (Karamanakos N et al 2008, Peterli R et al 2009, Chambers 
AP et al 2011, Basso N et al 2011, Peterli R et al 2012, and Ramon J M et al 2012). In 
our study RYGBP and SG led to greater initial insulin secretion from baseline followed 
by rapid return toward baseline secretion. The insulin area-under the- curve (AUC) was 
greater at 6 weeks after both procedures when compared to pre-operative levels. This 
rise was reversed at 12 weeks with improved insulin resistance. These findings are in 
keeping with recent studies (Lee et al 2010, Chambers AP et al 2011, Ramon J M et al 
2012, and Peterli R et al 2012). 
4.4.2 The role of active GLP-1 
 
It is known that surgery and not weight loss mediates an increase in GLP-1 (B. 
Laferrere et al 2008, B. Ahren et al 2003). A significant and similar decline in fasting 
glucose, insulin and HOMA-IR was seen after diet and RYGBP induced 10 kg weight 
loss (Oliván B et al 2009). However, a significant increase in glucose-stimulated GLP-1 
occurred only after RYGBP (Oliván B et al 2009). In our study there is no significant 
change in fasting active GLP-1 after either procedure. The temporal profile of meal 
stimulated active GLP-1 secretion is similarly and significantly altered after both 
RYGBP (p<0.0001) and SG (p<0.0001). Further the active GLP-1 response after 
RYGBP is almost three-fold higher than that after SG. There is a significant difference 
in the active GLP-1 AUC between the two groups at 6 (p= 0.014) and 12 weeks 
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(p=0.0005). The significant increase in active GLP-1 seen at six weeks is not altered at 
3 months after surgery. A similar parallel group study was done by Peterli and 
colleagues (Peterli R et al 2009, and Peterli R et al 2012). In the initial study, patients 
were studied at pre-operative, 1 week and 3 months after surgery after RYGBP and 
SG. The SG group had three diabetic patients but none in the RYGBP group. The 
fasting insulin concentrations and HOMA indices were significantly reduced, before any 
significant weight loss had occurred (Peterli R et al 2009). As with our study, the 
impaired postprandial active GLP-1 and insulin response was reversed in both groups, 
at a week after surgery. The authors argue that this points at endocrine mediators 
(Peterli R et al 2009, Peterli R et al 2012). As with our study, a marked increase in 
postprandial active GLP-1 and insulin concentrations was observed after RYGB and 
SG. As with our study the RYGBP patients had an exaggerated postprandial active 
GLP-1 response at 1 week that was significantly higher than that of the SG group 
(Peterli R et al 2009, and Peterli R et al 2012), but this difference in active GLP-1 
response was no longer significant at 3 months after surgery (Peterli R et al 2009, and 
Peterli R et al 2012). It is also noteworthy that the baseline active GLP-1 AUC are a 
third of the AUC in our study. By contrast, in our study, there is a significant increase in 
meal stimulated active GLP-1 secretion after both procedures at 6 and 12 weeks, but a 
more pronounced (3-fold) increase in meal stimulated active GLP-1 secretion after 
RYGBP when compared to SG that is maintained at 12 weeks. These discrepancies 
may be explained by a lack of standardization. 
 
The study by Kindel and colleagues to examine GLP-1 antagonists on glucose 
homeostasis after bariatric surgery does point to reversal of the improved glucose 
homeostasis by GLP-1 receptor antagonism (Kindel TL et al 2009). This does provide 
direct evidence that at least some of the improvement after RYGBP is mediated by hind 
gut hormones (reviewed by Laferrère B. 2011). A recent study in rodents confirms a 
link between augmented GLP-1 secretion and insulin secretion (Shin AC et al 2010). 
The discrepancy in meal stimulated active GLP-1 in our study does not seem to 
adversely effect insulin secretion or plasma glucose levels after SG when compared to 
patients that underwent RYGBP, in fact insulin secretion is significantly increased after 
SG in our study. The more pronounced decline in GLP-1 to insulin ratio after RYGBP 
may explain someof this discrepancy. This threshold effect of GLP-1 has been reported 
by others (Hansen E N et al 2011). In the SG group the change in active GLP-1 did 
correlate to change in amylin and also account for the improvement in glucose 
disposal. GLP-1 and insulin did show positive correlation after RYGBP that led to 
significantly lower post-prandial plasma glucose reaching that of lean controls (Shin AC 
et al 2010, Jacobsen S H et al 2012). In our study the meal stimulated active GLP-1 
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response after RYGBP correlates to PYY3-36. This correlation has been reported in 
rats after RYGBP (Shin AC et al 2010). However, our study is the first to report this in 
humans. Our study is also the first to report that meal stimulated active GLP-1 does 
also correlate to PYY3-36 and insulin after SG. In the RYGBP group, we are the first to 
report that the change in meal stimulated active GLP-1 after RYGBP does correlate to 
change in meal stimulated insulin and insulin: amylin ratio at 6 and 12 weeks after 
surgery. Others have identified a correlation between peak active GLP-1 and insulin 
after RYGBP
 
(Shin AC et al 2010, Jacobsen S H et al 2012). Further, in our study the 
change in active GLP-1 after SG did correlate to change in amylin. The above 
correlations may help explain the improvement in glucose disposal and remission of 
T2DM reported after SG. The change in GLP-1 from baseline did negatively correlate 
to prospective food consumption in the RYGBP group (p=0.036, r=0.19).  By 
comparison in the SG group satiety after the liquid meal did positively correlate to 
change in GLP-1 (p=0.001, r=0.4). Further, prospective food consumption also 
negatively correlate to GLP-1 (p=0.004, r=0.33).  
4.4.3 Plasma insulin, glucose homeostasis after RYGBP and SG 
 
In our study a similar post-meal temporal glucose profile is seen after both RYGBP and 
SG. However the improvement in post-meal plasma glucose after RYGBP is 
statistically significant. There is an equivalent fasting, meal stimulated insulin response 
after both RYGBP and SG. The disparate GLP-1 response seen after RYGBP and SG 
suggest different mechanisms at play in the two groups to produce an equivalent meal 
stimulated insulin secretion and similar plasma glucose profile after the two procedures. 
The pronounced GLP-1 response seen after RYGBP is thought to promote insulin 
secretion in this group (Whitson BA et al 2007, Dezaki K et al 2008, Peterli R et al 
2009, Li F et al 2009, Shin AC et al 2010, Chambers AP et al 2011, Jacobsen S H et al 
2012). It is thought that the lack of such a pronounced GLP-1 response after SG may 
be compensated for by the decrease in ghrelin seen after SG and improved insulin 
sensitivity (Karamanakos SN et al 2008, Peterli R et al 2009, Li F et al 2009, Papailiou 
J et al 2010, Rizzelo M et al 2010, Abbatini et al 2010, and Peterli R et al 2012). This 
points to a combination of foregut and hind gut hormones leading to equivalent clinical 
outcome after these procedures (Peterli R et al 2012). In our study there was no 
significant change in insulin AUC after both procedures. Others have shown greater 
insulin AUC (Chambers AP et al 2011). In contrast to a 100% resolution of T2DM in 
morbidly obese patients (Vidal et al 2008),
 
the resolution rate in over weight advanced 
T2DM is much lower at 50% a year after surgery (Lee et al 2010). The authors suggest 
the discrepancy may be due to the type of patients studied, highlighting a higher 
incidence of B-cell failure is present in the later study group (Lee et al 2010). It seems 
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therefore that bariatric surgery does influence both beta cell failure and insulin 
resistance.  
4.4.4 Acyl-ghrelin and HOMA IR 
 
In our study SG alone leads to a significant decline in fasting and meal stimulated acyl-
ghrelin. Further there is a rise in acyl-ghrelin between 6 and 12 weeks after RYGBP. 
This late paradoxical rise has also been identified in a recent study on acyl-ghrelin at 6 
to 12 months after surgery (Barazzoni R et al 2013). In contrast to our findings, Shin 
and colleagues found a significant suppression in acyl-ghrelin after RYGBP. This study 
utilized multiplex assay’s, with high inter-assay variability (<24%), and rats underwent 
one assessment at three months after surgery, therefore introducing both high 
variability in plasma hormone levels, and perhaps missing immediate physiological 
changes (Shin AC e al 2010). Other studies that have examined the role of ghrelin, 
conducted assays for total ghrelin in the absence of HCL and protease inhibitors, and 
despite this, yielding similar results to our active acyl-ghrelin results (Karamanakos SN 
et al 2008). The decrease in acyl-ghrelin secretion after SG may help restore insulin 
sensitivity (Peterli R et al 2009, Peterli R et al 2012). Some speculate that the weight 
independent resolution of type-2 DM and improvement in glucose homeostasis after 
bariatric surgery may in part be mediated by acyl- ghrelin (Papailiou J et al 2010). The 
decline in acyl-ghrelin is thought to facilitate maximal capacity in the islets enabling the 
islets to respond adequately to the hyper-glycaemia and meet the increased demand 
associated with obesity (Papailiou J et al 2010 and Abbatini et al 2010). Ghrelin is also 
known to decrease insulin secretion in vitro and in vivo ((Dezaki et al, 2008; Reimer et 
al, 2003). In another study, the greatest improvement from preoperative values in 
HOMA IR occurred in the SG group, the authors suggest that this may be due to the 
large drop in ghrelin seen after SG (Abbatini et al 2010),  also in keeping with our study 
findings.  
4.4.5 Summary 
In our study SG and RYGB markedly improved glucose homeostasis. Comparative 
analysis excluding the T2DM patient in the RYGBP group does not point to significant 
changes in the insulin profile. However as expected the glucose homeostasis is 
improved in the RYGBP group when the T2DM patient is excluded. The improvement 
in insulin secretion is thought to be through the augmented GLP-1 response, reduction 
in acyl-ghrelin and weight loss. The decrease in ghrelin secretion seen after SG may 
lead to improved insulin sensitivity, leading some to propose that the proximal small 
intestine may not mediate any of the improvement in glucose homeostasis (Peterli R et 
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al 2009, Karra et al 2010). The rise in meal stimulated GLP-1 seen in our study may 
lead to changes in glucose homeostasis through all the above effects. The rise in GLP-
1 after RYGBP and SG do not lead to equivalent glucose dependent insulin secretion. 
This may be related to a threshold phenomenon. The differential insulin amylin ratio 
after RYGBP and SG is noteworthy. The relatively lower amylin in the SG group may 
also contribute to the improved glucose homeostasis after SG, and this may further 
compensate for the relatively lower GLP-1. This may in part be due to the different 
GLP-1 responses after the respective procedures. The GLP-1 stimulated amylin 
response does also show a threshold phenomenon. However, there does not seem to 
be any difference between the two groups.  
 
Statistical analysis is based on assumption of independence between the model 
residuals, with no correlation in time or space. A study with repeated measures in 
individual subjects does therefore contain potential sources of non-independence, and 
negated when individuals are only measured once. It is postulated that for time-series 
data, unmeasured factors can produce correlations or temporal auto-correlation. In our 
study the temporal correlation between weight loss before and after surgery, low calorie 
consumption before and after surgery does make it difficult to isolate these changes. In 
light of recent publications on low calorie mediated improvement in glucose 
homeostasis, further work to undertake studies on active gut hormone changes 
standardized for calorie consumption through-out the study period would help isolate 
the effects of calorie consumption. Recent publications have identified areas that 
require clarification. It is well established that surgically induced direct early delivery of 
nutrients to the small intestine results in an enhanced GLP-1 response, in turn 
enhancing the insulin response. This response can be augmented by GLP-1 analogues 
and blocked by GLP-1 receptor blockers. It has also emerged that sudden negative 
calorie balance in type 2 diabetes normalizes plasma glucose levels within days. It is 
not yet clear as to what extent these two competing mechanisms play in the resolution 
or improvement in diabetes, nor the role of these two mechanisms on enhanced meal-
related insulin secretion. The role of GLP-1 secretion on long-term β-cell function is 
also yet to be elucidated.  
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Chapter 5 
Long term and short term 
metabolic signals influence risk-
sensitive reward in humans. 
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5.1 Introduction 
 
The procurement of food and food intake is regulated by a complex neuro-endocrine 
network (Lenard NR and Berthoud HR 2008). The neural network regulating food 
intake can be divided into homeostatic and non-homeostatic pathways (Gao Q and 
Horvath TL 2008). The non homeostatic pathway is thought to mediate the rewarding 
aspects of food (Lenard NR and Berthoud HR 2008, Gao Q and Horvath TL 2008). The 
two pathways are thought to interact to govern feeding behaviour (Morton GJ et al 
2006).  More recently, a number of studies have begun to explore the importance of 
non-hypothalamic and cortical regions in feeding behaviour (Berthoud, 2007). The 
homeostatic and non-homeostatic elements within the nervous system respond to 
information concerning internal state and external environment to maintain energy 
balance. Critical brain regions have been identified through experimental lesioning, 
electrical/chemical stimulation, targeted gene deletions and functional brain imaging 
studies (Berthoud, 2003). Neuronal tracing studies demonstrate the hypothalamus to 
be well connected to many other regions in the brain, resulting in a complex circuit that 
allows adaptation and coordination in an unpredictable environment (Berthoud, 2002). 
Imaging studies have begun to demonstrate that circulating appetite signals can 
modulate brain activity in areas beyond the hypothalamus and brainstem such as the 
OFC (Malik et al 2008); (Batterham et al 2007).  Peripheral signals relaying information 
regarding nutrient status appear to be essential for appetite regulation. A number of 
hormones released from the GI tract have been isolated and investigated for their roles 
in energy balance. In addition, the receptors of several of these hormones have been 
located in areas of the brain characterised for their involvement in appetite and 
bodyweight regulation (Chaudhri et al 2006). In the current calorie rich environment, it 
is clear that socio-economic and sensory influences such as availability, palatability, 
variety, social context and meal timing impact upon feeding behaviour (de Castro and 
Stroebele, 2002). Hence brain regions involved in the processing of the psychological 
features of appetite, such as liking, wanting, pleasure, hedonic value and reward as 
well as the memories of these features, have been under investigation recently 
(Berthoud, 2003).  
The concept that reward perception is subject to homeostatic regulation derives from 
evidence that food deprivation strongly augments the reward value. One mechanism to 
explain this effect proposes that metabolic signals such as leptin and insulin tonically 
inhibit brain reward circuitry and that, by lowering circulating levels of these hormones, 
energy restriction increases the sensitivity of reward circuits
 
(Fulton et al 2000 and 
Figlewicz et al 2004). More recently evidence from animal studies and functional 
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magnetic imaging has suggested that primary re-inforcers such as food (Beaver JD et 
al 2006 and Batterham RL et al 2007) and secondary re-inforcers such as psycho-
active drugs (Volkow ND and Wise RA 2005 ) and monetary rewards (Ernst et al 2004 
and Matthews et al 2004) are all thought to mediate their rewarding effects through the 
dopaminergic reward pathway.  
Animals take risks when foraging for food. Risk-sensitive foraging theory states that this 
risk is dependent on the animal’s baseline energy state, the energetic benefit of the 
food reward and the risks involved in achieving this energetic benefit (Caraco, T et al 
1980, Joseph M et al 1988, JM McNamara, AI Houston 1992). Many foraging animals 
have been shown to respond to food variability, by selecting the risk averse source or 
the least variable source when expected energy intake exceeds the caloric needs of 
the animal, and the more variable/ risky option when expected energy intake is less 
than that required for survival (Caraco T et al 1980, Joseph M et al 1988, JM 
McNamara and AI Houston 1992). This effect is seen across many species when 
energy reserves are depleted by fasting, or energy requirements are increased by 
altering ambient temperature (A Kacelnik and M Bateson 1996), such that when a meal 
has a small effect on metabolic state, and the animal is in a relatively low-energy state, 
here a greater risk-taking approach is taken so as not to fall below the metabolic target 
(Kacelnik A and Bateson M, 1996). The metabolic reference point is often taken in 
ecology as the intake required for survival. Baseline risk will depend upon baseline 
energy reserves, and energy requirements (Kacelnik A and Bateson M, 1996), and an 
increase in baseline risk-aversion is seen as energy reserves exceed a metabolic 
threshold. In other words animals that are energy-replete after a meal, do not need to 
indulge in risky behaviour around predators, and can do so without the danger of falling 
below a metabolic target. Foraging animals have developed sensitivity to environmental 
variation in food sources. Ecological theories on the feeding behaviour of foraging 
animals does account for the daily risks they take in searching for food sources; risk-
sensitive foraging theory describes an integration of risk and food reward in ecology 
(JM Mcnamara, AI Houston 1992). Baseline risk will depend upon baseline energy 
reserves, and energy requirements (Kacelnik A and Bateson M, 1996). Risk-sensitive 
foraging theory states that this risk is dependent on the animal’s baseline energy state, 
the energetic benefit of the food reward and the risks involved in achieving this 
energetic benefit (Caraco, T et al 1980, Joseph M et al 1988, JM Mcnamara, AI 
Houston 1992).  
 
It is known that activity in the reward pathway is related to presentation of conditioned 
stimuli linked to natural rewards in animals (Berridge, 1994). A study in monkeys, 
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showed activity linked to tasting food reward only initially, however after cues were 
introduced, the greatest activity in the reward pathway was elicited by the conditioned 
stimuli in anticipation of the reward (Berridge 1994). The reward pathway does not 
differentiate between rewarding experiences provoked by natural reinforcers like food, 
illicit drugs like cocaine, or behaviours like gambling (Kelley et al 2005). An individual’s 
approach to risk-sensitive financial reward is not dissimilar to a foraging animal’s 
approach to risk sensitive food reward (Lee D 2005). Economic theories on risk-
sensitive monetary reward date back to the eighteenth century. The expected utility 
theory proposed by Daniel Bernoulli states that individuals place subjective values or 
utilities on monetary outcomes. Utility is the product of the subjective value and the 
probability of that outcome (Lee D 2005). Modern financial and economic theories 
account for risk-sensitivity in humans (Chris Starmer 2000, Platt ML and Huettel SA 
2008). When a comparison between an individual’s decision making and animals that 
make risk-sensitive foraging decisions is made; like animals that have sufficient energy 
for the day,  humans are risk averse when they face potential monetary gains and risk 
prone when the choice involves potential monetary loss, as when an animal faces 
inadequate energetic benefit (Lee D 2005). Further, there is some evidence to point 
towards similarities between monetary and sugary fluid rewards in humans, a uniform 
pattern of risk sensitive decision making was seen in both humans and non-human 
primates (Hayden BY and Platt ML 2009). Recent fMRI studies have highlighted the 
link between risk-sensitive reward and the dopaminergic reward pathway; a study with 
a simple gambling
 
paradigm did show total winnings correlated with hemodynamic
 
response in the reward pathway (Elliott et al, 2000), other fMRI studies have also 
adopted this risk-sensitive reward paradigm (Ernst et al 2004 and Matthews et al 2004) 
and confirm increased activity in the reward pathway during selection of the high-
reward/risk option than during selection of low-reward/risk option. 
 
Further, there is some evidence to point towards similarities between monetary and 
sugary fluid rewards in humans. A recent human study to compare and assess choices 
made for sugary fluid rewards and monetary gains on gambling tasks, revealed a 
consistent pattern of decision making for both food and monetary rewards (Hayden BY 
and Platt ML 2009). Here a uniform pattern of risk sensitive decision making was seen 
in both humans and non-human primates (Hayden BY and Platt ML 2009). However, 
metabolic state is not known to play a part in economic theories on decision making in 
humans, this is in contrast to ecological theories on animal foraging behaviour. Risk-
sensitive reward in humans can be formally quantified with the aid of a variety of 
methods (G. W. Harrison, E. E. Rutström, 2008). We employed the paired lottery task 
(Hey and Orme 1994).  
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Takahashi attempts to link endocrine markers of energy homeostasis and feeding 
behavior with obesity utilizing mathematical modeling, utilizing economic theories as a 
framework. He proposes that neuroeconomic studies can examine the link between 
endocrine mediators of energy metabolism; ghrelin, leptin and satiety; amylin, GLP-1 
and PYY, and obesity using complex mathematical models based in economic 
theories, to study complex behavior linked to obesity. He points to the investigation of 
obesity attracting attention in several inter-related disciplines of neurobiology, 
psychiatry, and neuroeconomics, and suggests that therefore studies incorporating 
these disciplines into a mathematical model may yield insight into how neurobiological 
substrates can be integrated to predict outcome (Takahashi, 2010). 
 
5.2 Aims of the study:  
 
We conducted a single blind within subject randomised study to assay an individual’s 
risk sensitive reward seeking behavior in three different feeding states: fasted, fed or 
immediately, and 60 minutes post-meal. To assess the influence of metabolic state on 
risk sensitive monetary reward seeking behavior. 
5.3 Methods  
5.3.1 Ethics 
 
Ethical approval was obtained from University College London Research Ethics 
Committee. This study was carried out in accordance with the principles of the 
Declaration of Helsinki. All subjects attended a screening session where they received 
oral and written information about the study and were given the opportunity to ask any 
questions about the study. An informed consent form was signed on the first day of the 
study. Data collected was stored in accordance with the Data Protection Act 1998. 
5.3.2 Subject recruitment 
 
Healthy, normal weight male volunteers between the ages of 18 -60 were recruited 
through advertisements on the University College London campus. Exclusion criteria 
were the use of regular medications, smoking, food allergies and presence of any 
medical or psychiatric illnesses. All subjects were weight-stable for at least 3 months 
prior to recruitment.  On the day before each study day subjects were asked to 
maintain a similar schedule of activities and refrain from alcohol consumption. One 
subject dropped out of the study after the first visit, citing travel abroad, another was 
excluded due to fasting hyper-glycaemia. Randomisation errors led to three other 
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subjects being excluded from the analysis and a further subject was excluded from the 
biochemical analysis as some of his plasma samples were haemolysed. Eighteen 
subjects were included in the final analysis. 
5.3.3 Subject standardisation and acclimatization 
 
Subjects were asked to follow a standardization protocol on the day prior to the study 
morning. This involved refraining from alcohol and strenuous exercise (Chandarana, K 
et al, 2009). They consumed a standard 774 kcal meal between 19:30 and 20:30 on 
the evening before the study morning (Chandarana, K et al, 2009). Subjects then 
fasted and drank only water until attending our clinical facility the following morning. 
Details of the standard meals are listed (figure-71) 
5.3.4 Cognitive tasks undertaken in three metabolic states. 
 
We assayed a subject’s risk sensitive reward behaviour through the ordered paired 
lottery (Hey and Orme, 1994). Subjects were given two options of monetary reward per 
scenario and 200 scenarios at each visit. Each option had four monetary values. These 
scenarios were given in the same order on each subsequent visit, but unknown to the 
subjects, the placement of the monetary values in the two options in a scenario was 
changed from week to week. In each scenario, one option was defined as the safe 
option and the other risky. We calculated an individual’s risk averse score per visit, by 
calculating the percentage of times an individual chose the safe option. In order to 
make the presented scenarios of monetary risk taking as real as possible, subjects 
were told that the choices they made will be stored, and one of his choices played out 
at random, at the end, to determine payout. The subjects also did two other control 
computer tasks. In order to make these control tasks as real as possible, subjects were 
also paid monetary rewards according to their performance in these tasks. These 
control tasks were temporal discounting, where subjects were asked to make a choice 
between payment of a higher monetary value at a later date against a sooner payment 
of less monetary value; and a learning rate task, where subjects were asked to 
recognise patterns encrypted in a pixel maze. A single blind within subject randomised 
study was performed, with each subject tested on three separate occasions. Tasks 
were undertaken in three different feeding states: fasted (t=0 to t=60), fed/ immediately 
post-meal (t=90 to t=150) and 60 minutes post-meal (t=150-t=210). Subjects performed 
one of three tasks at each time point. This design was undertaken to ensure that equal 
attention being paid to each task throughout the experimental session. Each task was 
performed once in each week in randomised order 
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Figure-69; A schematic time line diagram of the decision making study 
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F i g u r e - 7 0 ;  t a b l e  o f  b a s e l i n e  a n t h r o p o m e t r i c  c h a r a c t e r i s t i c s   
a n d  f a s t i n g  p l a s m a  h o r m o n e  m e a s u r e m e n t s .  
 
 
 
 
 
 
 
 
 
 
 
 
 
S u b j e c t  
n u m b e r  
A g e  B M I  P e r c e n t a g e  
b o d y  f a t  
g l u c o s e  L e p t i n  
1  2 2  2 4 . 5  1 4  4 . 9  4 0 . 0 6  
2  2 0  2 2 . 2  1 2 . 5  4 . 9  5 9 . 0 6  
3  2 2  2 0 . 7  1 0 . 5  4 . 5  1 3 2 . 4 2  
6  3 2  2 1 . 2  1 1  5 . 2  2 4 8 . 6 2  
7  2 0  2 4 . 7  1 6 . 5  4 . 9  5 0 4 . 9  
9  2 0  2 1 . 6  1 2 . 5  4 . 5  1 1 6 . 8 3  
1 1  2 5  2 1 . 2  1 1 . 5  4 . 8  2 . 4 9  
1 2  2 2  2 2 . 8  1 3  4 . 7  9 9 . 4 6  
1 3  2 2  2 0 . 3  8 . 5  4 . 8  9 . 3 3  
1 4  2 2  2 0 . 4  9 . 5  4 . 7  1 . 1 7  
1 5  2 7  2 5  1 6  4 . 7  2 0 4 . 4 9  
1 8  2 2  2 0 . 3  1 0  4 . 9  1 8 0 . 4 9  
1 9  2 1  2 1 . 9  1 5 . 5  4 . 6  7 0 0 . 1 3  
2 0  2 2  2 3 . 1  1 5  4 . 9  7 9 . 8 1  
2 1  2 3  2 5  1 4 . 5  4 . 5  4 5 7 . 3 4  
2 2  3 4  2 4 . 8  1 9  4 . 5  2 6 8 . 4 7  
2 3  4 6  2 3 . 3  1 1 . 5  5 . 1  1 8 6 . 4 0  
2 4  2 0  2 2 . 9  1 2  4 . 8  1 1 7 . 3 0  
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5.3.5 Blood collection 
 
This is as described in detail in section 2.2.5. 
5.3.6 Reagents added to blood to preserve active hormones 
 
This is as described in 2.2.7. 
5.3.7 Visual analogue score 
 
This is as described in 2.2.8 
5.3.8 Standard meal 
 
 
 
Type of food 
  
Chicken 
Wrap 
100g Pringles 
crisps 
Chocolate 
drink 
Trifle Cheese
& 
tomato 
pizza 
Energy (kcal) 535 540 620 371 774 
Protein (g) 20.6 4.1 21.6 3.8 36.4 
Carbohydrate (g) 46.4 49 74.6 26.7 109.6 
Sugar (g) 4.2 1.9 72 19.7 11.2 
Fat (g) 30 36 26 28.3 21 
Saturated fat(g) 6.1 10 11.6 18 11.2 
Fibre (g) 4.4 3.6 3.6 1.56 6.6 
Na (g) 0.61 0.53 0.36 0.06 1.02 
Equivalent salt (g) 1.53   0.9    1.28 
 
Table-71; Nutritional composition of the standard meal is shown. The meal in bold 
italics was consumed on the night before the study day, all other components were 
consumed as the study day meal.  
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5.3.9 Payment 
Payment for the first two tasks (risk preference and inter-temporal choice) was through 
random lottery incentive mechanism. One choice from the three weeks was selected at 
random and played out for real to determine an individual’s winnings. One of either the 
risk elicitation task or the inter-temporal choice task was played out. This was chosen 
by random number generation on a computer. Winnings from the risk preference task 
ranged from £0-80. A baseline payment of £40/week was made for participation on 
completion of all three weeks. 
5.3.10 Hormone assays 
 
This is as described in 2.2.11 
5.3.11 Radioimmuno assay 
 
This is as described in 2.2.12 
5.3.12 ELISA 
 
This is as described in 2.2.13 
5.3.13 Statistical analysis 
 
This is as described in 2.2.17 
 
5.4 Results 
5.4.1 Feeding alters risky choices  
 
Feeding significantly (p=0.008) altered a subject’s risk averse score from the fasted 
(t=0) to the fed state (t=90), and showed a trend towards significance (p=0.137) from 
the fasted (t=0) to the 1-hour post-meal time point (t=150) (figure 72/ 73). Subjects 
became more risk seeking after the meal. There was a significant change in plasma 
ghrelin with feeding. Our temporal ghrelin profile is similar to that of other published 
studies on meal related change in ghrelin. For correlation analysis with change in risk 
averse scores, we calculated the change in plasma ghrelin from baseline (t=0 min). The 
baseline ghrelin value was defined as zero, the change from the baseline value to the 
end of the study (t=210 min), was calculated for each visit- delta ghrelin. 
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We also found a statistically significant correlation between the change in risk averse 
score from baseline to the satiety state (an hour past feeding, t=150min), and change in 
delta ghrelin for the corresponding time points (figure-8). Therefore an individual’s risk 
averse score for monetary rewards, an hour after feeding was significantly correlated to 
change in the ghrelin level. This was a negative correlation. Therefore a lesser change 
in ghrelin led to a higher risk seeking. Therefore both leptin and ghrelin did influence 
monetary reward seeking behaviour.  
 
  Percentage safe choices made Change in safe choices made 
subject fasted Fed 1 hour post meal 
Ä(fast-
fed) 
Ä (fast-1hour post 
meal) 
1 45.2 44.9 49.2 0.3 -4 
2 83.9 83.4 76.9 0.5 7 
3 71.4 75.9 70.9 -4.5 0.5 
6 75.4 71.4 69.8 4 5.5 
7 53.3 45.2 53.8 8 -0.5 
9 48.2 44.7 47 3.5 1.3 
11 44.9 35.6 40.2 9.3 4.7 
12 48.2 46.7 46.7 1.5 1.5 
13 69.3 67.8 66.3 1.5 3 
14 59.3 63.5 65.7 -4.2 -6.4 
15 79.4 78.4 78.4 1 1 
18 68.7 70.9 64.8 -2.2 3.9 
19 75.4 68.7 69.8 6.7 5.5 
20 69.2 65.8 56.3 3.4 12.9 
21 67.3 59.3 65.3 8 2 
22 52.3 48.2 61.8 4 -9.5 
23 76.9 69.8 71.9 7 5 
24 47 43.4 46.7 3.5 0.2 
 
Figure-72; Percentage of safe choices made in each of the metabolic states, and the 
change in safe choices made from the fasted state, in the paired lottery task are shown 
for all subjects included in the analysis. 
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  Fasted Fed 
1 hour post 
meal 
Number of values 18 18 18 
Mean 63.07 60.2 61.19 
Std. Deviation 13.21 14.42 11.53 
Std. Error 3.114 3.398 2.718 
        
        
Normality Test       
KS distance 0.1811 0.1862 0.1783 
P value P > 0.10 P > 0.10 P > 0.10 
Passed normality test 
(alpha=0.05)? Yes Yes Yes 
P value summary Ns ns ns 
Figure-73; table to summarise descriptive statistics from the decision making study. we 
undertook a normality test to ensure gausian distribution prior to undertaking statistical 
analysis. The analysis summary is shown. 
30 40 50 60 70 80 90
fasted safe choices
fed safe choices
1hour post-meal safe choices
**
% safe choices
 
Figure-74; A box-plot to show the change in safe choices made after the meal, and an 
hour after the meal 
 
5.4.2 Body fat mass correlates to plasma leptin and BMI 
 
There is a significant positive correlation between circulating plasma leptin 
concentrations and the body fat mass measured by impedence (p = 0.058, r=0.21). 
There is also a significant correlation between BMI and body fat percentage (p=0.0002, 
r = 0.59) in our subjects. Given this correlation, BMI and leptin both did correlate to 
change in risk averse choices made from the fasted to the fed state. 
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Figure-75; A scatter plots to show positive correlation between measured body fat 
percentage and plasma leptin (A), and BMI. 
 
5.4.3 Leptin and BMI correlate to change in risky choices from fasted to fed state 
 
There was a positive correlation between both leptin (p=0.034, r=0.25) and BMI 
(p=0.038, r=0.24), and the increase in risky choices made from the fasted to fed state.  
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Figure-76; scatter plots to show positive correlation between change in safe choices 
made from the fasted to fed state, and plasma leptin (A), and BMI (B) 
 
5.4.4 Temporal profile of acyl-ghrelin 
 
Consumption of the meal caused a significant decrease in plasma acyl-ghrelin (two-
way repeated-measures ANOVA, p <0.001), plasma acyl-ghrelin did peak just before 
the meal, showing an increase from t = 0 to t = 60 min, of 63.1  12.2 pmol/L, p<0.001, 
falling to trough level at t = 120 min, decreasing from t=0 to t=120 min by 98.7  12.0 
pmol/L, p < 0.001. There was no significant within-subjects difference in acyl-ghrelin 
profiles across weeks (p = 0.237). 
185 
 
0 30 60 90 120 150 180 210
0
50
100
150
200
250
300
350
Meal
time (mins)
A
c
y
l-
g
h
re
li
n
 (
p
M
)
 
Figure-77; A graph to show the post-prandial temporal change in plasma acyl-ghrelin 
concentration from fasted to fed, and at an hour after meal 
 
 
5.4.5 Temporal appetite and satiety profiles 
 
There was a significant decrease in subjective hunger score (VAS) from the fasted to 
the fed state, through the course of the study period, and across subjects (two-way 
repeated measures ANOVA- week, time point), there was a significant decrease across 
time point (p<0.001), and this effect was consistent across weeks, (p=0.48), however 
there was also a significant difference in hunger between weeks (p=0.0006), hunger 
scores were higher on subsequent visits, further, Bonferroni post-hoc test did show 
significant (p<0.001) increase in baseline (t=0) hunger from week-1 to week-3. Hunger 
increased from baseline to administration of the meal (t = 0 to t = 60) 10.7  1.7, p 
<0.001, then fell immediately after the meal, reaching a nadir at t =120 min, decreasing 
by (t=0 to t=120 min) 52.1  3.3, p <0.001.  There was also a significant (p<0.001) 
decrease in prospective food consumption ratings over the course of each session 
(two-way repeated measures ANOVA- week, time point) again there was a significant 
decrease across time points p<0.001, but there was no significant difference between 
weeks, p=0.084.  An increase in prospective food consumption occurred from t = 0 to t 
= 60 min: 9  1.5, p <0.001; which then decreased after the meal (t=0 to t=120) by 49.1  
  2.8, p < 0.001. 
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Figure-78; The temporal profile of VAS hunger and prospective food consumption 
 
5.4.6 Acyl-ghrelin correlates to hunger 
 
The mean hunger score at each time point across all visits did show a highly significant 
positive correlation (p=0.003, r=0.80) to the corresponding mean plasma acyl-ghrelin 
(figure-78).  
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Figure-79; A significant positive correlation between the mean hunger VAS and mean 
plasma acyl-ghrelin across all visits for all subjects 
 
5.4.7 Prandial Change in acyl-ghrelin correlates to change in risky choices  
 
We calculated changes in acyl-ghrelin from the t=0 min time point (Δ-ghrelin) to all 
other time points throughout a session, for each individual, to controls for small 
variations in fasting acyl-ghrelin level between weeks. The differences in Δ acyl-ghrelin 
between states was then calculated across weeks by calculating the change from the 
end of the interval in which each subject performed the task (t=30/60 min; t=120/150 
min; t=180/210 min). There was a significant negative correlation between increase in 
187 
 
risky choices from the fasted to the 1-hour post meal stage and the decrease in Δ acyl-
ghrelin at the corresponding time point (p=0.03, r=0.26). 
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Figure-80; scatter plot to confirm correlation between change in delta acyl-ghrelin and 
change in safe choices made an hour after the meal. 
 
5.4.8 Baseline leptin and acyl-ghrelin do not correlate 
 
There was no correlation between baseline acyl-ghrelin and leptin levels (p = 0.19) 
(figure-80). Additionally, there was no correlation between leptin, body mass index, or 
body fat percentage and mean risk averse score across across all sessions p=0.48, 
0.23 and 0.25. 
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Figure-81; Scatter plot to confirm no correlation between acyl-ghrelin and leptin 
 
5.5 Discussion 
 
According to the prospect theory, normal subjects tend to assign greater weight to loss 
than to gain (Hahnemann and Tversky, 1979 and Tversky and Kahneman, 1981). 
Furthermore, preferences are typically risk-averse in the gain domain and risk-seeking 
in the loss domain (Kahneman and Tversky, 1979 and Tversky and Kahneman, 1981). 
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Subjects in the decision making study were risk averse at baseline. A study with a 
simple gambling
 
paradigm did show total winnings correlated with haemodynamic
 
response in the reward pathway ((Elliott et al, 2000). A further study confirmed roles for 
the reward pathway, with an on-off
 
pattern of response in the reward pathway and the 
amygdala in relation to expectation, detection and occurrence of reward. In other words 
the neural substrates,
 
responsive to monetary reinforcement overlap extensively with
 
those responsive to primary reinforcers such as food in animals (Elliott et al 2003). 
Other fMRI studies have adopted a risk-sensitive reward paradigm (Ernst et al 2004 
and Matthews et al 2004) similar to ours and confirm increased activity in the reward 
pathway during selection of the high-reward/risk option than during selection of low-
reward/risk option. Further, in the study by Ino et al (Ino et al 2010), that evaluated 
fMRI activity whilst undertaking a monetary task in which subjects were endowed with 
money initially, and required to choose either high-reward/risk or low-reward/risk option, 
showed that the reward pathway was a main region activated when selecting the high-
risk/reward option compared to selecting the low-risk/reward option, and is consistent 
with the previous studies, showing that the reward pathway is a major neural substrate 
where alteration in activity is seen between the two options (Ino et al 2010). 
 
Results from the decision making study suggests that an individual’s metabolic state 
does influence risk-sensitive monetary reward. The change in an individual’s risk-
sensitive reward from the fasted to fed state is significantly correlated to his baseline 
energy stores indexed by the metabolic hormone leptin, further the change in risk 
sensitive reward at an hour after the meal (when acyl-ghrelin has reached its nadir) is 
correlated to ghrelin a hormone that indexes acute nutrient intake.  
 
The mid brain dopaminergic neural reward pathway is thought to mediate the rewarding 
aspects food, drugs of addiction and money (Elliott R et al 2003, Volkow ND and Wise 
RA 2005, Palmiter RD 2007, Platt ML and Huettel SA 2008). Recent evidence from in 
vivo studies confirms the presence of functional receptors to leptin and ghrelin in the 
dopaminergic reward pathway (Palmiter RD 2007). Metabolic hormones can activate 
(acyl-ghrelin) or inhibit (leptin) this dopaminergic reward pathway (Morton GJ et al 
2006, Palmiter RD 2007, Lenard NR and Berthoud HR 2008). The dopaminergic 
reward pathway is interconnected to other brain areas concerned with learning and 
memory (hippocampus), energy balance (hypothalamus and brainstem), motivation 
(amygdala), reward value (orbitofrontal cortex) and executive function (prefrontal 
cortex) (Beaver JD et al 2006, Morton GJ et al 2006, Lenard NR and Berthoud HR 
2008, Stoeckel LE et al 2008). The reward pathway is therefore able to assay 
metabolic signals and afferent neural inputs from other regions of the brain, and in turn 
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inform neural pathways to bring about an individual’s desired behavioural response 
(Lenard NR and Berthoud HR 2008). The dopaminergic reward pathway is thought to 
play a significant role in feeding behaviour in our current calorie abundant environment 
(Volkow ND and Wise RA 2005, Morton GJ et al 2006, Palmiter RD 2007, Lenard NR 
and Berthoud HR 2008, Stoeckel LE et al 2008).  
 
An individual’s approach to risk-sensitive monetary reward and a foraging animal’s 
approach to risk-sensitive food reward are known to share  common characteristics 
(Lee D 2005), further, as the vast majority of human studies on risk sensitive reward 
involve monetary rewards, a review of human risk preference and animal food reward, 
suggests that risk-sensitive reward in humans and animals share common 
characteristics, both are better predicted by a measure of risk that relates variability of 
outcomes to expected returns (EU Weber 2004).  
 
5.5.1 Metabolic state does influence human risk-sensitive reward  
 
In our subject population, a calorie rich meal significantly increased an individual’s risk 
sensitive monetary reward seeking behaviour, from the fasted to the fed state and 
showed a trend towards significance at an hour after the meal (p=0.137). It could be 
argued that the high calorie meal in a safe environment increased their reward seeking 
behaviour to gain other, namely monetary reward. In other words one rewarding 
experience increased their appetite for other rewarding experiences. The “priming” 
effect of a small amount of a palatable food on binge eating  described as the ‘priming’ 
effect is also seen in addiction behaviour,  where even a small dose tends to elicit a 
strong ‘craving’ and compulsion for further use, hence in our study food may have 
caused a ‘priming’ effect (Davis et al 2004) This concept is also supported by the 
dopamine hypothesis, which states that dopamine promotes the wanting of rewards, 
making animals work harder and faster to keep up the elevated levels of dopamine, 
which in turn makes the animals feel rewarded (Palmiter RD 2007). Recent evidence 
linking addiction behaviour and obesity to the reward pathway (Volkow ND and Wise 
RA 2005, Engelmann JB 2006, Palmiter RD 2007, Stoeckel LE et al 2008) also lends 
support to this concept of transfer of effect between food and money. Other evidence 
from in vivo studies link food reward to drugs of abuse; food deprivation augments the 
rewarding value of drugs of abuse and food reward (Morton GJ et al 2006), further, 
animal studies have shown a link between food deprivation and relapse of drug seeking 
behaviour, after a prolonged drug free period (Shalev U et al 2000). This effect was 
attenuated by leptin infusion, suggesting that food deprivation may augment 
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reinstatement of drug seeking, by its actions on the dopaminergic reward pathway 
(Shalev U et al 2000).    
 
5.5.2 Baseline energy stores influence the change in risk sensitive reward in 
humans 
 
In our study, BMI and plasma leptin is positively and significantly correlated to the 
change in monetary risk-sensitive reward from the fasted to fed state. This positive 
association between baseline energy stores and risk sensitive reward is similar to the 
risk-sensitive foraging for food seen in animals (Caraco T et al 1980, Lee D 2005). The 
lipostatic theory on energy homeostasis states that humoral signals generated from 
body fat stores, act through homeostatic centres to maintain body fat stores (Mayer J 
1955). In other words, the higher an individuals body fat stores, the more energy they 
need to sustain their current energy state. Therefore subjects with a higher percentage 
body fat and plasma leptin levels, would be expected to be relatively more risk seeking 
for food reward after the same meal. However, it is interesting that in our subjects this 
increase in risk-sensitive reward was not to food reward but to monetary rewards. This 
transfer of effect from food to monetary reward has not been reported before. The 
transfer of effect from one rewarding experience to another is supported by the 
dopamine hypothesis, and recent evidence suggesting similarities between decisions 
made for food reward and monetary reward in humans. A recent study compared an 
individual’s approach to risk sensitive monetary reward and sugary liquid treats in a 
gambling task, and found similarities in choices made for both sugary fluid rewards and 
monetary gains. There was no difference in an individual‘s pattern of decision making 
for both food and monetary rewards (Hayden BY et al 2009).  
 
However, the positive correlation between leptin and risk-sensitive reward does also 
raise further questions. The dopaminergic reward pathway is known to have functional 
leptin receptors that have an inhibitory effect on these neurons (Palmiter RD 2007, 
Lenard NR and Berthoud HR 2008). A review of in vivo studies on leptin and the 
reward pathway also point to an inhibitory effect of leptin (Morton GJ et al 2006, Fulton 
S 2006). In our study, the higher leptin level did not lead to an inhibitory effect on the 
reward pathway, and make those individual’s with higher adiposity less likely to seek 
further monetary reward, in fact the opposite occurred. Subjects with a higher leptin 
level displayed a risky approach to reward. 
 
A coherent model to explain the effects of leptin on reward seeking behaviour, at an 
organism level, will need to take account of the effects of leptin on both the homeostatic 
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pathways governing energy homeostasis, and the dopaminergic reward pathway. The 
homeostatic pathway and the reward pathway are interconnected and inter-related 
(Morton GJ et al 2006). The idea that reward perception is subject to homeostatic 
regulation is now accepted. A lack of availability of food exerts a global stimulatory 
effect on reward perception, including food reward (Morton GJ et al 2006). One 
proposed mechanism suggests that leptin and insulin tonically inhibit the reward 
circuitry, and food deprivation leads to a lower circulating level of these hormones, 
increasing the sensitivity of the reward circuitry. However, the opposing scenario, which 
occurs in obesity, when an individual’s abundant of energy store will be expected to 
lead to the opposite effect and decreased sensitivity, is still debated (Morton GJ et al 
2006). Therefore it could be argued that in our subject pool, individuals with a higher 
body fat mass and plasma leptin would need more energy to sustain their fat mass, and 
as suggested by the lipostatic theory, they will be more likely to seek further food 
reward to sustain their energy stores. 
  
There are also other possible explanations for this discrepancy. It is possible that like in 
obesity and drug addiction, where supra-physiological stimulation of the reward 
pathway leads to stimulus preferences, a high calorie meal led to the preference of a 
more rewarding stimulus (Volkow ND and Wise RA 200510), further, it is also possible 
that higher centres in the prefrontal cortex that are known to exert executive control 
over the reward pathway (Lenard NR and Berthoud HR 2008, Figlewicz DP and Benoit 
SC 2008) , may have played a role in choosing the higher gain monetary incentives on 
offer, in a predominantly student population.          
 
5.5.3 Post-prandial changes in acyl-ghrelin influence risk-sensitive reward 
seeking behaviour 
 
The temporal profile of acyl-ghrelin in our study, confirms that the plasma acyl-ghrelin 
level is significantly altered from fasting to an hour after feeding, this change in acyl-
ghrelin does also show positive and significant correlation to hunger VAS.  The 
magnitude of this change in plasma acyl-ghrelin is negatively correlated to the change 
in risk-sensitive reward seeking in our subject population. In other words, an individual 
with a small change in plasma acyl-ghrelin level became more risk seeking to monetary 
reward. 
 
The plasma acyl-ghrelin response after a meal is associated with the inter-meal interval 
in normal weight men (Blom WA et al 2009). It has also been shown that the change in 
plasma acyl-ghrelin from baseline to an hour after ingestion is proportional to calorific 
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intake (Callahan HS et al 2004). Acyl-ghrelin is able to promote feeding behaviour by 
its actions on the homeostatic and reward pathways; orexigenic neurons in the 
homeostatic pathway have functional ghrelin receptors that mediate feeding behaviour 
(Cummings DE 2006). Therefore acyl-ghrelin is able to relay information about energy 
gains from food intake to the homeostatic centre and regulate feeding behaviour. 
Ghrelin is also able to promote food intake by acting on the dopaminergic reward 
pathway (Ghigo E et al 2005, Cummings DE  2006, Palmiter RD 2007), where it is 
known to have an excitatory effect, on these neurons (Abizaid A et al 2006, Palmiter 
RD 2007), and the dopaminergic reward pathway is thought to mediate the rewarding 
aspects of food and financial reward (Volkow ND, and Wise RA 2005, Palmiter RD 
2007, Platt ML and Huettel SA 2008). This may explain the transfer of effect from food 
to money seen in our study. In those individuals with a relatively low suppression, 
ghrelin will be expected to promote further food intake by its action on the homeostatic 
pathway to maintain energy homeostasis, and acyl-ghrelin will also be expected to 
promote food intake through the reward pathway, in these same individuals. The risky 
approach to monetary reward, in individuals with low acyl-ghrelin suppression is in 
agreement with risk-sensitive foraging behaviour in animals, when an animal is not able 
to meet its daily energetic requirement with the “safe source” of food on offer, it would 
seek more variable and risk prone food sources (A Kacelnik and M Bateson 1996).  In 
our subjects, as with leptin, a transfer of effect from food to monetary reward is seen, 
again this has not been reported before. However our findings of an increase in risky 
choices after feeding in the cohort does contradict the decline in risk-sensitive 
monetary reward seeking behaviour with greater suppression of acyl-ghrelin.   
 
5.5.4 Leptin and acyl-ghrelin interact to signal energy stores  
 
It was initially thought that leptin regulated ghrelin levels (Barazzoni R et al 2003). 
Though more recent evidence points towards multiple factors regulating ghrelin 
secretion; nutrients (carbohydrate and protein suppress ghrelin more than lipid), insulin, 
intestinal osmolarity, enteric neural signalling and vagal response, have all been shown 
to suppress ghrelin secretion after a meal (Ghigo E et al 2005, Cummings DE. 2006, 
Klok MD et al 2007). There is some evidence pointing at insulin communicating 
information on both short term energy gains and long term energy stores, to ghrelin 
producing cells in the oxyntic mucosa (Cummings DE, Foster KE 2003, Klok MD et al 
2007). It is thought that adiposity related changes in insulin, but not leptin may convey 
information on long term energy stores to ghrelin producing cells (Cummings DE, 
Foster KE 2003, Cummings DE 2006). Ghrelin producing cells appose the basement 
membrane, in close proximity to the vascular compartment and are not known to be in 
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direct contact with the gastric lumen (Cummings DE 2006). Therefore ghrelin producing 
cells are more likely to respond to blood borne signals and less likely to respond to 
luminal contents.  
 
It is now thought that leptin and ghrelin act in parallel on the homeostatic and reward 
pathways (Cummings DE 2006, Cummings DE, Foster KE 2003, Klok MD et al 2007). 
They are metabolic counterparts with opposing actions. Ghrelin is an evolutionarily 
conserved protein, conveying information on intestinal energy stores, in lower non 
vertebrate organisms (Cummings DE, Foster KE 2003). 
 
5.5.5 Baseline energy stores and feeding alter reward behaviour  
 
The decision making study suggests that an individual’s metabolic state does influence 
his monetary decisions, risk-sensitive monetary decisions were influenced by both 
long-term metabolic signals indexing energy stores and short-term metabolic signals 
that index energy gains. This is not surprising, given that the homeostatic mechanisms 
that regulate body energy stores also influence reward pathways (Morton GJ et al 
2006).  
 
At the neurobiological level, our results suggest an overlap between food and monetary 
reward. This has significant implications for all decisions that incorporate risk and 
monetary reward. The implications of the results from the decision making study are 
wide ranging, given that all individual’s make assessment of risk and reward in many 
aspects of our daily lives, from crossing the road to placing a bet at the grand-national. 
An individual’s body mass index and his nutritional intake could alter behavioural 
patterns, In the financial services industry; as long term energy stores will influence risk 
sensitive reward seeking, should all who take risks to attain monetary reward be 
encouraged to adhere to a ideal body weight, further, after a meal, as the energetic 
value of the meal in relation to his energetic requirement will influence risk sensitive 
reward, should we also encourage these individuals to be satiated, though it could be 
argued that all aspects of human behaviour does assess risk and reward,  perhaps we 
should all take note of our hunger when it comes to pursuing any task that involves an 
assessment of risk and reward 
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Chapter 6 
Summary and discussion 
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6.1 RYGBP and SG lead to equivalent weight loss 
 
There is equivalent %EWL after both RYGBP and SG at 6 and 12 weeks. Despite 
starting with a lower BMI, the SG group lost similar BMI points to the RYGBP group. 
This is in keeping with other recent short term (Karamanakos et al 2008, Peterli R et al 
2009, Valderas JP et al 2010, Benaiges D et al 2011, Peterli R et al 2012, Ramon J M 
et al 2012) and long term (Morales MP et al 2010, de Gordejuela AG et al 2011, and 
Peterli R et al 2012) human studies. This is also seen in rodent studies (Chambers AP 
et al 2011). More recently conversion of both procedures to the opposite has been 
successfully undertaken for failure of weight loss. RYGBP was converted to SG and 
was seen to alter dietary behaviour (Dapri G et al 2011). Revision after SG for weight 
gain, gastric reflux and other complications, to RYGB also revealed sustained weight 
loss (Morales MP et al 2010).  
 
6.2.1 Differential change in hunger, satiety and prospective food consumption, 
and gut hormone levels 
 
With regard to changes in appetite following bariatric surgery, no study to date has 
found correlation between changes in active gut hormones after RYGBP and changes 
in perception of hunger, satiety or prospective food consumption. So far only a few 
studies have looked at appetite scores alongside gut hormones (Korner J et al, 2005, 
Korner J et al 2006, Buchwald et al 2007, Karamanakos SN et al 2008, DePaula AL et 
al 2009, Valderas JP et al 2010), and have shown significant decrease in hunger and 
increase in satiety, after RYGBP, and SG. However, none had employed a 
comprehensive VAS recording. Our study was unique in this respect. To date no 
correlation between changes in an individual’s VAS and an individual’s gut-hormones 
have been reported in the literature. Some studies utilised only two time points per visit 
(Korner J et al, 2005, Korner J et al 2006, Karamanakos et al 2008). Therefore 
correlation analysis between changes in gut hormones has not been feasible. Other 
studies with multiple time points, point to gut hormones altering appetite and satiety 
after surgery and thus engender weight loss after RYGBP and SG, though have been 
unable to correlate these outcomes in an individual (Korner J et al 2005, Valderas JP et 
al 2010, and Karamanakos SN et al 2008). The total PYY AUC did show positive 
correlation with satiety AUC (Valderas JP et al 2010). 
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In our study, RYGBP and SG seem to alter hunger, prospective food consumption and 
satiety differentially. RYGBP has a more pronounced influence on prospective food 
consumption and hunger, despite non-significant changes in acyl-ghrelin; whilst the 
converse is true of satiety. This variability does not fit with the overall gut hormone 
changes seen after these procedures. RYGBP leads to a more pronounced PYY3-36, 
GLP-1 and amylin response and would be expected to alter satiety more. The meal 
related satiety response is very similar in both groups at 6 weeks, but do differ at 12 
weeks, where the increase remains significant in the SG group alone. In the SG group, 
GLP-1 and Δ PYY does show positive correlation to satiety. SG by contrast does lead 
to a more pronounced and significant decline in acyl-ghrelin and thus expected to 
suppress hunger more than RYGBP. The Δ acyl-ghrelin does show negative correlation 
to prospective food consumption in both groups. Further, GLP-1, PYY3-36 and Δ 
PYY3-36 does also show negative correlation to prospective food consumption after 
RYGBP. In common with RYGBP, GLP-1 and Δ PYY3-36 do show a negative 
correlation to prospective food consumption after SG. Conversely acyl-ghrelin does 
positively correlate prospective food consumption after RYGBP. These correlations 
between active gut hormones, hunger, prospective food consumption and satiety have 
not been reported before. Our study provides a link between the change in gut 
hormones and measures of appetite and satiety, and confirms gut hormone changes 
that occur after RYGBP and SG may lead to a decline in appetite and an increase in 
satiety in an individual, and therefore favour weight loss.  
 
6.2.2 RYGBP and SG lead to a differential change in Δ hunger, Δ satiety and Δ 
prospective food consumption 
 
There was a pronounced decline in the Δ hunger in the SG group when compared to 
the RYGBP group. This is in keeping with acyl-ghrelin changes, and may point to Δ 
hunger being a better marker of change in plasma hormones. This does contrast with 
the VAS for hunger where there was a pronounced decline after RYGBP. There was a 
pronounced decline in Δ prospective food consumption after SG when compared to 
RYGBP. The Δ delta satiety was similar, but more pronounced after SG.  
 
6.3 RYGBP and SG lead to equivalent leptin decline which correlates to change 
in BMI, fat mass and VFA 
 
Fasting plasma leptin does decline significantly in keeping with adiposity after RYGP 
and SG. Further, there was no significant difference between the two groups. In the 
RYGBP and SG groups weight, BMI, fat mass and visceral fat area correlate to 
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circulating leptin. This is the first study to show such correlation, and argues against 
any other neuro-humoral cause in the first three months after surgery. It is known that 
fat mass is not the sole determinant of plasma leptin levels (Dubuc GR et al 1998). 
Nutritional factors such as recent energy intake are also involved in the regulation of 
leptin production (Dubuc GR et al 1998). Negative energy balance does also influence 
leptin production (Havel PJ 2001). Others have also demonstrated the correlation 
between circulating leptin and adiposity before and after RYGBP (Faraj M et al 2003). 
Paradoxically circulating leptin levels of obese subjects undergoing weight loss after 
RYGBP does fall below normal reference values despite them remaining obese. In 
other words there was a greater magnitude decline in leptin in this study (Faraj M et al 
2003). This is thought to be due to adiposity-independent energy balance changes 
(Faraj M et al 2003). In a recent study where RYGBP and SG led to similar weight loss 
a year after surgery, the fasting leptin levels were halved at 1 week after surgery, and 
plasma leptin continued to decline for up to 12 months after surgery (Woelnerhanssen 
B et al 2011). The early decline in leptin is unlikely to be mediated by weight loss alone. 
In our study plasma leptin levels did not fall below the reference range for women. The 
circulating plasma leptin was broadly in line with adiposity in our subjects, this is in 
keeping with other recent studies (Lee W J et al 2011, Dimitriadis E et al 2013). 
However others have suggested a significantly lower leptin after RYGBP in comparison 
to SG (Ramon J M et al 2012). The significant correlation between plasma leptin and 
weight/ BMI/ fat mass/ VFA in our groups argues against this. This is the first study to 
show correlation between several measured adiposity indices and fasting plasma leptin 
after SG.  
 
6.4 RYGBP and SG lead to similar significant improvement in meal stimulated 
PYY3-36 
 
The mean postprandial peak in PYY3-36 is increased by 2.5-fold after RYGBP and 1.7 
fold after SG. The meal stimulated PYY3-36 AUC is significantly increased after 
RYGBP and SG. There is no significant difference between the RYGBP and SG PYY3-
36 AUC at all time points. There have been no studies to investigate meal stimulated 
PYY3-36 secretion after SG. It is already known that the meal stimulated total PYY 
(Korner J et al 2005, Karamanakos SN et al 2008, Peterli R et al 2012, and Ramon J M 
et al 2012) response following SG is similar to that seen after RYGBP. However, 
fasting PYY3-36 is only significantly reduced at 12 weeks after RYGBP. Further, 
changes in PYY3-36 did correlate to perception of satiety and show a trend towards 
correlation to weight loss after RYGBP. This relationship between PYY3-36 and satiety 
and weight loss was also seen after SG, and the correlation to weight loss did reach 
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statistical significance in this group. Recent publications have also highlighted a 
pronounced hind-gut response after SG similar to that seen after RYGBP (Peterli R et 
al 2009, Peterli R et al 2012, and Ramon J M et al 2012). This is in keeping with our 
findings. In our study the secretion of the two distal gut hormones after surgery does 
correlate after both procedures adding weight to an exaggerated distal gut response.  
 
6.5 RYGBP leads to a significantly higher post-prandial GLP-1 response 
 
The temporal profile of meal stimulated active GLP-1 secretion is significantly 
increased after both RYGBP and SG. However the magnitude of change is three fold 
higher after RYGBP. This is maintained at 12 weeks. Further, there is a significant 
difference in the active GLP-1 AUC between the two groups at 6 and 12 weeks. A 
recent study reports an equivalent meal stimulated active GLP-1 AUC after RYGBP 
and SG at three months after surgery (Peterli R et al 2009, Peterli R et al 2012, Lee W 
J et al 2011, and Ramon J M et al 2012). The baseline difference in active GLP-1 AUC, 
the three fold higher AUC of meal stimulated active GLP-1 after RYGBP, even allowing 
for the higher calorie content (400Kcal vs. 500Kcal) in our meal, does suggest 
difference in measurement protocol and the importance of standardization (Petrli R et 
al 2009). There is a significant correlation between active GLP-1 and prospective food 
consumption in the RYGBP group though no correlation to weight loss is observed. 
However, in the SG group there is correlation between active GLP-1 satiety, 
prospective food consumption and weight loss at 12 weeks. The correlation between 
active GLP-1 changes and outcome measures after SG has not been shown before.  
 
6.6 SG but not RYGBP leads to significant decline in acyl-ghrelin 
 
At 12 weeks after surgery the fasting plasma acyl-ghrelin is significantly lower in the SG 
group in comparison to the RYGBP group. There is a significant decrease in the meal 
stimulated temporal profile of acyl-ghrelin after both RYGBP and SG. This finding is in 
keeping with that of others studying RYGBP
 
(Shin AC et al 2010, Barazzoni R et al 
2013, and Dimitriadis E et al 2013), but not all (Samat A et al 2013). Further at 12 
weeks the comparison of groups reveals a significant difference in AUC between 
RYGBP and SG groups. Recent studies in total ghrelin have reproduced our findings of 
superior suppression after SG (Peterli R et al 2012, Ramon J M et al 2012). Others 
have shown an increment in acyl-ghrelin with time after RYGBP (Barazzoni R et al 
2013). 
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Total ghrelin is known to be elevated after diet induced weight loss
 
(Oliván B et al 2009) 
and it was initially thought that a decrease in total ghrelin after SG may explain the 
superior weight loss and maintenance of weight loss after SG (Langer FB et al 2005). 
However, a recent meta-analysis of several studies was unable to reach a conclusion
 
(Frezza EE et al 2008). To date no study has measured acyl-ghrelin, the active 
octanoylated form collected under standardised conditions to prevent degradation (as 
recommended by the assay). The significant decline in acyl-ghrelin after SG is thought 
to be due to the complete removal of the gastric fundus, the segment of the stomach, 
thought to produce the vast majority of acyl-ghrelin
 
(Langer FB et al 2005). However, 
the change in acyl-ghrelin after RYGBP does correlate significantly to change in 
prospective food consumption after surgery, but not weight loss. This relationship 
between acyl-ghrelin and prospective food consumption is more pronounced in the SG 
group. Further there is a positive correlation between change in acyl-ghrelin and weight 
loss after SG. This study is the first report that changes in acyl-ghrelin correlate to 
outcome measures in humans. These changes do contrast with the higher acyl-ghrelin 
reported after diet induced weight loss and gastric banding
 
(Cummings D E et al 2002, 
Langer FB et al 2005, Oliván B et al 2009). However, the above studies did not look at 
meal stimulated acyl-ghrelin, following standardization.  
6.7 There is significant increase in amylin after RYGBP but not after SG 
There is a significant increase in the meal stimulated temporal profile of active amylin 
secretion after RYGBP but not SG. This is in keeping with active amylin secretion in 
rats undergoing RYGBP
 
(Shin AC et al 2010). However this is contrary to others who 
reported a decrease in total amylin after RYGBP (Mousumi Bose et al 2010) and and 
active amylin after SG (Dimitriadis E et al 2013). Others have reported no change in 
total amylin after RYGBP (Jacobsen et al 2012). No significant change in meal 
stimulated active amylin secretion was seen after SG in our study. Others have found 
significant increase in amylin when SG is combined with an ileal interposition on to the 
proximal duodenum and proximal jejunum (DePaula AL et al 2009). This study does 
not state if total or active amylin was measured, further this study does not specify 
inter-assay variations. However, the finding of this study does suggest that the 
exclusion of the duodenum may lead to an increase in amylin secretion. Further, the 
amylin changes on their own did not correlate to satiety, prospective food consumption 
or %EWL in the RYGBP group. This was mirrored in the only other study on active 
amylin in rodents, where no correlation between active amylin and weight loss was 
seen (Shin AC et al 2010). Interestingly in the SG group change in amylin AUC at 6 
and 12 weeks does correlate to %EWL at these corresponding time points. This is seen 
despite non-significant change in amylin after surgery in this group.  
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6.8.1 Gut hormone changes after RYGBP and SG correlate to weight loss 
 
The correlation between changes in gut hormone secretion and weight loss in an 
individual has not yet been shown after either procedure in humans, but has been 
shown in rats after RYGBP (Shin AC et al, 2010). This discrepancy as highlighted 
before, may be related to study design and sample processing. Several studies have 
shown a blunted hind gut hormone (PYY and GLP-1) response in the morbidly obese 
patients that is reversed by bariatric surgery (RYGBP and SG) (Karamanakos SN et al 
2008, Peterli R et al 2009, Basso N et al 2010, Chambers AP et al 2011, Umeda L M et 
al 2011, and Peterli R et al 2012, Dimitriadis E et al 2013). In a similar comparative 
study of RYGBP and SG, equivalent total PYY and active GLP-1 changes were noted 
at three months and one year with equivalent weight loss (Peterli R et al 2012). Others 
have shown a poor total PYY and GLP-1 response after SG led to poor weight loss and 
the opposite after RYGBP (Ramon J M et al 2012). In our study PYY3-36, GLP-1 and 
acyl-ghrelin correlate to measures of appetite in the RYGBP group. The Change in 
insulin/ amylin ratio after RYGBP did show correlation with %EWL. The change in 
PYY3-36 did also show a trend towards significance with EWL. In the SG group PYY3-
36, GLP-1 and acyl-gherlin correlate to measures of appetite. In the SG group the 
change in acyl-ghrelin at 6 weeks did correlate positively to %EWL at 6 weeks, and 
show a trend towards correlation at twelve weeks. The converse was true of PYY3-36, 
where there was a trend towards correlation at 6 weeks and significant correlation at 12 
weeks. The change in GLP-1 at 12 weeks after SG does also correlate positively to 
%EWL at 12 weeks. The change in amylin at 6 and 12 weeks does show a trend 
towards positive correlation with %EWL six weeks and 12 weeks. Further, the meal 
stimulated GLP-1 and PYY3-36 secretion do correlate after both procedures, pointing 
towards a similar exaggerated hind gut response after both procedures. However the 
strength of this correlation is more pronounced in the RYGBP group.  
 
In the SG group, changes in several gut hormones (PYY3-36, acyl-ghrelin, GLP-1 and 
amylin) independently correlate to weight loss, taken together, these findings suggest 
that gut hormone changes alone could account for the weight loss seen after SG, this 
contrasts with RYGBP, where despite equivalent or even more pronounced gut 
hormone change, correlation of gut hormone change to weight loss is poor. This 
fundamental difference between the two surgical procedures may be due to alteration 
in neural “circuitry” that follows the more invasive RYGBP surgery. It is possible that 
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RYGBP leads to other changes in neural signaling that favour weight loss, working 
alongside the endocrine changes that favour weight loss. This perspective was further 
advanced by Saeidi and colleagues recently, they point to local gut changes after 
anatomical changes in the gut leading to improved glucose homeostasis (Saeidi N et al 
2013, and reviewed by Berthoud R H 2013).  
 
6.8.2 Gut hormone changes after bariatric surgery predict failure of sleeve 
gastrectomy 
 
It is known that some patients fail to lose weight after RYGBP and SG. One patient in 
our SG group was noted to have lost no further weight between 3 and 12 months 
following surgery. This patient’s meal stimulated PYY3-36, acyl-ghrelin and amylin 
response at 3 months after surgery did differ from those of others in the SG group. The 
three month meal stimulated Δ PYY3-36 (change from baseline) response was below 
the pre-operative response. This altered meal stimulated response could be utilized to 
fast-track those patients predicted to fail to a second stage procedure. The correlation 
between weight loss; PYY3-36, acyl-ghrelin, GLP-1 and amylin, and the correlation 
between GLP-1, PYY3-36, acyl-ghrelin and VAS after SG together with the relationship 
between a poor 3 month amylin, Δ PYY3-36 and Δ acyl-ghrelin and poor outcome, 
does suggest that these gut hormones may account for the changes seen after SG. 
Whether poor gut hormone changes after RYGBP lead to a similar outcome is not 
clear. 
 
6.9 RYGBP leads to better glucose disposal in comparison to SG 
 
In keeping with our findings others have also shown improvement in glucose 
homeostasis within weeks of surgery (Peterli R et al 2009, Abbatini et al 2010, Basso N 
et al 2011, Umeda L M et al 2011, Peterli R et al 2012, Jacobsen et al 2012). It has 
become clear that the improvement in T2DM and insulin resistance precedes weight 
changes and may be mediated by change in the gut hormone profile (Mousumi Bose et 
al 2010, Jacobsen S H et al 2012, Jorgensen N B et al 2012, Peterli R et al 2012). In 
our study there is improvement in post-prandial glucose profile after RYGBP and SG. 
This improvement is more pronounced after RYGBP when the glucose AUC is 
compared. When temporal profiles are compared SG leads to a more pronounced 
decline after surgery. However, this can partly be explained by the lone T2DM patient 
in the RYGBP group. The late post-prandial peak is also reversed after RYGBP and 
SG. Baseline glucose AUC is significantly decreased at 6 and 12 weeks only after 
RYGBP.  
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Analysis of the temporal profile of insulin revealed no significant change after RYGBP 
but a highly significant increase after SG. Time to peak insulin did occur early in both 
groups. There was a non-significant change in plasma insulin AUC after RYGBP and 
SG surgery. There is an equivalent fasting, meal stimulated insulin response after both 
RYGBP and SG, given the disparate GLP-1 response; different mechanisms are at 
play in the two groups. Others have shown that the delayed pre-operative insulin 
secretion pattern does gradually change to an early secretion pattern after SG (Lee et 
al 2010). The pronounced GLP-1 response seen after RYGBP is thought to promote 
insulin secretion in this group (Peterli R et al 2009, Li F et al 2009, Dezaki K et al 
2008). It is thought that the lack of such a pronounced GLP-1 response after SG may 
be compensated for by the decrease in ghrelin seen after SG, this is thought to lead to 
improved insulin sensitivity after SG (Peterli R et al 2009, Li F et al 2009 Papailiou J et 
al 2010, Peterli R et al 2012, Ramon J M et al 2012). Further, others have shown an 
equivalent GLP-1 response after RYGBP and SG (Lee W J et al 2011, Chambers A P 
et al 2011, Peterli R et al 2012). Peterli and colleagues point to similar active GLP-1 
changes at 3 months and 1 year, after both RYGBP and SG. These discrepancies may 
be accounted for by the timing of sampling, inter-species variation in stomach emptying 
and lack of standardization in sampling. Barazzoni and colleagues also point to the rise 
in acyl-ghrelin after RYGBP limiting the improvement in insulin resistance (Barazzoni R 
et al 2013). 
 
6.10 Acyl ghrelin and HOMA IR  
 
A comparison of SG, RYGBP on glucose homeostasis in morbidly obese T2DM 
patients did point to restoration of insulin resistance to normal values in all patients 
(Abbatini et al 2010, Umeda et al 2011, Ramon J M et al 2012, Peterli R et al 2012). 
Chambers and colleagues adapted RYGBP and SG in humans to a rat model in order 
to study the mechanisms underlying the improvements in weight and glucose 
metabolism (Chambers AP et al 2011).  RYGBP and SG had comparable benefits. 
They led to comparable loss of body weight and body fat and a reduction in plasma 
insulin. They also caused comparable improvements in glucose tolerance (Chambers 
AP et al 2011). The two surgical procedures had similar metabolic effects despite 
different anatomical rearrangement of the gastrointestinal system (Chambers AP et al 
2011). However these studies were undertaken five months after surgery, when rats 
were in a weight stable position. The greatest improvement in insulin resistance was 
noted in the SG group in humans and may be due to the large drop in ghrelin seen 
after SG (Abbatini et al 2010, reviewed by Yada et al 2008, and Peterli R et al 2012). 
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Our data does also suggest this but the correlation is not significant. Other studies that 
have examined the role of ghrelin had conducted assays for total ghrelin in the absence 
of HCL and protease inhibitors. Despite this these studies have yielded similar results 
to our active acyl-ghrelin results (Karamanakos SN et al 2008, De Paula et al 2009, 
Peterli R et al 2012, and Barazzoni R et al 2013). This has led some to speculate that 
the weight independent resolution of T2DM and improvement in glucose homeostasis 
seen after bariatric surgery may in part be mediated by acyl- ghrelin (Peterli R et al 
2009, Li F et al 2009 and Papailiou J et al 2010, Peterli R et al 2012). There was a 
significant decline in HOMA IR at 6 and 12 weeks in the SG group. There was no 
significant decline in HOMA IR after RYGBP. There was a significant negative 
correlation between HOMA IR and meal stimulated acyl-ghrelin AUC all visits, in the 
RYGBP group. There was an expected positive correlation between Acyl-ghrelin and 
HOMA IR in the SG group. This did show a trend towards significance. The positive 
correlation between post-prandial acyl-ghrelin and HOMA IR seen in our SG group is in 
keeping with the growth hormone secretagogue receptor activation of acyl-ghrelin, and 
a decrease in this activity may lead to the improvement in insulin resistance seen in the 
SG group after surgery (reviewed by Yada et al 2008). The negative correlation 
between acyl-ghrelin and HOMA IR seen in the RYGBP group is difficult to explain, as 
the opposite would be expected. However, in our study there is a decrease in HOMA IR 
after surgery in this group, despite no significant change in acyl-ghrelin from pre-
operative to six weeks, and a trend towards increase between 6 and 12 weeks. This 
suggests that the changes in HOMA IR in this group occur despite the opposite change 
in acyl-ghrelin. In keeping with our findings other comparative studies between RYGBP 
and SG found lower acyl-ghrelin and des-acyl ghrelin in the SG group but similar 
glucagon-like peptide-1, PYY and leptin after these procedures (Lee WJ et al 2011, 
Peterli R et al 2012, Ramon J M et al 2012), and rising acyl-ghrelin after RYGBP 
(Barazzoni R et al 2013). The fasting insulin concentrations and HOMA indices were 
significantly reduced, before any significant weight loss had occurred (Peterli R et al 
2009, Peterli R et al 2012, Umeda L M et al 2011, Reed M A et al 2011, Jacobsen S H 
et al 2012, Jorgensen N B et al 2012). An improvement in glucose disposal occurs 
despite a decline in insulin secretion (Reed M A et al 2011). Recent evidence also 
points to a more direct effect of PYY3-36 on insulin sensitivity (van den Hoek et al 
2007). PYY3-36 is known to be co-secreted with GLP-1 by intestinal L cells in response 
to food intake. The role of PYY3-36 on insulin sensitivity independent of food intake is 
not confirmed. The T2DM patient in the RYGBP group could also have skewed the 
results. However, analysis of plasma glucose and plasma insulin excluding the T2DM 
patient did not suggest large discrepancies.  
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6.11 GLP-1 is likely to mediate improved glucose homeostasis after RYGBP 
 
SG and RYGBP are associated with similar T2DM remission rates (Romero F et al 
2012). The GLP-1 AUC was significantly and comparably improved after SG and 
RYGB (Romero F et al 2012, Peterli R et al 2012, and Ramon J M et al 2012). 
Enhanced insulin sensitivity and improved GLP-1 secretion contribute to the early 
control of glucose homeostasis after RYGBP (Falkén Y et al 2011, Samat A et al 2013). 
A progressive decrease in HOMA IR was noted after 2 months (Falkén Y et al 2011), 
and 12 months (Samat A et al 2013). This is in contrast to our findings. RYGBP and SG 
led to greater initial insulin secretion from baseline followed by rapid return toward 
baseline. The insulin area-under the- curve (AUC) was greater when compared to 
controls (Chambers AP et al 2011, Umeda L M et al 2011, Jacobsen S H et al 2012, 
Jorgensen N B et al 2012). These findings are in keeping with our study. Despite the 
discrepancy in peak active GLP-1, SG leads to restoration of first phase insulin 
secretion. In fact insulin secretion is significantly increased after SG in our study. 
However, there is a significant difference in the active GLP-1 AUC between the two 
groups at 6 and 12 weeks. A similar parallel group study on patients undergoing 
RYGBP and SG at pre-operative, 1 week and 3 months after surgery where the SG 
group had three diabetic patients was conducted by Peterli and colleagues. As with our 
study, the impaired postprandial active GLP-1, insulin response was reversed in both 
groups, at a week after surgery. As with our study, a marked increase in postprandial 
active GLP-1 and insulin concentrations was observed after RYGB and SG (Peterli R et 
al 2009). Recent evidence points to GLP-1 mediating some of the effects of bariatric 
surgery. However comparable results after RYGBP and SG have led some authors to 
propose alternative mechanisms (Chambers AP et al 2011). The study by Kindel and 
colleagues does provide direct evidence that at least some of the improvement after 
RYGBP is mediated by GLP-1 (reviewed by Laferrère B. 2011). Gill and colleagues 
also point out that the duodenal exclusion hypothesis is unlikely to be a viable 
explanation given the recent results on sleeve gastrectomy leading to diabetes 
remission in a large percentage of patients, accompanied by an increase in gut 
hormones not dissimilar to RYGBP, in spite of a functional duodenum- (Gill RS et al 
2010) (reviewed by Laferrère B. 2011). Further, a recent study points to local adaptive 
effects after surgery playing a significant part in improved glucose homeostasis (Saeidi 
et al 2013, reviewed by Berthoud R et al 201 
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6.12 Hind gut stimulation, not the foregut exclusion theory 
 
It is proposed that incompletely digested nutrients to the ileum and colon leads to an 
exaggerated PYY and GLP-1 response (reviewed by Karra, and Batterham, 2010, 
Peterli R et al 2012). Surgical procedures that increase nutrient delivery to the distal gut 
such as BPD, JIB and RYGB result in rapid resolution of T2DM (Buchwald et al 2004). 
Faster gastric emptying
 
(Braghetto I et al 2009) and small bowel transit time
 
(Shah S et 
al 2010), and increased foregut hormone secretion (Peterli R et al 2012) post SG 
surgery is thought to lead to quick delivery of nutrients to the hindgut and in-turn evoke 
a hind gut incretin hormone response not dissimilar to that seen following RYGBP 
(Peterli R et al 2009, Peterli R et al 2012, Ramon J M et al 2012), and improve insulin 
secretion (DePaula AL et al 2009, Peterli R et al 2012, Ramon J M et al 2012). The 
equivalent PYY response at 3 months and 1 year after RYGBP and SG (Peterli R et al 
2012) does lead to equivalent weight loss after both procedures. This is in addition to 
the improvement in insulin resistance
 
(Rizzello M et al 2010, Peterli R et al 2012, 
Ramon J M et al 2012, Lee W J et al 2011). These findings have led some to argue 
that the hindgut plays a major role in mediating anti-diabetic effects of bariatric surgery 
(Karra E et al 2010). In our study PYY3-36 and (GLP-1 mediated) insulin: amylin ratio 
correlates to weight loss after RYGBP. After SG PYY3-36, GLP-1, acyl-ghrelin and 
amylin all correlate to weight loss. These results and recent results of others (Peterli R 
et al 2009, Oliván B et al 2009) lends support to a hind gut factor mediating the effects 
of weight loss after RYGBP and SG surgery. We also note that RYGBP patients 
continued to lose weight despite an increase in acyl-ghrelin secretion between 6 and 12 
weeks. This finding is in keeping with a greater amount of weight loss after RYGBP 
despite a higher fasting and GTT stimulated total ghrelin in this group (Bose M et al 
2010, Barazzoni R et al 2013). Others have recently proposed a balance in foregut and 
hind gut hormones mediate outcome after RYGBP and SG (Peterli R et al 2012). In 
support of the foregut theory, some have shown differential effects of oral versus 
gastrostomy glucose loading after RYGBP with exclusion of the proximal small bowel 
from glucose passage inducing greater plasma insulin, GLP-1, and PYY responses 
with glucose loading by way of the gastrostomy tube (Pournaras DJ et al 2012). 
6.13 GLP-1 correlates to insulin, amylin and PYY3-36 
 
The meal stimulated active GLP-1 response after RYGBP correlates to PYY3-36. This 
correlation has been reported in rats after RYGBP (Shin AC et al 2010). However our 
study is the first to report this in humans. Our study is also the first to report that meal 
stimulated active GLP-1 does also correlate to PYY 3-36 and insulin after SG. Further, 
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in our study the change in active GLP-1 after SG did correlate to change in amylin. The 
change in insulin and amylin after SG also show positive correlation. The above 
correlations may help explain the improvement in glucose disposal reported in our 
study and by others (Karamanakos SN et al 2008, Peterli R et al 2009, Peterli R et al 
2012, and Ramon J M et al 2012). Our study does confirm correlation between GLP-1 
and insulin secretion after RYGBP. In the RYGBP group, change in GLP-1 after 
surgery does also positively correlate to change in insulin at 6 and 12 weeks. This has 
been reported by others recently (Umeda L M et al 2011). The meal stimulated plasma 
GLP-1 AUC does correlate to the corresponding plasma amylin AUC in the RYGBP 
and SG groups. The meal stimulated plasma GLP-1 AUC from all visits does correlate 
to the corresponding plasma amylin AUC after RYGBP. In the RYGBP group, we are 
the first to report that the change in meal stimulated active GLP-1 after RYGBP does 
correlates to change in insulin, amylin and insulin: amylin ratio after surgery. These 
correlations point towards GLP-1 mediated changes in insulin and amylin secretion 
after RYGBP. 
6.14 Analysis of RYGBP glucose and insulin profile excluding Type-2 DM patient 
 
The baseline mean fasting glucose is significantly reduced when the T2DM patient is 
excluded, and there is a significant decline in the temporal profile of glucose after 
RYGBP. Bonferroni post test analysis does confirm significant decline in glucose at 
similar time points after the meal at six weeks but at 12 weeks more early and late time 
points are significant when the T2DM patient is excluded. There is also a significant 
decline in the peak plasma glucose when the T2DM patient is excluded. However the 
timing of peak remains the same. There is a significant decline in the mean plasma 
glucose AUC when the T2DM patient is excluded. In summary excluding the T2DM 
patient did lead to a significant decline in mean fasting, mean peak plasma glucose, 
and mean glucose AUC. The temporal profile of glucose is also significantly altered.  
Fasting insulin did not alter significantly when the T2DM patient was excluded. The 
temporal profile was significantly altered after excluding the T2DM patient. There was 
now a trend towards significance in meal stimulated insulin profile after RYGBP.  
Further, Bonferroni post test analysis did confirm a significant increase at early time 
points and significant decline at late time points. The baseline peak insulin did alter 
significantly when the T2DM patient was excluded. However, the time at which the 
peak insulin concentrations occur did not alter between the two groups. The plasma 
insulin AUC did not alter significantly when the T2DM patient was excluded. In 
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summary the inclusion of a T2DM patient did not alter fasting insulin, time of peak 
insulin nor insulin AUC. However it did alter the peak plasma insulin concentration.  
 
6.15 A differential insulin amylin ratio after RYGBP and SG 
 
Insulin/ amylin ratio is altered differentially after RYGBP and SG. There is a significant 
decrease in the ratio after RYGBP surgery, In the SG group there is a significant 
increase in insulin amylin ratio after surgery. Further, physiologic concentrations of 
endogenous amylin may also effect insulin secretion (reviewed by Cluck MW et al 
2005). Insulin secretion is inhibited by amylin both in vitro and in vivo, (Gebre-Medhin S 
et al 1998, Wang ZL et al 1993 and reviewed by Cluck MW et al 2005). Recent studies 
have highlighted a role for amylin therapy in obesity (Ravussin E et al 2009, Smith SR 
et al 2008). In our study the increase in amylin content could explain the poor GLP-1 to 
insulin ratio after RYGBP surgery (Hansen EN et al 2011). The meal stimulated insulin 
to active GLP-1 AUC ratio declined by around 60% after RYGBP. There is a significant 
reduction in the amount of insulin secreted in response to an equivalent active GLP-1 
stimulus after both procedures. However, the decline is more pronounced after 
RYGBP. This may also be related to a threshold effect. 
 
This change in insulin: amylin ratio did correlate to %EWL at those time points in the 
RYGBP group. The superior GLP-1 response seen after RYGBP may have contributed 
to this. The change in GLP-1 after surgery does correlate to change in insulin/ amylin 
ratio after RYGBP. However, relative increase in amylin secretion did not adversely 
influence glucose homeostasis in that group. One previous study examined the role of 
portal amylin: insulin ratio at time of gastric by-pass surgery, and found an inverse 
relationship to glucose disposal rate 7 months after surgery (Blackard WG et al 1994). 
We did not find a correlation between insulin: amylin ratio and plasma glucose after 
RYGBP and SG. There have been no studies on meal stimulated active amylin 
secretion after SG. Others have measured total amylin (Dimitriadis E et al 2013). This 
study points to a reduction in fasting and meal stimulated total amylin. We found no 
significant difference in amylin secretion after SG. The change in amylin secretion after 
SG did correlate to weight loss at 6 and 12 weeks after surgery. This contrasting 
alteration in ratio did not correlate to satiety, prospective food consumption or weight 
loss after SG. Daily exenatide (GLP-1) treatment led to improved glucose and 
increased amylin/ insulin ratio in response to a mixed meal (Faradji RN et al 2009). At 
three months after GLP-1 treatment a significant increase in amylin AUC and an 
increased baseline amylin/ insulin ratio were observed (Faradji RN et al 2009). It is also 
possible that GLP-1 could increase amylin secretion from sites other than the islets 
208 
 
(Zaki M et al 2002). In our study there is a significant reduction in the amount of amylin 
secreted in response to an equivalent active GLP-1 stimulus after both procedures. 
Again this may represent a threshold effect. 
In our study GLP-1 secretion does show a positive correlation to amylin secretion in 
both groups, before and after surgical intervention. It is interesting that the Change in 
meal stimulated amylin does show a positive correlation to the change in meal 
stimulated insulin at 12 weeks after SG. The insulin secretion is significantly improved 
after SG and does not change significantly between 6 and 12 weeks. The amylin 
secretion is unchanged between 6 and 12 weeks. Therefore it is likely that other factors 
such as GIP, fatty acyl molecules that can differentially regulate amylin, insulin 
synthesis and secretion leading to an alteration in the relationship between insulin and 
amylin after SG, between these time points. There was a significant correlation 
between the AUC for GLP-1 and amylin for all visits in the RYGBP and SG groups. The 
outlying markedly high GLP-1 and amylin response seen in one patient adds further 
weight to this correlation.  Also, post operative GLP-1 response in the SG group at 12 
weeks did correlate to amylin response at that time point. In support of this others have 
proposed that amylin synthesis and secretion may be under the influence of GLP-1 
(Ahrén B et al 1997), and amylin in turn may mediate some of the biological actions of 
GLP-1 (Asmar M et al 2010).  
In contrast to our findings Bose and colleagues found a non-significant decline in total 
amylin after RYGBP. However, a decline in total amylin in the diet induced weight loss 
control group suggests that sample collection and processing may have played a part 
in this un-expected result (Mousumi Bose et al 2010). Others have recently reported a 
decline after SG (Dimitriadis E et al 2013). De Paula and colleagues showed an 
increase in amylin secretion that did not reach statistical significance (De Paula et al 
2009). However, they do not reveal if this was active or total amylin. Further, Shin and 
colleagues found an increase in active amylin after RYGBP in rodents (Shin AC et al 
2010). The latter findings are in keeping with our study.  
6.16 Feeding alters risk-sensitive reward in healthy individuals 
 
The mid brain neural reward pathway is thought to mediate the rewarding aspects food, 
drugs of addiction and money (Elliott R et al 2003, Volkow ND and Wise RA 2005, 
Palmiter RD 2007, Platt ML and Huettel SA 2008). Recent evidence from in vivo 
studies confirms the presence of functional receptors to leptin and ghrelin in the reward 
pathway (Palmiter RD 2007). Metabolic hormones can activate (acyl-ghrelin) or inhibit 
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(leptin) this reward pathway (Morton GJ et al 2006, Palmiter RD 2007, Lenard NR and 
Berthoud HR 2008).  
The concept that reward perception is subject to homeostatic regulation derives from 
evidence that food deprivation strongly augments the reward value. One mechanism to 
explain this effect proposes that metabolic signals such as leptin and insulin tonically 
inhibit brain reward circuitry and that, by lowering circulating levels of these hormones, 
energy restriction increases the sensitivity of reward circuits
 
(Fulton et al 2000 and 
Figlewicz et al 2004). More recently evidence from animal studies and functional 
magnetic imaging has suggested that primary re-inforcers such as food (Beaver JD et 
al 2006 and Batterham RL et al 2007) and secondary re-inforcers such as psycho-
active drugs (Volkow ND and Wise RA 2005 ) and monetary rewards (Ernst et al 2004 
and Matthews et al 2004) are all thought to mediate their rewarding effects through the 
reward pathway.  
Animals take risks when foraging for food. Risk-sensitive foraging theory states that this 
risk is dependent on the animal’s baseline energy state, the energetic benefit of the 
food reward and the risks involved in achieving this energetic benefit (Caraco T et al 
1980, Joseph M et al 1988, JM McNamara, AI Houston 1992). The metabolic reference 
point is often taken in ecology as the intake required for survival. The baseline risk will 
depend upon baseline energy reserves, and energy requirements (Kacelnik A and 
Bateson M 1996). In other words animals that are energy-replete after a meal, do not 
need to indulge in risky behaviour around predators, and can do so without the danger 
of falling below a metabolic target. Risk-sensitive foraging theory describes an 
integration of risk and food reward in ecology (JM Mcnamara and AI Houston 1992). It 
is known that activity in the reward pathway is related to presentation of conditioned 
stimuli linked to natural rewards in animals (Berridge 1994). A comparison between an 
individual’s decision making and animals that make risk-sensitive foraging decisions 
point to; like animals that have sufficient energy for the day, humans are risk averse 
when they face potential monetary gains and risk prone when the choice involves 
potential monetary loss, as when an animal faces inadequate energetic benefit (Lee D 
2005). Further, there is some evidence to point towards similarities between monetary 
and sugary fluid rewards in humans. A uniform pattern of risk sensitive decision making 
was seen in both humans and non-human primates (Hayden BY and Platt ML 2009). 
Recent fMRI studies have highlighted the link between risk-sensitive reward and the 
reward pathway. A study with a simple gambling
 
paradigm did show total winnings 
correlated with hemodynamic
 
response in the reward pathway (Elliott et al, 2000), other 
fMRI studies have also adopted this risk-sensitive reward paradigm (Ernst et al 2004 
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and Matthews et al 2004) and confirm increased activity in the reward pathway during 
selection of the high-reward/risk option than during selection of low-reward/ risk option. 
A recent human study to compare and assess choices made for sugary fluid rewards 
and monetary gains on gambling tasks, revealed a consistent pattern of decision 
making for both food and monetary rewards (Hayden BY and Platt ML 2009). Here a 
uniform pattern of risk sensitive decision making was seen in both humans and non-
human primates (Hayden BY and Platt ML 2009). However, metabolic state is not 
known to play a part in economic theories on decision making in humans, this is in 
contrast to ecological theories on animal foraging behaviour.  
 
6.17 Baseline leptin and BMI correlate to risk sensitive reward immediately after a 
meal in healthy subjects 
 
In our study, BMI and plasma leptin is positively and significantly correlated to the 
change in monetary risk-sensitive reward from the fasted to fed state. This positive 
association between baseline energy stores and risk sensitive reward is similar to the 
risk-sensitive foraging for food seen in animals (Caraco T et al 1980, Lee D 2005). 
Further, in our subjects this increase in risk-sensitive reward was not to food reward but 
to monetary rewards. There is a significant positive correlation between circulating 
plasma leptin and body fat mass. There is also a significant correlation between BMI 
and body fat percentage. Given this correlation, BMI and leptin did correlate to change 
in risk averse choices made from the fasted to the fed state. The lipostatic theory on 
energy homeostasis states that humoral signals generated from body fat stores, act 
through homeostatic centres to maintain body fat stores (Mayer J 1955). In other 
words, the higher an individuals body fat stores, the more energy they need to sustain 
their current energy state. Therefore subjects with a higher percentage body fat and 
plasma leptin levels, would be expected to be relatively more risk seeking for food 
reward after the same meal. However, it is interesting that in our subjects this increase 
in risk-sensitive reward was not to food reward but to monetary rewards. This transfer 
of effect from food to monetary reward has not been reported before. Subjects in the 
decision making study were risk averse at baseline. The transfer of effect from one 
rewarding experience to another is supported by recent evidence suggesting 
similarities between decisions made for food reward and monetary reward in humans.  
 
However, the positive correlation between leptin and risk-sensitive reward does also 
raise further questions. The reward pathway is known to have functional leptin 
receptors that have an inhibitory effect on these neurons (Palmiter RD 2007, Lenard 
NR and Berthoud HR 2008). A review of in vivo studies on leptin and the reward 
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pathway also point to an inhibitory effect of leptin (Morton GJ et al 2006, Fulton S 
2006). In our study, the higher leptin level did not lead to an inhibitory effect on the 
reward pathway, and make those individual’s with higher adiposity less likely to seek 
further monetary reward, in fact the opposite occurred. Subjects with a higher leptin 
level displayed a risky approach to reward. 
 
A coherent model to explain the effects of leptin on reward seeking behaviour, at an 
organism level, will need to take account of the effects of leptin on both the homeostatic 
pathways governing energy homeostasis, and the reward pathway. The homeostatic 
pathway and the reward pathway are interconnected and inter-related (Morton GJ et al 
2006). The idea that reward perception is subject to homeostatic regulation is now 
accepted. A lack of availability of food exerts a global stimulatory effect on reward 
perception, including food reward (Morton GJ et al 2006). However, the opposing 
scenario, which occurs in obesity, when an individual’s abundant of energy store will be 
expected to lead to the opposite effect and decreased sensitivity, is still debated 
(Morton GJ et al 2006). Therefore it could be argued that in our subject pool, individuals 
with a higher body fat mass and plasma leptin would need more energy to sustain their 
fat mass, and as suggested by the lipostatic theory, they will be more likely to seek 
further food reward to sustain their energy stores. 
  
There are also other possible explanations for this discrepancy. It is possible that like in 
obesity and drug addiction, where supra-physiological stimulation of the reward 
pathway leads to stimulus preferences, a high calorie meal led to the preference of a 
more rewarding stimulus (Volkow ND and Wise RA 2005). Further, it is also possible 
that higher centres in the prefrontal cortex that are known to exert executive control 
over the reward pathway (Lenard NR and Berthoud HR 2008, Figlewicz DP and Benoit 
SC 2008) , may have played a role in choosing the higher gain monetary incentives on 
offer, in a predominantly student population.          
 
6.18 Acyl-ghrelin after a meal correlates to risk sensitive reward when satiated in 
healthy subjects 
 
Feeding significantly altered a subject’s risk averse score from the fasted to the fed 
state and showed a trend towards significance from the fasted to the 1-hour post-meal 
time point. Subjects became more risk seeking after the meal. Consumption of the 
meal caused a significant decrease in plasma acyl-ghrelin. In keeping with this there 
was a significant decrease in subjective hunger score (VAS) from the fasted to the fed 
state. The mean hunger score at each time point across all visits did show a highly 
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significant positive correlation to the corresponding mean plasma acyl-ghrelin. There 
was a significant negative correlation between increase in risky choices from the fasted 
to the 1-hour post meal stage and the decrease in Δ acyl-ghrelin at the corresponding 
time point. Results from the decision making study suggests that an individual’s 
metabolic state does influence risk-sensitive monetary reward. The change in an 
individual’s risk-sensitive reward from the fasted to fed state is significantly correlated 
to his baseline energy stores indexed by the metabolic hormone leptin, further the 
change in risk sensitive reward at an hour after the meal (when acyl-ghrelin has 
reached its nadir) is correlated to acyl-ghrelin a hormone that indexes acute nutrient 
intake. 
 
Other fMRI studies have adopted a risk-sensitive reward paradigm (Ernst et al 2004 
and Matthews et al 2004). A study with a simple gambling
 
paradigm did show total 
winnings correlated with haemodynamic
 
response in the reward pathway (Elliott et al, 
2000). In other words the neural substrates,
 
responsive to monetary reinforcement 
overlap extensively with
 
those responsive to primary reinforcers such as food in 
animals (Elliott et al 2003).  
 
An individual’s approach to risk-sensitive monetary reward and a foraging animal’s 
approach to risk-sensitive food reward are known to share common characteristics 
(Lee D 2005). Further, as the vast majority of human studies on risk sensitive reward 
involve monetary rewards, a review of human risk preference and animal food reward, 
suggests that risk-sensitive reward in humans and animals share common 
characteristics, both are better predicted by a measure of risk that relates variability of 
outcomes to expected returns (EU Weber 2004). The reward pathway is able to assay 
metabolic signals and afferent neural inputs from other regions of the brain, and in turn 
inform neural pathways to bring about an individual’s desired behavioural response 
(Lenard NR and Berthoud HR 2008). The reward pathway is thought to play a 
significant role in feeding behaviour in our current calorie abundant environment 
(Volkow ND and Wise RA 2005, Morton GJ et al 2006, Palmiter RD 2007, Lenard NR 
and Berthoud HR 2008, Stoeckel LE et al 2008).  
 
In our subject population, a calorie rich meal significantly increased an individual’s risk 
sensitive monetary reward seeking behaviour, from the fasted to the fed state and 
showed a trend towards significance at an hour after the meal (p=0.137). It could be 
argued that the high calorie meal in a safe environment increased their reward seeking 
behaviour to gain other, namely monetary reward. In other words one rewarding 
experience increased their appetite for other rewarding experiences. The “priming” 
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effect of a small amount of a palatable food on binge eating  described as the ‘priming’ 
effect is also seen in addiction behaviour,  where even a small dose tends to elicit a 
strong ‘craving’ and compulsion for further use, hence in our study food may have 
caused a ‘priming’ effect (Davis et al 2004) Recent evidence linking addiction behaviour 
and obesity to the reward pathway (Volkow ND and Wise RA 2005, Engelmann JB 
2006, Palmiter RD 2007, Stoeckel LE et al 2008) also lends support to this concept of 
transfer of effect between food and money. Animal studies have shown a link between 
food deprivation and relapse of drug seeking behaviour, after a prolonged drug free 
period (Shalev U et al 2000). This effect was attenuated by leptin infusion, suggesting 
that food deprivation may augment reinstatement of drug seeking, by its actions on the 
dopaminergic reward pathway (Shalev U et al 2000).    
 
The temporal profile of acyl-ghrelin in our study, confirms that the plasma acyl-ghrelin 
level is significantly altered from fasting to an hour after feeding, this change in acyl-
ghrelin does also show positive and significant correlation to hunger VAS.  The 
magnitude of this change in plasma acyl-ghrelin is negatively correlated to the change 
in risk-sensitive reward seeking in our subject population. In other words, an individual 
with a small change in plasma acyl-ghrelin level became more risk seeking to monetary 
reward. Acyl-ghrelin is able to promote feeding behaviour by its actions on the 
homeostatic and reward pathways (Cummings DE 2006). Therefore acyl-ghrelin is able 
to relay information about energy gains from food intake to the homeostatic centre and 
regulate feeding behaviour. Ghrelin is also able to promote food intake by acting on the 
reward pathway (Ghigo E et al 2005, Cummings DE  2006, Palmiter RD 2007), where it 
is known to have an excitatory effect, on these neurons (Abizaid A et al 2006, Palmiter 
RD 2007), and the reward pathway is thought to mediate the rewarding aspects of food 
and financial reward (Volkow ND, and Wise RA 2005, Palmiter RD 2007, Platt ML and 
Huettel SA 2008). This may explain the transfer of effect from food to money seen in 
our study. In those individuals with a relatively low suppression of acyl-ghrelin will be 
expected to promote further food intake by its action on the homeostatic pathway to 
maintain energy homeostasis, and acyl-ghrelin will also be expected to promote food 
intake through the reward pathway, in these same individuals. The risky approach to 
monetary reward, in individuals with low acyl-ghrelin suppression is in agreement with 
risk-sensitive foraging behaviour in animals, when an animal is not able to meet its 
daily energetic requirement with the “safe source” of food on offer, it would seek more 
variable and risk prone food sources (A Kacelnik and M Bateson 1996).  In our 
subjects, as with leptin, a transfer of effect from food to monetary reward is seen, again 
this has not been reported before. However our findings of an increase in risky choices 
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after feeding in the cohort does contradict the decline in risk-sensitive monetary reward 
seeking behaviour with greater suppression of acyl-ghrelin.   
 
6.19 Leptin and acyl-ghrelin interact to signal energy stores  
 
It was initially thought that leptin regulated ghrelin levels (Barazzoni R et al 2003). 
Though more recent evidence points towards multiple factors regulating ghrelin 
secretion; nutrients (carbohydrate and protein suppress ghrelin more than lipid), insulin, 
intestinal osmolarity, enteric neural signalling and vagal response, have all been shown 
to suppress ghrelin secretion after a meal (Ghigo E et al 2005, Cummings DE. 2006, 
Klok MD et al 2007). There is some evidence pointing at insulin communicating 
information on both short term energy gains and long term energy stores, to ghrelin 
producing cells in the oxyntic mucosa (Cummings DE, Foster KE 2003, Klok MD et al 
2007). It is thought that adiposity related changes in insulin, but not leptin may convey 
information on long term energy stores to ghrelin producing cells (Foster KE 2003, 
Cummings DE 2006). Ghrelin producing cells appose the basement membrane, in 
close proximity to the vascular compartment and are not known to be in direct contact 
with the gastric lumen (Cummings DE 2006). Therefore ghrelin producing cells are 
more likely to respond to blood borne signals and less likely to respond to luminal 
contents. It is now thought that leptin and ghrelin act in parallel on the homeostatic and 
reward pathways (Cummings DE 2006, Cummings DE, Foster KE 2003, Klok MD et al 
2007). They are metabolic counterparts with opposing actions. Ghrelin is an 
evolutionarily conserved protein, conveying information on intestinal energy stores, in 
lower non vertebrate organisms (Cummings DE, Foster KE 2003). 
 
6.20 Energy stores and feeding alter reward behaviour  
 
The decision making study suggests that an individual’s metabolic state does influence 
his monetary decisions. The risk-sensitive monetary decisions were influenced by both 
long-term metabolic signals indexing energy stores, and short-term metabolic signals 
that index energy gains. This is not surprising, given that the homeostatic mechanisms 
that regulate body energy stores also influence reward pathways (Morton GJ et al 
2006). At the neurobiological level, our results suggest an overlap between food and 
monetary reward. This has significant implications for all decisions that incorporate risk 
and monetary reward. The implications of the results from the decision making study 
are wide ranging, given that all individual’s make assessment of risk and reward in 
many aspects of our daily lives, from crossing the road to placing a bet at the grand-
national. An individual’s body mass index and his nutritional intake could alter 
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behavioural patterns in the financial services industry; as long term energy stores will 
influence risk sensitive reward seeking, should all who take risks to attain monetary 
reward be encouraged to adhere to a ideal body weight. Further, after a meal, as the 
energetic value of the meal in relation to an individual’s energetic requirement will 
influence risk sensitive reward. Should these individuals to be satiated at time of risk 
taking? It could be argued that all aspects of human behaviour does assess risk and 
reward,  perhaps we should all take note of our hunger when it comes to pursuing any 
task that involves an assessment of risk and reward.  
 
My bariatric study and decision making study have both identified correlation between 
acyl-ghrelin, the active gut hormone and appetite, and risk sensitive reward seeking 
behaviour. I propose to undertake further work utilising acyl-ghrelin infusions in healthy 
volunteers to induce risky choices in the risk reward paradigm. Further, studying post-
operative RYGBP and SG subjects with the disparate changes in acyl-ghrelin will 
enable me to compare and contrast risk sensitive reward seeking behaviour in these 
patients after surgery and correlate that to acyl-ghrelin changes after RYGBP and SG.    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
216 
 
References 
 
Aaboe K, Krarup T, Madsbad S and Holst JJ (2008) GLP-1: physiological effects and 
potential therapeutic applications. Diabetes Obes Metab ; 10:994-1003. 
 
Abbatini F, Rizzello M, Casella G, Alessandri G, Capoccia D, Leonetti F, Basso N 
(2010) Long-term effects of laparoscopic sleeve gastrectomy, gastric bypass, and 
adjustable gastric banding on type 2 diabetes. Surg Endosc.; 2010; 24(5):1005-10. 
 
Abbott CR, Monteiro M, Small CJ, Sajedi A, Smith KL, Parkinson JR, Ghatei MA and 
Bloom SR (2005a) The inhibitory effects of peripheral administration of peptide YY(3-
36) and glucagon-like peptide-1 on food intake are attenuated by ablation of the vagal- 
brainstem-hypothalamic pathway. Brain Res; 1044:127-131. 
 
Abbott CR, Small CJ, Kennedy AR, Neary NM, Sajedi A, Ghatei MA and Bloom SR 
(2005b) Blockade of the neuropeptide Y Y2 receptor with the specific antagonist 
BIIE0246 attenuates the effect of endogenous and exogenous peptide YY(3-36) on 
food intake. Brain Res; 1043:139-144. 
Abel E D, Peroni O, Kim J K, Kim Y, Boss O, Hadro E, Minnemann T, Shulman G I and 
Kahn B (2001). Adipose-selective targeting of the GLUT4 gene impairs insulin action in 
muscle and liver. Nature 409, Nature 409, 729-733.  
Abizaid A, Liu ZW, Andrews ZB, Shanabrough M, Borok E, Elsworth JD, Roth RH, 
Sleeman MW, Picciotto MR, Tschöp MH, Gao XB, Horvath TL (2006). Ghrelin 
modulates the activity and synaptic input organization of midbrain dopamine neurons 
while promoting appetite. J Clin Invest.;116:3229-39 
Ackroyd R, Mouiel J, Chevallier JM, Daoud F (2006). Cost-effectiveness and budget 
impact of obesity surgery in patients with type-2 diabetes in three European countries. 
Obes Surg; 16 (11):1488-1503. 
Adami GF, Campostano A, Cella F, Scopinaro N. (2002). Serum leptin concentration in 
obese patients with binge eating disorder, Int J Obes Relat Metab Disord.; 26:1125-8.  
 
Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte 
MJ, Stroup AM and Hunt SC (2007) Long-term mortality after gastric bypass surgery. N 
Engl J Med; 357:753-761. 
 
217 
 
Adams TD, Davidson LE, Litwin SE, Kolotkin RL, LaMonte MJ, Pendleton RC, Strong 
MB, Vinik R, Wanner NA, Hopkins PN, Gress RE, Walker JM, Cloward TV, Nuttall RT, 
Hammoud A, Greenwood JL, Crosby RD, McKinlay R, Simper SC, Smith SC, Hunt SC 
(2012). Health benefits of gastric bypass surgery after 6 years. JAMA. 2012 Sep 
19;308 (11):1122-31. 
Adewale AS, Macarthur H, Westfall TC (2007). Neuropeptide Y-induced enhancement 
of the evoked release of newly synthesized dopamine in rat striatum: mediation by Y2 
receptors. Neuropharmacology; 52 (6):1396-402.  
Adrian TE, Ferri GL, Bacarese-Hamilton AJ, Fuessl HS, Polak JM and Bloom SR 
(1985a) Human distribution and release of a putative new gut hormone, peptide YY. 
Gastroenterology; 89:1070-1077. 
 
Agerso H, Jensen LB, Elbrond B, Rolan P and Zdravkovic M (2002) The 
pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-
acting GLP-1 derivative, in healthy men. Diabetologia; 45:195-202. 
 
Aguirre V, Stylopoulos N, Grinbaum R, Kaplan LM (2008). An endoluminal sleeve 
induces substantial weight loss and normalizes glucose homeostasis in rats with diet-
induced obesity, Obesity (Silver Spring) 16 (12) pp. 2585–2592. 
Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E and Flier JS 
(1996). Role of leptin in the neuroendocrine response to fasting. Nature; 382:250-252. 
Ahrén B, Gutniak M (1997). No correlation between insulin and islet amyloid 
polypeptide after stimulation with glucagon-like peptide-1 in type 2 diabetes.Eur J 
Endocrinol.; 137(6): 643-9. 
Ahrén B, Holst J J and Mari A (2003). Characterization of GLP-1 effects on beta-cell 
function after meal ingestion in humans. Diabetes Care 26 (10), pp. 2860–2864.  
 
Alberti KG and Zimmet PZ (1998). Definition, diagnosis and classification of diabetes 
mellitus and its complications. Part 1: diagnosis and classification of diabetes mellitus 
provisional report of a WHO consultation. Diabet Med; 15:539-553 
 
Allender S, Rayner M (2007). The burden of overweight and obesity-related ill health in 
the UK. Obes Rev.; 8(5): 467-73. 
 
218 
 
Allison DB, Fontaine KR, Manson JE, Stephens J, VanItalie TB (1999). Annual deaths 
attributable to obesity in the United States. JAMA; 282 (16): 1530–38. 
Alvarez Bartolome M, Borque M, Martinez-Sarmiento J, Aparicio E, Hernandez C, 
Cabrerizo L and Fernandez-Represa JA (2002). Peptide YY secretion in morbidly 
obese patients before and after vertical banded gastroplasty. Obes Surg; 12:324-327 
Allison DB, Kalinsky LB, Gorman BS. (1992). The comparative psychometric properties 
of three measures of dietary restraint. Psychol Assess; 4: 391-8. 
Anand BK, Brobeck JR (1951). Localization of a "feeding center" in the hypothalamus 
of the rat. Proc Soc Exp Biol Med.; 77(2): 323-4. 
Anderson DA, Shapiro JR, Lundgren JD, Spataro LE, Frye CA (2002). Self-reported 
dietary restraint is associated with elevated levels of salivary cortisol. Appetite.; 38(1): 
13-7.  
Anderson JW, Grant L, Gotthelf L, Stifler L (2007). Weight loss and long-term follow-up 
of severely obese individuals treated with an intense behavioral program. Int J Obes 
31(3):488–493. 
 
Anini Y, Hansotia T, Brubaker PL (2002). Muscarinic receptors control postprandial 
release of glucagon-like peptide-1: in vivo and in vitro studies in rats. Endocrinology; 
143: 2420–2426.  
 
Anini Y and Brubaker PL (2003) Role of leptin in the regulation of glucagon-like 
peptide-1 secretion. Diabetes; 52:252-259. 
 
Arterburn DE, Maciejewski ML, Tsevat J (2005). Impact of morbid obesity on medical 
expenditures in adults. Int J Obes (Lond); 29(3):334-339. 
 
Arnold M, Mura A, Langhans W, Geary N. (2006) Gut vagal afferents are not necessary 
for the eating-stimulatory effect of intraperitoneally injected ghrelin in the rat. J 
Neurosci; 26: 11052–11060. 
 
Asakawa A, Inui A, Kaga T, Yuzuriha H, Nagata T, Ueno N, Makino S, Fujimiya M, 
Niijima A, Fujino MA and Kasuga M (2001) Ghrelin is an appetite-stimulatory signal 
from stomach with structural resemblance to motilin. Gastroenterology; 120: 337-345 
 
219 
 
Asakawa A, Inui A, Kaga T, Katsuura G, Fujimiya M, Fujino MA and Kasuga M (2003) 
Antagonism of ghrelin receptor reduces food intake and body weight gain in mice. Gut; 
52: 947-952. 
 
Ashrafian H. and le Roux CW, Metabolic surgery and gut hormones (2009) — a review 
of bariatric entero-humoral modulation, Physiol Behav.; 97(5):620-31 
 
Asmar M, Bache M, Knop FK et al (2010). Do the actions of glucagon-like peptide-1 on 
gastric emptying, appetite, and food intake involve release of amylin in humans?  
J Clin Endocrinol Metab.; 95(5):2367-75. 
Asmar M, Højberg PV, Deacon CF, Hare K, Holst JJ, Madsbad S (2010). Pancreatic 
beta-cell responses to GLP-1 after near-normalization of blood glucose in patients with 
type 2 diabetes. Regul Pept. 25;160(1-3):175-80.  
Baggio LL, Huang Q, Brown TJ and Drucker DJ (2004) Oxyntomodulin and glucagon-
like peptide-1 differentially regulate murine food intake and energy expenditure. 
Gastroenterology; 127 (2):546-558. 
 
Balasubramaniam A, Joshi R, Su C, Friend LA and James JH (2007) Neuropeptide Y 
(NPY) Y2 receptor-selective agonist inhibits food intake and promotes fat metabolism in 
mice: Combined anorectic effects of Y2 and Y4 receptor-selective agonists. Peptides 
NPY AND COHORTS IN HUMAN DISEASE, Proceedings of the 8th International NPY 
meeting 2006; 28:235-240. 
 
Balkan B and Li X (2000) Portal GLP-1 administration in rats augments the insulin 
response to glucose via neuronal mechanisms. Am J Physiol Regul Integr Comp 
Physiol; 279: R1449-1454. 
 
Balleine BW (2007). The neural basis of choice and decision making, J Neurosci.;27: 
8159–8160 
 
Banks WA, DiPalma CR and Farrell CL (1999) Impaired transport of leptin across the 
blood-brain barrier in obesity. Peptides; 20:1341-1345 
 
Banks WA, Tschop M, Robinson SM and Heiman ML (2002) Extent and direction of 
ghrelin transport across the blood-brain barrier is determined by its unique primary 
structure. J Pharmacol Exp Ther; 302:822-827 
 
220 
 
Barazzoni R, Zanetti M, Stebel M, Biolo G, Cattin L, Guarnieri G. (2003). 
Hyperleptinemia prevents increased plasma ghrelin concentration during short-term 
moderate caloric restriction in rats. Gastroenterology; 124:1188-92 (2003). 
 
Barazzoni R, Zanetti M, Nagliati C, Cattin MR, Ferreira C, Giuricin M, Palmisano S, 
Edalucci E, Dore F, Guarnieri G, de Manzini N (2013). Gastric bypass does not 
normalize obesity-related changes in ghrelin profile and leads to higher acylated ghrelin 
fraction. Obesity (Silver Spring); 21(4):718-22 (2013). 
 
Barakat HA, Mooney N, O'Brien K, Long S, Khazani PG, Pories W, Caro JF (1993). 
Coronary heart disease risk factors in morbidly obese women with normal glucose 
tolerance. Diabetes Care 16 (1): pp 144–149 (1993). 
Barsh G S, Farooqi I S & O'Rahilly S (2000). Genetics of body-weight regulation Nature 
404, 644-651.  
Basso N, Capoccia D, Rizzello M, Abbatini F, Mariani P, Maglio C, Coccia F, 
Borgonuovo G, De Luca ML, Asprino R, Alessandri G, Casella G, Leonetti F (2011). 
First-phase insulin secretion, insulin sensitivity, ghrelin, GLP-1, and PYY changes 72 h 
after sleeve gastrectomy in obese diabetic patients: the gastric hypothesis. Surg 
Endosc.; 25(11):3540-50.  
 
Batterham RL, Cowley MA, Small CJ, Herzog H, Cohen MA, Dakin CL, Wren AM, 
Brynes AE, Low MJ, Ghatei MA, Cone RD and Bloom SR (2002) Gut hormone PYY3-
36 physiologically inhibits food intake. Nature; 418: 650–654 
 
Batterham RL, Cohen MA, Ellis SM, Le Roux CW, Withers DJ, Frost GS, Ghatei MA 
and Bloom SR (2003) Inhibition of Food Intake in Obese Subjects by Peptide YY3-36. 
N Engl J Med; 349: 941-948. 
 
Batterham RL, Heffron H, Kapoor S, Chivers JE, Chandarana K, Herzog H, Le Roux 
CW, Thomas EL, Bell JD and Withers DJ (2006) Critical role for peptide YY in protein-
mediated satiation and body-weight regulation. Cell Metabolism; 4: 223-233. 
 
Batterham RL, ffytche DH, Rosenthal JM, Zelaya FO, Barker GJ, Withers DJ and 
Williams SC (2007) PYY modulation of cortical and hypothalamic brain areas predicts 
feeding behaviour in humans. Nature; 450:106-109. 
 
221 
 
Bayliss WM and Starling EH (1902). The mechanism of pancreatic secretion. J Physiol 
28: 325-353 
 
Beaver JD, Lawrence AD, van Ditzhuijzen J, Davis MH, Woods A, Calder AJ. (2006) 
Individual differences in reward drive predict neural responses to images of food. J 
Neurosci.; 26: 5160-6. 
 
Beck B, Richy S and Stricker-Krongrad A (2004). Feeding response to ghrelin agonist 
and antagonist in lean and obese Zucker rats. Life Sci; 76: 473-478. 
 
Benaiges D, Goday A, Ramon JM, Hernandez E, Pera M, Cano JF Obemar Group 
(2011). Laparoscopic sleeve gastrectomy and laparoscopic gastric bypass are equally 
effective for reduction of cardiovascular risk in severely obese patients at one year of 
follow-up. Surg Obes Relat Dis.; 7(5):575-80. 
 
Benotti PN, Forse RA (1995). The role of gastric surgery in the multidisciplinary 
management of severe obesity. Am J Surg; 169: 361-7. 
 
Bergmann R N, Ader M (2000). Free Fatty Acids and Pathogenesis of Type 2 Diabetes 
Mellitus Trends Endocrinol. Metab. 11(9), 351-356. 
 
Berridge KC (1996). Food reward: brain substrates of wanting and liking.. Neurosci 
Biobehav Rev.;20(1): 1-25. 
 
Berridge KC (2009).'Liking' and 'wanting' food rewards: brain substrates and roles in 
eating disorders. Physiol Behav. Jul 14; 97(5):537-50. 
 
Berridge KC (2004). Motivation concepts in behavioral neuroscience. Physiol Behav. ; 
81: 179-209. 
 
Berthoud HR (2002). Multiple neural systems controlling food intake and body weight. 
Neurosci Biobehav Rev; 26:393-428. 
 
Berthoud HR (2003). Neural systems controlling food intake and energy balance in the 
modern world. Curr Opin Clin Nutr Metab Care; 6: 615-620 
222 
 
Berthoud HR (2004). Neural control of appetite: cross-talk between homeostatic and 
non-homeostatic systems, Appetite 43; 315–317 
Berthoud HR (2006). Homeostatic and non-homeostatic pathways involved in the 
control of food intake and energy balance. Obesity; 14: 197S–200S  
Berthoud HR (2007) Interactions between the "cognitive" and "metabolic" brain in the 
control of food intake, Physiol Behav; 91:486-498 
 
Berthoud HR (2013). Medicine. Why does gastric bypass surgery work? 
Science. 2013 Jul 26; 341(6144):351-2.  
Biagini J, Karam L (2008). Ten years experience with laparoscopic adjustable gastric 
banding. Obes Surg ;18 (5):573-7.  
Bigaard J, Tjonneland A, Thomsen BL, Overvad K, Heitmann BL, Sorensen TI (2003). 
Waist circumference, BMI, smoking, and mortality in middle-aged men and women. 
Obes Res 11:895-903. 
 
Blackard WG, Clore JN, Kellum JM (1994). Amylin/insulin secretory ratios in morbidly 
obese man: inverse relationship with glucose disappearance rate. J Clin Endocrinol 
Metab.; 78:1257-60. 
Blander G, Guarente L (2004). The SIR2 Family of protein deacetylases. Annual 
Review of Biochemistry. Vol. 73: 417-435. 
Blom WA, de Graaf C, Lluch A, Stafleu A, Schaafsma G, Hendriks HF (2009). 
Postprandial ghrelin responses are associated with the intermeal interval in time-
blinded normal weight men, but not in obese men. Physiol Behav.;96(4-5):742-8. 
Blundell JE, Levin F, King NA, Barkeling B, Gustafsson T, Hellstrom PM, Holst JJ, 
Naslund E (2008). Overconsumption and obesity: peptides and susceptibility to weight 
gain. Regul Pept.149 (1-3):32-8. 
Boan J, Kolotkin RL, Westman EC, McMahon RL, Grant JP. (2004) Binge eating, 
quality of life and physical activity improve after Roux-en-Y gastric bypass for morbid 
obesity. Obes Surg.; 14: 341-8. 
223 
 
Bobowicz M, Lehmann A, Orlowski M, Lech P, Michalik M (2011). Preliminary 
Outcomes 1 Year after Laparoscopic Sleeve Gastrectomy Based on Bariatric Analysis 
and Reporting Outcome System (BAROS). Obes Surg. 21:1843–1848.  
Boden G, Shulman G I, Free fatty acids in obesity and type 2 diabetes (2002). defining 
their role in the development of insulin resistance and β-cell dysfunction. European 
Journal of Clinical Investigation Eur. J. Clin. Invest. 32 (suppl. s3), 14-23. 
Boey D, Lin S, Enriquez RF, Lee NJ, Slack K, Couzens M, Baldock PA, Herzog H and 
Sainsbury A (2008) PYY transgenic mice are protected against diet-induced and 
genetic obesity. Neuropeptides; 42:19-30. 
 
Bohdjalian A, Langer FB, Shakeri-Leidenmühler S, Gfrerer L, Ludvik B, Zacherl J, 
Prager G (2010). Sleeve gastrectomy as sole and definitive bariatric procedure: 5-year 
results for weight loss and ghrelin. Obes Surg.; 20: 535-40. 
Borg CM, le Roux CW, Ghatei MA, Bloom SR, Patel AG and Aylwin SJ (2006) 
Progressive rise in gut hormone levels after Roux-en-Y gastric bypass suggests gut 
adaptation and explains altered satiety. Br J Surg; 93: 210-215 
Boroni Moreira AP
1
, Fiche Salles Teixeira T, do C Gouveia Peluzio M, de Cássia 
Gonçalves Alfenas R (2012). Gut microbiota and the development of obesity. Nutr 
Hosp. 2012 Sep-Oct; 27(5):1408-14. 
Bowirrat A and Oscar-Berman M (2005), Relationship between dopaminergic 
neurotransmission, alcoholism, and reward deficiency syndrome, American Journal of 
Medical Genetics Part B-Neuropsychiatric Genetics; 132B: 29–37 
Braghetto I, Davanzo C, Korn O et al (2009) Scintigraphic evaluation of gastric 
emptying in obese patients submitted to sleeve gastrectomy compared to normal 
subjects. Obes Surg.; 19(11):1515-21. 
 
Bray GA (1991) Weight homeostasis. Annu Rev Med 42: 205-216. 
Bray G A & Tartaglia L A (2000). Medicinal strategies in the treatment of obesity  
Nature 404, 672-677. 
Brethauer SA
1
, Aminian A, Romero-Talamás H, Batayyah E, Mackey J, Kennedy L, 
Kashyap SR, Kirwan JP, Rogula T, Kroh M, Chand B, Schauer PR (2013). Can 
224 
 
diabetes be surgically cured? Long-term metabolic effects of bariatric surgery in obese 
patients with type 2 diabetes mellitus. Ann Surg.;258(4):628-36;  
Bretherton-Watt D, Gilbey SG, Ghatei MA, Beacham J, Macrae A D and Bloom S R 
(1992). Very high concentrations of islet amyloid polypeptide are necessary to alter the 
insulin response to intravenous glucose in man. J Clin Endocrinol Metab. vol. 74 no. 5 
1032-1035. 
Brightman MW and Broadwell RD (1976). The morphological approach to the study of 
normal and abnormal brain permeability. Adv Exp Med Biol 69:41-54. 
 
Brolin RE, Bariatric surgery and long-term control of morbid obesity (2002), J. Am. 
Med. Assoc. 288 (22), pp. 2793–2796. 
Buchwald H, Buchwald JN (2002). Evolution of operative procedures for the 
management of morbid obesity 1950-2000. Obes Surg; 12 (5):705-17. 
Buchwald H, Avidor Y, Braunwald E et al (2004). Bariatric surgery: a systematic review 
and meta-analysis. JAMA.; 13;292(14):1724-37. 
 
Buchwald H, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP and 
Sledge I (2009) Weight and type 2 diabetes after bariatric surgery: systematic review 
and meta-analysis. Am J Med; 122:248-256. 
Bulik CM, Sullivan PF, Kendler KS (2003) Genetic and environmental contributions to 
obesity and binge eating.  Int J Eat Disord; 33:293–298 
Bullock BP, Heller RS and Habener JF (1996) Tissue distribution of messenger 
ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology; 137: 
2968-2978 
 
Burgmer R, Grigutsch K, Zipfel S, Wolf AM, de Zwaan M, Husemann B, Albus C, Senf 
W, Herpertz S (2005). The influence of eating behaviour and eating pathology on 
weight loss after gastric restriction operations. Obes Surg.; 15: 684-91. 
Burns E M, Naseem H, Bottle A, Lazzarino A I, Aylin P, Darzi A, Moorthy K, Faiz O 
(2010). Introduction of laparoscopic bariatric surgery in England: observational 
population cohort study. BMJ 341,pp 4296. 
225 
 
Burton-Freeman B (2005). Sex and cognitive dietary restraint influence cholecystokinin 
release and satiety in response to preloads varying in fatty acid composition and 
content. J Nutr:; 135: 1407–1414. 
Buse JB, Henry RR, Han J, Kim DD, Fineman MS and Baron AD (2004) Effects of 
exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated 
patients with type 2 diabetes. Diabetes Care; 27:2628-2635. 
 
Butler PC, Chou J, Carter WB, Wang YN, Bu BH, Chang D et al (1990) Effects of meal 
ingestion on plasma amylin concentration in NIDDM and non-diabetic humans, 
Diabetes; 39: 752–756. 
 
Byrne MM, Gliem K, Wank U, Arnold R, Katschinski M, Polonsky KS and Goke B 
(1998) Glucagon-like peptide 1 improves the ability of the beta-cell to sense and 
respond to glucose in subjects with impaired glucose tolerance. Diabetes; 47:1259-
1265. 
 
Callahan HS, Cummings DE, Pepe MS, Breen PA, Matthys CC and Weigle DS (2004) 
Postprandial suppression of plasma ghrelin level is proportional to ingested caloric load 
but does not predict intermeal interval in humans. J Clin Endocrinol Metab; 89:1319-
1324. 
 
Camastra S, Manco M, Mari A, Baldi S, Gastaldelli A, Greco AV, Mingrone G, 
Ferrannini E (2005): Beta-cell function in morbidly obese subjects during free living: 
long-term effects of weight loss. Diabetes 54 (8):2382–2389. 
 
Camastra S, Manco M, Mari A, Greco AV, Frascerra S, Mingrone G, Ferrannini E 
(2007). Beta-cell function in severely obese type 2 diabetic patients: long-term effects 
of bariatric surgery. Diabetes Care 30 (4):1002–1004. 
 
Capella JF, Capella RF (1996). The weight reduction operation of choice: Vertical 
banded gastroplasty or gastric bypass? Am J Surg.;171, 74–9.  
 
Caraco T, Martindale S & Whittam TS (1980). An empirical demonstration of risk-
sensitive foraging preferences, Animal. Behaviour; 28: 820–830. 
Carr KD (2002). Augmentation of drug reward by chronic food restriction: behavioral 
evidence and underlying mechanisms, Physiol. Behav.; 76: 353–364. 
226 
 
Carr KD (2007). Chronic food restriction: enhancing effects on drug reward and striatal 
cell signaling, Physiology & Behavior; 9: 459–472. 
Carroll ME, France CP & Meisch RA (1979). Food deprivation increases oral and 
intravenous drug intake in rats. Science; 205: 319–321. 
Challis BG, Pinnock SB, Coll AP, Carter RN, Dickson SL and O'Rahilly S (2003). Acute 
effects of PYY3-36 on food intake and hypothalamic neuropeptide expression in the 
mouse. Biochem Biophys Res Commun; 311:915-919. 
Chambers A P, Stefater M A, Wilson-Perez H E, Jessen L, Sisley S, Ryan K K, 
Gaitonde S, Sorrell J E, Toure M, Berger J, D'Alessio D A, Sandoval D A, Seeley R J 
and Woods S C (2011). Similar effects of roux-en-Y gastric bypass and vertical sleeve 
gastrectomy on glucose regulation in rats. Physiology & Behavior, Volume 105, Issue 
1, 30 pp 120-123.  
Chambers AP, Jessen L, Ryan KK, Sisley S, Wilson-Pérez HE, Stefater MA, Gaitonde 
SG, Sorrell JE, Toure M, Berger J, D'Alessio DA, Woods SC, Seeley RJ, Sandoval DA 
(2011). Weight-independent changes in blood glucose homeostasis after gastric 
bypass or vertical sleeve gastrectomy in rats. Gastroenterology;141(3):950-8.  
 
Chandarana K, Drew ME, Emmanuel J, Karra E, Gelegen C, Chan P, Cron NJ, 
Batterham RL (2009). Subject standardization, acclimatization, and sample processing 
affect gut hormone levels and appetite in humans. Gastroenterology.; 136: 2115-26. 
 
Chaudhri O, Small C and Bloom S (2006) Gastrointestinal hormones regulating 
appetite. Philos TransR Soc Lond B Biol Sci; 361:1187-1209 
  
Chelikani PK, Haver AC and Reidelberger RD (2004) Comparison of the inhibitory 
effects of PYY (3-36) and PYY (1-36) on gastric emptying in rats. Am J Physiol Regul 
Integr Comp Physiol; 287:R1064-1070. 
 
Chen H, Charlat O, Tartaglia LA, Woolf EA, Weng X, Ellis SJ, Lakey ND, Culpepper J, 
Moore KJ, Breitbart RE, Duyk GM, Tepper RI and Morgenstern JP (1996). Evidence 
that the diabetes gene encodes the leptin receptor: identification of a mutation in the 
leptin receptor gene in db/db mice. Cell; 84:491-495 
 
227 
 
Chen WJ, Armour S, Way J, Chen G, Watson C and Irving P et al (1997). Expression 
cloning and receptor pharmacology of human calcitonin receptors from MCF-7 cells 
and their relationship to amylin receptors, Mol Pharmacol; 52: 1164–1175. 
Christou NV, Sampalis JS, Liberman M, Look D, Auger S, McLean AP, MacLean LD 
(2004). Surgery decreases long-term mortality, morbidity, and health care use in 
morbidly obese patients. Ann Surg.;240 (3):416-23; discussion 423-4. 
Christou NV, Look D, Maclean LD (2006). Weight gain after short- and long-limb gastric 
bypass in patients followed for longer than 10 years. Ann Surg 244 (5):734–740. 
 
Cizza G
1
, Rother KI (2011). Beyond fast food and slow motion: weighty contributors to 
the obesity epidemic. J Endocrinol Invest. 2012 Feb;35(2):236-42. 
 
Cline MA, Nandar W, Smith ML, Pittman BH, Kelly M and Rogers JO (2008). Amylin 
causes anorexigenic effects via the hypothalamus and brain stem in chicks, Regul 
Pept; 146:140–146 
 
Cluck M W, Chan C Y and Adrian T E (2005). The Regulation of Amylin and Insulin 
Gene Expression and Secretion. Pancreas Volume 30 - Issue 1 - pp 1-14. 
Cohen MX, Young J, Baek JM, Kessler C and Ranganath C (2005). Individual 
differences in extraversion and DA genetics predict neural reward responses, Cognitive 
Brain Research; 25: 851–861 
Coleman DL (1973) Effects of parabiosis of obese with diabetes and normal mice. 
Diabetologia; 9: 294-298 
 
Colquitt JL, Picot J, Loveman E, Clegg AJ (2009). Surgery for obesity. Cochrane 
Database Syst Rev.15; (2):CD003641. 
Colquitt J L, Clegg A, Loveman E, Royle P, Sidhu MK (2005). Surgery for morbid 
obesity. Cochrane Database Syst Rev.;4: CD00364 
Considine RV, Sinha MK, Heiman ML, Kriauciunas A, Stephens TW, Nyce MR, 
Ohannesian JP, Marco CC, McKee LJ, Bauer TL and et al (1996) Serum 
immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J 
Med; 334:292-295 
228 
 
Cottam D, Qureshi F G, Mattar S G, Sharma S, Holover S, Bonanomi G, Ramanathan 
R and  Schauer P (2006). Laparoscopic sleeve gastrectomy as an initial weight-loss 
procedure for high-risk patients with morbid obesity. Surg Endosc Volume 20, Number 
6; 859-863. 
Couzin J (2008). Medicine. Bypassing medicine to treat diabetes. Science; 320:438-
440. 
 
Cox JE and Randich A (2004) Enhancement of feeding suppression by PYY (3-36) in 
rats with area postrema ablations. Peptides; 25:985-989. 
Cremieux PY, Buchwald H, Shikora SA, Ghosh A, Yang HE, Buessing M (2008). A 
study on the economic impact of bariatric surgery. Am J Manag Care.;14(9):589-96.  
Cummings DE, Purnell JQ, Frayo RS, Schmidova K, Wisse BE and Weigle DS (2001). 
A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. 
Diabetes; 50: 1714–1719. 
 
Cummings DE, Clement K, Purnell JQ, Vaisse C, Foster KE, Frayo RS, Schwartz MW, 
Basdevant A and Weigle DS (2002a) Elevated plasma ghrelin levels in Prader Willi 
syndrome. Nat Med; 8:643-644. 
 
Cummings DE, Weigle DS, Frayo RS, Breen PA, Ma MK, Dellinger EP and Purnell JQ 
(2002b) Plasma ghrelin levels after diet-induced weight loss or gastric bypass surgery. 
N Engl J Med; 346:1623-1630. 
 
Cummings DE, Foster KE (2003). Ghrelin-leptin tango in body-weight regulation. 
Gastroenterology; 124: 1532-5 
 
Cummings, D.E. Overduin J, Foster-Schubert KE (2004). Gastric bypass for obesity: 
mechanisms of weight loss and diabetes resolution. J. Clin. Endocrinol. Metab. 89 (6), 
2608–2615. 
 
Cummings DE, Frayo RS, Marmonier C, Aubert R and Chapelot D (2004) Plasma 
ghrelin levels and hunger scores in humans initiating meals voluntarily without time- 
and food-related cues. Am J Physiol Endocrinol Metab; 287:E297-304. 
 
Cummings DE (2006). Ghrelin and the short- and long-term regulation of appetite and 
body weight.  Physiol Behav.; 89: 71-84.  
229 
 
 
Cummings DE, Overduin J, Foster-Schubert KE, Carlson MJ (2007). Role of the 
bypassed proximal intestine in the anti-diabetic effects of bariatric surgery. Surg Obes 
Relat Dis 3 (2):109–115. 
 
Cummings DE and Flum DR (2008). Gastrointestinal surgery as a treatment for 
diabetes. JAMA; 299:341-343. 
 
Cytos Biotechnology (2006). Phase I/IIa clinical trial with obese individuals shows no 
effect of CYT009-GhrQb on weight loss, in Cytos Biotechnology : Press Release 
November 7, 2006. 
 
Damci T,  Yalin S, Balci H, Osar Z, Korugan U, Ozyazar M, and Ilkova H (2004). 
Orlistat Augments Postprandial Increases in Glucagon-like Peptide 1 in Obese Type 2 
Diabetic Patients Diabetes Care, vol. 27 (5) 1077-1080. 
Dapri G, Cadière GB, Himpens J (2011). Laparoscopic conversion of Roux-en-Y gastric 
bypass to sleeve gastrectomy as first step of duodenal switch: technique and 
preliminary outcomes. Obes Surg.; 21(4):517-23.  
Dapri G, Cadière GB, Himpens J (2011). Laparoscopic conversion of Roux-en-Y gastric 
bypass to sleeve gastrectomy as first step of duodenal switch: technique and 
preliminary outcomes. Obesity Surgery; 21(4):517-23. 
Das M, Gabriely I, Barzilai N (2004). Caloric restriction, body fat and ageing in 
experimental models. Obesity Reviews, Volume 5, Issue 1, pages 13–19.  
Deacon CF, Johnsen AH and Holst JJ (1995) Degradation of glucagon-like peptide-1 
by human plasma in vitro yields an N- terminally truncated peptide that is a major 
endogenous metabolite in vivo. J.Clin.Endo.Met. 80(3), pp. 952-7.  
 
Deacon CF (2005). What do we know about the secretion and degradation of incretin 
hormones? Regul. Pept.; 128:117-124 
 
Deacon CF (2009) Potential of liraglutide in the treatment of patients with type 2 
diabetes. Vascular health and risk management; 5:199-211. 
 
de Castro JM and Stroebele N (2002) Food intake in the real world: implications for 
nutrition and aging. Clin Geriatr Med; 18:685-697. 
230 
 
 
DeCarr LB, Buckholz TM, Milardo LF, Mays MR, Ortiz A and Lumb KJ (2007) A long-
acting selective neuropeptide Y2 receptor PEGylated peptide agonist reduces food 
intake in mice. Bioorganic & medicinal chemistry letters; 17:1916-1919. 
 
de Fatima Haueisen Sander Diniz M, de Azeredo Passos VM and Diniz MT (2006) Gut-
brain communication: how does it stand after bariatric surgery? Curr Opin Clin Nutr 
Metab Care; 9:629-636. 
 
DeFronzo RA (2004) Pathogenesis of type 2 diabetes mellitus. Med Clin North Am; 
88:787-835. 
 
Degen L, Oesch S, Casanova M, Graf S, Ketterer S, Drewe J and Beglinger C (2005) 
Effect of peptide YY3-36 on food intake in humans. Gastroenterology; 129:1430-1436. 
de Gordejuela A G R, Gebelli P J, García N V, Alsina EF, Medayo LS, Noguera C M 
(2011). Is sleeve gastrectomy as effective as gastric bypass for remission of type 2 
diabetes in morbidly obese patients? Surg Obes Relat Dis. Volume 7, Issue 4, pp 506–
509. 
den Hoed M, Smeets AJPG, Veldhorst MAB, Nieuwenhuizen AG, Bouwman FG, 
Heidema AG, Mariman ECM, Westerterp-Plantenga MS and Westerterp KR. (2008) 
SNP analyses of postprandial responses in (an)orexigenic hormones and feelings of 
hunger reveal long-term physiological adaptations to facilitate homeostasis, 
International Journal of Obesity; 32: 1790–1798 
DePaula AL, Macedo AL, Schraibman V et al (2009). Hormonal evaluation following 
laparoscopic treatment of type 2 diabetes mellitus patients with BMI 20-34. Surg 
Endosc.; 23 (8):1724-32. 
 
De Silva A, Salem V, Long CJ, Makwana A, Newbould RD, Rabiner EA, Ghatei MA, 
Bloom SR, Matthews PM, Beaver JD, Dhillo WS (2011). The gut hormones PYY 3-36 
and GLP-1 7-36 amide reduce food intake and modulate brain activity in appetite 
centers in humans. Cell Metab. ; 14 (5):700-6.  
 
De Smet B, Depoortere I, Moechars D, Swennen Q, Moreaux B, Cryns K, Tack J, 
Buyse J, Coulie B and Peeters TL (2006) Energy homeostasis and gastric emptying in 
ghrelin knockout mice. J Pharmacol Exp Ther; 316: 431-439. 
 
231 
 
Deurenberg P, Weststrate JA, Seidell JC (1991). Body mass index as a measure of 
body fatness: age and sex specific prediction formulas. Br J Nutr 65:105–114. 
 
De Vriese, F. Gregoire, R. Lema-Kisoka, M. Waelbroeck, P. Robberecht and C. 
Delporte (2004). Ghrelin degradation by serum and tissue homogenates: identification 
of the cleavage sites. Endocrinology; 145: 4997–5005 
 
Dezaki K, Sone H and Yada T (2008) Ghrelin is a physiological regulator of insulin 
release in pancreatic islets and glucose homeostasis. Pharmacol Ther.; 118:239-249 
 
Diamond J (2003). The double puzzle of diabetes Nature 423, 599-602 (2003) 
Dietz W H (2004). Overweight in Childhood and Adolescence N. Engl. J. Med. 350:855-
857.  
Di Chiara G (1995), The role of dopamine in drug abuse viewed from the perspective of 
its role in motivation. Drug Alcohol Depend; 38: 95–137. 
Dimitriadis E, Daskalakis M, Kampa M, Peppe A, Papadakis JA, Melissas J (2013). 
Alterations in gut hormones after laparoscopic sleeve gastrectomy: a prospective 
clinical and laboratory investigational study. Ann Surg.; 257 (4):647-54 (2013). 
 
Dixon JB, O'Brien PE, Playfair J, Chapman L, Schachter LM, Skinner S, Proietto J, 
Bailey M, Anderson M (2008). Adjustable gastric banding and conventional therapy for 
type 2 diabetes: a randomized controlled trial, J. Am. Med. Assoc. 299 (3), pp. 316–
323. 
Doogue M P, Begg E J, Moore M P, Lunt H, Pemberton C J and Mei Zhang (2008). 
British Journal of Clinical Pharmacology. Metformin increases plasma ghrelin in Type 2 
diabetes: Volume 68, Issue 6, pages 875–882. 
 
Drazen DL, Vahl TP, D'Alessio DA, Seeley RJ and Woods SC (2006). Effects of a fixed 
meal pattern on ghrelin secretion: evidence for a learned response independent of 
nutrient status. Endocrinology; 147:23-30 
 
Drucker DJ, Philippe J, Mojsov S, Chick WL and Habener JF (1987) Glucagon-like 
peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat 
islet cell line. Proc Natl Acad Sci USA; 84:3434-3438. 
232 
 
 
Drucker D J (2003a). Glucagon-like peptides: regulators of cell proliferation, 
differentiation and apoptosis, Mol. Endocrinol. 17(2): pp 161-171. 
 
Drucker DJ (2003b) Glucagon-like peptide-1 and the islet beta-cell: augmentation of 
cell proliferation and inhibition of apoptosis. Endocrinology; 144:5145-5148. 
 
Drucker DJ (2006). The biology of incretin hormones. Cell Metab; 3(3):153-65.  
 
Dubuc GR, Phinney SD, Stern JS and Havel PJ (1998). Changes of serum leptin and 
endocrine and metabolic parameters after 7 days of energy restriction in men and 
women. Metabolism 47:429–434. 
 
Dumont Y, Moyse E, Fournier A and Quirion R (2007). Distribution of peripherally 
injected peptide YY ([125I] PYY (3-36)) and pancreatic polypeptide ([125I] hPP) in the 
CNS: enrichment in the area postrema. J Mol Neurosci; 33:294-304. 
 
Duncan M, Griffith M,  Rutter H and Goldacre M J (2010). Certification of obesity as a 
cause of death in England 1979–2006 Eur J Public Health 20 (6): 671-675. 
Dunlop B Wand Nemeroff C B (2007). The role of dopamine in the pathophysiology of 
depression, Arch. Gen. Psychiatry; 64: 327–337 
Dunn JP, Cowan RL, Volkow ND, Feurer ID, Li R, Williams DB, Kessler RM, Abumrad 
NN. (2010). Decreased dopamine type 2 receptor availability after bariatric surgery: 
Preliminary findings. Brain Res.; 1350:123-30. 
Dymek MP, le Grange D, Neven K, Alverdy J (2001). Quality of life and psychosocial 
adjustment in patients after Roux-en-Y gastric bypass: a brief report. Obes Surg.;11 
(1):32-9. 
A. Dzaja, M.A. Dalal, H. Himmerich, M. Uhr, T. Pollmacher and A. Schuld (2004). Sleep 
enhances nocturnal plasma ghrelin levels in healthy subjects, Am J Physiol Endocrinol 
Metab; 286: E963–E967. 
 
Eissele R, Goke R, Willemer S, Harthus HP, Vermeer H, Arnold R and Goke B (1992). 
Glucagon-like peptide-1 cells in the gastrointestinal tract and pancreas of rat, pig and 
man. European journal of clinical investigation; 22: 283-291. 
233 
 
Elliott R, Friston KJ, Dolan RJ (2000) Dissociable neural responses associated with 
reward, punishment and risk-taking behaviour. J Neurosci; 20:6159-6165. 
Elliott R, Newman JL, Longe OA, Deakin JF (2003). Differential response patterns in 
the striatum and orbitofrontal cortex to financial reward in humans: a parametric 
functional magnetic resonance imaging study, J Neurosci.: 23: 303-7. 
 
Elmquist JK, Elias CF and Saper CB (1999) From lesions to leptin: hypothalamic 
control of food intake and body weight. Neuron; 22: 221-232. 
 
Elrick H, Stimmler L, Hlad CJ, Jr. and Arai Y (1964) Plasma Insulin Response to Oral 
and Intravenous Glucose Administration. J Clin Endocrinol Metab; 24:1076-1082. 
 
English PJ, Ghatei MA, Malik IA, Bloom SR and Wilding JP (2002). Food fails to 
suppress ghrelin levels in obese humans. J Clin Endocrinol Metab; 87:2984. 
 
English PJ, Ashcroft A, Patterson M, Dovey TM, Halford JC, Harrison J, Eccleston D, 
Bloom SR, Ghatei MA, Wilding JP (2007). Metformin prolongs the postprandial fall in 
plasma ghrelin concentrations in type 2 diabetes. Diabetes Metab Res Rev.;23(4):299-
303.   
Enoki S, Mitsukawa T, Takemura J, Nakazato M, Aburaya J, Toshimori H, Matsukara S 
(1992). Plasma islet amyloid polypeptide levels in obesity, impaired glucose tolerance 
and noninsulin-dependent diabetes mellitus. Diabetes Res Clin Pract. Volume 15, Issue 
1, Pages 97–102.  
M. Ernst, E.E. Nelson, E.B. McClure, C.S. Monk, S. Munson and N. Eshel et al (2004). 
Choice selection and reward anticipation: an fMRI study, Neuropsychologia; 42: 1585–
1597. 
Essah PA, Levy JR, Sistrun SN, Kelly SM and Nestler JE (2007). Effect of 
macronutrient composition on postprandial peptide YY levels. J Clin Endocrinol Metab: 
92(10):4052-5.  
 
Falkén Y, Hellström PM, Holst JJ, Näslund E (2011). Changes in glucose homeostasis 
after Roux-en-Y gastric bypass surgery for obesity at day three, two months, and one 
year after surgery: role of gut peptides. J Clin Endocrinol Metab.;96(7):2227-35. 
234 
 
Faradji RN, Froud T, Messinger S, Monroy K, Pileggi A, Mineo D, Tharavanij T, 
Mendez AJ, Ricordi C, Alejandro R (2009). Long-term metabolic and hormonal effects 
of exenatide on islet transplant recipients with allograft dysfunction. Cell 
Transplantation, Volume 18, Numbers 10-11, pp. 1247-1259.  
Faraj M, Havel P J, Phélis S, Blank D,  Sniderman A D and Cianflone K (2003). Plasma 
Acylation-Stimulating Protein, Adiponectin, Leptin, and Ghrelin before and after Weight 
Loss Induced by Gastric Bypass Surgery in Morbidly Obese Subjects. The Journal of 
Clinical Endocrinology & Metabolism, vol. 88 no. 4, pp 1594-1602.    
 
Favretti F, Segato G, Ashton D, Busetto L, De Luca M, Mazza M, Ceoloni A, Banzato 
O, Calo E, Enzi G (2007). Laparoscopic adjustable gastric banding in 1,791 
consecutive obese patients: 12-year results. Obes Surg 17(2):168–175. 
 
Farooqi IS, Jebb SA, Langmack G, Lawrence E, Cheetham CH, Prentice AM, Hughes 
IA, McCamish MA and O'Rahilly S (1999) Effects of recombinant leptin therapy in a 
child with congenital leptin deficiency. N Engl J Med; 341:879-884. 
 
Farooqi I S, Keogh J M , Kamath S, Jones S, Gibson W T, Trussell R, Jebb S A, Lip G 
Y H, O’Rahilly S (2001). Nature 414, 34-35.  
 
Farooqi IS, Bullmore E, Keogh J, et al (2007). Leptin regulates striatal regions and 
human eating behavior. Science; 317:1355. 
Fenske WK, Bueter M, Miras AD, Ghatei MA, Bloom SR, le Roux CW (2012). 
Exogenous peptide YY3-36 and Exendin-4 further decrease food intake, whereas 
octreotide increases food intake in rats after Roux-en-Y gastric bypass. International 
Journal of Obesity 36, 379-384. 
Ferrannini E, Gastaldelli A, Miyazaki Y, Matsuda M, Mari A, DeFronzo RA (2005). β-
Cell function in subjects spanning the range from normal glucose tolerance to overt 
diabetes: a new analysis. J Clin Endocrinol Metab 90 (1):493–500. 
Figlewicz et al (2004). Intraventricular insulin and leptin reverse place preference 
conditioned with high-fat diet in rats. Behav. Neurosci; 118, 479–487. 
Figlewicz, D. P. (2003) Adiposity signals and food reward: expanding the CNS roles of 
insulin and leptin. Am. J. Physiol. Regul. Integr. Comp. Physiol.; 284, R882–R892. 
235 
 
Figlewicz DP, Benoit SC. Insulin, leptin, and food reward: update 2008 (2009). Am J 
Physiol Regul Integr Comp Physiol.; 296 (1): R9-R19. 
 
Flegal KM, Carroll MD, Oden CL (2002). Prevalence and trends in obesity among US 
adults, 1999-2000. JAMA; 288 (14):1723-1727.  
 
Flint A RA, Blundell JE, Astrup A (2000) Reproducibility, power and validity of visual 
analogue scales in assessment of appetite sensations in single test meal studies. Int J 
Obes; 24:38-48. 
 
Foster-Schubert KE (2011). Hypoglycemia complicating bariatric surgery: incidence 
and mechanisms. Curr Opin Endocrinol Diabetes Obes. ;18(2):129-33.  
 
Fridolf T and Ahren B (1991) GLP-1(7-36) amide stimulates insulin secretion in rat 
islets: studies on the mode of action. Diabetes Res; 16:185-191. 
Friedman J M (2002). The Function of Leptin in Nutrition, Weight, and Physiology 
Nutrition Reviews Volume 60, Issue Supplement s10, pages S1–S14. 
 
Frisch R E, McArthur J W (1974)., Science: Vol. 185 no. 4155 pp. 949-951.   
 
Frohlich, A (1901). Ein Fall von Tumor der Hypophysis cerebri ohne Akromegalie. Wien 
Klin. Rundschau.15, 883-886, 906-908.  
 
Fuhlendorff J, Johansen NL, Melberg SG, Thogersen H and Schwartz TW (1990) The 
antiparallel pancreatic polypeptide fold in the binding of neuropeptide Y to Y1 and Y2 
receptors. J Biol Chem; 265:11706-11712. 
 
Fukase N, Igarashi M, Takahashi H, Manaka H, Yamatani K, Daimon M, Tominaga M 
and Sasaki H (1993) Hypersecretion of truncated glucagon-like peptide-1 and gastric 
inhibitory polypeptide in obese patients. Diabet Med; 10: 44-49. 
Fulton S., Woodside B. & Shizgal P (2000). Modulation of brain reward circuitry by 
leptin. Science; 287: 125–128. 
Fulton S, Pissios P, Manchon RP, Stiles L, Frank L, Pothos EN, Maratos-Flier E, Flier 
JS. (2006). Leptin regulation of the mesoaccumbens dopamine pathway. Neuron; 51: 
811- 22. 
 
236 
 
Furnsinn C, Leuvenink H, Roden M, Nowotny P, Schneider B, Rohac M, Pieber T, 
Clodi M, Waldhausl W (1994). Islet amyloid polypeptide inhibits insulin secretion in 
conscious rats. Am J Physiol; 267:E300–5. 
 
Gamberino WC and Gold MS (1999). Neurobiology of tobacco smoking and other 
addictive behaviours. Addictive Disorders; 22: 301–312. 
 
Gao Q, Horvath TL (2008), Neuronal control of energy homeostasis. FEBS Lett. 9; 
582(1):132-41.  
Gebre-Medhin S, Mulder H, Pekny M, Westermark G, Törnell J, Westermark P, Sundler 
F, Ahrénf B, Betsholtz C (1998). Increased insulin secretion and glucose tolerance in 
mice lacking islet amyloid polypeptide (amylin). Biochem Biophys Res Commun. 
Volume 250, Issue 2, pp 271–277.  
Geloneze B, Tambascia MA, Pareja JC, Repetto EM, Magna LA, Pereira SG (2001). 
Serum leptin levels after bariatric surgery across a range of glucose tolerance from 
normal to diabetes. Obes Surg; 11(6):693-8. 
 
Ghigo E, Broglio F, Arvat E, Maccario M, Papotti M, Muccioli G (2005). Ghrelin: more 
than a natural GH secretagogue and/or an orexigenic factor. Clin Endocrinol 
(Oxf).;62(1):1-17. 
 
Gill RS, Birch DW, Shi X, Sharma AM, Karmali S (2010). Sleeve gastrectomy and type 
2 diabetes mellitus: a systematic review. Surg Obes Relat Dis. Volume 6, Issue 6, pp 
707–713. 
 
Gill R S, Karmali S and Sharma A M (2011). Treating Type 2 Diabetes Mellitus With 
Sleeve Gastrectomy in Obese Patients. Obesity 19 4, 701–702.   
 
Gloy VL
1
, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, Bucher HC, 
Nordmann AJ (2013). Bariatric surgery versus non-surgical treatment for obesity: a 
systematic review and meta-analysis of randomised controlled trials. BMJ.; 
22;347:f5934.  
 
Harrison G W and Rutstrom  E E (2008). Risk Aversion in the Laboratory, Research in 
Experimental Economics, Volume12, Page:41-196 ISSN: 0193-2306.   
 
237 
 
Gray, J A (1987). The psychology of fear and stress. Cambridge:Cambridge University 
Press. 
 
Griffen WO Jr, Young VL, Stevenson CC (1977). A prospective comparison of gastric 
and jejunoileal bypass procedures for morbid obesity. Ann. Surg. 186 (4), 500–509. 
 
Gnanapavan S, Kola B, Bustin SA, Morris DG, McGee P, Fairclough P, Bhattacharya 
S, Carpenter R, Grossman AB and Korbonits M (2002). The tissue distribution of the 
mRNA of ghrelin and subtypes of its receptor, GHS-R, in humans. J Clin Endocrinol 
Metab 87(6):2988. 
 
Gomez-Pinilla F (2008) Brain foods: the effects of nutrients on brain function. Nat Rev 
Neurosci; 9:568-578. 
 
Grandt D TS, Schimiczek M, Reeve JR Jr, Feth F, Rascher W, Hirche H, Singer MV, 
Layer P, Goebell H, et al (1992) Novel generation of hormone receptor specificity by 
amino terminal processing of peptide YY. Biochem Biophys Res Commun 186:1299-
1306. 
 
Grandt D, Dahms P, Schimiczek M, Eysselein VE, Reeve JR, Jr. and Mentlein R (1993) 
[Proteolytic processing by dipeptidyl aminopeptidase IV generates receptor selectivity 
for peptide YY (PYY)]. Med Klin (Munich); 88:143-145. 
 
Grill HJ (2006) Distributed neural control of energy balance: contributions from 
hindbrain and hypothalamus. Obesity (Silver Spring); Md 14 Suppl 5:216S-221S. 
 
Guo Y, Ma L, Enriori PJ, Koska J, Franks PW, Brookshire T, Cowley MA, Salbe AD, 
Delparigi A and Tataranni PA (2006) Physiological evidence for the involvement of 
peptide YY in the regulation of energy homeostasis in humans. Obesity (Silver Spring); 
Md 14:1562-1570. 
 
Haas V, Onur S, Paul T, Nutzinger D O, Bosy-Westphal A and Hauer M et al (2005), 
Leptin and body weight regulation in patients with anorexia nervosa before and during 
weight recovery, Am J Clin Nutr.; 81: 889–896. 
 
Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, 
Burley SK, Friedman JM (1995). Weight-reducing effects of the plasma protein 
encoded by the obese gene. Science 269:543–546.  
238 
 
 
Hafner RJ, Watts JM and Rogers J (1991). Quality of life after gastric bypass for morbid 
obesity. Int J Obes; 15: 555-560. 
 
Hajnal A, Mark G P, Rada P V, Lenard L and Hoebel B G (1997). Norephinephrine 
microinjections in the hypothalamic paraventricular nucleus increase extracellular 
dopamine and decrease acetylcholine in the nucleus accumbens: Relevance for 
feeding reinforcement. Journal of Neurochemistry; 68: 667–674. 
 
Halaas JL, Gajiwala KS, Maffei M, Cohen SL, Chait BT, Rabinowitz D, Lallone RL, 
Burley SK and Friedman JM (1995). Weight-reducing effects of the plasma protein 
encoded by the obese gene. Science; 269:543-546. 
 
Halatchev IG, Ellacott KL, Fan W and Cone RD (2004) Peptide YY3-36 inhibits food 
intake in mice through a melanocortin-4 receptor-independent mechanism. 
Endocrinology 145: 2585-2590. 
 
Halatchev IG and Cone RD (2005) Peripheral administration of PYY(3-36) produces 
conditioned taste aversion in mice Cell Metab; 1(3):159-68. 
 
Halem HA, Taylor JE, Dong JZ, Shen Y, Datta R, Abizaid A, Diano S, Horvath T, 
Zizzari P, Bluet- Pajot MT, Epelbaum J and Culler MD (2004) Novel analogs of ghrelin: 
physiological and clinical implications. Eur J Endocrinol; 151 Suppl 1: S71-75. 
 
Hales C N, Barker D J P (1992). Type 2 (non-insulin-dependent) diabetes mellitus: the 
thrifty phenotype hypothesis, Diabetologia Volume 35, Number 7 595-601. 
 
Halmi KA, Mason E, Falk JR and Stunkard A (1981). Appetitive behavior after gastric 
bypass for obesity. Int J Obes; 5: 457-464. 
 
Hansen L, Deacon CF, Orskov C and Holst JJ (1999). Glucagon-like peptide-1-(7-
36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase 
IV in the capillaries supplying the L cells of the porcine intestine. Endocrinology; 140: 
5356-5363. 
Hansen EN, Tamboli RA, Isbell JM, Saliba J, Dunn JP, Marks-Shulman PA, Abumrad 
NN (2011). Role of the foregut in the early improvement in glucose tolerance and 
239 
 
insulin sensitivity following Roux-en-Y gastric bypass surgery. Am J Physiol 
Gastrointest Liver Physiol.; 300 (5):G795-802.  
Haqq AM, Farooqi IS, O'Rahilly S, Stadler DD, Rosenfeld RG, Pratt KL, LaFranchi SH 
and Purnell JQ (2003) Serum ghrelin levels are inversely correlated with body mass 
index, age, and insulin concentrations in normal children and are markedly increased in 
Prader-Willi syndrome. J Clin Endocrinol Metab; 88:174-178. 
 
Haslam DW, James WP (2005). Obesity, Lancet; 366: 1197–1209. 
 
Hartter E, T. Svoboda, B. Ludvik, M. Schuller, B. Lell and E. Kuenburg et al (1991). 
Basal and stimulated plasma levels of pancreatic amylin indicate its co-secretion with 
insulin in humans, Diabetologia; 34: 52–54. 
 
Havel PJ (2001). Peripheral signals conveying metabolic information to the brain: short-
term and long-term regulation of food intake and energy homeostasis. Exp Biol Med 
226:963–977. 
Hawkins SC, Osborne A, Finlay IG, Alagaratnam S, Edmond JR, Welbourn R (2007). 
Paid work increases and state benefit claims decrease after bariatric surgery. Obes 
Surg; 17 (4):434-7. 
Hayden BY, Platt ML (2009). Gambling for Gatorade: risk-sensitive decision making for 
fluid rewards in humans.. Anim Cogn.; 12: 201-7. 
 
Heijboer AC, van den Hoek A M, Parlevliet ET, Havekes LM, Romijn JA, Pijl H and 
Corssmit EP (2006). Ghrelin differentially affects hepatic and peripheral insulin 
sensitivity in mice. Diabetologia; 49:732-738. 
 
Helmling S, Maasch C, Eulberg D, Buchner K, Schroder W, Lange C, Vonhoff S, 
Wlotzka B, Tschop MH, Rosewicz S and Klussmann S (2004). Inhibition of ghrelin 
action in vitro and in vivo by an RNA-Spiegelmer. Proc Natl Acad Sci USA; 101:13174-
13179. 
 
Helou N, Obeid O, Azar ST and Hwalla N (2008). Variation of postprandial PYY 3-36 
response following ingestion of differing macronutrient meals in obese females. Annals 
of nutrition & metabolism; 52:188-195. 
 
240 
 
Herrmann C, Goke R, Richter G, Fehmann H C, Arnold R and Goke B (1995). 
Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma 
levels in response to nutrients, Digestion; 56: 117–126. 
 
Herrmann-Rinke C, Voge A, Hess M, Goke B. (1995). Regulation of glucagon-like 
peptide-1 secretion from rat ileum by neurotransmitters and peptides. J 
Endocrinol.;147: 25–31.  
 
Hey JD, C Orme (1994). Investigating generalizations of expected utility theory using 
experimental data. Econometrica: Journal of the Econometric Society; 62: 1291-1326. 
 
Heymsfield SB, Greenberg AS, Fujioka K, Dixon RM, Kushner R, Hunt T, Lubina JA, 
Patane J, Self B, Hunt P and McCamish M (1999). Recombinant leptin for weight loss 
in obese and lean adults: a randomized, controlled, dose-escalation trial. JAMA; 
282:1568-1575. 
 
Heymsfield SB, van Mierlo CA, van der Knaap HC, Heo M and Frier HI (2003). Weight 
management using a meal replacement strategy: meta and pooling analysis from six 
studies. Int J Obes Relat Metab Disord; 27:537-549. 
 
Hickey M S, Pories W J, MacDonald K G Jr, Cory K A, Dohm G L, Swanson M S, Israel 
R G, Barakat H A, Considine R V, Caro J F and Houmard J A (1998). A new paradigm 
for type 2 diabetes mellitus: could it be a disease of the foregut? Annals Surg 227, pp. 
637–643. 
 
Hill JO and Peters JC (1998). Environmental contributions to the obesity epidemic. 
Science; 280:1371-1374. 
Himpens J, Dapri G and Cadière G B (2006). A prospective randomized study between 
laparoscopic gastric banding and laparoscopic isolated sleeve gastrectomy: results 
after 1 and 3 years, Obes. Surg. 16 (11), pp. 1450–1456.   
Himpens J, Dobbeleir J, Peeters G (2010). Long-term results of laparoscopic sleeve 
gastrectomy for obesity. Ann Surg.; 252(2):319-24. 
 
Hinney A, Hoch A, Geller F, Schafer H, Siegfried W, Goldschmidt H, Remschmidt H 
and Hebebrand J (2002). Ghrelin gene: identification of missense variants and a 
241 
 
frameshift mutation in extremely obese children and adolescents and healthy normal 
weight students. J Clin Endocrinol Metab; 87: 2716. 
 
Hoebel B G, Hernandez D H, Schwartz D H, Mark G P and Hunter G A (1989). 
Microdialysis studies of brain norepinephrine, serotonin, and dopamine release during 
ingestive behaviour: theoretical and clinical implications. The psychobiology of human 
eating disorders: preclinical and clinical perspectives Ann NY Acad Sci, New York 
Academy of Sciences, New York: 171–193. 
 
Hojberg PV, Zander M, Vilsboll T, Knop FK, Krarup T, Volund A, Holst JJ, Madsbad S 
(2008). Near normalisation of blood glucose improves the potentiating effect of GLP-1 
on glucose-induced insulin secretion in patients with type 2 diabetes. Diabetologia 
;51:632–40. 
 
Holdstock C, Engström B E,  Öhrvall M, Lind L, Sundbom M and Karlsson F A (2003). 
Ghrelin and adipose tissue regulatory peptides: effect of gastric bypass surgery in 
obese humans, J. Clin. Endocrinol. Metab. 88 (7) pp. 3177–3183. 
 
Holst JJ, Schwartz TW, Lovgreen NA, Pedersen O and Beck-Nielsen H (1983). Diurnal 
profile of pancreatic polypeptide, pancreatic glucagon, gut glucagon and insulin in 
human morbid obesity. Int J Obes; 7:529-538. 
 
Holst JJ, Orskov C, Nielsen OV and Schwartz TW (1987). Truncated glucagon-like 
peptide I, an insulin-releasing hormone from the distal gut. FEBS Lett; 211:169-174. 
 
Holst JJ and Deacon CF (2005). Glucagon-like peptide-1 mediates the therapeutic 
actions of DPP-IV inhibitors. Diabetologia; 48: 612-615. 
 
Holst JJ, Deacon CF, Vilsboll T, Krarup T and Madsbad S (2008). Glucagon-like 
peptide-1, glucose homeostasis and diabetes. Trends in molecular medicine; 14:161-
168. 
Hommel JD, Trinko R, Sears RM, Georgescu D, Liu ZW, Gao XB, Thurmon JJ, 
Marinelli M, DiLeone RJ. (2006). Leptin receptor signaling in midbrain dopamine 
neurons regulates feeding. Neuron.; 51: 801-10.  
Ho-Pham L T, Lai T Q, Nguyen N D, Barrett-Connor E and Nguyen T V (2010). 
Similarity in Percent Body Fat Between White and Vietnamese Women: Implication for 
a Universal Definition of Obesity. Obesity 18 (6): 1242-1246. 
242 
 
 
Hosoda H, Kojima M, Matsuo H and Kangawa K (2000). Ghrelin and des-acyl ghrelin: 
two major forms of rat ghrelin peptide in gastrointestinal tissue. Biochem Biophys Res 
Commun; 279: 909-913. 
House of Commons Health Committee. Obesity. Third report of session 2003-2004. 
Volume 1, 2004. 
Howard L, Malone M, Michalek A, Carter J, Alger S, Van Woert J (1995). Gastric 
bypass and vertical banded gastroplasty – a prospective randomized comparison and 
5-year follow-up, Obes. Surg. 5 (1), pp. 55–60. 
Information Centre. Statistics on obesity, physical activity and diet: England, 2006. 
Ino T, Nakai R, Azuma T, Kimura T, Fukuyama H (2010) Differential activation of the 
striatum for decision making and outcomes in a monetary task with gain and loss 
Cortex.; 46: 2-14.  
Isbell JM, Tamboli RA, Hansen EN, Saliba J, Dunn JP, Phillips SE, Marks-Shulman PA, 
Abumrad NN (2010). The importance of caloric restriction in the early improvements in 
insulin sensitivity after Roux-en-Y gastric bypass surgery. Diabetes Care; 33(7):1438-
42. 
Jacobsen SH, Olesen SC, Dirksen C, Jørgensen NB, Bojsen-Møller KN, Kielgast U, 
Worm D, Almdal T, Naver LS, Hvolris LE, Rehfeld JF, Wulff BS, Clausen TR, Hansen 
DL, Holst JJ, Madsbad S (2012). Changes in gastrointestinal hormone responses, 
insulin sensitivity, and beta-cell function within 2 weeks after gastric bypass in non-
diabetic subjects. Obes Surg 22(7):1084-96. 
 
Jebb SA, Elia M (1993). Techniques for the measurement of body composition: a 
practical guide. Int J Obes 17(11):611-21. 
 
Jenuwein T, Allis C D (2001). Translating the Histone Code Science 293 (5532): 1074-
1080. 
 
Jerlhag E, Egecioglu E, Dickson SL, et al (2007). Ghrelin administration into tegmental 
areas stimulates locomotor activity and increases extracellular concentration of 
dopamine in the nucleus accumbens. Addict Biol.; 12: 6–16.  
 
243 
 
Jørgensen NB, Jacobsen SH, Dirksen C, Bojsen-Møller KN, Naver L, Hvolris L, 
Clausen TR, Wulff BS, Worm D, Lindqvist Hansen D, Madsbad S, Holst JJ (2012). 
Acute and long-term effects of Roux-en-Y gastric bypass on glucose metabolism in 
subjects with Type 2 diabetes and normal glucose tolerance. Am J Physiol Endocrinol 
Metab; 303(1):E122-31. 
 
Kacelnik A and Bateson M (1996). Risky Theories—The Effects of Variance on 
Foraging Decisions; American Zoologist; 36: 402-434. 
 
Kahn S E, Hull R L and Utzschneider K M (2006). Mechanisms linking obesity to insulin 
resistance and type 2 diabetes; Nature 444, 840-846.  
Kahneman D and Tversky A, (1979). Prospect theory: an analysis of decision under 
risk, Econometrica; 47: 263–291.  
Kakei M, Yada T, Nakagawa A, Nakabayashi H. (2002). Glucagon-like peptide-1 
evokes action potentials and increases cytosolic Ca2+ in rat nodose ganglion neurons. 
Auton Neurosci.;102: 39–44.  
Kalarchian MA, Wilson GT, Brolin RE, Bradley L. (1999). Effects of bariatric surgery on 
binge eating and related psychopathology; Eat Weight Disord. ; 4: 1-5. 
Kalarchian MA, Marcus MD, Wilson GT, Labouvie EW, Brolin RE, LaMarca LB (2002). 
Binge eating among gastric bypass patients at long-term follow-up. Obes Surg.; 12: 
270-5.  
Karamanakos SN, Vagenas K, Kalfarentzos F et al (2008). Weight loss, appetite 
suppression, and changes in fasting and postprandial ghrelin and peptide-YY levels 
after Roux-en-Y gastric bypass and sleeve gastrectomy: a prospective, double blind 
study. Ann Surg.; 247: 401-7. 
 
Karlsson E (1999). IAPP as a regulator of glucose homeostasis and pancreatic 
hormone secretion. Int J Mol Med. 3(6): pp577-84. 
 
Karra E, Yousseif A, Batterham RL (2010). Mechanisms facilitating weight loss and 
resolution of type 2 diabetes following bariatric surgery. Trends Endocrinol Metab.; 
21(6):337-44. 
 
244 
 
Karra, E. and Batterham, R.L (2010). The role of gut hormones in the regulation of 
body weight and energy homeostasis. Mol. Cell. Endocrinol. 316(2):120-8. 
Kautzky-Willer A, Thomaseth K, Pacini G, Clodi M, Ludvik B, Streli C, Waldhäusl W 
and  Prager R (1994). Role of islet amyloid polypeptide secretion in insulin-resistant 
humans. Diabetologia. Volume 37, Number 2 188-194. 
Kehagias I, Karamanakos SN, Argentou M, Kalfarentzos F (2011). Randomized Clinical 
Trial of Laparoscopic Roux-en-Y Gastric Bypass Versus Laparoscopic Sleeve 
Gastrectomy for the Management of Patients with BMI  < 50 kg/m2 Obesity Surgery, 
Volume 21, Issue 11, pp 1650-1656.  
 
Kelley DE, Wing R, Buonocore C, Sturis J, Polonsky K, Fitzsimmons M (1993). Relative 
effects of calorie restriction and weight loss in non insulin-dependent diabetes mellitus, 
J. Clin. Endocrinol. Metab. 77 (5), pp. 1287–1293.   
Kelley AE & Berridge KC (2002). The neuroscience of natural rewards: relevance to 
addictive drugs. J. Neurosci.; 22: 3306–3311. 
A.E. Kelley, Schiltz and C.F. Landry (2005a). Neural systems recruited by drug- and 
food-related cues: Studies of gene activation in corticolimbic regions, Physiology & 
Behavior; 86: 11–14. 
Kelley AE, Baldo BA, Pratt WE & Will MJ (2005b). Corticostriatal-hypothalamic circuitry 
and food motivation: integration of energy, action and reward. Physiol. Behav.; 86: 
773–795.  
Kendrick ML, Dakin GF (2006). Surgical approaches to obesity. Mayo Clin Proc.;81(10 
suppl):S18-S24. 
 
Kennedy GC (1953). The role of depot fat in the hypothalamic control of food intake in 
the rat. Proc R Soc Lond B Biol Sci; 140:578-596. 
 
Kenler HA, Brolin RE and Cody RP (1990). Changes in eating behavior after horizontal 
gastroplasty and Roux-en-Y gastric bypass. The American journal of clinical nutrition; 
52: 87-92. 
 
Kenny PJ (2011). Reward mechanisms in obesity: new insights and future directions. 
Neuron. 24;69(4):664-79. 
245 
 
 
Kershaw E E, Flier J S (2004). Adipose Tissue as an Endocrine Organ J. Clin. 
Endocrinol. Metab. vol. 89 no. 6, 2548-2556. 
 
Kevin G. Murphy and Stephen R. Bloom (2006). Hormones and the regulation of 
energy homeostasis Nature 444, 854-859.  
 
Kim S, Richards WO (2010). Long-term follow-up of the metabolic profiles in obese 
patients with type 2 diabetes mellitus after Roux-en-Y gastric bypass Ann Surg. Volume 
251 - Issue 6 - pp 1049-1055. 
 
Kim BJ, Carlson OD, Jang HJ, Elahi D, Berry C and Egan JM (2005). Peptide YY is 
secreted after oral glucose administration in a gender-specific manner. J Clin 
Endocrinol Metab; 90: 6665-6671. 
 
Kindel TL, Yoder SM, Seeley RJ, D'Alessio DA, Tso P (2009). Duodenal-jejunal 
exclusion improves glucose tolerance in the diabetic, Goto-Kakizaki rat by a GLP-1 
receptor-mediated mechanism, J. Gastrointest. Surg. 13 (10), pp. 1762–1772. 
 
Kiyici S, Ersoy C, Oz Gul O, Sarandol E, Demirci M, Tuncel E, Sigirli D, Erturk E, 
Imamoglu S (2009). Total and acylated ghrelin levels in type 2 diabetic patients: similar 
levels observed after treatment with metformin, pioglitazone or diet therapy. Exp Clin 
Endocrinol Diabetes.; 117(8):386-90.  
 
Kjems LL, Holst JJ, Volund A and Madsbad S (2003). The influence of GLP-1 on 
glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and 
nondiabetic subjects. Diabetes; 52:380-386. 
 
Klok MD, Jakobsdottir S, and Drent ML (2007). The role of leptin and ghrelin in the 
regulation of food intake and body weight in humans: a review. Obes Rev.; 8: 21-34. 
 
Knop FK, Taylor R (2013). Mechanism of metabolic advantages after bariatric surgery: 
it's all gastrointestinal factors versus it's all food restriction.Diabetes Care;36 Suppl 
2:S287-91. 
 
246 
 
Kobelt P, Helmling S, Stengel A, Wlotzka B, Andresen V, Klapp BF, Wiedenmann B, 
Klussmann S and Monnikes H (2006) Anti-ghrelin Spiegelmer NOX-B11 inhibits 
neurostimulatory and orexigenic effects of peripheral ghrelin in rats. Gut; 55:788-792. 
Koda S, Date Y, Murakami N, Shimbara T, Hanada T, Toshinai K, Niijima A, Furuya M, 
Inomata N, Osuye K and Nakazato M (2005). The role of the vagal nerve in peripheral 
PYY3-36-induced feeding reduction in rats. Endocrinology; 146: 2369-2375. 
Koegler FH, Enriori PJ, Billes SK, Takahashi DL, Martin MS, Clark RL, Evans AE, 
Grove KL, Cameron JL and Cowley MA (2005). Peptide YY(3-36) inhibits morning, but 
not evening, food intake and decreases body weight in rhesus macaques. Diabetes; 
54:3198-3204. 
 
M. Kojima, H. Hosoda, Y. Date, M. Nakazato, H. Matsuo and K. Kangawa (1999). 
Ghrelin is a growth-hormone-releasing acylated peptide from stomach, Nature; 402: 
656–660. 
 
Kolaczynski JW, Ohannesian JP, Considine RV, Marco CC and Caro JF (1996). 
Response of leptin to short-term and prolonged overfeeding in humans. J Clin 
Endocrinol Metab; 81:4162-4165. 
Koopmans  H S, Ferri G L, Sarson D L, Polak J M, Bloom S R (1984). The effects of 
ileal transposition and jejunoileal bypass on food intake and GI hormone levels in rats, 
Physiol. Behav. 33 (4) pp. 601–609. 
Kopelman PG (2000). Obesity as a medical problem. Nature; 404:635-643 
 
Kopp HP, Kopp CW, Festa A, Krzyzanowska K, Kriwanek S, Minar E, Roka R, 
Schernthaner G (2003). Impact of weight loss on inflammatory proteins and their 
association with the insulin resistance syndrome in morbidly obese patients. 
Arterioscler Thromb Vasc Biol 23 (6):1042–1047. 
 
Korbonits M, Gueorguiev M, O'Grady E, Lecoeur C, Swan DC, Mein CA, Weill J, 
Grossman AB and Froguel P (2002). A variation in the ghrelin gene increases weight 
and decreases insulin secretion in tall, obese children. J Clin Endocrinol Metab; 87: 
4005-4008. 
 
Korner J, Bessler M, Cirilo LJ, Conwell IM, Daud A, Restuccia NL and Wardlaw SL 
(2005). Effects of Roux-en-Y gastric bypass surgery on fasting and postprandial 
247 
 
concentrations of plasma ghrelin, peptide YY, and insulin. J Clin Endocrinol Metab; 
90:359-365. 
 
Korner J, Inabnet W, Conwell IM, Taveras C, Daud A, Olivero-Rivera L, Restuccia NL 
and Bessler M (2006). Differential Effects of Gastric Bypass and Banding on Circulating 
Gut Hormone and Leptin Levels. Obesity; 14:1553-1561. 
Korner J, Bessler M, Inabnet W, Taveras C and Holst J J (2007). Exaggerated 
glucagon-like peptide-1 and blunted glucose-dependent insulinotropic peptide secretion 
are associated with Roux-en-Y gastric bypass but not adjustable gastric banding, Surg. 
Obes. Relat. Dis. 3 (6), pp. 597–601. 
Kremen AJ, Linner JH and Nelson CH (1954). An experimental evaluation of the 
nutritional importance of proximal and distal small intestine. Ann Surg; 140:439-448. 
 
Kreymann B, Williams G, Ghatei MA and Bloom SR (1987). Glucagon-like peptide-1 7-
36: a physiological incretin in man. Lancet; 2:1300-1304. 
Krugel U, Schraft T, Kittner H, Kiess W and Illes P (2003). Basal and feeding-evoked 
dopamine release in the rat nucleus accumbens is depressed by leptin, Eur. J. 
Pharmacol.; 482: 185–187. 
Kusaka I, Nagasaka S, Horie H, Ishibashi S (2008). Metformin, but not pioglitazone, 
decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible 
role in weight stability? Diabetes Obes Metab.; 10(11):1039-46. 
 
Laferrere B, Heshka S, Wang K, Khan Y, McGinty J, Teixeira J, Hart AB and Olivan B 
(2007). Incretin levels and effect are markedly enhanced 1 month after Roux-en-Y 
gastric bypass surgery in obese patients with type 2 diabetes. Diabetes Care; 30:1709-
1716. 
 
Laferrère B, Teixeira J, McGinty J, Tran H, Egger J R, Colarusso A, Kovack B, Bawa B, 
Koshy N, Lee H, Yapp K and Olivan B (2008). Effect of weight loss by gastric bypass 
surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 
diabetes, J. Clin. Endocrinol. Metab. 93 (7), pp. 2479–2485. 
 
Lambeir AM, Durinx C, Scharpe S and De Meester I (2003) Dipeptidyl-peptidase IV 
from bench to bedside: an update on structural properties, functions, and clinical 
248 
 
aspects of the enzyme DPP IV. Critical reviews in clinical laboratory sciences; 40:209-
294. 
 
Langer F B, Bohdjalian A, Shakeri-Leidenmühler S, Schoppmann S F, Zacherl J and 
Prager G (2010). Conversion from Sleeve Gastrectomy to Roux-en-Y Gastric Bypass—
Indications and Outcome. Obesity Surgery 20:835–840. 
 
Lawrence CB, Snape AC, Baudoin FM and Luckman SM (2002). Acute central ghrelin 
and GH secretagogues induce feeding and activate brain appetite centers. 
Endocrinology; 143:155-162. 
Lazar A (2005). How Obesity Causes Diabetes: Not a Tall Tale Science: 373-375. Vol. 
307 no. 5708 pp. 373-375.   
Ledford H (2010). Slim spoils for obesity drugs  Nature, Volume 468, Issue 7326, pp. 
878. 
Lee WJ, Ser KH, Chong K, Lee YC, Chen SC, Tsou JJ, Chen JC, Chen CM (2010). 
Laparoscopic sleeve gastrectomy for diabetes treatment in non-morbidly obese 
patients: efficacy and change of insulin secretion. Surgery; 147 (5): 664-9. 
Lee WJ, Chen CY, Chong K, Lee YC, Chen SC, Lee SD (2011). Changes in 
postprandial gut hormones after metabolic surgery: a comparison of gastric bypass and 
sleeve gastrectomy. Surg Obes Relat Dis.; 7(6):683-90. 
 
Lee D (2005). Neuroeconomics: making risky choices in the brain.. Nat Neurosci.; 8: 
1129-30. 
 
Leff R D, Heath D (2009). Surgery for obesity in adulthood BMJ 339: b3402. 
 
Lenard NR, Berthoud HR (2008). Central and peripheral regulation of food intake and 
physical activity: pathways and genes. Obesity (Silver Spring); 16 Suppl 3:S11-22.   
 
Leibel RL, Rosenbaum M and Hirsch J (1995). Changes in energy expenditure 
resulting from altered body weight. N Engl J Med; 332:621-628. 
 
Lenard NR and Berthoud HR (2008). Central and peripheral regulation of food intake 
and physical activity: pathways and genes. Obesity (Silver Spring); 16 Suppl 3: S11-22. 
 
249 
 
Leonetti F, Silecchia G, Iacobellis G, Ribaudo M C, Zappaterreno A, Tiberti C, Iannucci 
C V, Perrotta N, Bacci V, Basso M S, Basso N and Di Mario U (2003). Different plasma 
ghrelin levels after laparoscopic gastric bypass and adjustable gastric banding in 
morbid obese subjects, J. Clin. Endocrinol. Metab. 88 (9) pp. 4227–4231. 
 
le Roux CW, Patterson M, Vincent RP, Hunt C, Ghatei MA and Bloom SR (2005). 
Postprandial plasma ghrelin is suppressed proportional to meal calorie content in 
normal-weight but not obese subjects. J Clin Endocrinol Metab; 90:1068-1071. 
 
le Roux CW, Neary NM, Halsey TJ, Small CJ, Martinez-Isla AM, Ghatei MA, Theodorou 
NA, Bloom SR (2005). Ghrelin does not stimulate food intake in patients with surgical 
procedures involving vagotomy, J Clin Endocrinol Metab 90; (8): 4521–4524. 
 
le Roux CW, Batterham RL, Aylwin SJB, Patterson M, Borg CM, Wynne KJ, Kent A, 
Vincent RP, Gardiner J, Ghatei MA and Bloom SR (2006) Attenuated Peptide YY 
Release in Obese Subjects Is Associated with Reduced Satiety. Endocrinology; 147: 3-
8. 
 
le Roux CW, Aylwin SJ, Batterham RL, Borg CM, Coyle F, Prasad V, Shurey S, Ghatei 
MA, Patel AG, Bloom SR (2006). Gut hormone profiles following bariatric surgery favor 
an anorectic state, facilitate weight loss, and improve metabolic parameters. Ann Surg. 
;243(1):108-14. 
 
le Roux CW, Welbourn R, Werling M, Osborne A, Kokkinos A and Laurenius A et al 
(2007). Gut hormones as mediators of appetite and weight loss after Roux-en-Y gastric 
bypass, Ann Surg; 246: 780–785. 
 
Levy JC, Matthews DR, Hermans MP (1998). Correct Homeostasis Model Assessment 
(HOMA) Evaluation uses the computer program. Diabetes Care; 21: 2191-2192. 
 
Li F, Zhang G, Liang J, Ding X, Cheng Z and Hu S (2009). Sleeve gastrectomy 
provides a better control of diabetes by decreasing ghrelin in the diabetic Goto-Kakizaki 
rats. J Gastrointest Surg. Volume 13, Number 12 2302-2308.  
 
Licinio J, Caglayan S, Ozata M, Yildiz BO, de Miranda PB, O'Kirwan F, Whitby R, Liang 
L, Cohen P, Bhasin S, Krauss RM, Veldhuis JD, Wagner AJ, DePaoli AM, McCann SM 
and Wong ML (2004) Phenotypic effects of leptin replacement on morbid obesity, 
250 
 
diabetes mellitus, hypogonadism, and behavior in leptin-deficient adults. Proc Natl 
Acad Sci USA; 101: 4531-4536. 
 
Lopez PP, Nicholson SE, Burkhardt GE et al (2009). Development of a sleeve 
gastrectomy weight loss model in obese Zucker rats. J Surg Res.;157: 243-50.  
Lorenzo A, Deurenberg P, Pietrantuono M, Daniele N, Cervelli V and A. Andreoli 
(2003). How fat is obese? Acta Diabetologica, Volume 40, Supplement 1, pp s254-
s257. 
Lowe MR and Levine AS (2005). Eating motives and the controversy over dieting: 
eating less than needed versus less than wanted, Obesity Research; 13(2005): 797–
806. 
 
Lutter M, Nestler EJ (2009). Homeostatic and hedonic signals interact in the regulation 
of food intake.. J Nutr; 139: 629-32.  
 
Lukaski HC (1987). Methods for the assessment of body composition: traditional and 
new. Am J Clin Nutr.; volume 46 (4):437–456. 
 
Lutter M, Nestler EJ (2009). Homeostatic and hedonic signals interact in the regulation 
of food intake. J Nutr; 139(3):629-32.  
 
MacLean LD, Rhode BM, Nohr CW (2001). Long- or short-limb gastric bypass? J. 
Gastrointest. Surg. 5 (5), 525–530. 
 
Maffei M, Halaas J, Ravussin E, Pratley RE, Lee GH, Zhang Y, Fei H, Kim S, Lallone 
R, Ranganathan S and et al (1995). Leptin levels in human and rodent: measurement 
of plasma leptin and ob RNA in obese and weight-reduced subjects. Nat Med; 1:1155-
1161. 
Magro DO , Geloneze B, Delfini R, Pareja B C, Callejas F and Pareja J C (2008). Long-
term weight regain after gastric bypass: a 5-year prospective study. Obes Surg; 18: 
648–51. 
Malik S, McGlone F, Bedrossian D and Dagher A (2008). Ghrelin modulates brain 
activity in areas that control appetitive behavior, Cell Metab.; 7: 400–409. 
 
251 
 
Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, Ciani S, 
Messeri G, Rotella CM (2001). Effect of metformin on glucagon-like peptide 1 (GLP-1) 
and leptin levels in obese nondiabetic subjects. Diabetes Care 24:489–494.   
 
Mannucci E, Tesi F, Bardini G, Ognibene A, Petracca MG, Ciani S, Pezzatini A, Brogi 
M, Dicembrini I, Cremasco F, Messeri G, Rotella CM (2004). Effects of metformin on 
glucagon-like peptide-1 levels in obese patients with and without type 2 diabetes. 
Diabetes Nutr Metab 17:336–342. 
 
Mark AL (2008). Dietary therapy for obesity: an emperor with no clothes. Hypertension 
51: 1426-1434.  
 
Martin NM, Small CJ, Sajedi A, Patterson M, Ghatei MA and Bloom SR (2004) Pre-
obese and obese agouti mice are sensitive to the anorectic effects of peptide YY(3-36) 
but resistant to ghrelin. Int J Obes Relat Metab Disord; 28: 886-893. 
 
Martins C, Robertson MD, Morgan LM Proc Nutr Soc. (2008). Effects of exercise and 
restrained eating behaviour on appetite control; 67: 28-41. 
 
Martinsen OG and Grimnes S – (2011) Bioimpedance and bioelectricity basics (book) 
 
Mason E E and Ito C. Ito (1967), Gastric bypass in obesity, Surg. Clin. North Am. 47 
(6), pp. 1345–1351.  
 
Mason E E (2005). The mechanisms of surgical treatment of type 2 diabetes, Obes. 
Surg.; 15 pp. 459–461. 
 
Masuda Y, Tanaka T, Inomata N, Ohnuma N, Tanaka S, Itoh Z, Hosoda H, Kojima M 
and Kangawa K (2000). Ghrelin stimulates gastric acid secretion and motility in rats. 
Biochem Biophys Res Commun.; 276: 905-908. 
Matthews SC, Simmons AN, Lane SD and Paulus MP (2004). Selective activation of 
the nucleus accumbens during risk-taking decision-making, NeuroReport; 15: 2123–
2127. 
Mayer J (1955). Regulation of energy intake and the body weight: the glucostatic theory 
and the lipostatic hypothesis. Ann N Y Acad Sci.; 63: 15-43. 
 
252 
 
Mayer J and Thomas DW (1967). Regulation of food intake and obesity. Science; 
156:328-337. 
 
McAlister FA, Man J, Bistritz L, Amad H, Tandon P (2003). Diabetes and coronary 
artery bypass surgery: an examination of perioperative glycemic control and outcomes, 
Diabetes Care 26 (5), pp. 1518–1524.  
 
McLaughlin T, Abbasi F, Lamendola C, Frayo RS and Cummings DE (2004). Plasma 
ghrelin concentrations are decreased in insulin-resistant obese adults relative to 
equally obese insulin sensitive controls. J Clin Endocrinol Metab; 89:1630-1635. 
 
McMinn JE, Baskin DG and Schwartz MW (2000). Neuroendocrine mechanisms 
regulating food intake and body weight. Obes Rev; 1: 37-46. 
 
Mcnamara JM, Houston AI (1992). Risk-sensitive foraging: a review of the theory. 
Bulletin of mathematical biology; 54: 355-378. 
 
MDRNA (2008). MDRNA Announces Phase 2 Trial of PYY(3-36) Does not Meet 
Weight Loss Endpoint, in MDRNA : Press Release July 31st, 2008. 
 
Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi 
M, Small CJ, Goldstone AP, Taylor GM, Sunter D, Steere J, Choi SJ, Ghatei MA and 
Bloom SR (1999) Repeated intracerebroventricular administration of glucagon-like 
peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology; 
140:244-250. 
Mela DJ (2006), Eating for pleasure or just wanting to eat? Reconsidering sensory 
hedonic responses as a driver of obesity, Appetite; 47: 10–17. 
Meier JJ, Gallwitz B, Salmen S, et al (2003) Normalization of glucose concentrations 
and deceleration of gastric emptying after solid meals during intravenous glucagon-like 
peptide 1 in patients with type 2 diabetes. J Clin Endocrinol Metab.; 88: 2719–25. 
 
Mentlein R, Dahms P, Grandt D and Kruger R (1993) Proteolytic processing of 
neuropeptide Y and peptide YY by dipeptidyl peptidase IV. Regul Pept; 49:133-144. 
 
Mentlein R, Gallwitz B and Schmidt WE (1993). Dipeptidyl-peptidase IV hydrolyses 
gastric inhibitory polypeptide, glucagon-like peptide-1(7-36) amide, peptide histidine 
253 
 
methionine and is responsible for their degradation in human serum, Eur J Biochem; 
214: 829–835. 
 
Mercer JG and Speakman JR (2001) Hypothalamic neuropeptide mechanisms for 
regulating energy balance: from rodent models to human obesity. Neurosci Biobehav 
Rev.; 25: 101-116. 
 
Miras AD
1
, le Roux CW (2014). Can medical therapy mimic the clinical efficacy or 
physiological effects of bariatric surgery? Int J Obes (Lond). 2014 Mar;38(3):325-33.  
 
Misra M, Miller KK, Tsai P, Gallagher K, Lin A, Lee N, Herzog DB and Klibanski A 
(2006). Elevated peptide YY levels in adolescent girls with anorexia nervosa. J Clin 
Endocrinol Metab; 91:1027-1033. 
 
Moesgaard SG, Ahren B, Carr RD, Gram DX, Brand CL and Sundler F (2004). Effects 
of high-fat feeding and fasting on ghrelin expression in the mouse stomach. Regulatory 
peptides; 120: 261-267. 
 
Mojsov S, Heinrich G, Wilson IB, Ravazzola M, Orci L and Habener JF (1986). 
Preproglucagon gene expression in pancreas and intestine diversifies at the level of 
post-translational processing. J Biol Chem; 261: 11880-11889. 
 
Mokdad A H, Ford E S, Bowman B A, Dietz WH, Vinicor F, Bales V S and Marks J S 
(2003). Prevalence of Obesity, Diabetes, and Obesity-Related Health Risk Factors, 
2001. JAMA. 289(1):76-79. 
 
Mokdad AH, Marks JS, Stroup DF, Gerberding JL (2004). Actual causes of death in the 
United States, 2000. JAMA 2004; 291 (10): 1238–45. Erratum JAMA 2005; 293: 293–
94. 
 
Moore CX and Cooper GJ (1991). Co-secretion of amylin and insulin from cultured islet 
beta-cells: modulation by nutrient secretagogues, islet hormones and hypoglycemic 
agents, Biochem Biophys Res Commun.; 179: 1–9. 
 
Morales MP, Wheeler AA, Ramaswamy A, Scott JS, de la Torre RA (2010). 
Laparoscopic revisional surgery after Roux-en-Y gastric bypass and sleeve 
gastrectomy. Surgical Obesity Related Disease; 6(5):485-90.  
254 
 
Morínigo R, Moizé V, Musri M, Lacy A M, Navarro S, Marín J L, Delgado S, 
Casamitjana R and Josep Vidal J (2006). Glucagon-like peptide-1, peptide YY, hunger 
and satiety after gastric bypass surgery in morbidly obese subjects. J. Clin. Endocrinol. 
Metab. 91 (5) pp. 1735–1740.  
Morley JE and Flood JF (1991). Amylin decreases food intake in mice, Peptides; 12: 
865–869. 
 
Morley JE and Flood JF (1994). Effect of competitive antagonism of NO synthetase on 
weight and food intake in obese and diabetic mice, Am J Physiol; 266: R164–168. 
 
Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW (2006). Central 
nervous system control of food intake and body weight. Nature; 21;443(7109):289-95.  
Morton GJ, Cummings DE, Baskin DG, Barsh GS, Schwartz MW (2006). Central 
nervous system control of food intake and body weight. Nature; 443(7109):289-95.  
Mousumi Bose, Sriram Machineni, Blanca Oliván et al (2010). Superior Appetite 
Hormone Profile After Equivalent Weight Loss by Gastric Bypass Compared to Gastric 
Banding. Obesity (Silver Spring).: 18(6):1085-91. 
Mulder H, Ahren B, Sundler F (1996). Islet amyloid polypeptide and insulin gene 
expression are regulated in parallel by glucose in vivo in rats. Am J Physiol Endo 
Metab. vol. 271 no. 6 pp, E1008-E1014.     
Mulherin AJ, Oh AH, Kim H, Grieco A, Lauffer LM, Brubaker PL (2011). Mechanisms 
Underlying Metformin-Induced Secretion of Glucagon-Like Peptide-1 from the Intestinal 
L Cell. Endocrinology vol. 152 no. 12 pp 4610-4619.  
 
Murphy KG, Bloom SR (2006). Gut hormones and the regulation of energy 
homeostasis. Nature 444, 854-859. 
 
Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, Kigoshi T, 
Nakayama K, Uchida K (2004). Receptor gene expression of glucagon-like peptide-1, 
but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. 
Auton Neurosci.;110: 36–43. 
 
Nakahara T, Kojima S, Tanaka M, Yasuhara D, Harada T, Sagiyama K-i, Muranaga T, 
Nagai N, Nakazato M, Nozoe S-i, Naruo T and Inui A (2007). Incomplete restoration of 
255 
 
the secretion of ghrelin and PYY compared to insulin after food ingestion following 
weight gain in anorexia nervosa. Journal of Psychiatric Research; 41:814-820. 
 
Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K and Matsukura S 
(2001). A role for ghrelin in the central regulation of feeding. Nature; 409:194-198. 
 
Näslund E, Grybäck P, Hellström P M, Jacobsson H, Holst J J, Theodorsson E and L 
Backman (1997). Gastrointestinal hormones and gastric emptying 20 years after 
jejunoileal bypass for massive obesity, Int. J. Obes. Relat. Metab. Disord. 21 (5); pp. 
387–392. 
 
Naslund E, Bogefors J, Skogar S, Gryback P, Jacobsson H and Holst JJ et al (1999). 
GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in 
humans, Am J Physiol; 277: R910–916. 
 
Naslund E, King N, Mansten S, Adner N, Holst JJ and Gutniak M et al (2004). Prandial 
subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human 
subjects, Br J Nutr.; 91: 439–446. 
 
National Audit Office. Tackling obesity in England: a report by the Controller and 
Auditor General. London: National Audit Office, (2001). 
 
National Institute for Health and Clinical Excellence (2006). Obesity: the prevention, 
identification, assessment and management of overweight and obesity in adults and 
children. Clinical guideline 43. 
 
Nauck M, Stockmann F, Ebert R and Creutzfeldt W (1986). Reduced incretin effect in 
type 2 (noninsulin-dependent) diabetes. Diabetologia; 29: 46-52. 
Nauck MA, Kleine N, Orskov C, Holst JJ, Willms B, Creutzfeldt W (1993) Normalization 
of fasting hyperglycaemia by exogenous glucagon-like peptide 1 (7-36 amide) in type 2 
(non-insulin-dependent) diabetic patients. Diabetologia; 36: 741-4. 
 
Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R and Schmiegel WH 
(1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its 
insulinotropic effects in healthy humans. Am J Physiol.; 273: E981-988. 
 
256 
 
Neary NM, Small CJ, Druce MR, Park AJ, Ellis SM, Semjonous NM, Dakin CL, 
Filipsson K, Wang F, Kent AS, Frost GS, Ghatei MA and Bloom SR (2005). Peptide 
YY3-36 and Glucagon-Like Peptide-17-36 Inhibit Food Intake Additively, 
Endocrinology; 146: 5120–5127. 
Neary MT, Batterham RL (2009). Gut hormones: implications for the treatment of 
obesity. Pharmacol Ther.; 124: 44-56.   
Nederkoorn C, Braet C, Van Eijs Y, Tanghe A, Jansen A. (2006). Why obese children 
cannot resist food: the role of impulsivity. Eat Behav.; 7: 315-22.  
Neel J V (1962). Diabetes Mellitus: A “Thrifty” Genotype Rendered Detrimental by 
“Progress”? Am J Hum Genet; 14(4): 353–362. 
Nyholm B, Orskov L, Hove KY, Gravholt C H, Møller N, George  K, Alberti M M, 
Moyses C, Kolterman O, Schmitz O (1999). The amylin analog pramlintide improves 
glycemic control and reduces postprandial glucagon concentrations in patients with 
type 1 diabetes mellitus. Metabolism. Volume 48, Issue 7, pp 935–941. 
Obici S, Feng Z, Morgan K, Stein D, Karkanias G and Rossetti L (2002). Central 
Administration of Oleic Acid Inhibits Glucose Production and Food Intake. Diabetes vol. 
51(2) 271-275. 
Obici S, Feng Z, Arduini A, Conti R & Rossetti L (2003). Inhibition of hypothalamic 
carnitine palmitoyltransferase-1 decreases food intake and glucose production Nature 
Medicine 9,756–761.   
 
O’Brien PE, McPhail T, Chaston TB, Dixon JB (2006). Systematic review of medium-
term weight loss after bariatric operations. Obes Surg.;16 (8):1032-40. 
 
O'Brien PE, Dixon JB, Laurie C, Skinner S, Proietto J, McNeil J, Strauss B, Marks S, 
Schachter L, Chapman L, Anderson M (2006). Treatment of mild to moderate obesity 
with laparoscopic adjustable gastric banding or an intensive medical program: a 
randomized trial. Ann Intern Med 144 (9):625–633. 
Ockander L, Hedenbro J L, Rehfeld J F and Sjölund K. Jejunoileal (2003). Bypass 
changes the duodenal cholecystokinin and somatostatin cell density, Obes. Surg. 13 
(4) pp. 584–590. 
257 
 
Ogden CL, Carroll MD, Curtin LR, McDowell MA, Tabak CJ, Flegal KM (2006). 
Prevalence of overweight and obesity in the United States, 1999-2004. JAMA.; 295: 
1549-55. 
Oliván B, Teixeira J, Bose M, Bawa B, Chang T, Summe H, Lee H, Laferrère B. (2009). 
Effect of weight loss by diet or gastric bypass surgery on peptide YY3-36 levels. Ann 
Surg. ; 249(6): 948-53. 
Organ CH Jr, Kessler E, Lane M. (1984). Long-term results of jejunoileal bypass in the 
young. Am. Surg. 50 (11); 589–593. 
 
O'Rahilly S (2009). Human genetics illuminates the paths to metabolic disease. Nature 
462, 307-314.  
 
Orskov C, Holst JJ and Nielsen OV (1988). Effect of truncated glucagon-like peptide-1 
[proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and 
nonantral stomach. Endocrinology; 123:2009-2013. 
 
Orskov C, Rabenhoj L, Wettergren A, Kofod H and Holst JJ (1994). Tissue and plasma 
concentrations of amidated and glycine-extended glucagon-like peptide I in humans. 
Diabetes; 43: 535-539. 
 
Orskov C, Wettergren A and Holst JJ (1996). Secretion of the incretin hormones 
glucagon-like peptide-1 and gastric inhibitory polypeptide correlates with insulin 
secretion in normal man throughout the day, Scand J Gastroenterol.; 31: 665–670. 
 
Ortiz AA, Milardo LF, DeCarr LB, Buckholz TM, Mays MR, Claus TH, Livingston JN, 
Mahle CD and Lumb KJ (2007). A novel long-acting selective neuropeptide Y2 receptor 
polyethylene glycol-conjugated peptide agonist reduces food intake and body weight 
and improves glucose metabolism in rodents. J Pharmacol Exp Ther; 323: 692-700. 
 
Otto B, Cuntz U, Fruehauf E, Wawarta R, Folwaczny C, Riepl RL, Heiman ML, Lehnert 
P, Fichter M and Tschop M (2001). Weight gain decreases elevated plasma ghrelin 
concentrations of patients with anorexia nervosa. Eur J Endocrinol; 145: 669-673. 
 
Otto B, Cuntz U, Otto C, Heldwein W, Riepl RL and Tschop MH (2007). Peptide YY 
release in anorectic patients after liquid meal. Appetite; 48: 301-304. 
 
258 
 
Ozcan L, Ergin AS, Lu A, Chung J, Sarkar S, Nie D, Myers MG, Jr. and Ozcan U 
(2009). Endoplasmic reticulum stress plays a central role in development of leptin 
resistance. Cell Metab; 9: 35-51. 
 
Palmiter RD (2007). Is dopamine a physiologically relevant mediator of feeding 
behavior?. Trends Neurosci.; 30: 375-81.  
 
Papailiou J, Albanopoulos K, Toutouzas KG, Tsigris C, Nikiteas N, Zografos G (2010). 
Morbid Obesity and Sleeve Gastrectomy: How Does It Work? Obes Surg.; 
20(10):1448-55. 
 
Patriti A, Facchiano E, Annetti C, Aisa MC, Galli F, Fanelli C, Donini A (2005). Early 
improvement of glucose tolerance after ileal transposition in a non-obese type 2 
diabetes rat model, Obes. Surg. 15 (9), pp. 1258–1264. 
 
Permert J, Larsson J, Westermark GT, Herrington M K, Christmanson L, Pour P M, 
Westermark P and Adrian T E (1994). Islet amyloid polypeptide in patients with 
pancreatic cancer and diabetes. N Engl J Med.; 330 (5):313–318. 
 
Pessin JE and Saltiel AR (2000). Signaling pathways in insulin action: molecular 
targets of insulin resistance. J Clin Invest 106:165-169. 
 
Peterli R, Wölnerhanssen B, Peters T, Devaux N, Kern B, Christoffel-Courtin C, Drewe 
J, von Flüe M, Beglinger C (2009). Improvement in glucose metabolism after bariatric 
surgery: comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic 
sleeve gastrectomy: a prospective randomized trial. Ann Surg.; 250 (2); 234-41. 
 
Peterli R, Steinert RE, Woelnerhanssen B, Peters T, Christoffel-Courtin C, Gass M, 
Kern B, von Fluee M, Beglinger C (2012). Metabolic and hormonal changes after 
laparoscopic Roux-en-Y gastric bypass and sleeve gastrectomy: a randomized, 
prospective trial. Obes Surg. Vol-22(5); 740-748. 
 
Pfluger PT, Kampe J, Castaneda TR, Vahl T, D'Alessio DA, Kruthaupt T, Benoit SC, 
Cuntz U, Rochlitz HJ, Moehlig M, Pfeiffer AF, Koebnick C, Weickert MO, Otto B, 
Spranger J and Tschop MH (2007). Effect of human body weight changes on 
circulating levels of peptide YY and peptide YY3-36. J Clin Endocrinol Metab; 92: 583-
588. 
259 
 
Pickering AD and Gray JA (2001). Dopamine, appetitive reinforcement, and the 
neuropsychology of human learning: An individual differences approach. In: A. Eliasz 
and A. Angleitner, Editors, Advances in individual differences research, PABST 
Science Publishers, Lengerich Germany (2001): 113–149. 
Pickering AD, Gray JA (1999). The neuroscience of personality. In: Handbook of 
personality: theory and research (Pervin LA, John OP, eds.) Ed 2:  277–299. New York: 
Guilford. 
Pi-Sunyer FX (1993) Medical Hazards of Obesity. Ann Intern Med; 119:655-660. 
 
Pi-Sunyer F X (2003). A clinical view of the obesity problem. Science; 299: 859–860. 
 
Pittner RA, Moore CX, Bhavsar SP, Gedulin BR, Smith PA, Jodka CM, Parkes DG, 
Paterniti JR, Srivastava VP and Young AA (2004). Effects of PYY[3-36] in rodent 
models of diabetes and obesity. Int J Obes Relat Metab Disord.; 28: 963-971. 
 
Platt ML, Huettel SA. (2008). Risky business: the neuroeconomics of decision making 
under uncertainty. Nat Neurosci.; 11: 398-403.  
 
Pories WJ, Swanson MS, MacDonald KG, Long SB, Morris PG, Brown BM, Barakat 
HA, deRamon RA, Israel G, Dolezal JM and et al (1995). Who would have thought it? 
An operation proves to be the most effective therapy for adult-onset diabetes mellitus. 
Ann Surg.; 222:339-350; discussion 350-352. 
Poirier P (2007). Adiposity and cardiovascular disease: are we using the right definition 
of obesity? Eur Heart J 28 (17): 2047-2048.  
Porte D Jr. (2001). Clinical importance of insulin secretion and its interaction with 
insulin resistance in the treatment of type 2 diabetes mellitus and its complications. 
Diabetes/Metabolism Research and Reviews Volume 17, Issue 3, pages 181–188. 
Pournaras D J, Osborne A, Hawkins S C, Mahon D, Ghatei M A, Bloom S R,  Welbourn 
R and le Roux C W (2010). The Gut Hormone Response Following Roux-en-Y Gastric 
Bypass: Cross-sectional and Prospective Study. Obesity Surgery, Volume 20, Number 
1, Pages 56-60. 
Pournaras DJ, Aasheim ET, Bueter M, Ahmed AR, Welbourn R, Olbers T, le Roux CW 
(2012). Effect of bypassing proximal gut on gut hormones involved with glycemic 
260 
 
control and weight loss. Surg Obes Relat Dis. Surg Obes Relat Dis. 2012 Mar 3. [Epub 
ahead of print]. 
Poykko SM, Kellokoski E, Horkko S, Kauma H, Kesaniemi YA and Ukkola O (2003). 
Low plasma ghrelin is associated with insulin resistance, hypertension, and the 
prevalence of type 2 diabetes. Diabetes; 52: 2546-2553. 
Prittwitz S, Blum WF and Ziegler A (1997). Restrained eating is associated with low 
leptin levels in underweight females. Mol Psychiatry; 2: 420–422. 
Prospective Studies Collaboration, Whitlock G, Lewington S, Sherliker P, Clarke R, 
Emberson J, Halsey J, Qizilbash N, Collins R and Peto R (2009). Body-mass index and 
cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective 
studies. Lancet; 373 (9669):1083-96. 
 
Purnell JQ, Weigle DS, Breen P and Cummings DE (2003). Ghrelin levels correlate 
with insulin levels, insulin resistance, and high-density lipoprotein cholesterol, but not 
with gender, menopausal status, or cortisol levels in humans. J Clin Endocrinol Metab; 
88: 5747-5752. 
 
Quesada I, Tuduri E, Ripoll C and Nadal A (2008). Physiology of the pancreatic alpha-
cell and glucagon secretion: role in glucose homeostasis and diabetes. J Endocrinol.; 
199:5-19. 
 
Raben A, Tagliabue A and Astrup A (1995). The reproducibility of subjective appetite 
scores. The British journal of nutrition; 73: 517-530. 
 
Rahardjo GL, Huang XF, Tan YY and Deng C (2007) Decreased plasma peptide YY 
accompanied by elevated peptide YY and Y2 receptor binding densities in the medulla 
oblongata of dietinduced obese mice. Endocrinology; 148: 4704-4710. 
 
Ramon JM, Salvans S, Crous X, Puig S, Goday A, Benaiges D, Trillo L, Pera M, 
Grande L (2012). Effect of Roux-en-Y gastric bypass vs sleeve gastrectomy on glucose 
and gut hormones: a prospective randomsied trial. J Gastrointest Surg, Vol-16 (6), 
1116-1122. 
 
Ranganath LR, Beety JM, Morgan LM, Wright JW, Howland R and Marks V (1996). 
Attenuated GLP-1 secretion in obesity: cause or consequence? Gut; 38: 916-919. 
261 
 
Ravussin E,Smith S R, Mitchell J A, Shringarpure R, Kevin Shan, Holly Maier, Koda J E 
and Weyer C (2009). Enhanced Weight Loss With Pramlintide/Metreleptin: An 
Integrated Neurohormonal Approach to Obesity Pharmacotherapy. Obesity 17 (9), 
1736–1743.  
 
Reda TK, Geliebter A, Pi-Sunyer FX (2002). Amylin, food intake, and obesity. Obes 
Res.;10: 1087-91. 
 
Reed MA, Pories WJ, Chapman W, Pender J, Bowden R, Barakat H, Gavin TP, Green 
T, Tapscott E, Zheng D, Shankley N, Yieh L, Polidori D, Piccoli SP, Brenner-Gati L, 
Dohm GL (2011). Roux-en-Y gastric bypass corrects hyperinsulinemia implications for 
the remission of type 2 diabetes. J Clin Endocrinol Metab.; 96(8):2525-31. 
 
Rexrode KM, Carey VJ, Hennekens CH, Walters EE, Colditz GA, Stampfer MJ, Willett 
WC, Manson JE (1998). Abdominal adiposity and coronary heart disease in women. 
JAMA;280 (21):1843-1848. 
 
Rickels M R, Collins H W, Naji N (2008). Amyloid and transplanted islets. N. Engl. J. 
Med. 359 (25):2729–2730; author reply 2729–2731. 
 
Rizzello M, Abbatini F, Casella G, Alessandri G, Fantini A, Leonetti F, Basso N (2010). 
Early postoperative insulin-resistance changes after sleeve gastrectomy. Obes Surg 
20(1):50–55. 
 
Ratner RE, Maggs D, Nielsen LL, Stonehouse AH, Poon T, Zhang B, Bicsak TA, 
Brodows RG (2006). Long-term effects of exenatide therapy over 82 weeks on 
glycaemic control and weight in over-weight metformin-treated patients with type 2 
diabetes mellitus, Diabetes Obes Metab; 8: 419–428. 
 
Reimer MK, Pacini G and Ahren B (2003). Dose-dependent inhibition by ghrelin of 
insulin secretion in the mouse. Endocrinology; 144:916-921. 
 
Riediger T, Schmid HA, Lutz T and Simon E (2001). Amylin potently activates AP 
neurons possibly via formation of the excitatory second messenger cGMP, Am J 
Physiol Regul Integr Comp Physiol.; 281: R1833–1843. 
 
262 
 
Roberge JN and Brubaker PL (1991). Secretion of proglucagon-derived peptides in 
response to intestinal luminal nutrients. Endocrinology; 128:3169-3174. 
 
Robinson TE and Berridge KC (2003). Addiction. Annual Review of Psychology; 54: 
10.1–10.29.  
 
Robinson TE and Berridge KC (2000). Animal models in craving research. The 
psychology and neurobiology of addiction: an incentive-sensitization view. Addiction; 95 
Suppl. 2: S91–S117. 
 
Rocca AS, Brubaker PL (1999). Role of the vagus nerve in mediating proximal nutrient-
induced glucagon-like peptide-1 secretion. Endocrinology; 140(4):1687-94. 
 
 
Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M 
(2008). First human experience with endoscopically delivered and retrieved duodenal-
jejunal bypass sleeve, Surg. Obes. Relat. Dis. 4 (1), pp. 55–59. 
Rogers PJ, Smit HJ (2000). Food craving and food "addiction": a critical review of the 
evidence from a biopsychosocial perspective. Pharmacol Biochem Behav.; 66: 3-14.  
Romero-Corral A, Somers VK, Sierra-Johnson J, Thomas R J, Collazo-Clavell M L, 
Korinek J, Allison T G, Batsis J A, Sert-Kuniyoshi F H and Lopez-Jimenez F (2008). 
Accuracy of body mass index in diagnosing obesity in the adult general population. Int 
J Obes (Lond) 32, 959–966. 
Romero F, Nicolau J, Flores L, Casamitjana R, Ibarzabal A, Lacy A, Vidal J (2012). 
Comparable early changes in gastrointestinal hormones after sleeve gastrectomy and 
Roux-En-Y gastric bypass surgery for morbidly obese type 2 diabetic subjects. Surg 
Endosc. Surg Endosc. 2012 Feb 1. [Epub ahead of print]. 
Rosenbaum M, Leibel RL, Hirsch J (1997). Obesity. N Engl J Med.;337 (6):396-407 
(1997) Erratum in: N Engl J Med; 338 (3): 555 (1998).  
Rosen ED and Spiegelman BM (2006). Adipocytes as regulators of energy balance and 
glucose homeostasis. Nature; 444: 847-853. 
 
263 
 
Rosenbaum M, Ravussin E, Matthews DE, Gilker C, Ferraro R, Heymsfield SB, Hirsch 
J and Leibel RL (1996). A comparative study of different means of assessing long-term 
energy expenditure in humans. Am J Physiol.; 270: R496-504. 
 
Rosenbaum M, Sy M, Pavlovich K, Leibel RL and Hirsch J (2008). Leptin reverses 
weight loss induced changes in regional neural activity responses to visual food stimuli. 
J Clin Invest.; 118:2583-2591. 
Rosenthal R, Li X, Samuel S, Martinez P, Zheng C. (2009). Effect of sleeve 
gastrectomy on patients with diabetes mellitus. Surg Obes Relat Dis.; 5: 429-34. 
Roth CL, Enriori PJ, Harz K, Woelfle J, Cowley MA and Reinehr T (2005). Peptide YY 
Is a Regulator of Energy Homeostasis in Obese Children before and after Weight Loss. 
J Clin Endocrinol Metab.; 90: 6386-6391. 
 
Roth JD, Roland BL, Cole RL, Trevaskis JL, Weyer C, Koda JE, Anderson CM, Parkes 
DG and Baron AD (2008). Leptin responsiveness restored by amylin agonism in diet-
induced obesity: evidence from nonclinical and clinical studies. Proc Natl Acad Sci 
USA; 105: 7257-7262. 
Rothemund YC, Preuschhof C, Bohner G, Bauknecht HC and Klingebiel R et al (2007). 
Differential activation of the dorsal striatum by high-calorie visual food stimuli in obese 
individuals, NeuroImage; 37: 410–421. 
Rubino F and Marescaux J (2004). Effect of duodenal–jejunal exclusion in a non-obese 
animal model of type 2 diabetes: a new perspective for an old disease, Ann. Surg. 239 
pp. 1–11 . 
 
Rubino F, Zizzari P, Tomasetto C, Bluet-Pajot M, Forgione A, Vix M, Grouselle D and 
Marescaux J (2005). The role of the small bowel in the regulation of circulating ghrelin 
levels and food intake in the obese Zucker rat, Endocrinology 146, pp. 1745–1751. 
 
Rubino F, Forgione A, Cummings DE, Vix M, Gnuli D, Mingrone G, Castagneto M, 
Marescaux J (2006). The mechanism of diabetes control after gastrointestinal bypass 
surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 
diabetes, Ann. Surg. 244 (5) pp. 741–749. 
 
Ruderman AJ, Dietary restraint: A theoretical and empirical review. (1986). Psychol. 
Bull.; 99: 247–262. 
264 
 
 
Rushing PA, Hagan MM, Seeley RJ, Lutz TA and Woods SC (2000). Amylin: a novel 
action in the brain to reduce body weight, Endocrinology 141: 850–853. 
 
Rydén A, Sullivan M, Torgerson JS, Karlsson J, Lindroos AK, Taft C (2003). Severe 
obesity and personality: a comparative controlled study of personality traits. Int J Obes 
Relat Metab Disord.;  27: 1534-40 (2003). 
 
Saeidi N, Meoli L, Nestoridi E, Gupta NK, Kvas S, Kucharczyk J, Bonab AA, Fischman 
AJ, Yarmush ML, Stylopoulos N (2013). Reprogramming of intestinal glucose 
metabolism and glycemic control in rats after gastric bypass. Science. 2013 Jul 
26;341(6144):406-10. 
 
Samat A, Malin SK, Huang H, Schauer PR, Kirwan JP, Kashyap SR (2013). Ghrelin 
suppression is associated with weight loss and insulin action following gastric bypass 
surgery at 12 months in obese adults with type 2 diabetes. Diabetes Obes Metab. 2013 
May 16. doi: 10.1111/dom.12118.  
 
Sánchez-Santos R, Masdevall C, Baltasar A, Martínez-Blázquez C, García Ruiz de 
Gordejuela A, Ponsi E, Sánchez-Pernaute A, Vesperinas G, Del Castillo D, Bombuy E, 
Durán-Escribano C, Ortega L, Ruiz de Adana JC, Baltar J, Maruri I, García-Blázquez E, 
Torres A (2009). Short- and mid-term outcomes of sleeve gastrectomy for morbid 
obesity: the experience of the Spanish National Registry. Obes Surg;19 (9):1203-10.  
 
Santry HP, Gillen DL, Lauderdale DS (2005): Trends in bariatric surgical procedures. 
JAMA 294 (15):1909–1917. 
 
Sarson DL, Scopinaro N, Bloom SR (1981). Find all citations by this author (default).Or 
filter your current search Gut hormone changes after jejunoileal (JIB) or biliopancreatic 
(BPB) bypass surgery for morbid obesity, Int. J. Obes. 5 (5), pp. 471–480. 
 
Sawaya RA
1
, Jaffe J, Friedenberg L, Friedenberg FK (2012). Vitamin, mineral, and 
drug absorption following bariatric surgery. Curr Drug Metab.;13(9):1345-55. 
 
Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, Thomas S, 
Abood B, Nissen SE, Bhatt DL (2012). Bariatric surgery versus intensive medical 
therapy in obese patients with diabetes. N Engl J Med. 26; 366(17):1567-76. 
265 
 
Scheres A, Sanfey AG. (2006). Individual differences in decision making: Drive and 
Reward Responsiveness affect strategic bargaining in economic games. Behav Brain 
Funct. 2006 18; 2: 35. 
 
Schernthaner G and Morton J M (2008). Bariatric Surgery in Patients with Morbid 
Obesity and Type 2 Diabetes; Diabetes Care. 31:S297-S302. 
 
Scholz GH, Englaro P, Thiele I, Scholz M, Klusmann T, Kellner K, Rascher W. Blum 
WF (1996). Dissociation of serum leptin concentration and body fat content during long 
term dietary intervention in obese individuals. Horm Metab Res 28:718–723. 
Schwartz M W, Woods S C, Porte D Jr,  Seeley R J and Baskin D G (2000). Central 
nervous system control of food intake Nature 404, 661-671. 
Schwartz M W and Porte D Jr. (2005). Diabetes, Obesity, and the Brain Science Vol. 
307 no. 5708 pp. 375-379.   
Schultz W (1998). Predictive reward signal of dopamine neurons, Journal of 
Neurophysiolology 80; (1998): 1–27. 
Schultz W and Dickinson A (2000), Neuronal coding of prediction errors, Annu. Rev. 
Neurosci.; 23: 473–500. 
Schur EA, Cummings DE, Callahan HS, Foster-Schubert KE. (2008). Association of 
cognitive restraint with ghrelin, leptin, and insulin levels in subjects who are not weight-
reduced. Physiol Behav. 18; 93(4-5):706-12. 
 
Schwartz MW, Figlewicz DP, Baskin DG, Woods SC and Porte D, Jr. (1992). Insulin in 
the brain: a hormonal regulator of energy balance. Endocr Rev 13:387-414. 
 
Schwartz MW, Woods SC, Porte D, Seeley RJ and Baskin DG (2000). Central nervous 
system control of food intake. Nature; 404:661-671. 
 
Sclafani A, Koopmans HS, Vasselli JR, Reichman M (1978). Effects of intestinal 
bypass surgery on appetite, food intake and body weight in obese and lean rats. Am. J. 
Physiol. 234 (4), E389–E398. 
 
266 
 
Sclafani A (1981). Appetitive behavior after jejunoileal bypass. Int. J. Obes. 5 (5), 449–
455. 
 
Scott WR, Batterham RL (2011). Roux-en-Y gastric bypass and laparoscopic sleeve 
gastrectomy: understanding weight loss and improvements in type 2 diabetes after 
bariatric surgery. Am J Physiol Regul Integr Comp Physiol.; 301(1):R15-27. 
 
Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL and 
Drucker DJ (1996). Glucose intolerance but normal satiety in mice with a null mutation 
in the glucagonlike peptide 1 receptor gene. Nat Med 2:1254-1258. 
 
Seeley R J, Woods S C (2003). Monitoring of stored and available fuel by the CNS: 
implications for obesity, Nature Rev. Neurosci. 4; 901.  
 
Seeley RJ, Woods SC (2006). Monitoring of stored and available fuel by the CNS: 
implications for obesity. Nat Rev Neurosci. Nov; 4(11):901-9 (2003). Erratum in: Nat 
Rev Neurosci. Feb; 7 (2):167. 
 
Sepple CP and Read NW (1989). Gastrointestinal correlates of the development of 
hunger in man. Appetite 13:183-191. 
 
Shah S, Todkar J, Shah P (2009). Effect of laparoscopic sleeve gastrectomy (LSG) on 
HbA1c levels in T2DM patients: results at one year. Obes Surg, IFSO P–080. 
 
Shah S, Shah P, Todkar J (2010). Prospective controlled study of effect of laparoscopic 
sleeve gastrectomy on small bowel transit time and gastric emptying half-time in 
morbidly obese patients with type 2 diabetes mellitus Surg Obes Relat Dis.; 6: 152-7. 
 
Shalev U, Yap J and Shaham Y (2001). Leptin attenuates acute food deprivation-
induced relapse to heroin seeking, J. Neurosci.; 21: RC129*. 
 
Shalev U, Highfield D, Yap J, Shaham Y. (2000). Stress and relapse to drug seeking in 
rats: studies on the generality of the effect. Psychopharmacology (Berl); 150: 337-46. 
 
Sharkey KA (2011). Animal models of bariatric/metabolic surgery shed light on the 
mechanisms of weight control and glucose homeostasis: view from the chair. Int J 
Obes (Lond); 35 Suppl 3:S31-4. 
 
267 
 
Shearman LP, Wang SP, Helmling S, Stribling DS, Mazur P, Ge L, Wang L, Klussmann 
S, Macintyre DE, Howard AD and Strack AM (2006). Ghrelin neutralization by a 
ribonucleic acid-SPM ameliorates obesity in diet-induced obese mice. Endocrinology 
147:1517-1526. 
 
Shen Y, Joachimiak A, Rosner MR and Tang WJ (2006). Structures of human insulin-
degrading enzyme reveal a new substrate recognition mechanism, Nature; 443: 870–
874.   
 
Shepherd LM, Campbell SC, Macfarlane WM (2004). Transcriptional regulation of the 
IAPP gene in pancreatic beta-cells. Biochim Biophys Acta.; 1681(1):28-37. 
 
Shi X, Karmali S, Sharma AM, Birch DW (2010). A review of laparoscopic sleeve 
gastrectomy for morbid obesity. Obes Surg.; 20 (8):1171-7. 
 
Shiiya T, Nakazato M, Mizuta M, Date Y, Mondal MS, Tanaka M, Nozoe S, Hosoda H, 
Kangawa K, Matsukura S (2002). Plasma ghrelin levels in lean and obese humans and 
the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab.; 87: 240-4. 
 
Shin AC, Zheng H, Townsend RL et al (2010).  Meal-induced hormone responses in a 
rat model of Roux-en-Y gastric bypass surgery. Endocrinology.; 151: 1588-97. 
 
Siahanidou T, Mandyla H, Vounatsou M, Anagnostakis D, Papassotiriou I and 
Chrousos GP (2005). Circulating peptide YY concentrations are higher in preterm than 
full-term infants and correlate negatively with body weight and positively with serum 
ghrelin concentrations. Clin Chem 51:2131-2137. 
 
Siahanidou T MH, Militsi H, Papassotiriou I, Chrousos G (2007). Peptide YY (3-36) 
represents a high percentage of total PYY immunoreactivity in preterm and full-term 
infants and correlates independently with markers of adiposity and serum ghrelin 
concentrations. Pediatr Res 62: 200- 203. 
 
Silecchia G, Boru C, Pecchia A, Rizzello M, Casella G, Leonetti F and Basso N (2006). 
Effectiveness of laparoscopic sleeve gastrectomy (first stage of biliopancreatic 
diversion with duodenal switch) on co-morbidities in super-obese high-risk patients. 
Obes Surg Volume 16, Number 9 pp 1138-1144. 
 
268 
 
Silvestre RA, Rodriguez-Gallardo J, Jodka C, Parkes DG, Pittner RA and Young AA et 
al (2001). Selective amylin inhibition of the glucagon response to arginine is extrinsic to 
the pancreas, Am J Physiol Endocrinol Metab; 280: E443–449. 
 
Sims EA, Danforth E, Jr., Horton ES, Bray GA, Glennon JA and Salans LB (1973). 
Endocrine and metabolic effects of experimental obesity in man. Recent Prog Horm 
Res 29:457-496. 
 
Sjostrom L, Lindroos A-K, Peltonen M, Torgerson J, Bouchard C, Carlsson B, Dahlgren 
S, Larsson B, Narbro K, Sjostrom CD, Sullivan M, Wedel H and the Swedish Obese 
Subjects Study Scientific Group (2004). Lifestyle, Diabetes, and Cardiovascular Risk 
Factors 10 Years after Bariatric Surgery. N Engl J Med 351:2683-2693. 
 
Sjöström L (2006): Bariatric surgery in diabetic patients: what is the evidence? 42nd 
EASD Meeting, Copenhagen, Denmark, 2006. Diabetologia (Suppl.1). 
 
Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan 
M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, 
Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren 
G and Carlsson LM (2007). Effects of bariatric surgery on mortality in Swedish obese 
subjects. N Engl J Med 357:741-752. 
 
Sloth B, Holst JJ, Flint A, Gregersen NT and Astrup A (2007). Effects of PYY1-36 and 
PYY3-36 on appetite, energy intake, energy expenditure, glucose and fat metabolism in 
obese and lean subjects. Am J Physiol Endocrinol Metab 292:E1062-1068. 
 
Small DM, Jones-Gotman M and Dagher A (2003). Feeding-induced dopamine release 
in dorsal striatum correlates with meal pleasantness ratings in healthy human 
volunteers, Neuroimage; 19: 1709–1715. 
 
Smith S R, Aronne L J, Burns C M, Kesty N C, Halseth A E and  Weyer C (2008). 
Sustained Weight Loss Following 12-Month Pramlintide Treatment as an Adjunct to 
Lifestyle Intervention in Obesity. Diabetes Care vol. 31 no. 9, 1816-1823. 
 
Spiegelman BM and Flier JS (2001). Obesity and the regulation of energy balance. Cell 
104:531-543. 
 
269 
 
Spitz, M.R., Detry, M.A., Pillow, P., Hu, Y., Amos, C.I., Hong, W.K. and Wu X. (2000). 
Variant alleles of the D2 dopamine receptor gene and obesity. Nutrition Research; 20: 
371–380. 
 
Sodowski K, Zwirska-Korczala K, Kuka D, Kukla M, Budziszewska P, Czuba B, Wloch 
A, Cnota W, Bielanski W, Brzozowski T, Rehfeld JF, Zdun R and Konturek PC (2007). 
Basal and postprandial gut peptides affecting food intake in lean and obese pregnant 
women. J Physiol Pharmacol 58 Suppl 1:37-52. 
 
Starmer C (2000). Developments in Non-Expected Utility Theory: The Hunt for a 
Descriptive Theory of Choice under Risk., Journal of Economic Literature; 38: 332-382. 
Steele K E, Prokopowicz G P, Schweitzer M A, Magunsuon T H, Lidor A O, Kuwabawa 
H, Kumar A, Brasic J and Wong  D F (2010). Alterations of central dopamine receptors 
before and after gastric bypass surgery, Obes. Surg; 20(3):369-74. 
Stellar E (1954). The physiology of motivation. Psychol Rev 61:5-22. 
 
Stellar JR, Stellar E (1985). The neurobiology of motivation and reward. New York, 
Springer-Verlag; 1985. 
 
Stevens J, Nowicki EM (2003). Body mass index and mortality in asian populations: 
implications for obesity cut-points. Nutr Rev.;61 (3):104–107.   
 
Stock S, Leichner P, Wong AC, Ghatei MA, Kieffer TJ, Bloom SR and Chanoine JP 
(2005). Ghrelin, peptide YY, glucose-dependent insulinotropic polypeptide, and hunger 
responses to a mixed meal in anorexic, obese, and control female adolescents. J Clin 
Endocrinol Metab 90:2161-2168. 
 
Stoeckel LE, Weller RE, Giddings M and Cox JE (2008). Peptide YY levels are 
associated with appetite suppression in response to long-chain fatty acids. Physiol 
Behav. 93(1-2):289-95. 
 
Stoeckel LE, Weller RE, Cook EW 3rd, Twieg DB, Knowlton RC, Cox JE (2008). 
Widespread reward-system activation in obese women in response to pictures of high-
calorie foods. Neuroimage; 41(2):636-47. 
 
Strader AD, Vahl TP, Jandacek RJ, Woods SC, D'Alessio DA, Seeley RJ (2005). 
Weight loss through ileal transposition is accompanied by increased ileal hormone 
270 
 
secretion and synthesis in rats, Am. J. Physiol. Endocrinol. Metab. 288 (2), pp. E447–
E453. 
Stroh C, Birk D, Flade-Kuthe R, Frenken M, Herbig B, Höhne S, Köhler H, Lange V, 
Ludwig K, Matkowitz R, Meyer G, Meyer F, Pick P, Horbach T, Krause S, Schäfer L, 
Schlensak M, Shang E, Sonnenberg T, Susewind M, Voigt H, Weiner R, Wolff S, 
Lippert H, Wolf AM, Schmidt U, Manger T; Bariatric Surgery Working Group (2009). A 
nationwide survey on bariatric surgery in Germany--results 2005-2007. Obes 
Surg.;19(1):105-12.  
Stuber, G. D., Evans, S. B., Higgins, M. S., Pu, Y. & Figlewicz, D. P. (2002). Food 
restriction modulates amphetamine-conditioned place preference and nucleus 
accumbens dopamine release in the rat. Synapse; 46: 83–90.  
Sturm R (2007). Increases in morbid obesity in the USA: 2000-2005. Public Health ;121 
(7):492-496. 
Sun Y, Ahmed S and Smith RG (2003). Deletion of ghrelin impairs neither growth nor 
appetite. Mol Cell Biol; 23:7973-7981. 
Sundbom M, Holdstock C, Engström B E and Karlsson F A (2007). Early changes in 
ghrelin following Roux-en-Y gastric bypass: influence of vagal nerve functionality?, 
Obes. Surg. Volume 17, Number 3 pp. 304–310. 
Taheri S, Lin L, Austin D, Young T and Mignot E (2004). Short sleep duration is 
associated with reduced leptin, elevated ghrelin, and increased body mass index, PLoS 
Med; 1: e62. 
Takahashi T (2010). Toward molecular neuroeconomics of obesity. Med Hypotheses. 
75(4):393-6.  
Talsania T, Anini Y, Siu S, Drucker DJ and Brubaker PL (2005). Peripheral Exendin-4 
and Peptide YY3-36 Synergistically Reduce Food Intake through Different Mechanisms 
in Mice; Endocrinology.; 146(9):3748-56. 
 
Tamura H, Kamegai J, Shimizu T, Ishii S, Sugihara H and Oikawa S (2002). Ghrelin 
stimulates GH but not food intake in arcuate nucleus ablated rats. Endocrinology 
143:3268-3275. 
 
271 
 
Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M and 
Sheikh SP (1996). Central administration of GLP-1-(7-36) amide inhibits food and water 
intake in rats. Am JPhysiol 271:R848-856. 
 
Tatemoto K and Mutt V (1980). Isolation of two novel candidate hormones using a 
chemical method for finding naturally occurring polypeptides. 285:417-418. 
 
Thaler JP, Schwartz MW (2010). Inflammation and obesity pathogenesis: the 
hypothalamus heats up. Endocrinology. 151(9):4109-15. 
 
Thomaseth K, Pacini G, Clodi M, Kautzky-Willer A, Nolan JJ and Prager R et al (1997). 
Amylin release during oral glucose tolerance test, Diabet Med 14; (Suppl 2): S29–34. 
 
TM Pharma (2008) TM Pharma has initiated Phase I/IIa clinical trial with TM30339 for 
the treatment of obesity and related metabolic disorders, in 7TM Pharma: Press 
Release September 2nd, 2008. 
 
Tsai AG and Wadden TA (2005). Systematic review: an evaluation of major commercial 
weight loss programs in the United States. Ann Intern Med 142: 56-66. 
 
Tschop M, Smiley DL and Heiman ML (2000). Ghrelin induces adiposity in rodents. 
Nature 407:908-913. 
 
Tschop M, Castaneda TR, Joost HG, Thone-Reineke C, Ortmann S, Klaus S, Hagan 
MM, ChandlerPC, Oswald KD, Benoit SC, Seeley RJ, Kinzig KP, Moran TH, Beck-
sickinger AG, KoglinN, Rodgers RJ, Blundell JE, Ishii Y, Beattie AH, Holch P, Allison 
DB, Raun K, Madsen K,Wulff BS, Stidsen CE, Birringer M, Kreuzer OJ, Schindler M, 
Arndt K, Rudolf K, Mark M, Deng XY, Whitcomb DC, Halem H, Taylor J, Dong J, Datta 
R, Culler M, Craney S, Flora D, Smiley D and Heiman ML (2004). Physiology: does gut 
hormone PYY3-36 decrease food intake in rodents? Nature; 430 (6996): 1 p following 
165; discussion 2 p following 165. 
 
Tschop M, Smiley D L and Heiman M L, Ghrelin induces adiposity in rodents (2000). 
Nature; 407: 908–913. 
 
Tschöp M, Weyer C, Tataranni PA, Devanarayan V, Ravussin E, Heiman ML (2001). 
Circulating ghrelin levels are decreased in human obesity. Diabetes; 50:707-9. 
 
272 
 
Tseng CC, Zhang XY and Wolfe MM (1999). Effect of GIP and GLP-1 antagonists on 
insulin release in the rat. Am J Physiol; 276: E1049-1054. 
 
Tsilchorozidou T, Batterham RL, Conway GS (2008). Metformin increases fasting 
plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome 
(PCOS). Clin Endocrinol (Oxf).; 69(6):936-42.  
 
Turner RC, Holman RR (1976).  Beta cell deficiency in the maturity onset of diabetes 
Diabetologia; 12: 398-399. 
 
Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, Choi SJ, Taylor GM, 
Heath MM, Lambert PD, Wilding JP, Smith DM, Ghatei MA, Herbert J and Bloom SR 
(1996). A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 
379:69-72. 
Tversky A and Kahneman D, The framing of decisions and psychology of choice 
(1981). Science; 211: 453–458. 
Ukkola O, Ravussin E, Jacobson P, Perusse L, Rankinen T, Tschop M, Heiman ML, 
Leon AS, Rao DC, Skinner JS, Wilmore JH, Sjostrom L and Bouchard C (2002). Role 
of ghrelin polymorphisms in obesity based on three different studies. Obes Res; 
10:782-791. 
 
Umeda LM, Silva EA, Carneiro G, Arasaki CH, Geloneze B, Zanella MT (2011). Early 
improvement in glycemic control after bariatric surgery and its relationships with insulin, 
GLP-1, and glucagon secretion in type 2 diabetic patients. Obes Surg; 21(7): 896-901. 
 
Unniappan S, McIntosh C, Demuth H-U, Heiser U, Wolf R and Kieffer T (2006). Effects 
of dipeptidyl peptidase IV on the satiety actions of peptide YY. Diabetologia; 49:1915-
1923. 
 
Unniappan S and Kieffer TJ (2008). Leptin extends the anorectic effects of chronic 
PYY(3-36) administration in ad libitum-fed rats. Am J Physiol Regul Integr Comp 
Physiol; 295:R51-58. 
 
Valderas JP, Irribarra V, Boza C, de la Cruz R et al (2010). Medical and surgical 
treatments for obesity have opposite effects on peptide YY and appetite: a prospective 
study controlled for weight loss. J Clin Endocrinol Metab.; 95: 1069-75. 
273 
 
 
van den Hoek AM, Heijboer AC, Corssmit EP, Voshol PJ, Romijn JA, Havekes LM, Pijl 
H (2004). PYY3-36 reinforces insulin action on glucose disposal in mice fed a high-fat 
diet, Diabetes 53 (8), pp. 1949–1952.  
 
Van den Hoek AM, Heijboer AC, Voshol PJ, et al (2007). Chronic PYY3–36 treatment 
promotes fat oxidation and ameliorates insulin resistance in C57BL6 mice. Am J 
Physiol Endocrinol Metab.; 292: E238–45. 
 
Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi AB, Graziano MP, Sybertz 
EJ, Strader CD and Davis HR, Jr. (1997). Diet-induced obese mice develop peripheral, 
but not central, resistance to leptin. J Clin Invest; 99:385-390. 
van Jaarsveld BC, Hackeng WH, Lips CJ, Erkelens DW (1993). Plasma concentrations 
of islet amyloid polypeptide after glucagon administration in type 2 diabetic patients and 
non-diabetic subjects. Diabet Med; 10:327–30. 
Verdich C, Flint A, Gutzwiller JP, Naslund E, Beglinger C, Hellstrom PM, Long SJ, 
Morgan LM, Holst JJ and Astrup A (2001a). A meta-analysis of the effect of glucagon-
like peptide-1 (7-36) amide on ad libitum energy intake in humans. J Clin Endocrinol 
Metab; 86:4382-4389. 
 
Verdich C, Toubro S, Buemann B, Lysgard Madsen J, Juul Holst J and Astrup A 
(2001b). The role of postprandial releases of insulin and incretin hormones in meal-
induced satiety--effect of obesity and weight reduction. Int J Obes Relat Metab Disord; 
25:1206-1214. 
Vidal J, Ibarzabal A, Romero F, Delgado S, Momblán D, Flores L and Lacy A (2008). 
Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in 
severely obese subjects. Obes Surg Volume 18, Number 9; 1077-1082.  
Vizcarra JA, Kirby JD, Kim SK and Galyean ML (2007). Active immunization against 
ghrelin decreases weight gain and alters plasma concentrations of growth hormone in 
growing pigs. Domest Anim Endocrinol; 33:176-189. 
 
Vidal J, Ibarzabai F, Romero F, Deigado S, Momblan D and Lacy FA (2008). Type 2 
diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely 
obese subjects, Obes Surg; 18: 1077–1082. 
 
274 
 
Vilsboll T, Krarup T, Sonne J, Madsbad S, Volund A, Juul AG and Holst JJ (2003). 
Incretin secretion in relation to meal size and body weight in healthy subjects and 
people with type 1 and type 2 diabetes mellitus. J Clin Endocrinol Metab; 88:2706-
2713. 
Vogels N, Mariman ECM, Bouwman FG, Diepvens K, Westerterp-Plantenga MS 
(2005). Relationship of weight maintenance and dietary restraint with PPARgamma2, 
GRL and CNTF polymorphisms. Am J Clin Nutr; 82: 740–746, 
Volkow ND, Wang GJ, Fowler JS et al (2002). Non-hedonic food motivation in humans 
involves dopamine in the dorsal striatum and methylphenidate amplifies this effect. 
Synapse; 44: 175–180. 
 
Volkow, N.D., Wang, G.-J., Fowler, J.S., Logan, J., Gatley, S.J., Gifford, A., Hitzemann, 
R., Ding, Y.-S. and Pappas, N (1999). Prediction of reinforcing responses to 
psychostimulants in humans by brain dopamine D2 receptor levels. American Journal 
of Psychiatry; 156: 1440–1443. 
 
Volkow ND, Wise RA (2005). How can drug addiction help us understand obesity?  
Nat Neurosci.; 8: 555-60. 
Wang ZL, Bennet WM, Ghatei MA, Byfield P G H, Smith D M and Stephen R Bloom S 
R (1993). Influence of islet amyloid polypeptide and the 8-37 fragment of islet amyloid 
polypeptide on insulin release from perifused rat islets. Diabetes; vol. 42 no. 2, 330-
335. 
Wang Z, Wang RM, Owji AA, Smith DM, Ghatei MA and Bloom SR (1995). Glucagon-
like peptide-1is a physiological incretin in rat. J Clin Invest; 95:417-421. 
 
Wang, G.-J., Volkow, N.D., Logan, J., Pappas, N.R., Wong, C.T., Zhu, W., Netusil, N. 
and Fowler, J.S (2001). Brain dopamine and obesity. The Lancet; 357: 354–357. 
 
Wang GJ, Volkow ND and Fowler JS (2002). Dopamine's role in motivation for food in 
humans: implications for obesity. Expert Opinion; 6: 601–609. 
 
Wang GJ, Volkow ND, Thanos PK and Fowler JS (2003). Positron emission 
tomography evidence of similarity between obesity and drug addiction. Psychiatric 
Annals; 33: 104–111. 
 
275 
 
Wang HJ, Geller F, Dempfle A, Schauble N, Friedel S, Lichtner P, Fontenla-Horro F, 
Wudy S, Hagemann S, Gortner L, Huse K, Remschmidt H, Bettecken T, Meitinger T, 
Schafer H, Hebebrand J and Hinney A (2004). Ghrelin receptor gene: identification of 
several sequence variants in extremely obese children and adolescents, healthy 
normal-weight and underweight students, and children with short normal stature. J Clin 
Endocrinol Metab 89:157-162. 
 
Wang Y and J. Liu (2009), Plasma ghrelin modulation in gastric band operation and 
sleeve gastrectomy, Obes. Surg. 19 (3); pp. 357–362. 
 
Wang TT, Hu SY, Gao HD, Zhang GY, Liu CZ, Feng JB, Frezza EE (2008). Ileal 
transposition controls diabetes as well as modified duodenal jejunal bypass with better 
lipid lowering in a nonobese rat model of type II diabetes by increasing GLP-1, Ann. 
Surg. 247 (6) pp. 968–975. 
 
Wang Yand Liu J (2009). Plasma ghrelin modulation in gastric band operation and 
sleeve gastrectomy, Obes. Surg. 19 (3) pp. 357–362. 
 
Weber EU, S Shafir, AR Blais, R Israel (2004). Predicting Risk-Sensitivty in Humans 
and Lower Animals: Risk as Variance or Coefficient of Variation - Psychological 
Review; 111: 430. 
 
Weigle DS (1994). Appetite and the regulation of body composition. FASEB J; 8: 302-
310. 
 
Weigle DS, Duell PB, Connor WE, Steiner RA, Soules MR and Kuijper JL (1997). Effect 
of fasting, refeeding, and dietary fat restriction on plasma leptin levels. J Clin 
Endocrinol Metab; 82: 561-565. 
 
Welbourn R, Fiennes A, Kinsman R & Walton P The United Kingdom National Bariatric 
Surgery Registry—First Registry Report to March 2010 (2011). The Association of 
Upper Gastrointestinal Surgeons of Great Britain and Ireland [online](2011). 
Weng HB, Gu Q, Liu M, Cheng NN, Li D, Gao X (2008). Increased secretion and 
expression of amylin in spontaneously diabetic Goto-Kakizaki rats treated with rhGLP-1 
(7-36). Acta Pharmacol Sin.; 29(5):573-9.  
276 
 
Welt C K, Chan J L, Bullen J, Murphy R, Smith P, DePaoli AM , Karalis A, and 
Mantzoros C S (2004). Recombinant Human Leptin in Women with Hypothalamic 
Amenorrhea N Engl J Med; 351:987-997. 
 
Weyer C, Wolford J K, Hanson R L, Foley J E, Tataranni P A, Bogardus C, Pratley R E 
(2001). Subcutaneous Abdominal Adipocyte Size, a Predictor of Type 2 Diabetes, Is 
Linked to Chromosome 1q21–q23 and Is Associated with a Common Polymorphism in 
LMNA in Pima Indians Mol. Genet. Metab. Volume 72, Issue 3, Pages 231–238. 
 
White S, Brooks E, Jurikova L, Stubbs RS (2005). Long-term outcomes after gastric 
bypass. Obes Surg 15 (2):155–163. 
 
Whitson BA, Leslie DB, Kellogg TA, Maddaus MA, Buchwald H, Billington CJ, 
Ikramuddin S (2007). Entero-endocrine changes after gastric bypass in diabetic and 
non-diabetic patients: a preliminary study J Surg Res.; 141(1): 31-9. 
 
WHO (2000). Obesity: preventing and managing the global epidemic. WHO Technical 
Report Series no. 894. Geneva,  
 
WHO(1998). Obesity: Preventing and managing the global epidemic. Report on a WHO 
Consultation on Obesity, Geneva, 3–5 June, 1997 WHO/NUT/NCD/98.1, WHO, 
Geneva, Switzerland.  
 
WHO (1995). Physical Status: The use and interpretation of anthropometry. Technical 
Report Series 854. WHO, Geneva. 
 
Wickremesekera K, Miller G, Naotunne TD, Knowles G and Stubbs RS (2005). Loss of 
insulin resistance after Roux-en-Y gastric bypass surgery: a time course study. Obes 
Surg;15: 474- 481. 
 
Williams DL, Grill HJ, Cummings DE and Kaplan JM (2003). Vagotomy dissociates 
short- and long-term controls of circulating ghrelin, Endocrinology; 144: 5184–5187. 
 
Wise RA (2002). Brain reward circuitry: insights from unsensed incentives. Neuron; 36: 
229–240. 
 
Woelnerhanssen B, Peterli R, Steinert R E, Peters T, Borbély Y, Beglinger C (2011). 
Effects of postbariatric surgery weight loss on adipokines and metabolic parameters: 
277 
 
comparison of laparoscopic Roux-en-Y gastric bypass and laparoscopic sleeve 
gastrectomy—a prospective randomized trial. Surgery for Obesity and related 
diseases. Volume 7, Issue 5, p 561–568. 
Wolf AM, Schmidt U, Manger T (2009). Bariatric Surgery Working Group. A nationwide 
survey on bariatric surgery in Germany—results 2005-2007. Obes Surg;19 (1):105-12. 
Wolfe WL and Maisto SA (2000). The relationship between eating disorders and 
substance use: moving beyond co-prevalence research. Clin Psychol Rev; 20: 617–
631. 
 
Wortley KE, Anderson KD, Garcia K, Murray JD, Malinova L, Liu R, Moncrieffe M, 
Thabet K, Cox HJ, Yancopoulos GD, Wiegand SJ and Sleeman MW (2004). Genetic 
deletion of ghrelin does not decrease food intake but influences metabolic fuel 
preference. Proc Natl Acad Sci USA; 101:8227-8232. 
 
Wren AM, Small CJ, Ward HL, Murphy KG, Dakin CL, Taheri S, Kennedy AR, Roberts 
GH, Morgan DG, Ghatei MA and Bloom SR (2000). The novel hypothalamic peptide 
ghrelin stimulates food intake and growth hormone secretion. Endocrinology; 141: 
4325-4328. 
 
Wren AM, Seal LJ, Cohen MA, Brynes AE, Frost GS, Murphy KG, Dhillo WS, Ghatei 
MA and Bloom SR (2001). Ghrelin enhances appetite and increases food intake in 
humans. J Clin Endocrinol Metab; 86:5992. 
 
Wunderle JM, Jr. Zopraida Cotto-Navarro (1988). Constant vs. Variable Risk-Aversion 
in Foraging Bananaquits. Ecology; 69: 1434-1438. 
Torgerson JS, Hauptman J, Boldrin MN, Sjöström L (2004). XENical in the prevention 
of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an 
adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients. 
Diabetes Care. 2004 Jan; 27(1):155-61. Erratum in: Diabetes Care. 2004 
Mar;27(3):856. 
Yada T, Dezaki K, Sone H, Masaru K,  Boldbaatar D, Masanori N, Masafumi K (2008). 
“Ghrelin regulates insulin release and glycemia: physiological role and therapeutic 
potential,” Current Diabetes Reviews, vol. 4, no. 1, pp. 18–23.  
Yale CE, Weiler SJ (1991). Weight control after vertical banded gastroplasty for morbid 
obesity. Am J Surg.;162: 13-8. 
278 
 
 
Yang N, Wang C, Xu M, Mao L, Liu L and Sun X (2005). Interaction of dietary 
composition and PYY gene expression in diet-induced obesity in rats. Journal of 
Huazhong University of Science and Technology Medical sciences = Hua zhong ke ji 
da xue xue bao Yi xue Ying De wen ban Huazhong keji daxue xuebao; 25:243-246. 
 
Yang J, Brown MS, Liang G, Grishin NV and Goldstein JL (2008a). Identification of the 
acyltransferase that octanoylates ghrelin, an appetite-stimulating peptide hormone. 
Cell; 132: 387-396. 
 
Yang J, Zhao TJ, Goldstein JL and Brown MS (2008b). Inhibition of ghrelin O-
acyltransferase (GOAT) by octanoylated pentapeptides. Proc Natl Acad Sci USA; 
105:10750-10755. 
 
Yanovski SZ
1
, Yanovski JA (2014).Long-term drug treatment for obesity: a systematic 
and clinical review. JAMA. 2014 Jan 1;311(1):74-86. 
 
Yermilov I, McGory ML, Shekelle PW, Ko CY, Maggard MA (2009). Appropriateness 
criteria for bariatric surgery: beyond the NIH guidelines. Obesity (Silver Spring);17 
(8):1521-7. 
Young AA, Gedulin BR and Rink TJ (1996). Dose-responses for the slowing of gastric 
emptying in a rodent model by glucagon-like peptide (7-36) NH2, amylin, 
cholecystokinin, and other possible regulators of nutrient uptake, Metabolism; 45: 1–3. 
 
Young A (2005). Inhibition of gastric emptying. Adv Pharmacol.; 52: 99–121.  
 
Yousseif A, Emmanuel J, Karra E, Millet Q, Elkalaawy M, Jenkinson AD, Hashemi M, 
Adamo M, Finer N, Fiennes AG, Withers DJ, Batterham RL (2013). Differential Effects 
of Laparoscopic Sleeve Gastrectomy and Laparoscopic Gastric Bypass on Appetite, 
Circulating Acyl-ghrelin, Peptide YY3-36 and Active GLP-1 Levels in Non-diabetic 
Humans. Obes Surg. 2013 Aug 31. 
 
 
Zaki M, Koduru S, McCuen R, Vuyyuru L, Schubert M L (2002). Amylin, released from 
the gastric fundus, stimulates somatostatin and thus inhibits histamine and acid 
secretion in mice. Gastroenterology 123:247–255. 
279 
 
 
Zander M, Madsbad S, Madsen JL and Holst JJ (2002). Effect of 6-week course of 
glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function 
in type 2 diabetes: a parallel-group study. Lancet; 359:824-830. 
 
Zapecka-Dubno B, Czyzyk A, Dworak A, Bak MI (1999). Effect of oral antidiabetic 
agents on plasma amylin level in patients with non-insulin-dependent diabetes mellitus 
(type 2). Arzneimittelforschung; 49(4):330-4. 
 
Zhang Y, Proenca R, Maffei M, Barone M, Leopold L and Friedman JM (1994). 
Positional cloning of the mouse obese gene and its human homologue. Nature; 
372:425-432. 
 
Zheng H and Berthoud HR (2008). Neural systems controlling the drive to eat: mind 
versus metabolism. Physiology (Bethesda); 23:75-83. 
 
Zigman JM, Nakano Y, Coppari R, Balthasar N, Marcus JN, Lee CE, Jones JE, 
Deysher AE, Waxman AR, White RD, Williams TD, Lachey JL, Seeley RJ, Lowell BB 
and Elmquist JK (2005). Mice lacking ghrelin receptors resist the development of diet-
induced obesity. J Clin Invest; 115:3564-3572. 
 
Zimmet P, Thomas C R (2003). Genotype, obesity and cardiovascular disease – has 
technical and social advancement outstripped evolution? Journal of Internal Medicine 
Volume 254 (2), pp 114–125.  
 
Zimmet P, George K, Alberti M M, Rubino F, Dixon J B (2011). IDF’s view of bariatric 
surgery in type 2 diabetes   The Lancet, Volume 378, Issue 9786, pp 108-110. 
 
Zorrilla EP, Iwasaki S, Moss JA, Chang J, Otsuji J, Inoue K, Meijler MM and Janda KD 
(2006). Vaccination against weight gain. Proc Natl Acad Sci USA; 103:13226-13231. 
 
 
 
 
